[{"Element":"<div class=\"WordSection1\"> <p class=\"MsoNormal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">ANNEX I<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <h1><span lang=\"EN-GB\">SUMMARY OF PRODUCT CHARACTERISTICS<\/span><\/h1> <b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:27.0pt;margin-bottom:.0001pt;text-align:left;text-indent:-27.0pt\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">1.      NAME OF THE MEDICINAL PRODUCT<\/span><\/b><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Stalevo 50 mg\/12.5 mg\/200 mg film-coated tablets<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Stalevo 75 mg\/18.75 mg\/200 mg film-coated tablets<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Stalevo 100 mg\/25 mg\/200 mg film-coated tablets<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Stalevo 125<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">mg\/31.25<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">mg\/200<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">mg film-coated tablets<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Stalevo 150 mg\/37.5 mg\/200 mg film-coated tablets<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Stalevo 175 mg\/43.75 mg\/200 mg film-coated tablets<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Stalevo 200 mg\/50 mg\/200 mg film-coated tablets <\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:27.0pt;margin-bottom:.0001pt;text-align:left;text-indent:-27.0pt\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">2.      QUALITATIVE AND QUANTITATIVE COMPOSITION<\/span><\/b><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">50 mg\/12.5 mg\/200 mg<\/span><\/u><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Each tablet contains 50 mg of levodopa, 12.5 mg of carbidopa and 200 mg of entacapone.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Excipient with known effect:<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">Each tablet contains 1.2 mg of sucrose<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">75 mg\/18.75 mg\/200 mg<\/span><\/u><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Each tablet contains 75 mg of levodopa, 18.75 mg of carbidopa and 200 mg of entacapone.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Excipient with known effect: <\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">Each tablet contains <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">1.4 <\/span><span style=\"font-size:11.0pt\">mg of sucrose<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">100 mg\/25 mg\/200 mg <\/span><\/u><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Each tablet contains 100 mg of levodopa, 25 mg of carbidopa and 200 mg of entacapone.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Excipient with known effect: <\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">Each tablet contains <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">1.6 mg<\/span><span style=\"font-size:11.0pt\"> of sucrose<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">125<\/span><\/u><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">mg\/31.25<\/span><\/u><u><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">mg\/200<\/span><\/u><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">mg<\/span><\/u><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Each tablet contains 125 mg of levodopa, 31.25 mg of carbidopa and 200 mg of entacapone.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Excipient with known effect: <\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">Each tablet contains <\/span><span style=\"font-size:\r 11.0pt\">1.6 <\/span><span style=\"font-size:11.0pt\">mg of sucrose<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">150 mg\/37.5 mg\/200 mg<\/span><\/u><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Each tablet contains 150 mg of levodopa, 37.5 mg of carbidopa and 200 mg of entacapone.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Excipient with known effect: <\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">Each tablet contains <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">1.9 mg<\/span><span style=\"font-size:11.0pt\"> of sucrose<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">175 mg\/43.75 mg\/200 mg<\/span><\/u><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Each tablet contains 175 mg of levodopa, 43.75 mg of carbidopa and 200 mg of entacapone.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Excipient with known effect: <\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">Each tablet contains <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">1.89 <\/span><span style=\"font-size:11.0pt\">mg of sucrose<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">200 mg\/50 mg\/200 mg<\/span><\/u><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Each tablet contains 200 mg of levodopa, 50 mg of carbidopa and 200 mg of entacapone.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Excipient with known effect: <\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">Each tablet contains <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">2.3 mg<\/span><span style=\"font-size:11.0pt\"> of sucrose<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">For the full list of excipients, see section 6.1.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:27.0pt;margin-bottom:.0001pt;text-align:left;text-indent:-27.0pt\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">3.      PHARMACEUTICAL FORM<\/span><\/b><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Film-coated tablet (tablet)<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">50 mg\/12.5 mg\/200 mg<\/span><\/u><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Brownish or greyish red, round, convex, unscored film-coated tablets marked with \u2018LCE 50\u2019 on one side.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">75 mg\/18.75 mg\/200 mg<\/span><\/u><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Light b<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">rownish red, <\/span><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">oval<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> film-coated tablets marked with <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">\u2018LCE 75\u2019 <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">on one side.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">100 mg\/25 mg\/200 mg<\/span><\/u><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Brownish or greyish red, oval, unscored film-coated tablets marked with \u2018LCE 100\u2019 on one side.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">125<\/span><\/u><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">mg\/31.25<\/span><\/u><u><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">mg\/200<\/span><\/u><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">mg<\/span><\/u><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Light b<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">rownish red, <\/span><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">oval<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> film-coated tablets marked with <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">\u2018LCE 125\u2019 <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">on one side.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">150 mg\/37.5 mg\/200 mg<\/span><\/u><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Brownish or greyish red, elongated-ellipse shaped, unscored film-coated tablets marked with \u2018LCE 150\u2019 on one side.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">175 mg\/43.75 mg\/200 mg<\/span><\/u><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Light b<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">rownish red, <\/span><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">oval, <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">unscored film-coated tablets marked with <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">\u2018LCE 175\u2019 <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">on one side.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">200 mg\/50 mg\/200 mg<\/span><\/u><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Dark brownish red, oval, unscored film-coated tablets marked with \u2018LCE 200\u2019 on one side.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:27.0pt;margin-bottom:.0001pt;text-align:left;text-indent:-27.0pt\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">4.      <span style=\"text-transform:uppercase\">Clinical particulars<\/span><\/span><\/b><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:27.0pt;margin-bottom:.0001pt;text-indent:-27.0pt\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">4.1    Therapeutic indications<\/span><\/b><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Stalevo is indicated for the treatment of adult patients with Parkinson\u2019s disease and end-of-dose motor fluctuations not stabilised on levodopa\/dopa decarboxylase (DDC) inhibitor treatment.<\/span><\/p> <p class=\"MsoEndnoteText\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:27.0pt;margin-bottom:.0001pt;text-align:left;text-indent:-27.0pt\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">4.2    Posology and method of administration<\/span><\/b><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Posology<\/span><\/u><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">The optimum daily dose must be determined by careful titration of levodopa in each patient. The daily dose should be preferably optimised using one of the seven available tablet strengths (50 mg\/12.5 mg\/200 mg, 75 mg\/18.75 mg\/200 mg, 100 mg\/25 mg\/200 mg, 125 mg\/31.25 mg\/200 mg, 150 mg\/37.5 mg\/200 mg, 175 mg\/43.75 mg\/200 mg or 200 mg\/50 mg\/200 mg levodopa\/carbidopa\/entacapone). <\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Patients should be instructed to take only one Stalevo tablet per dose administration. Patients receiving less than 70-100 mg carbidopa a day are more likely to experience nausea and vomiting. While the experience with total daily dose greater than 200 mg carbidopa is limited, the maximum recommended daily dose of entacapone is 2,000 mg and therefore the maximum dose is 10 tablets per day for the Stalevo strengths of 50 mg\/12.5 mg\/200 mg, 75 mg\/18.75 mg\/200 mg 100 mg\/25 mg\/200 mg, 125 mg\/31.25 mg\/200 mg and 150 mg\/37.5 mg\/200 mg. Ten tablets of Stalevo 150 mg\/37.5 mg\/200 mg equals 375 mg of carbidopa a day. According to this daily carbidopa dose, the maximum recommended daily dose of Stalevo 175 mg\/43.75 mg\/200 mg is 8 tablets per day and Stalevo 200 mg\/50 mg\/200 mg dose is 7 tablets per day.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Usually Stalevo is to be used in patients who are currently treated with corresponding doses of standard release levodopa\/DDC inhibitor and entacapone. <\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">How to transfer patients taking levodopa\/DDC inhibitor (carbidopa or benserazide) preparations and entacapone tablets to Stalevo <\/span><\/i><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">a<\/span><\/i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">. Patients who are currently treated with entacapone\r and with standard release levodopa\/carbidopa in doses equal to Stalevo tabletstrengths can be directly transferred to corresponding Stalevo tablets. <\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">For example, a patient taking one tablet of 50 mg\/12.5 mg of levodopa\/carbidopa with one tablet of entacapone 200 mg four times daily can take one 50 mg\/12.5 mg\/200 mg Stalevo tablet four times daily in place of their usual levodopa\/carbidopa and entacapone doses. <\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p class=\"MsoNormal\"><i><span lang=\"EN-GB\">b. <\/span><\/i><span lang=\"EN-GB\">When initiating Stalevo therapy for patients currently treated with entacapone and levodopa\/carbidopa in doses not equal to Stalevo tablets (50 mg\/12.5 mg\/200 mg or 75 mg\/18.75 mg\/200 mg or 100 mg\/25 mg\/200 mg or 125 mg\/31.25 mg\/200 mg or 150 mg\/37.5 mg\/200 mg or 175 mg\/43.75 mg\/200 mg or 200 mg\/50 mg\/200 mg), Stalevo dosing should be carefully titrated for optimal clinical response. At the initiation, Stalevo should be adjusted to correspond as closely as possible to the total daily dose of levodopa currently used. <\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">c.<\/span><\/i><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> When initiating Stalevo in patients currently treated with entacapone and levodopa\/benserazide in a standard release formulation, <\/span><span style=\"font-size:11.0pt\">the<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> dosing of levodopa\/benserazide should be discontinued in the previous night, and Stalevo should be started in the next morning. The starting dose of Stalevo should provide either the same amount of levodopa or slightly (5-10%) more. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:6.8pt\"><\/p> <p class=\"Text\" style=\"margin-top:0in\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">How to transfer patients not currently treated with entacapone to Stalevo<\/span><\/i><\/p> <p class=\"Text\" style=\"margin-top:0in\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Initiation of Stalevo may be considered at corresponding doses to current treatment in some patients with Parkinson's disease and end-of-dose motor fluctuations, who are not stabilised on their current standard release levodopa\/DDC inhibitor treatment. However, a direct switch from levodopa\/DDC inhibitor to Stalevo is not recommended for patients who have dyskinesias or whose daily levodopa dose is above 800 mg. In such patients it is advisable to introduce entacapone treatment as a separate treatment (entacapone tablets) and adjust the levodopa dose if necessary, before switching to Stalevo.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Entacapone enhances the effects of levodopa. It may therefore be necessary, particularly in patients with dyskinesia, to reduce levodopa dose by 10-30% within the first days to first weeks after initiating Stalevo treatment. The daily dose of levodopa can be reduced by extending the dosing intervals and\/or by reducing the amount of levodopa per dose, according to the clinical condition of the patient. <\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p class=\"Text\" style=\"margin-top:0in\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Dose adjustment during the course of the treatment<\/span><\/i><\/p> <p class=\"Text\" style=\"margin-top:0in\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">When more levodopa is required, an increase in the frequency of doses and\/or the use of an alternative strength of Stalevo should be considered, within the dose recommendations. <\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">When less levodopa is required, the total daily dose of Stalevo should be reduced either by decreasing the frequency of administration by extending the time between doses, or by decreasing the strength of Stalevo at an administration.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">If other levodopa products are used concomitantly with a Stalevo tablet, the maximum dose recommendations should be followed.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><i><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\"><\/span><\/u><\/i><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><i><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Discontinuation of Stalevo therapy<\/span><\/u><\/i><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">: <\/span><\/i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">If Stalevo treatment (levodopa\/carbidopa\/entacapone) is discontinued and the patient is transferred to levodopa\/DDC inhibitor therapy without entacapone, it is necessary to adjust the dosing of other antiparkinsonian treatments, especially levodopa, to achieve a sufficient level of control of the parkinsonian symptoms.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><i><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\"><\/span><\/u><\/i><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><i><u><span style=\"font-size:11.0pt\">Paediatric population<\/span><\/u><\/i><i><span style=\"font-size:11.0pt\">:<\/span><\/i><span style=\"font-size:11.0pt\"> The safety and efficacy of Stalevo in children aged below 18 years have not been established. No data are available.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><i><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Elderly<\/span><\/u><\/i><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">:<\/span><\/i><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> No dose adjustment of Stalevo is required for elderly.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><i><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\"><\/span><\/u><\/i><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><i><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Hepatic impairment<\/span><\/u><\/i><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">: <\/span><\/i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">It is advised that Stalevo should be administered cautiously to patients with mild to moderate hepatic impairment. Dose reduction may be needed (see section 5.2). <\/span><span style=\"font-size:11.0pt\">For severe hepatic impairment see section 4.3.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><i><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Renal impairment<\/span><\/u><\/i><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">:<\/span><\/i><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> Renal <\/span><span style=\"font-size:11.0pt\">impairment<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> does not affect the pharmacokinetics of entacapone. No particular studies are reported on the pharmacokinetics of levodopa and carbidopa in patients with renal insufficiency, therefore Stalevo therapy should be administered cautiously to patients in severe renal impairment including those receiving dialysis therapy (see section 5.2). <\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Method of administration<\/span><\/u><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Each tablet is to be taken orally either with or without food (see section 5.2). One tablet contains one treatment dose and the tablet may only be administered as whole tablets.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt\"><b><span lang=\"EN-GB\">4.3    Contraindications<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Hypersensitivity to the active substances or to any of the excipients <\/span><span style=\"font-size:\r 11.0pt\">listed in section 6.1<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Severe hepatic impairment.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Narrow-angle glaucoma.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Pheochromocytoma.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Coadministration of Stalevo with non-selective monoamine oxidase (MAO-A and MAO-B) inhibitors (e.g. phenelzine, tranylcypromine). <\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Coadministration with a selective MAO-A inhibitor and a selective MAO-B inhibitor (see section 4.5). <\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">A previous history of Neuroleptic Malignant Syndrome (NMS) and\/or non-traumatic rhabdomyolysis.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">4.4     Special warnings and precautions for use <\/span><\/b><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Stalevo is not recommended for the treatment of drug-induced extrapyramidal reactions. <\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;text-transform:uppercase\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Stalevo therapy should be administered cautiously to patients with ischemic heart disease, severe cardiovascular or pulmonary disease, bronchial asthma, renal or endocrine disease, history of peptic ulcer disease or history of convulsions. <\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">In patients with a history of myocardial infarction who have residual atrial nodal or ventricular arrhythmias; cardiac function should be monitored with particular care during the period of initial dose adjustments.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">All patients treated with Stalevo should be monitored carefully for the development of mental changes, depression with suicidal tendencies, and other serious antisocial behaviour. Patients with past or current psychosis should be treated with caution.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Concomitant\r administration of antipsychotics with dopamine receptor-blocking properties,\r particularly D<sub>2<\/sub> receptor antagonists should be carried out with\r caution, and the patient carefully observed for loss of antiparkinsonian effect\r or worsening of parkinsonian symptoms.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Patients with chronic wide-angle glaucoma may be treated with Stalevo with caution, provided the intra-ocular pressure is well controlled and the patient is monitored carefully for changes in intra-ocular pressure.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Stalevo may induce orthostatic hypotension. Therefore Stalevo should be given cautiously to patients who are taking other medicinal products which may cause orthostatic hypotension.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Entacapone in association with levodopa has been associated with somnolence and episodes of sudden sleep onset in patients with Parkinson\u2019s disease and caution should therefore be exercised when driving or operating machines (see section 4.7).<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">In clinical studies, <\/span><span style=\"font-size:11.0pt\">dopaminergic adverse reactions<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">, e.g. dyskinesia, were more common in patients who received entacapone and dopamine agonists (such as bromocriptine), selegiline or amantadine compared to those who received placebo with this combination. The doses of other antiparkinsonian medicinal products may need to be adjusted when Stalevo treatment is substituted for a patient currently not treated with entacapone.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Rhabdomyolysis secondary to severe dyskinesias or neuroleptic malignant syndrome (NMS) has been observed rarely in patients with Parkinson\u2019s disease. Therefore, any abrupt dose reduction or withdrawal of levodopa should be carefully observed, particularly in patients who are also receiving neuroleptics. NMS, including rhabdomyolysis and hyperthermia, is characterised by motor symptoms (rigidity, myoclonus, tremor), mental status changes (e.g., agitation, confusion, coma), hyperthermia, autonomic dysfunction (tachycardia, labile blood pressure) and elevated serum creatine phosphokinase. In individual cases, only some of these symptoms and\/or findings may be evident. The early diagnosis is important for the appropriate management of NMS. A syndrome resembling the neuroleptic malignant syndrome including muscular rigidity, elevated body temperature, mental changes and increased serum creatine phosphokinase has been reported with the abrupt withdrawal of antiparkinsonian agents. Neither NMS nor rhabdomyolysis have been reported in association with entacapone treatment from controlled trials in which entacapone was discontinued abruptly. Since the introduction of entacapone into the market, isolated cases of NMS have been reported, especially following abrupt reduction or discontinuation of entacapone and other concomitant dopaminergic medicinal products. When considered necessary, the replacement of Stalevo with levodopa and DDC inhibitor without entacapone or other dopaminergic treatment should proceed slowly and an increase in levodopa dose may be necessary.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">If general anaesthesia is required, therapy with Stalevo may be continued for as long as the patient is permitted to take fluids and medicinal products by mouth. If therapy has to be stopped temporarily, Stalevo may be restarted as soon as oral medicinal products can be taken at the same daily dose as before. <\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Periodic evaluation of hepatic, haematopoietic, cardiovascular and renal function is recommended during extended therapy with Stalevo.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">For patients experiencing diarrhoea, a follow-up of weight is recommended in order to avoid potential excessive weight decrease. Prolonged or persistent diarrhoea appearing during use of entacapone may be a sign of colitis. In the event of prolonged or persistent diarrhoea, the drug should be discontinued and appropriate medical therapy and investigations considered.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Patients should be regularly monitored for the development of impulse control disorders. Patients and carers should be made aware that behavioural symptoms of impulse control disorders including pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists and\/or other dopaminergic treatments containing levodopa including Stalevo. Review of treatment is recommended if such symptoms develop.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Dopamine Dysregulation Syndrome (DDS) is an addictive disorder resulting in excessive use of the product seen in some patients treated with carbidopa\/levodopa. Before initiation of treatment, patients and caregivers should be warned of the potential risk of developing DDS (see also section 4.8).<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">For patients who experience progressive anorexia, asthenia and weight decrease within a relatively short period of time, a general medical evaluation including liver function should be considered.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Levodopa\/carbidopa may cause false positive result when a dipstick is used to test for urinary ketone and this reaction is not altered by boiling the urine sample. The use of glucose oxidase methods may give false negative results for glycosuria.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Stalevo contains sucrose, and therefore patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:27.0pt;margin-bottom:.0001pt;text-align:left;text-indent:-27.0pt\"><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:27.0pt;margin-bottom:.0001pt;text-indent:-27.0pt\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">4.5    Interaction with other medicinal products and other forms of interaction <\/span><\/b><\/p> <p class=\"Text\" style=\"margin-top:0in\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Other antiparkinsonian medicinal products<\/span><\/i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">: To date there has been no indication of interactions that would preclude concurrent use of standard antiparkinsonian medicinal products with Stalevo therapy. Entacapone in high doses may affect the absorption of carbidopa. However, no interaction with carbidopa has been observed with the recommended treatment schedule (200 mg of entacapone up to 10 times daily). Interactions between entacapone and selegiline have been investigated in repeated dose studies in Parkinson's disease patients treated with levodopa\/DDC inhibitor and no interaction was observed. When used with Stalevo, the daily dose of selegiline should not exceed 10 mg.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><s><span lang=\"EN-GB\" style=\"font-size:11.0pt\"><\/span><\/s><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Caution should be exercised when the following active substances are administered concomitantly with levodopa therapy.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Antihypertensives<\/span><\/i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">: Symptomatic postural hypotension may occur when levodopa is added to the treatment of patients already receiving antihypertensives. Dose adjustment of the antihypertensive agent may be required. <\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Antidepressants: <\/span><\/i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Rarely, reactions including hypertension and dyskinesia have been reported with the concomitant use of tricyclic antidepressants and levodopa\/carbidopa. Interactions between entacapone and imipramine and between entacapone and moclobemide have been investigated in single dose studies in healthy volunteers. No pharmacodynamic interactions were observed. A significant number of Parkinson's disease patients have been treated with the combination of levodopa, carbidopa and entacapone with several active substances including MAO-A inhibitors, tricyclic antidepressants, noradrenaline reuptake inhibitors such as desipramine, maprotiline and venlafaxine and medicinal products that are metabolised by COMT (e.g. catechol-structured compounds, paroxetine). No pharmacodynamic interactions have been observed. However, caution should be exercised when these medicinal products are used concomitantly with Stalevo (see sections 4.3 and 4.4).<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Other active substances: <\/span><\/i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Dopamine receptor antagonists (e.g. some antipsychotics and antiemetics), phenytoin and papaverine may reduce the therapeutic effect of levodopa. Patients taking these medicinal products with Stalevo should be carefully observed for loss of therapeutic response.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Due to entacapone's affinity to cytochrome\r P450 2C9 <i>in vitro<\/i> (see section 5.2), Stalevo may potentially\r interfere with active substances whose metabolism is dependent on this\r isoenzyme, such as S-warfarin. However, in an interaction study with healthy\r volunteers, entacapone did not change the plasma levels of S-warfarin, while\r the AUC for R-warfarin increased on average by 18% [CI<sub>90<\/sub> 11-26%].\r The INR values increased on average by 13% [CI<sub>90<\/sub> 6-19%]. Thus, a\r control of INR is recommended when Stalevo is initiated for patients receiving\r warfarin.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Other forms of interactions:<\/span><\/i><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> Since levodopa competes with certain amino acids, the absorption of Stalevo may be impaired in some patients on high protein diet.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Levodopa and entacapone may form chelates with iron in the gastrointestinal tract. Therefore, Stalevo and iron preparations should be taken at least 2-3 hours apart (see section 4.8).<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">In vitro data:<\/span><\/i><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> Entacapone binds to human albumin binding site II\r which also binds several other medicinal products, including diazepam and\r ibuprofen. According to <i>in vitro<\/i> studies, significant displacement is\r not anticipated at therapeutic concentrations of the medicinal products.\r Accordingly, to date there has been no indication of such interactions.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p class=\"Text\" style=\"margin-top:0in\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">4.6     Fertility, pregnancy and lactation<\/span><\/b><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Pregnancy<\/span><\/u><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">There are no adequate data from the use of the combination of levodopa\/carbidopa\/entacapone in pregnant women. Studies in animals have shown reproductive toxicity of the separate compounds (see section 5.3). The potential risk for humans is unknown. Stalevo should not be used during pregnancy unless the benefits for the mother outweigh the possible risks to the foetus.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Breast-feeding<\/span><\/u><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Levodopa is excreted in human breast milk. There is evidence that breast-feeding is suppressed during treatment with levodopa. Carbidopa and entacapone were excreted in milk in animals but is not known whether they are excreted in human breast milk. The safety of levodopa, carbidopa or entacapone in the infant is not known. Women should not breast-feed during treatment with Stalevo.<\/span><\/p> <p class=\"Text\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Fertility <\/span><\/u><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">No adverse reactions on fertility were observed in preclinical studies with entacapone, carbidopa or levodopa alone. Fertility studies in animals have not been conducted with the combination of entacapone, levodopa and carbidopa.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p class=\"Text\" style=\"margin-top:0in\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">4.7     Effects on ability to drive and use machines<\/span><\/b><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Stalevo may have a major influence on the ability to drive and use machines. Levodopa, carbidopa and entacapone together may cause dizziness and symptomatic orthostatism. Therefore, caution should be exercised when driving or using machines.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Patients being treated with Stalevo and presenting with somnolence and\/or sudden sleep onset episodes must be instructed to refrain from driving or engaging in activities where impaired alertness may put themselves or others at risk of serious injury or death (e.g. operating machines) until such recurrent episodes have resolved (see section 4.4).<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p class=\"Text\" style=\"margin-top:0in\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">4.8     Undesirable effects<\/span><\/b><\/p> <p class=\"Text\" style=\"margin-top:0in\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:0in;text-indent:0in;line-height:normal\"><b><span lang=\"EN-GB\">a.<\/span><\/b><b><span lang=\"EN-GB\">Summary of the safety profile<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"text-align:justify\"><\/p> <p class=\"MsoNormal\" style=\"text-align:justify\"><span lang=\"EN-GB\">The most frequently reported adverse reactions with Stalevo are dyskinesias occurring in approximately 19% of patients; gastrointestinal symptoms including nausea and diarrhoea occurring in approximately 15% and 12% of patients, respectively; muscle, musculoskeletal and connective tissue pain occurring in approximately 12% of patients; and harmless reddish-brown discolouration of urine (chromaturia) occurring in approximately 10% of patients. Serious events of gastrointestinal haemorrhage (uncommon) and angioedema (rare) have been identified from the clinical trials with Stalevo or entacapone combined with levodopa\/DDC inhibitor. Serious hepatitis with mainly cholestatic features, rhabdomyolysis and neuroleptic malignant syndrome may occur with Stalevo although no cases have been identified from the clinical trial data. <\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:0in;text-indent:0in;line-height:normal\"><b><span lang=\"EN-GB\">b.<\/span><\/b><b><span lang=\"EN-GB\">Tabulated list of adverse reactions<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">The following adverse reactions, listed in Table 1, have been accumulated both from a pooled data of eleven double-blind clinical trials consisting of 3230 patients (1810 treated with Stalevo or entacapone combined with levodopa\/DDC inhibitor, and 1420 treated with placebo combined with levodopa\/DDC inhibitor or cabergoline combined with levodopa\/ DDC inhibitor), and from the post-marketing data since the introduction of entacapone into the market for the combination use of entacapone with levodopa\/DDC inhibitor. <\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"text-align:justify\"><span lang=\"EN-GB\">Adverse reactions are ranked under headings of frequency, the most frequent first, using the following convention: Very common (\u22651\/10); common (\u22651\/100 to &lt;1\/10); uncommon (\u22651\/1,000 to &lt;1\/100); rare (\u22651\/10,000 to &lt;1\/1,000), very rare (&lt;1\/10,000), not known (cannot be estimated from the available data, since no valid estimate can be derived from clinical trials or epidemiological studies).<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Table 1.<\/span><\/b><span lang=\"EN-GB\"> Adverse reactions<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Blood and lymphatic system disorders<\/span><\/i><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Common:              Anaemia<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Uncommon:          Thrombocytopenia<\/span><\/p> <p class=\"MsoNormal\"><b><\/b><\/p> <p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Metabolism and nutrition disorders<\/span><\/i><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Common:              Weight decreased*, decreased appetite*<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><i><span lang=\"FR\">Psychiatric disorders<\/span><\/i><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:85.05pt;text-indent:-85.05pt\"><span lang=\"FR\">Common:              Depression, hallucination, confusional state*, abnormal dreams*, anxiety, insomnia<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:85.05pt;text-indent:-85.05pt\"><span lang=\"FR\">Uncommon:          P<\/span><span lang=\"EN-GB\">sychosis,<\/span><span lang=\"FR\"> agitation* <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:85.05pt;text-indent:-85.05pt\"><span lang=\"EN-GB\">Not known:           Suicidal behaviour, Dopamine dysregulation syndrome<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Nervous system disorders<\/span><\/i><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:85.05pt;text-indent:-85.05pt\"><span lang=\"EN-GB\">Very common:      Dyskinesia*<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:85.05pt;text-indent:-85.05pt\"><span lang=\"EN-GB\">Common:              Parkinsonism aggravated (e.g. bradykinesia)*, tremor, on and off phenomenon, dystonia, mental impairment (e.g. memory impairment, dementia), somnolence, dizziness*, headache<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:85.05pt;text-indent:-85.05pt\"><span lang=\"EN-GB\">Not known:           Neuroleptic malignant syndrome*<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:85.05pt;text-indent:-85.05pt\"><b><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:85.05pt;text-indent:-85.05pt\"><b><i><span lang=\"EN-GB\">Eye disorders<\/span><\/i><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:85.05pt;text-indent:-85.05pt\"><span lang=\"EN-GB\">Common:              Blurred vision<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:85.05pt;text-indent:-85.05pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:85.05pt;text-indent:-85.05pt\"><b><i><span lang=\"EN-GB\">Cardiac disorders<\/span><\/i><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:85.05pt;text-indent:-85.05pt\"><span lang=\"EN-GB\">Common:              Ischemic heart disease events other than myocardial infarction (e.g. angina pectoris)**, irregular heart rhythm <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:85.05pt;text-indent:-85.05pt\"><span lang=\"EN-GB\">Uncommon:          Myocardial infarction**<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Vascular disorders<\/span><\/i><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Common:              Orthostatic hypotension, hypertension<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Uncommon:          Gastrointestinal haemorrhage<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Respiratory, thoracic and mediastinal disorders<\/span><\/i><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Common:              Dyspnoea<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Gastrointestinal disorders<\/span><\/i><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Very common:      Diarrhoea*, nausea*<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:85.05pt;text-indent:-85.05pt\"><span lang=\"EN-GB\">Common:              Constipation*, vomiting*, dyspepsia, abdominal pain and discomfort*, dry mouth*<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:85.05pt;text-indent:-85.05pt\"><span lang=\"EN-GB\">Uncommon:          Colitis*, dysphagia<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Hepatobiliary disorders<\/span><\/i><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Uncommon:          Hepatic function test abnormal*<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Not known:           Hepatitis with mainly cholestatic features (see section 4.4)*<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Skin and subcutaneous tissue disorders<\/span><\/i><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Common:              Rash*, hyperhidrosis<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Uncommon:          Discolourations other than urine (e.g. skin, nail, hair, sweat)*<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Rare:                    Angioedema<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Not known:           Urticaria*<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Musculoskeletal and connective tissue disorders<\/span><\/i><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Very common:      Muscle, musculoskeletal and connective tissue pain*<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Common:              Muscle spasms, arthralgia<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Not known:           Rhabdomyolysis*<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Renal and urinary disorders<\/span><\/i><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Very common:      Chromaturia*<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Common:              Urinary tract infection<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Uncommon:          Urinary retention<\/span><\/p> <p class=\"MsoNormal\"><b><\/b><\/p> <p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">General disorders and administration site conditions<\/span><\/i><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:85.05pt;text-indent:-85.05pt\"><span lang=\"EN-GB\">Common:              Chest pain, peripheral oedema, fall, gait disturbance, asthenia, fatigue<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:85.05pt;text-indent:-85.05pt\"><span lang=\"EN-GB\">Uncommon:          Malaise<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"text-align:justify\"><span lang=\"EN-GB\">*Adverse reactions that are mainly attributable to entacapone or are more frequent (by the frequency difference of at least 1% in the clinical trial data) with entacapone than levodopa\/DDC inhibitor alone. See section c.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"text-align:justify\"><span lang=\"EN-GB\">**The incidence rates of myocardial infarction and other ischemic heart disease events (0.43% and 1.54%, respectively) are derived from an analysis of 13 double-blind studies involving 2082 patients with end-of-dose motor fluctuations receiving entacapone<\/span><span lang=\"EN\">.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:0in;text-indent:0in;line-height:normal\"><b><span lang=\"EN-GB\">c.<\/span><\/b><b><span lang=\"EN-GB\">Description of selected adverse reactions<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"text-align:justify\"><\/p> <p class=\"MsoNormal\" style=\"text-align:justify\"><span lang=\"EN-GB\">Adverse reactions that are mainly attributable to entacapone or are more frequent with entacapone than levodopa\/DDC inhibitor alone are indicated with an asterisk in Table 1, section 4.8b. Some of these adverse reactions relate to the increased dopaminergic activity (e.g. dyskinesia, nausea and vomiting) and occur most commonly at the beginning of the treatment. Reduction of levodopa dose decreases the severity and frequency of these dopaminergic reactions. Few adverse reactions are known to be directly attributable to the active substance entacapone including diarrhoea and reddish-brown discolouration of urine. Entacapone may in some cases cause also discolouration of e.g. skin, nail, hair and sweat. Other adverse reactions with an asterisk in Table 1, section 4.8b are marked based on either their more frequent occurring (by the frequency difference of at least 1%) in the clinical trial data with entacapone than levodopa\/DDCI alone or the individual case safety reports received after the introduction of entacapone into the market.<\/span><\/p> <p class=\"MsoNormal\" style=\"text-align:justify\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Convulsions have occurred rarely with levodopa\/carbidopa; however a causal relationship to levodopa\/carbidopa therapy has not been established.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Impulse control disorders: Pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists and\/or other dopaminergic treatments containing levodopa including Stalevo (see section 4.4).<\/span><\/p> <p class=\"Text\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Dopamine Dysregulation Syndrome (DDS) is an addictive disorder seen in some patients treated with carbidopa\/levodopa. Affected patients show a compulsive pattern of dopaminergic drug misuse above<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">doses adequate to control motor symptoms, which may in some cases result in severe dyskinesias (see also section 4.4).<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p class=\"MsoNormal\" style=\"text-align:justify\"><span lang=\"EN-GB\">Entacapone in association with levodopa has been associated with isolated cases of excessive daytime somnolence and sudden sleep onset episodes.<\/span><\/p> <p class=\"MsoNormal\" style=\"text-align:justify\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"text-align:justify\"><u><span lang=\"EN-GB\">Reporting of suspected adverse reactions<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"text-align:justify\"><span lang=\"EN-GB\">Reporting suspected\r adverse reactions after authorisation of the medicinal product is important. It\r allows continued monitoring of the benefit\/risk balance of the medicinal\r product. Healthcare professionals are asked to report any suspected adverse\r reactions via <span style=\"background:silver\">the national reporting system\r listed in <a href=\"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Template_or_form\/2013\/03\/WC500139752.doc\">Appendix\r V<\/a><\/span>.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p class=\"Text\" style=\"margin-top:0in\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">4.9     Overdose<\/span><\/b><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">The post-marketing data includes isolated cases of overdose in which the reported highest daily doses of levodopa and entacapone have been at least 10,000 mg and 40,000 mg, respectively. The acute symptoms and signs in these cases of overdose included agitation, confusional state, coma, bradycardia, ventricular tachycardia, Cheyne-Stokes respiration, discolourations of skin, tongue and conjunctiva, and chromaturia. Management of acute overdose with Stalevo therapy is similar to acute overdose with levodopa. Pyridoxine, however, is not effective in reversing the actions of Stalevo. Hospitalisation is advised and general supportive measures should be employed with immediate gastric lavage and repeated doses of charcoal over time. This may hasten the elimination of entacapone in particular by decreasing its absorption\/reabsorption from the GI tract. The adequacy of the respiratory, circulatory and renal systems should be carefully monitored and appropriate supportive measures employed. ECG monitoring should be started and the patient carefully monitored for the possible development of arrhythmias. If required, appropriate anti-arrhythmic therapy should be given. The possibility that the patient has taken other active substances in addition to Stalevo should be taken into consideration. The value of dialysis in the treatment of overdose is not known.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:27.0pt;margin-bottom:.0001pt;text-indent:-27.0pt\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">5.      PHARMACOLOGICAL PROPERTIES<\/span><\/b><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:27.0pt;margin-bottom:.0001pt;text-indent:-27.0pt\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">5.1     Pharmacodynamic properties<\/span><\/b><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:27.0pt;margin-bottom:.0001pt;text-indent:-27.0pt\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Pharmacotherapeutic group: anti-parkinson\r drugs, dopa and dopa derivatives, ATC code:N04BA03<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">According to the current understanding, the symptoms of Parkinson\u2019s disease are related to depletion of dopamine in the corpus striatum. Dopamine does not cross the blood-brain barrier. Levodopa, the precursor of dopamine, crosses the blood brain barrier and relieves the symptoms of the disease. As levodopa is extensively metabolised in the periphery, only a small portion of a given dose reaches the central nervous system when levodopa is administered without metabolic enzyme inhibitors. <\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Carbidopa and benserazide are peripheral DDC inhibitors which reduce the peripheral metabolism of levodopa to dopamine, and thus, more levodopa is available to the brain. When decarboxylation of levodopa is reduced with the co-administration of a DDC inhibitor, a lower dose of levodopa can be used and the incidence of adverse reactions such as nausea is reduced. <\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;background:white\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:black\">With inhibition of the\r decarboxylase by a DDC inhibitor, catechol-<i>O<\/i>-methyltransferase (COMT)\r becomes the major peripheral metabolic pathway catalyzing the conversion of\r levodopa to 3-O-methyldopa (3-OMD), a potentially harmful metabolite of\r levodopa. Entacapone is a reversible, specific and mainly peripherally acting COMT\r inhibitor designed for concomitant administration with levodopa. Entacapone\r slows the clearance of levodopa from the bloodstream resulting in an increased\r area under the curve (AUC) in the pharmacokinetic profile of levodopa.\r Consequently the clinical response to each dose of levodopa is enhanced and\r prolonged.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;background:white\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">The evidence of the therapeutic effects of\r Stalevo is based on two phase III double-blind studies, in which 376\r Parkinson\u2019s disease patients with end-of-dose motor fluctuations received\r either entacapone or placebo with each levodopa\/DDC inhibitor dose. Daily ON\r time with and without entacapone was recorded in home-diaries by patients. In\r the first study, entacapone increased the mean daily ON time by\r 1 h 20 min (CI <sub>95%<\/sub> 45 min,\r 1 h 56 min) from baseline. This corresponded to an 8.3% increase\r in the proportion of daily ON time. Correspondingly, the decrease in daily OFF\r time was 24% in the entacapone group and 0% in the placebo group. In the second\r study, the mean proportion of daily ON time increased by 4.5% (CI<sub>95%<\/sub>\r 0.93%, 7.97%) from baseline. This is translated to a mean increase of\r 35 min in the daily ON time. Correspondingly, the daily OFF time decreased\r by 18% on entacapone and by 5% on placebo. Because the effects of Stalevo\r tablets are equivalent with entacapone 200 mg tablet administered\r concomitantly with the commercially available standard release\r carbidopa\/levodopa preparations in corresponding doses these results are applicable\r to describe the effects of Stalevo as well.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:27.0pt;margin-bottom:.0001pt;text-indent:-27.0pt\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">5.2    Pharmacokinetic properties<\/span><\/b><\/p> <p class=\"Text\" style=\"margin-top:0in\"><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:27.0pt;margin-bottom:.0001pt;text-indent:-27.0pt\"><i><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">General characteristics of the active substances<\/span><\/u><\/i><\/p> <p class=\"Text\" style=\"margin-top:0in\"><b><\/b><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><i><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Absorption\/distribution<\/span><\/u><\/i><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">:<\/span><\/i><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> There are substantial inter- and intra-individual\r variations in the absorption of levodopa, carbidopa<sup> <\/sup>and entacapone.\r Both levodopa and entacapone are rapidly absorbed and eliminated. Carbidopa is\r absorbed and eliminated slightly slower compared with levodopa. When given\r separately without the two other active substances, the bioavailability for\r levodopa is 15-33%, for carbidopa 40-70% and for entacapone 35% after a\r 200 mg oral dose. Meals rich in large neutral amino acids may delay and\r reduce the absorption of levodopa. Food does not significantly affect the\r absorption of entacapone. The distribution volume of both levodopa (Vd\r 0.36-1.6 l\/kg) and entacapone (Vd<sub>ss<\/sub> 0.27 l\/kg) is\r moderately small while no data for carbidopa are available.<\/span><\/p> <p class=\"MsoNormal\" style=\"text-align:justify\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><span lang=\"EN-GB\">Levodopa is\r bound to plasma protein only to a minor extent of about 10-30% and c<span style=\"layout-grid-mode:line\">arbidopa <\/span>is bound <span style=\"layout-grid-mode:\r line\">approximately 36%<\/span>, <span style=\"layout-grid-mode:line\">while e<\/span>ntacapone\r is extensively bound to plasma proteins (about 98%) \u2013mainly to serum albumin.\r At therapeutic concentrations, entacapone does not displace other extensively\r bound active substances (e.g. warfarin, salicylic acid, phenylbutazone, or\r diazepam), nor is it displaced to any significant extent by any of these\r substances at therapeutic or higher concentrations.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><i><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\"><\/span><\/u><\/i><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><i><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Biotransformation and elimination<\/span><\/u><\/i><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">:<\/span><\/i><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> Levodopa is extensively metabolised to various metabolites: decarboxylation by dopa decarboxylase (DDC) and O-methylation by catechol-O-methyltransferase (COMT) being the most important pathways.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Carbidopa is metabolized to two main metabolites which are excreted in the urine as glucuronides and unconjugated compounds. Unchanged carbidopa accounts for 30% of the total urinary excretion.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Entacapone is almost completely metabolized\r prior to excretion via urine (10 to 20%) and bile\/faeces(80 to 90%).\r The main metabolic pathway is glucuronidation of entacapone and its active\r metabolite, the cis-isomer, which accounts for about 5% of plasma total amount.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><s><span lang=\"EN-GB\" style=\"font-size:11.0pt\"><\/span><\/s><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Total clearance for levodopa is in the\r range of 0.55-1.38 l\/kg\/h and for entacapone is in the range of\r 0.70 l\/kg\/h. The elimination-half life is (t<sub>1\/2<\/sub>) is 0.6-1.3\r hours for levodopa, 2-3 hours for carbidopa and 0.4-0.7 hours for entacapone,\r each given separately.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Due to short elimination half-lives, no true accumulation of levodopa or entacapone occurs on repeated administration.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Data from <i>in vitro<\/i> studies using\r human liver microsomal preparations indicate that entacapone inhibits\r cytochrome P450 2C9 (IC50 ~ 4 \u00b5M). Entacapone showed little or no\r inhibition of other types of P450 isoenzymes (CYP1A2, CYP2A6, CYP2D6, CYP2E1,\r CYP3A and CYP2C19); see section 4.5.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p class=\"Text\" style=\"margin-top:0in\"><i><u><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">Characteristics in patients<\/span><\/u><\/i><\/p> <p class=\"Text\" style=\"margin-top:0in\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><i><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Elderly<\/span><\/u><\/i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">: When given without carbidopa and entacapone, the absorption of levodopa is greater and elimination is slower in elderly than in young people. However, after combination of carbidopa with levodopa, the absorption of levodopa is similar between the elderly and the young people, but the AUC is still 1.5 fold greater in the elderly due to decreased DDC activity and lower clearance by aging. There are no significant differences in the AUC of carbidopa or entacapone between younger (45\u201364 years) and elderly (65\u201375 years).<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><i><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Gender<\/span><\/u><\/i><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">: <\/span><\/i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Bioavailability\r of levodopa is significantly higher in women than in men. In the\r pharmacokinetic studies with Stalevo<sup> <\/sup>the bioavailability of levodopa\r is higher in women than in men, primarily due to the difference in body weight,\r while there is no gender difference with carbidopa and entacapone.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><i><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Hepatic impairment<\/span><\/u><\/i><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">: <\/span><\/i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">The metabolism of entacapone is slowed in patients\r with mild to moderate hepatic impairment (Child-Pugh Class A and B) leading to\r an increased plasma concentration of entacapone both in the absorption and\r elimination phases (see sections 4.2 and 4.3). No particular studies on the\r pharmacokinetics of carbidopa and levodopa in patients with hepatic impairment\r are reported, however, it is advised that Stalevo<sup> <\/sup>should be\r administered cautiously to patients with mild or moderate hepatic impairment. <\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><i><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Renal impairment<\/span><\/u><\/i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">: Renal impairment does not affect the pharmacokinetics of entacapone. No particular studies are reported on the pharmacokinetics of levodopa and carbidopa in patients with renal impairment. However, a longer dosing interval of Stalevo may be considered for patients who are receiving dialysis therapy (see section 4.2).<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:27.0pt;margin-bottom:.0001pt;text-indent:-27.0pt\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">5.3    Preclinical safety data<\/span><\/b><\/p> <p class=\"Text\" style=\"margin-top:0in\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Preclinical data of levodopa, carbidopa and entacapone, tested alone or in combination, revealed no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, and carcinogenic potential. In repeated dose toxicity studies with entacapone, anaemia most likely due to iron chelating properties of entacapone was observed. Regarding reproduction toxicity of entacapone, decreased foetal weight and a slightly delayed bone development were noticed in rabbits treated at systemic exposure levels in the therapeutic range. Both levodopa and combinations of carbidopa and levodopa have caused visceral and skeletal malformations in rabbits. <\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt\"><b><span lang=\"EN-GB\">6.      PHARMACEUTICAL PARTICULARS<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt\"><b><span lang=\"EN-GB\">6.1    List of excipients<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Tablet core<\/span><\/u><span lang=\"EN-GB\">:<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Croscarmellose sodium<br\/>\r Magnesium stearate<br\/>\r Maize starch<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Mannitol (E421)<br\/>\r Povidone K 30 (E1201) <\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"IT\">Film-coating of <\/span><\/u><u><span lang=\"EN-GB\">50\/12.5\/200 mg, 100\/25\/200 mg and 150<\/span><span lang=\"EN-GB\">\/37.5\/200 mg<\/span><\/u><span lang=\"IT\">:<\/span><\/p> <p align=\"left\" class=\"MsoBodyText3\" style=\"text-align:left\"><span lang=\"IT\" style=\"font-weight:normal;font-style:normal\">Glycerol (85 per cent) (E422)<\/span><\/p> <p align=\"left\" class=\"MsoBodyText3\" style=\"text-align:left\"><span lang=\"IT\" style=\"font-weight:normal;font-style:normal\">Hypromellose<\/span><\/p> <p align=\"left\" class=\"MsoBodyText3\" style=\"text-align:left\"><span lang=\"IT\" style=\"font-weight:normal;font-style:normal\">Magnesium stearate<\/span><\/p> <p align=\"left\" class=\"MsoBodyText3\" style=\"text-align:left\"><span lang=\"IT\" style=\"font-weight:normal;font-style:normal\">Polysorbate 80<\/span><\/p> <p align=\"left\" class=\"MsoBodyText3\" style=\"text-align:left\"><span lang=\"IT\" style=\"font-weight:normal;font-style:normal\">Red iron oxide (E172)<\/span><\/p> <p align=\"left\" class=\"MsoBodyText3\" style=\"text-align:left\"><span lang=\"IT\" style=\"font-weight:normal;font-style:normal\">Sucrose<\/span><\/p> <p align=\"left\" class=\"MsoBodyText3\" style=\"text-align:left\"><span lang=\"IT\" style=\"font-weight:normal;font-style:normal\">Titanium dioxide (E171)<\/span><\/p> <p align=\"left\" class=\"MsoBodyText3\" style=\"text-align:left\"><span lang=\"IT\" style=\"font-weight:normal;font-style:normal\">Yellow iron oxide (E172)<\/span><\/p> <p align=\"left\" class=\"MsoBodyText3\" style=\"text-align:left\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Film-coating of 75\/18.75\/200 mg, 125\/31.25\/200 mg, 175\/43.75\/200 mg and 200\/50\/200 mg<\/span><\/u><span lang=\"EN-GB\">:<\/span><\/p> <p align=\"left\" class=\"MsoBodyText3\" style=\"text-align:left\"><span lang=\"IT\" style=\"font-weight:normal;font-style:normal\">Glycerol (85 per cent) (E422)<\/span><\/p> <p align=\"left\" class=\"MsoBodyText3\" style=\"text-align:left\"><span lang=\"IT\" style=\"font-weight:normal;font-style:normal\">Hypromellose<\/span><\/p> <p align=\"left\" class=\"MsoBodyText3\" style=\"text-align:left\"><span lang=\"IT\" style=\"font-weight:normal;font-style:normal\">Magnesium stearate<\/span><\/p> <p align=\"left\" class=\"MsoBodyText3\" style=\"text-align:left\"><span lang=\"IT\" style=\"font-weight:normal;font-style:normal\">Polysorbate 80<\/span><\/p> <p align=\"left\" class=\"MsoBodyText3\" style=\"text-align:left\"><span lang=\"IT\" style=\"font-weight:normal;font-style:normal\">Red iron oxide (E172)<\/span><\/p> <p align=\"left\" class=\"MsoBodyText3\" style=\"text-align:left\"><span lang=\"IT\" style=\"font-weight:normal;font-style:normal\">Sucrose<\/span><\/p> <p align=\"left\" class=\"MsoBodyText3\" style=\"text-align:left\"><span lang=\"IT\" style=\"font-weight:normal;font-style:normal\">Titanium dioxide (E171)<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt\"><b><span lang=\"EN-GB\">6.2    Incompatibilities<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Not applicable.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt\"><b><span lang=\"EN-GB\">6.3    Shelf life<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">3 years.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt\"><b><span lang=\"EN-GB\">6.4    Special precautions for storage<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">This medicinal product does not require any special storage conditions.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt\"><b><span lang=\"EN-GB\">6.5    Nature and contents of container<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">HDPE bottle with a child resistant PP-closure.<\/span><\/p> <p class=\"MsoEndnoteText\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Pack sizes of 50\/12.5\/200 mg, 100\/25\/200 mg and 150<\/span><span lang=\"EN-GB\">\/37.5\/200 mg<\/span><span lang=\"EN-GB\">:<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">10, 30, 100, 130, 175 and 250 tablets.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Pack sizes of 75\/18.75\/200 mg, 125\/31.25\/200 mg, 175\/43.75\/200 mg and 200\/50\/200 mg:<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">10, 30, 100, 130 and 175 tablets.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Not all pack sizes may be marketed.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt\"><b><span lang=\"EN-GB\">6.6    Special precautions for disposal<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Any unused medicinal product or waste material should be disposed of in accordance with local requirements.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt\"><b><span lang=\"EN-GB\">7.<\/span><\/b><b><span lang=\"EN-GB\">MARKETING AUTHORISATION HOLDER<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Orion Corporation<\/span><\/p> <p class=\"Figure\" style=\"margin-top:0in;page-break-after:auto\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Orionintie 1<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">FI-02200 Espoo<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Finland<\/span><\/p> <p class=\"MsoEndnoteText\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt\"><b><span lang=\"EN-GB\">8.      MARKETING AUTHORISATION NUMBERS <\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">50 mg\/12.5 mg\/200 mg<\/span><\/u><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">EU\/1\/03\/260\/001-004<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">EU\/1\/03\/260\/013<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">EU\/1\/03\/260\/016<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">75 mg\/18.75 mg\/200 mg<\/span><\/u><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">EU\/1\/03\/260\/024-028<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">100 mg\/25 mg\/200 mg<\/span><\/u><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">EU\/1\/03\/260\/005-008<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">EU\/1\/03\/260\/014<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">EU\/1\/03\/260\/017<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">125 mg\/31.25 mg\/200 mg<\/span><\/u><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">EU\/1\/03\/260\/029-033<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">150 mg\/37.5 mg\/200 mg<\/span><\/u><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">EU\/1\/03\/260\/009-012<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">EU\/1\/03\/260\/015<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">EU\/1\/03\/260\/018<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">175 mg\/43.75 mg\/200 mg<\/span><\/u><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">EU\/1\/03\/260\/034-038<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">200 mg\/50 mg\/200 mg<\/span><\/u><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">EU\/1\/03\/260\/019-023<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt\"><b><span lang=\"EN-GB\">9.      DATE OF FIRST AUTHORISATION\/RENEWAL OF THE AUTHORISATION<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Date of first authorisation: 17 October 2003<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Date of latest renewal: 17 October 2008<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt\"><b><span lang=\"EN-GB\">10.    DATE OF REVISION OF THE TEXT<\/span><\/b><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Detailed information on this medicinal\r product is available on the website of European Medicines Agency <a href=\"http:\/\/www.ema.europa.eu\">http:\/\/www.ema.europa.eu<\/a>.<\/span><\/p> <b><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:27.0pt;margin-bottom:.0001pt;text-align:left;text-indent:-27.0pt\"> <\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:28.35pt;text-align:center;\r text-indent:-28.35pt\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:28.35pt;text-align:center;\r text-indent:-28.35pt\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:28.35pt;text-align:center;\r text-indent:-28.35pt\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:28.35pt;text-align:center;\r text-indent:-28.35pt\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:28.35pt;text-align:center;\r text-indent:-28.35pt\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:28.35pt;text-align:center;\r text-indent:-28.35pt\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:28.35pt;text-align:center;\r text-indent:-28.35pt\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:28.35pt;text-align:center;\r text-indent:-28.35pt\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:28.35pt;text-align:center;\r text-indent:-28.35pt\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:28.35pt;text-align:center;\r text-indent:-28.35pt\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:28.35pt;text-align:center;\r text-indent:-28.35pt\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:28.35pt;text-align:center;\r text-indent:-28.35pt\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:28.35pt;text-align:center;\r text-indent:-28.35pt\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:28.35pt;text-align:center;\r text-indent:-28.35pt\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:28.35pt;text-align:center;\r text-indent:-28.35pt\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:28.35pt;text-align:center;\r text-indent:-28.35pt\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:28.35pt;text-align:center;\r text-indent:-28.35pt\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:28.35pt;text-align:center;\r text-indent:-28.35pt\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:28.35pt;text-align:center;\r text-indent:-28.35pt\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:28.35pt;text-align:center;\r text-indent:-28.35pt\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:28.35pt;text-align:center;\r text-indent:-28.35pt\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:28.35pt;text-align:center;\r text-indent:-28.35pt\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:28.35pt;text-align:center;\r text-indent:-28.35pt\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:28.35pt;text-align:center;\r text-indent:-28.35pt\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">ANNEX II<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.8pt;margin-bottom:\r 0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.8pt;margin-bottom:\r 0in;margin-left:74.7pt;margin-bottom:.0001pt;text-indent:-.25in\"><b><span lang=\"EN-GB\">A.<\/span><\/b><b><span lang=\"EN-GB\">MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:74.7pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.8pt;margin-bottom:\r 0in;margin-left:74.7pt;margin-bottom:.0001pt;text-indent:-.25in\"><b><span lang=\"EN-GB\">B.<\/span><\/b><b><span lang=\"EN-GB\">CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:74.7pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:77.9pt;margin-bottom:\r 0in;margin-left:74.7pt;margin-bottom:.0001pt;text-indent:-.25in\"><b><span lang=\"EN-GB\">C.<\/span><\/b><b><span lang=\"EN-GB\">OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.05pt;margin-bottom:\r 0in;margin-left:74.7pt;margin-bottom:.0001pt\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"margin-left:74.7pt;text-indent:-.25in\"><b><span lang=\"EN-GB\">D.<\/span><\/b><b><span lang=\"EN-GB\">CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.8pt;margin-bottom:\r 0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><\/p> <b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b> <h1 align=\"left\" style=\"text-align:left\"><span lang=\"EN-GB\">A       MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE<\/span><\/h1> <p class=\"MsoNormal\" style=\"margin-right:70.8pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\">Name and address of the manufacturers responsible for batch release<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Orion Corporation Orion Pharma<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Joensuunkatu 7<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">FI-24100 Salo<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Finland<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"IT\">Orion Corporation <\/span><span lang=\"EN-GB\">Orion Pharma<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"IT\">Orionintie 1<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"IT\">FI-02200 Espoo<\/span><\/p> <p class=\"MsoEndnoteText\"><span lang=\"IT\">Finland<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"IT\">The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <h1 align=\"left\" style=\"text-align:left\"><span lang=\"EN-GB\">B       CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE<\/span><\/h1> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal\"><\/p> <p class=\"MsoEndnoteText\"><span lang=\"EN-GB\">Medicinal product subject to medical prescription.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <h1 align=\"left\" style=\"margin-left:28.35pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\">C       OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION <\/span><\/h1> <p class=\"MsoNormal\" style=\"margin-right:28.35pt;text-align:justify;line-height:\r normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:28.35pt;margin-bottom:\r 0in;margin-left:0in;margin-bottom:.0001pt;text-indent:0in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<\/span><b><span lang=\"EN-GB\">Periodic safety update reports (PSURs)<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:28.35pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:28.35pt\"><span lang=\"EN-GB\">The requirements for submission of PSURs for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001\/83\/EC and any subsequent updates published on the European medicines web portal.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:28.35pt;text-align:justify;line-height:\r normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:28.35pt;text-align:justify;line-height:\r normal\"><\/p> <h1 align=\"left\" style=\"margin-left:28.35pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\">D.      CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT <\/span><\/h1> <p class=\"MsoNormal\" style=\"margin-right:28.35pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:28.35pt;margin-bottom:\r 0in;margin-left:0in;margin-bottom:.0001pt;text-indent:0in;line-height:normal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<\/span><b><span lang=\"EN-GB\">Risk management plan (RMP)<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:28.35pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:28.35pt;line-height:normal\"><span lang=\"EN-GB\">Not applicable.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:28.35pt;text-align:justify;line-height:\r normal\"><\/p> <b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:28.35pt;text-align:center;\r text-indent:-28.35pt\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:28.35pt;text-align:center;\r text-indent:-28.35pt\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:28.35pt;text-align:center;\r text-indent:-28.35pt\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:28.35pt;text-align:center;\r text-indent:-28.35pt\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:28.35pt;text-align:center;\r text-indent:-28.35pt\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:28.35pt;text-align:center;\r text-indent:-28.35pt\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:28.35pt;text-align:center;\r text-indent:-28.35pt\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:28.35pt;text-align:center;\r text-indent:-28.35pt\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:28.35pt;text-align:center;\r text-indent:-28.35pt\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:28.35pt;text-align:center;\r text-indent:-28.35pt\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:28.35pt;text-align:center;\r text-indent:-28.35pt\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:28.35pt;text-align:center;\r text-indent:-28.35pt\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:28.35pt;text-align:center;\r text-indent:-28.35pt\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:28.35pt;text-align:center;\r text-indent:-28.35pt\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:28.35pt;text-align:center;\r text-indent:-28.35pt\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:28.35pt;text-align:center;\r text-indent:-28.35pt\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:28.35pt;text-align:center;\r text-indent:-28.35pt\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:28.35pt;text-align:center;\r text-indent:-28.35pt\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:28.35pt;text-align:center;\r text-indent:-28.35pt\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:28.35pt;text-align:center;\r text-indent:-28.35pt\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:28.35pt;text-align:center;\r text-indent:-28.35pt\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:28.35pt;text-align:center;\r text-indent:-28.35pt\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:28.35pt;text-align:center;\r text-indent:-28.35pt\"><b><span lang=\"EN-GB\">ANNEX III<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:28.35pt;text-align:center;\r text-indent:-28.35pt\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:28.35pt;text-align:center;\r text-indent:-28.35pt\"><b><span lang=\"EN-GB\">LABELLING AND PACKAGE LEAFLET<\/span><\/b><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:28.3pt\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <h1><span lang=\"EN-GB\">A. LABELLING<\/span><\/h1> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr style=\"height:52.0pt\"> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:52.0pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">PARTICULARS TO APPEAR ON THE OUTER   PACKAGING AND THE IMMEDIATE PACKAGING<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">BOTTLE LABEL AND OUTER CARTON TEXT<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">1.       NAME OF THE MEDICINAL PRODUCT<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Stalevo 50 mg\/12.5 mg\/200 mg film-coated tablets <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">levodopa\/carbidopa\/entacapone<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">2.       STATEMENT OF ACTIVE SUBSTANCE(S)<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Each film-coated tablet contains 50 mg of levodopa, 12.5 mg of carbidopa and 200 mg of entacapone.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">3.       LIST OF EXCIPIENTS<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Contains sucrose. <\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">4.       PHARMACEUTICAL FORM AND CONTENTS<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><i><span lang=\"EN-GB\" style=\"background:silver\">Carton<\/span><\/i><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">10 film-coated tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">30 film-coated tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">100 film-coated tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">130 film-coated tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">175 film-coated tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">250 film-coated tablets<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><i><span lang=\"EN-GB\" style=\"background:silver\">Label<\/span><\/i><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">10 tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">30 tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">100 tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">130 tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">175 tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">250 tablets<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">5.       METHOD AND ROUTE(S) OF ADMINISTRATION<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Read the package leaflet before use.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Oral use.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">6.       SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED   OUT OF THE SIGHT AND REACH OF CHILDREN<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Keep out of the sight and reach of children.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">7.       OTHER SPECIAL WARNING(S), IF NECESSARY<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">8.       EXPIRY DATE<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">EXP<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">9.       SPECIAL STORAGE CONDITIONS<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">10.     SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL   PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF   APPROPRIATE<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">11.     NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><i><span lang=\"EN-GB\" style=\"background:silver\">Carton<\/span><\/i><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Orion Corporation<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Orionintie 1<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">FI-02200 Espoo<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Finland<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><i><span lang=\"IT\" style=\"background:silver\">Label<\/span><\/i><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Orion Corporation<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">12.     MARKETING AUTHORISATION NUMBER(S)<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">EU\/1\/03\/260\/001 \r <span style=\"color:black;background:silver\">10 film-coated tablets<\/span><\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"background:silver\">EU\/1\/03\/260\/002  <span style=\"color:black\">30 film-coated tablets<\/span><\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"background:silver\">EU\/1\/03\/260\/003  <span style=\"color:black\">100 film-coated tablets<\/span><\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"background:silver\">EU\/1\/03\/260\/004  <span style=\"color:black\">250 film-coated tablets<\/span><\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"background:silver\">EU\/1\/03\/260\/013  175<span style=\"color:black\"> film-coated tablets<\/span><\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">EU\/1\/03\/260\/016  130 film-coated tablets<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">13.     BATCH NUMBER<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Batch<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">14.     GENERAL CLASSIFICATION FOR SUPPLY<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">15.     INSTRUCTIONS ON USE<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">16.     INFORMATION IN BRAILLE<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">stalevo 50\/12.5\/200 mg <i><span style=\"background:silver\">[carton only]<\/span><\/i><\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><u><span lang=\"EN-GB\" style=\"color:black\"><\/span><\/u><\/b><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">17.     UNIQUE IDENTIFIER \u2013 2D BARCODE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black;background:silver\">2D barcode carrying the unique identifier included<\/span><span lang=\"EN-GB\" style=\"color:black\"> <i><span style=\"background:#D9D9D9\">[carton only]<\/span><\/i><\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">18.     UNIQUE IDENTIFIER - HUMAN READABLE DATA<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><i><span lang=\"EN-GB\" style=\"color:black;background:#D9D9D9\">[carton only]:<\/span><\/i><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">PC <span style=\"background:silver\">{number}<\/span> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">SN <span style=\"background:silver\">{number}<\/span> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">&lt;NN <span style=\"background:silver\">{number}<\/span>&gt;<\/span><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr style=\"height:52.0pt\"> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:52.0pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">PARTICULARS TO APPEAR ON THE OUTER   PACKAGING AND THE IMMEDIATE PACKAGING<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">BOTTLE LABEL AND OUTER CARTON TEXT<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">1.       NAME OF THE MEDICINAL PRODUCT<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Stalevo 75 mg\/18.75 mg\/200 mg film-coated tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">levodopa\/carbidopa\/entacapone<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">2.       STATEMENT OF ACTIVE SUBSTANCE(S)<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Each film-coated tablet contains 75 mg of levodopa, 18.75 mg of carbidopa and 200 mg of entacapone.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">3.       LIST OF EXCIPIENTS<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Contains sucrose. <\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">4.       PHARMACEUTICAL FORM AND CONTENTS<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><i><span lang=\"EN-GB\" style=\"background:silver\">Carton<\/span><\/i><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">10 film-coated tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">30 film-coated tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">100 film-coated tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">130 film-coated tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">175 film-coated tablets<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><i><span lang=\"EN-GB\" style=\"background:silver\">Label<\/span><\/i><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">10 tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">30 tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">100 tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">130 tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">175 tablets<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">5.       METHOD AND ROUTE(S) OF ADMINISTRATION<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Read the package leaflet before use.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Oral use.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">6.       SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED   OUT OF THE SIGHT AND REACH OF CHILDREN<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Keep out of the sight and reach of children.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">7.       OTHER SPECIAL WARNING(S), IF NECESSARY<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">8.       EXPIRY DATE<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">EXP<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">9.       SPECIAL STORAGE CONDITIONS<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">10.     SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL   PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF   APPROPRIATE<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">11.     NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><i><span lang=\"IT\" style=\"background:silver\">Carton<\/span><\/i><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Orion Corporation<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Orionintie 1<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">FI-02200 Espoo<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Finland<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><i><span lang=\"IT\" style=\"background:silver\">Label<\/span><\/i><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Orion Corporation<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">12.     MARKETING AUTHORISATION NUMBER(S)<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">EU\/1\/03\/260\/024 \r <span style=\"color:black;background:silver\">10 film-coated tablets<\/span><\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"background:silver\">EU\/1\/03\/260\/025  <span style=\"color:black\">30 film-coated tablets<\/span><\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"background:silver\">EU\/1\/03\/260\/026  <span style=\"color:black\">100 film-coated tablets<\/span><\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"background:silver\">EU\/1\/03\/260\/027  <span style=\"color:black\">130 film-coated tablets<\/span><\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"background:silver\">EU\/1\/03\/260\/028  175<span style=\"color:black\"> film-coated tablets<\/span><\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">13.     BATCH NUMBER<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Batch<\/span><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">14.     GENERAL CLASSIFICATION FOR SUPPLY<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">15.     INSTRUCTIONS ON USE<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">16.     INFORMATION IN BRAILLE<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">stalevo 75\/18.75\/200 mg <i><span style=\"background:silver\">[carton only]<\/span><\/i><\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><u><span lang=\"EN-GB\" style=\"color:black\"><\/span><\/u><\/b><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">17.     UNIQUE IDENTIFIER \u2013 2D BARCODE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black;background:silver\">2D barcode carrying the unique identifier included<\/span><span lang=\"EN-GB\" style=\"color:black\"> <i><span style=\"background:#D9D9D9\">[carton only]<\/span><\/i><\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">18.     UNIQUE IDENTIFIER - HUMAN READABLE DATA<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><i><span lang=\"EN-GB\" style=\"color:black;background:#D9D9D9\">[carton only]:<\/span><\/i><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">PC <span style=\"background:silver\">{number}<\/span> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">SN <span style=\"background:silver\">{number}<\/span> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">&lt;NN <span style=\"background:silver\">{number}<\/span>&gt;<\/span><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr style=\"height:52.0pt\"> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:52.0pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">PARTICULARS TO APPEAR ON THE OUTER   PACKAGING AND THE IMMEDIATE PACKAGING<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">BOTTLE LABEL AND OUTER CARTON TEXT<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">1.       NAME OF THE MEDICINAL PRODUCT<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Stalevo 100 mg\/25 mg\/200 mg film-coated tablets <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">levodopa\/carbidopa\/entacapone<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">2.       STATEMENT OF ACTIVE SUBSTANCE(S)<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Each film-coated tablet contains 100 mg of levodopa, 25 mg of carbidopa and 200 mg of entacapone.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">3.       LIST OF EXCIPIENTS<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Contains sucrose.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">4.       PHARMACEUTICAL FORM AND CONTENTS<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><i><span lang=\"EN-GB\" style=\"background:silver\">Carton<\/span><\/i><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">10 film-coated tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">30 film-coated tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">100 film-coated tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">130 film-coated tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">175 film-coated tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">250 film-coated tablets<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><i><span lang=\"EN-GB\" style=\"background:silver\">Label<\/span><\/i><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">10 tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">30 tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">100 tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">130 tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">175 tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">250 tablets<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">5.       METHOD AND ROUTE(S) OF ADMINISTRATION<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Read the package leaflet before use.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Oral use.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">6.       SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED   OUT OF THE SIGHT AND REACH OF CHILDREN<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Keep out of the sight and reach of children.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">7.       OTHER SPECIAL WARNING(S), IF NECESSARY<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">8.       EXPIRY DATE<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">EXP<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">9.       SPECIAL STORAGE CONDITIONS<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">10.     SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL   PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF   APPROPRIATE<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">11.     NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><i><span lang=\"IT\" style=\"background:silver\">Carton<\/span><\/i><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Orion Corporation<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Orionintie 1<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">FI-02200 Espoo<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Finland<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><i><span lang=\"IT\" style=\"background:silver\">Label<\/span><\/i><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Orion Corporation<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">12.     MARKETING AUTHORISATION NUMBER(S)<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">EU\/1\/03\/260\/005 \r <span style=\"color:black;background:silver\">10 film-coated tablets<\/span><\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"background:silver\">EU\/1\/03\/260\/006  <span style=\"color:black\">30 film-coated tablets<\/span><\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"background:silver\">EU\/1\/03\/260\/007  <span style=\"color:black\">100 film-coated tablets<\/span><\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"background:silver\">EU\/1\/03\/260\/008  <span style=\"color:black\">250 film-coated tablets<\/span><\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"background:silver\">EU\/1\/03\/260\/014  175 film-coated tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">EU\/1\/03\/260\/017  130 film-coated tablets<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">13.     BATCH NUMBER<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Batch<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">14.     GENERAL CLASSIFICATION FOR SUPPLY<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">15.     INSTRUCTIONS ON USE<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">16.     INFORMATION IN BRAILLE<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">stalevo 100\/25\/200 mg <i><span style=\"background:silver\">[carton only]<\/span><\/i><\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><u><span lang=\"EN-GB\" style=\"color:black\"><\/span><\/u><\/b><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">17.     UNIQUE IDENTIFIER \u2013 2D BARCODE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black;background:silver\">2D barcode carrying the unique identifier included<\/span><span lang=\"EN-GB\" style=\"color:black\"> <i><span style=\"background:#D9D9D9\">[carton only]<\/span><\/i><\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">18.     UNIQUE IDENTIFIER - HUMAN READABLE DATA<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><i><span lang=\"EN-GB\" style=\"color:black;background:#D9D9D9\">[carton only]:<\/span><\/i><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">PC: <span style=\"background:silver\">{number}<\/span> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">SN <span style=\"background:silver\">{number}<\/span> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">&lt;NN <span style=\"background:silver\">{number}<\/span>&gt;<\/span><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr style=\"height:52.0pt\"> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:52.0pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">PARTICULARS TO APPEAR ON THE OUTER   PACKAGING AND THE IMMEDIATE PACKAGING<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">BOTTLE LABEL AND OUTER CARTON TEXT<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">1.       NAME OF THE MEDICINAL PRODUCT<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Stalevo 125 mg\/31.25 mg\/200 mg film-coated tablets <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">levodopa\/carbidopa\/entacapone<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">2.       STATEMENT OF ACTIVE SUBSTANCE(S)<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Each film-coated tablet contains 125 mg of levodopa, 31.25 mg of carbidopa and 200 mg of entacapone.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">3.       LIST OF EXCIPIENTS<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Contains sucrose.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">4.       PHARMACEUTICAL FORM AND CONTENTS<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><i><span lang=\"EN-GB\" style=\"background:silver\">Carton<\/span><\/i><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">10 film-coated tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">30 film-coated tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">100 film-coated tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">130 film-coated tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">175 film-coated tablets<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><i><span lang=\"EN-GB\" style=\"background:silver\">Label<\/span><\/i><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">10 tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">30 tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">100 tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">130 tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">175 tablets<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">5.       METHOD AND ROUTE(S) OF ADMINISTRATION<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Read the package leaflet before use.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Oral use.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">6.       SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED   OUT OF THE SIGHT AND REACH OF CHILDREN<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Keep out of the sight and reach of children.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">7.       OTHER SPECIAL WARNING(S), IF NECESSARY<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">8.       EXPIRY DATE<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">EXP<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">9.       SPECIAL STORAGE CONDITIONS<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">10.     SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL   PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF   APPROPRIATE<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">11.     NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><i><span lang=\"IT\" style=\"background:silver\">Carton<\/span><\/i><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Orion Corporation<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Orionintie 1<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">FI-02200 Espoo<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Finland<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><i><span lang=\"IT\" style=\"background:silver\">Label<\/span><\/i><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Orion Corporation<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">12.     MARKETING AUTHORISATION NUMBER(S)<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">EU\/1\/03\/260\/029 <span style=\"color:black;background:silver\">10 film-coated tablets<\/span><\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"background:silver\">EU\/1\/03\/260\/030 <span style=\"color:black\">30 film-coated tablets<\/span><\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"background:silver\">EU\/1\/03\/260\/031 <span style=\"color:black\">100 film-coated tablets<\/span><\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"background:silver\">EU\/1\/03\/260\/032 <span style=\"color:black\">130 film-coated tablets<\/span><\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"background:silver\">EU\/1\/03\/260\/033 175<span style=\"color:black\"> film-coated tablets<\/span><\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">13.     BATCH NUMBER<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Batch<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">14.     GENERAL CLASSIFICATION FOR SUPPLY<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">15.     INSTRUCTIONS ON USE<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">16.     INFORMATION IN BRAILLE<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">stalevo 125\/31.25\/200 mg <i><span style=\"background:silver\">[carton only]<\/span><\/i><\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><u><span lang=\"EN-GB\" style=\"color:black\"><\/span><\/u><\/b><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">17.     UNIQUE IDENTIFIER \u2013 2D BARCODE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black;background:silver\">2D barcode carrying the unique identifier included<\/span><span lang=\"EN-GB\" style=\"color:black\"> <i><span style=\"background:#D9D9D9\">[carton only]<\/span><\/i><\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">18.     UNIQUE IDENTIFIER - HUMAN READABLE DATA<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><i><span lang=\"EN-GB\" style=\"color:black;background:#D9D9D9\">[carton only]:<\/span><\/i><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">PC <span style=\"background:silver\">{number}<\/span> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">SN <span style=\"background:silver\">{number}<\/span> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">&lt;NN <span style=\"background:silver\">{number}<\/span>&gt;<\/span><\/p> <p class=\"MsoNormal\"><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr style=\"height:52.0pt\"> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:52.0pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">PARTICULARS TO APPEAR ON THE OUTER   PACKAGING AND THE IMMEDIATE PACKAGING<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">BOTTLE LABEL AND OUTER CARTON TEXT<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">1.       NAME OF THE MEDICINAL PRODUCT<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Stalevo 150 mg\/37.5 mg\/200 mg film-coated tablets <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">levodopa\/carbidopa\/entacapone<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">2.       STATEMENT OF ACTIVE SUBSTANCE(S)<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Each film-coated tablet contains 150 mg of levodopa, 37.5 mg of carbidopa and 200 mg of entacapone.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">3.       LIST OF EXCIPIENTS<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Contains sucrose. <\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">4.       PHARMACEUTICAL FORM AND CONTENTS<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><i><span lang=\"EN-GB\" style=\"background:silver\">Carton<\/span><\/i><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">10 film-coated tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">30 film-coated tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">100 film-coated tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">130 film-coated tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">175 film-coated tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">250 film-coated tablets<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><i><span lang=\"EN-GB\" style=\"background:silver\">Label<\/span><\/i><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">10 tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">30 tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">100 tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">130 tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">175 tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">250 tablets<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">5.       METHOD AND ROUTE(S) OF ADMINISTRATION<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Read the package leaflet before use.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Oral use. <\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">6.       SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED   OUT OF THE SIGHT AND REACH OF CHILDREN<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Keep out of the sight and reach of children.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">7.       OTHER SPECIAL WARNING(S), IF NECESSARY<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">8.       EXPIRY DATE<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">EXP<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">9.       SPECIAL STORAGE CONDITIONS<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">10.     SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL   PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">11.     NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><i><span lang=\"IT\" style=\"background:silver\">Carton<\/span><\/i><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Orion Corporation<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Orionintie 1<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">FI-02200 Espoo<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Finland<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><i><span lang=\"IT\" style=\"background:silver\">Label<\/span><\/i><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Orion Corporation<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">12.     MARKETING AUTHORISATION NUMBER(S)<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">EU\/1\/03\/260\/009 \r <span style=\"color:black;background:silver\">10 film-coated tablets<\/span><\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"background:silver\">EU\/1\/03\/260\/010  <span style=\"color:black\">30 film-coated tablets<\/span><\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"background:silver\">EU\/1\/03\/260\/011  <span style=\"color:black\">100 film-coated tablets<\/span><\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"background:silver\">EU\/1\/03\/260\/012  <span style=\"color:black\">250 film-coated tablets<\/span><\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"color:black;background:silver\">EU\/1\/03\/260\/015  175 film-coated tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">EU\/1\/03\/260\/018  130 film-coated tablets<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">13.     BATCH NUMBER<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Batch<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">14.     GENERAL CLASSIFICATION FOR SUPPLY<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">15.     INSTRUCTIONS ON USE<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">16.     INFORMATION IN BRAILLE<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">stalevo 150\/37.5\/200 mg <i><span style=\"background:silver\">[carton only]<\/span><\/i><\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><u><span lang=\"EN-GB\" style=\"color:black\"><\/span><\/u><\/b><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">17.     UNIQUE IDENTIFIER \u2013 2D BARCODE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black;background:silver\">2D barcode carrying the unique identifier included<\/span><span lang=\"EN-GB\" style=\"color:black\"> <i><span style=\"background:#D9D9D9\">[carton only]<\/span><\/i><\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">18.     UNIQUE IDENTIFIER - HUMAN READABLE DATA<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><i><span lang=\"EN-GB\" style=\"color:black;background:#D9D9D9\">[carton only]:<\/span><\/i><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">PC <span style=\"background:silver\">{number}<\/span> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">SN <span style=\"background:silver\">{number}<\/span> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">&lt;NN <span style=\"background:silver\">{number}<\/span>&gt;<\/span><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr style=\"height:52.0pt\"> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:52.0pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">PARTICULARS TO APPEAR ON THE OUTER   PACKAGING AND THE IMMEDIATE PACKAGING<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">BOTTLE LABEL AND OUTER CARTON TEXT<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">1.       NAME OF THE MEDICINAL PRODUCT<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Stalevo 175 mg\/43.75 mg\/200 mg film-coated tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">levodopa\/carbidopa\/entacapone<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">2.       STATEMENT OF ACTIVE SUBSTANCE(S)<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Each film-coated tablet contains 175 mg of levodopa, 43.75 mg of carbidopa and 200 mg of entacapone.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">3.       LIST OF EXCIPIENTS<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Contains sucrose. <\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">4.       PHARMACEUTICAL FORM AND CONTENTS<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><i><span lang=\"EN-GB\" style=\"background:silver\">Carton<\/span><\/i><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">10 film-coated tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">30 film-coated tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">100 film-coated tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">130 film-coated tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">175 film-coated tablets<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><i><span lang=\"EN-GB\" style=\"background:silver\">Label<\/span><\/i><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">10 tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">30 tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">100 tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">130 tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">175 tablets<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">5.       METHOD AND ROUTE(S) OF ADMINISTRATION<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Read the package leaflet before use.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Oral use.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">6.       SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED   OUT OF THE SIGHT AND REACH OF CHILDREN<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Keep out of the sight and reach of children.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">7.       OTHER SPECIAL WARNING(S), IF NECESSARY<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">8.       EXPIRY DATE<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">EXP<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">9.       SPECIAL STORAGE CONDITIONS<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">10.     SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL   PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF   APPROPRIATE<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">11.     NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><i><span lang=\"IT\" style=\"background:silver\">Carton<\/span><\/i><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Orion Corporation<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Orionintie 1<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">FI-02200 Espoo<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Finland<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><i><span lang=\"IT\" style=\"background:silver\">Label<\/span><\/i><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Orion Corporation<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">12.     MARKETING AUTHORISATION NUMBER(S)<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">EU\/1\/03\/260\/034 <span style=\"color:black;background:#CCCCCC\">10 film-coated tablets<\/span><\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"background:silver\">EU\/1\/03\/260\/035 <span style=\"color:black\">30 film-coated tablets<\/span><\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"background:silver\">EU\/1\/03\/260\/036 <span style=\"color:black\">100 film-coated tablets<\/span><\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"background:silver\">EU\/1\/03\/260\/037 <span style=\"color:black\">130 film-coated tablets<\/span><\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"background:silver\">EU\/1\/03\/260\/038 175<\/span><span lang=\"EN-GB\" style=\"color:black;background:#CCCCCC\"> film-coated tablets<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">13.     BATCH NUMBER<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Batch<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">14.     GENERAL CLASSIFICATION FOR SUPPLY<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">15.     INSTRUCTIONS ON USE<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">16.     INFORMATION IN BRAILLE<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">stalevo 175\/43.75\/200 mg <i><span style=\"background:silver\">[carton only]<\/span><\/i><\/span><\/p> <p class=\"MsoNormal\"><b><u><span lang=\"EN-GB\" style=\"color:black\"><\/span><\/u><\/b><\/p> <p class=\"MsoNormal\"><b><u><span lang=\"EN-GB\" style=\"color:black\"><\/span><\/u><\/b><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">17.     UNIQUE IDENTIFIER \u2013 2D BARCODE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black;background:silver\">2D barcode carrying the unique identifier included<\/span><span lang=\"EN-GB\" style=\"color:black\"> <span style=\"background:#D9D9D9\">[<i>carton only<\/i>]<\/span><\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">18.     UNIQUE IDENTIFIER - HUMAN READABLE DATA<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black;background:#D9D9D9\">[<i>carton only<\/i>]:<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">PC <span style=\"background:silver\">{number}<\/span> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">SN <span style=\"background:silver\">{number}<\/span> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">&lt;NN <span style=\"background:silver\">{number}<\/span>&gt;<\/span><\/p> <p class=\"MsoNormal\"><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <p class=\"MsoNormal\"> <\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr style=\"height:52.0pt\"> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:52.0pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">PARTICULARS TO APPEAR ON THE OUTER   PACKAGING AND THE IMMEDIATE PACKAGING<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">BOTTLE LABEL AND OUTER CARTON TEXT<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">1.       NAME OF THE MEDICINAL PRODUCT<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Stalevo 200 mg\/50 mg\/200 mg film-coated tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">levodopa\/carbidopa\/entacapone<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">2.       STATEMENT OF ACTIVE SUBSTANCE(S)<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Each film-coated tablet contains 200 mg of levodopa, 50 mg of carbidopa and 200 mg of entacapone.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">3.       LIST OF EXCIPIENTS<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Contains sucrose. <\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">4.       PHARMACEUTICAL FORM AND CONTENTS<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><i><span lang=\"EN-GB\" style=\"background:silver\">Carton<\/span><\/i><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">10 film-coated tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">30 film-coated tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">100 film-coated tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">130 film-coated tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">175 film-coated tablets<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><i><span lang=\"EN-GB\" style=\"background:silver\">Label<\/span><\/i><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">10 tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">30 tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">100 tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">130 tablets<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">175 tablets<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">5.       METHOD AND ROUTE(S) OF ADMINISTRATION<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Read the package leaflet before use.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Oral use.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">6.       SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED   OUT OF THE SIGHT AND REACH OF CHILDREN<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Keep out of the sight and reach of children.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">7.       OTHER SPECIAL WARNING(S), IF NECESSARY<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">8.       EXPIRY DATE<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">EXP<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">9.       SPECIAL STORAGE CONDITIONS<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">10.     SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL   PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF   APPROPRIATE<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">11.     NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><i><span lang=\"IT\" style=\"background:silver\">Carton<\/span><\/i><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Orion Corporation<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Orionintie 1<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">FI-02200 Espoo<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Finland<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><i><span lang=\"IT\" style=\"background:silver\">Label<\/span><\/i><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Orion Corporation<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">12.     MARKETING AUTHORISATION NUMBER(S)<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">EU\/1\/03\/260\/019 \r <span style=\"color:black;background:silver\">10 film-coated tablets<\/span><\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"background:silver\">EU\/1\/03\/260\/020  <span style=\"color:black\">30 film-coated tablets<\/span><\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"background:silver\">EU\/1\/03\/260\/021  <span style=\"color:black\">100 film-coated tablets<\/span><\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"background:silver\">EU\/1\/03\/260\/022  <span style=\"color:black\">130 film-coated tablets<\/span><\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"background:silver\">EU\/1\/03\/260\/023  175<span style=\"color:black\"> film-coated tablets<\/span><\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">13.     BATCH NUMBER<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Batch<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">14.     GENERAL CLASSIFICATION FOR SUPPLY<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">15.     INSTRUCTIONS ON USE<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">16.     INFORMATION IN BRAILLE<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">stalevo 200\/50\/200 mg <i><span style=\"background:silver\">[carton only]<\/span><\/i><\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">17.     UNIQUE IDENTIFIER \u2013 2D BARCODE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black;background:silver\">2D barcode carrying the unique identifier included<\/span><span lang=\"EN-GB\" style=\"color:black\"> <span style=\"background:#D9D9D9\">[<i>carton only<\/i>]<\/span><\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">18.     UNIQUE IDENTIFIER - HUMAN READABLE DATA<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><i><span lang=\"EN-GB\" style=\"color:black;background:#D9D9D9\">[carton only<\/span><\/i><span lang=\"EN-GB\" style=\"color:black;background:#D9D9D9\">]:<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">PC <span style=\"background:silver\">{number}<\/span> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">SN <span style=\"background:silver\">{number}<\/span> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">&lt;NN <span style=\"background:silver\">{number}<\/span>&gt;<\/span><\/p> <p class=\"MsoNormal\"><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <p class=\"MsoNormal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <h1><span lang=\"EN-GB\">B. PACKAGE LEAFLET<\/span><\/h1> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\" style=\"color:black\">Package leaflet: Information for the user<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">s<\/span><\/b><b><span lang=\"EN-GB\">talevo 50 mg\/12.5 mg\/200 mg film-coated tablets<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"IT\">levodopa\/carbidopa\/entacapone<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">Keep this leaflet. You may need to read it again.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">If you have any further questions, ask your doctor or pharmacist.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-        This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">If you get any side effects, talk to your doctor or pharmacist.<\/span><span lang=\"EN-GB\">This includes any possible side effects not listed in this leaflet. See section 4.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><\/p> <p class=\"Normal11\"><b><span lang=\"FR\">What is in this leaflet:<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">1.       What Stalevo is and what it is used for<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">2.       What you need to know before you take Stalevo<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">3.       How to take Stalevo<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">4.       Possible side effects<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">5        How to store Stalevo<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">6.       Contents of the pack and other information<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:37.05pt;text-indent:-37.05pt\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">1.<\/span><\/b><b><span lang=\"EN-GB\">What Stalevo is and what it is used for<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p align=\"left\" class=\"MsoBodyText3\" style=\"text-align:left;line-height:normal\"><span lang=\"EN-GB\" style=\"font-weight:normal;font-style:normal\">Stalevo contains three active substances (levodopa, carbidopa and entacapone) in one film-coated tablet. Stalevo is used for the treatment of Parkinson\u2019s disease. <\/span><\/p> <p align=\"left\" class=\"MsoBodyText3\" style=\"text-align:left;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Parkinson\u2019s disease is caused by low levels of a substance called dopamine in the brain. Levodopa increases the amount of dopamine and hence reduces the symptoms of Parkinson\u2019s disease. Carbidopa and entacapone improve the antiparkinson effects of levodopa. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">2.       What you need to know before you take Stalevo<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Do not take Stalevo if you:<\/span><\/b><\/p> <p class=\"MsoNormal\"> <\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">are allergic to levodopa, carbidopa or entacapone, or any of the other ingredients of this medicine <\/span><span style=\"font-size:11.0pt\">(listed in section 6)<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">have narrow-angle glaucoma (an eye disorder)<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">have a tumour of the adrenal gland<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">are taking certain medicines for treating depression (<\/span><span style=\"font-size:11.0pt\">combinations of <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">selective MAO-A and MAO-B inhibitors, or non-selective MAO-inhibitors)<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">have ever had neuroleptic malignant syndrome (NMS \u2013 this is a rare reaction to medicines used to treat severe mental disorders)<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">have ever had non-traumatic rhabdomyolysis (a rare muscle disorder)<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">have a severe liver disease. <\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Warnings and precautions <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Talk to your doctor or pharmacist before taking Stalevo if you have or have ever had<\/span><\/u><span lang=\"EN-GB\">:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">a heart attack or any other diseases of the heart including cardiac arrhythmias, or of the blood vessels<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">asthma or any other disease of the lungs<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">a liver problem, because your dose may need to be adjusted<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">kidney or hormone-related diseases<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">stomach ulcers or convulsions<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">if you experience prolonged diarrhoea consult your doctor as it may be a sign of inflammation of the colon<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">any form of severe mental disorder like psychosis<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">chronic wide-angle glaucoma, because your dose may need to be adjusted and the pressure in your eyes may need to be monitored.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Consult your doctor if you are currently taking<\/span><\/u><span lang=\"EN-GB\">:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">antipsychotics (medicines used to treat psychosis)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">a medicine which may cause low blood pressure when rising from a chair or bed. You should be aware that Stalevo may make these reactions worse.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Consult your doctor if during the treatment with Stalevo you<\/span><\/u><span lang=\"EN-GB\">:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">notice that your muscles get very rigid or jerk violently,\r or if you get tremors, agitation, confusion, fever, rapid pulse, or wide\r fluctuations in your blood pressure. If any of this happens, <b>contact your doctor immediately<\/b><\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">feel depressed, have suicidal thoughts, or notice unusual changes in your behaviour<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">find yourself suddenly falling asleep, or if you feel very drowsy. If this happens, you should not drive or use any tools or machines (see also section 'Driving and using machines')<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">notice that uncontrolled movements begin or get worse after you started to take Stalevo. If this happens, your doctor may need to change the dose of your antiparkinson medicine <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">experience diarrhoea: monitoring of your weight is recommended in order to avoid potentially excessive weight loss<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">experience progressive anorexia, asthenia (weakness, exhaustion) and weight decrease within a relatively short period of time. If this happens, a general medical evaluation including liver function should be considered<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">feel the need to stop using Stalevo, see section 'If you stop taking Stalevo'.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Tell your doctor if you or your family\/carer notices you are developing addiction-like symptoms leading to craving for large doses of Stalevo and other medicines used to treat Parkinson\u2019s disease.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\">Tell your doctor if you or your family\/carer notices you are\r developing urges or cravings to behave in ways that are unusual for you or you\r cannot resist the impulse, drive or temptation to carry out certain activities\r that could harm yourself or others. These behaviours are called impulse control\r disorders and can include addictive gambling, excessive eating or spending, an\r abnormally high sex drive or a preoccupation with an increase in sexual\r thoughts or feelings. <u>Your doctor may need to review your treatments.<\/u> <\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Your doctor may take some regular laboratory tests during a long term treatment with Stalevo.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">If you must undergo surgery, please tell your doctor that you are using Stalevo.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Stalevo is not recommended to be used for treatment of extrapyramidal symptoms (e.g. involuntary movements, shaking, muscle rigidity and muscle contractions<\/span><span lang=\"EN\">)<\/span><span lang=\"EN-GB\"> caused by other medicines.<\/span><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Children<\/span><span lang=\"EN-GB\" style=\"color:black\"> and adolescents<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Experience with Stalevo in patients under 18 years is limited. Therefore, the use of Stalevo in children or adolescents is not recommended.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Other medicines and Stalevo<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoBodyText\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"font-weight:normal;font-style:normal\">Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.<\/span><\/p> <p class=\"MsoBodyText\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Do not take Stalevo if you are taking certain medicines for treating depression (combinations of selective MAO-A and MAO-B inhibitors, or non-selective MAO inhibitors).<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Stalevo may increase the effects and side effects of certain medicines. These include: <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">medicines used to treat depression such as moclobemide, amitriptyline, desipramine, maprotiline, venlafaxine and paroxetine <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif'>-<\/span><span lang=\"EN-GB\">rimiterole and isoprenaline, used to treat respiratory diseases<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">adrenaline, used <\/span><span lang=\"PT\">for severe allergic reactions<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">noradrenaline, dopamine and dobutamine, used to treat heart diseases and low blood pressure<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">alpha-methyldopa, used to treat high blood pressure <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-        apomorphine, which is used to treat Parkinson\u2019s disease.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">The effects of Stalevo may be weakened by certain medicines. These include: <\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-        dopamine antagonists used to treat mental disorders<\/span><span style=\"font-size:11.0pt\">, nausea and vomiting<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">phenytoin, used to prevent convulsions <\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">papaverine used to relax the muscles.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Stalevo may make it harder for you to digest iron. Therefore, do not take Stalevo and iron supplements at the same time. After taking one of them, wait at least 2 to 3 hours before taking the other.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Stalevo with food and drink<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoBodyText\" style=\"text-align:justify;line-height:normal\"><span lang=\"EN-GB\" style=\"font-weight:normal;font-style:normal\">Stalevo may be taken with or without food. For some patients, Stalevo may not be well absorbed if it is taken with, or shortly after eating protein-rich food (such as meats, fish, dairy products, seeds and nuts). Consult your doctor if you think this applies to you.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Pregnancy, breast-feeding and fertility<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoBodyText\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"font-weight:normal;font-style:normal\">If you are pregnant<\/span><span lang=\"EN-GB\" style=\"font-weight:normal;font-style:normal\">or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. <\/span><\/p> <p class=\"MsoBodyText\" style=\"line-height:normal\"><\/p> <p class=\"MsoBodyText\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"font-weight:normal;font-style:normal\">You should not breast-feed during treatment with Stalevo.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Driving and using machines<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Stalevo may lower your blood pressure, which may make you feel light-headed or dizzy. Therefore, be particularly careful when you drive or when you use any tools or machines.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">If you feel very drowsy, or if you sometimes find yourself suddenly falling asleep, wait until you feel fully awake again before driving or doing anything else that requires you to be alert. Otherwise, you may put yourself and others at risk of serious injury or death.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Stalevo contains sucrose<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Stalevo contains sucrose (1.2 mg\/tablet). If you have been told by your doctor that you have intolerance to some sugars, contact your doctor before taking this medicinal product.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">3.       <\/span><span lang=\"EN-GB\">How to take Stalevo<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><u><span lang=\"EN-GB\">For adults and elderly<\/span><\/u><span lang=\"EN-GB\">:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-        Your doctor will tell you exactly how many tablets of Stalevo to take each day. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif'>-<\/span><span lang=\"EN-GB\">The tablets are not intended to be split or broken into smaller pieces.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif'>-<\/span><span lang=\"EN-GB\">You should take only one tablet each time.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif'>-<\/span><span lang=\"EN-GB\">Depending on how you respond to treatment, your doctor may suggest a higher or lower dose. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif'>-<\/span><span lang=\"EN-GB\">If you are taking Stalevo 50 mg\/12.5 mg\/200 mg, 75 mg\/18.75 mg\/200 mg, 100 mg\/25 mg\/200 mg, 125 mg\/31.25 mg\/200 mg or 150 mg\/37.5 mg\/200 mg tablets, do not take more than 10 tablets per day.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;text-align:justify;line-height:\r normal\"><span lang=\"EN-GB\">Talk to your doctor or pharmacist if you think the effect of Stalevo is too strong or too weak, or if you experience possible side effects.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;text-align:justify;line-height:\r 12.0pt\"><span lang=\"EN-GB\"><img border=\"0\" height=\"122\" src=\"data:image\/png;base64,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\" width=\"624\"\/><\/span><\/p> <p class=\"Normal11\"><b><span lang=\"FR\">If you take more Stalevo than you should<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">If you have accidentally taken more Stalevo tablets than you should, talk to your doctor or pharmacist immediately. In case of an overdose you may feel confused or agitated, your heart rate may be slower or faster than normal or the colour of your skin, tongue, eyes or urine may change.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">If you forget to take Stalevo<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Do not take a double dose to make up for a forgotten tablet.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><u><span lang=\"EN-GB\">If it is more than 1 hour until your next dose<\/span><\/u><span lang=\"EN-GB\">: <\/span><\/p> <p class=\"MsoBodyText\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"font-weight:normal;font-style:normal\">Take one tablet as soon as you remember, and the next tablet at the normal time. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><u><span lang=\"EN-GB\">If it is less than 1 hour until your next dose<\/span><\/u><span lang=\"EN-GB\">: <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Take a tablet as soon as you remember, wait 1 hour, then take another tablet. After that carry on as normal. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Always leave at least an hour between Stalevo tablets, to avoid possible side effects.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">If you stop taking Stalevo <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Do not stop taking Stalevo unless your doctor tells you to. In such a case your doctor may need to adjust your other antiparkinson medicines, especially levodopa, to give sufficient control of your symptoms. If you suddenly stop taking Stalevo and other antiparkinsonian medicines it may result in unwanted side effects. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">If you have any further questions on the use of this medicine, ask your doctor or pharmacist.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">4.       Possible side effects<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.4pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Like all medicines, this medicine can cause side effects, although not everybody gets them. Many of the side effects can be relieved by adjusting the dose. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.4pt;line-height:normal\"><\/p> <p class=\"Text\" style=\"margin-top:0in\"><span style=\"font-size:11.0pt\">If you\r during the treatment with Stalevo experience the following symptoms, <b>contact your doctor immediately<\/b>: <\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span style=\"font-size:11.0pt\">Your muscles get very rigid or jerk violently, you get tremors, agitation, confusion, fever, rapid pulse, or wide fluctuations in your blood pressure. These can be symptoms <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">of neuroleptic malignant syndrome (NMS, a rare severe reaction to medicines used to treat disorders of the central nervous system) or rhabdomyolysis (a rare severe muscle disorder).<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Allergic reaction, the signs may include hives (nettle rash), itching, rash, swelling of your face, lips, tongue or throat. This may cause difficulties in breathing or swallowing.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.4pt;line-height:normal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Very common (may affect more than 1 in 10 people)<\/span><\/u><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">uncontrolled movements (dyskinesias)<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">feeling sick (nausea)<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">harmless reddish-brown discolouration of urine<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">muscle pain<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span style=\"font-size:11.0pt\">diarrhoea<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Common (may affect up to 1 in 10 people)<\/span><\/u><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">light-headedness or fainting due to low blood pressure, high blood pressure<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">worsening of Parkinson`s symptoms, dizziness, drowsiness<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">vomiting, abdominal pain and discomfort, heartburn, dry mouth, constipation<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">inability to sleep, hallucinations, confusion, abnormal dreams (including nightmares), tiredness<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">mental changes \u2013 including problems with memory, anxiety and depression (possibly with thoughts of suicide) <\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span style=\"font-size:11.0pt\">heart or artery disease events (e.g. chest pain), irregular heart rate or rhythm <\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">more frequent falling <\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">shortness of breath <\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">increased sweating, rashes<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">muscle cramps, swelling of legs<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">blurred vision  <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">anaemia<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">decreased appetite, decreased weight<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">headache, joint pain<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">urinary tract infection<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Uncommon <\/span><\/u><u><span style=\"font-size:11.0pt;color:black\">(may affect up to 1 in 100 people)<\/span><\/u><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">heart attack<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">bleeding in the gut<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">changes in the blood cell count which may result in bleeding, abnormal liver function tests<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">convulsions<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">feeling agitated<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">psychotic symptoms <\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">colitis (inflammation of the colon) <\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">discolourations other than urine (e.g. skin, nail, hair, sweat)<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">swallowing difficulties<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span style=\"font-size:11.0pt\">inability to urinate<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Not known (cannot be estimated from the available data)<\/span><\/u><\/p> <p class=\"Text\" style=\"margin-top:0in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Craving for large doses of Stalevo in excess of that required to control motor symptoms, known as dopamine dysregulation syndrome. Some patients experience severe abnormal involuntary movements (dyskinesias), mood swings or other side effects after taking large doses of Stalevo.<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in\"><\/p> <p class=\"Text\" style=\"margin-top:0in\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">The following side effects have also been reported<\/span><\/u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">:<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">hepatitis <\/span><span style=\"font-size:11.0pt\">(inflammation of the liver)<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">itching<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:4.8pt\"><u><span lang=\"EN-GB\" style=\"color:black\">You may experience the following side effects: <\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:4.8pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif;color:black'>-<\/span><span lang=\"EN-GB\" style=\"color:black\">Inability to resist the impulse to perform an action that could be harmful, which may include:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:4.8pt;margin-bottom:0in;\r margin-left:42.55pt;margin-bottom:.0001pt;text-indent:-14.2pt;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif;color:black'>-<\/span><span lang=\"EN-GB\" style=\"color:black\">strong impulse to gamble excessively despite serious personal or family consequences<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:4.8pt;margin-bottom:0in;\r margin-left:42.55pt;margin-bottom:.0001pt;text-indent:-14.2pt;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif;color:black'>-<\/span><span lang=\"EN-GB\" style=\"color:black\">altered or increased sexual interest and behaviour of significant concern to you or to others, for example, an increased sexual drive<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:4.8pt;margin-bottom:0in;\r margin-left:42.55pt;margin-bottom:.0001pt;text-indent:-14.2pt;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif;color:black'>-<\/span><span lang=\"EN-GB\" style=\"color:black\">uncontrollable excessive shopping or spending<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:4.8pt;margin-bottom:0in;\r margin-left:42.55pt;margin-bottom:.0001pt;text-indent:-14.2pt;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif;color:black'>-<\/span><span lang=\"EN-GB\" style=\"color:black\">binge eating (eating large amounts of food in a short time period) or compulsive eating (eating more food than normal and more than is needed to satisfy your hunger).<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:4.8pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:4.8pt\"><span lang=\"EN-GB\" style=\"color:black\">Tell your doctor if you experience any of these behaviours; they will discuss ways of managing or reducing the symptoms.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><b><span lang=\"EN-GB\">Reporting of side effects<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">If you get any side effects, talk to your doctor or pharmacist. This\r includes any possible side effects not listed in this leaflet. You can also\r report side effects directly via <span style=\"background:silver\">the national\r reporting system listed in <a href=\"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Template_or_form\/2013\/03\/WC500139752.doc\">Appendix\r V<\/a><\/span>. By reporting side effects you can help provide more information\r on the safety of this medicine.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"Normal11\"><b><span lang=\"FR\">5.        How to store Stalevo<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Keep this medicine out of the sight and reach of children.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Do not use this medicine after the expiry date which is stated on the bottle and the carton after EXP. The expiry date refers to the last day of that month.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">This medicinal product does not require any special storage conditions.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Do not <\/span><span lang=\"EN-GB\">throw away any medicines <\/span><span lang=\"EN-GB\">via wastewater or household waste. Ask your pharmacist how to <\/span><span lang=\"EN-GB\">throw away <\/span><span lang=\"EN-GB\">medicines you no longer use. These measures will help to protect the environment.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">6.       Contents of the pack and other information<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">What Stalevo contains<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:27.0pt;margin-bottom:.0001pt;text-indent:-27.0pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">The active substances of Stalevo are levodopa, carbidopa and entacapone.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Each Stalevo 50 mg\/12.5 mg\/200 mg tablet contains 50 mg of levodopa, 12.5 mg of carbidopa and 200 mg of entacapone.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">The other ingredients in the tablet core are croscarmellose sodium, magnesium stearate, maize starch, mannitol (E421) and povidone (E1201)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">The ingredients in the film-coating are glycerol (85 per cent) (E422), hypromellose, magnesium stearate, polysorbate 80, red iron oxide (E172), sucrose, titanium dioxide (E171), and yellow iron oxide (E172).<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;line-height:\r normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;line-height:\r normal\"><b><span lang=\"EN-GB\">What Stalevo looks like and contents of the pack<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;line-height:\r normal\"><\/p> <p class=\"MsoEndnoteText\"><span lang=\"EN-GB\">Stalevo 50 mg\/12.5 mg\/200 mg: brownish or greyish red, round, convex unscored film-coated tablets marked with \u2018LCE 50\u2019 on one side.<\/span><\/p> <p class=\"MsoEndnoteText\"><\/p> <p class=\"MsoEndnoteText\"><span lang=\"EN-GB\">Stalevo comes in six different pack sizes (10, 30, 100, 130, 175 or 250 tablets). Not all pack sizes may be marketed.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;line-height:\r normal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Marketing Authorisation Holder<\/span><\/b><\/p> <p class=\"MsoEndnoteText\"><span lang=\"IT\">Orion Corporation<\/span><\/p> <p class=\"MsoEndnoteText\"><span lang=\"IT\">Orionintie 1<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"IT\">FI-02200 Espoo<\/span><\/p> <p class=\"MsoEndnoteText\"><span lang=\"IT\">Finland<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><b><span lang=\"EN-GB\">Manufacturer<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><span lang=\"EN-GB\">Orion Corporation Orion Pharma<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><span lang=\"EN-GB\">Joensuunkatu 7<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><span lang=\"EN-GB\">FI-24100 Salo<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Finland<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoEndnoteText\"><span lang=\"IT\">Orion Corporation <\/span><span lang=\"EN-GB\">Orion Pharma<\/span><\/p> <p class=\"MsoEndnoteText\"><span lang=\"IT\">Orionintie 1<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"IT\">FI-02200 Espoo<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"IT\">Finland<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse\" width=\"628\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"MsoNormal\"><b><span lang=\"FR\">Belgi\u00eb\/Belgique\/Belgien<\/span><\/b><span lang=\"FR\"><br\/> <\/span><strong><span lang=\"EN-GB\" style=\"font-weight:normal\">Orion Pharma   BVBA\/SPRL<\/span><\/strong><\/p> <p class=\"Text\" style=\"margin-top:0in\"><span style=\"font-size:11.0pt\">T\u00e9l\/Tel:   +32 (0)15 64 10 20<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"FI\">Lietuva<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"FI\">UAB Orion Pharma<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"FI\">Tel. +370 5 276 9499<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"color:black\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Orion Pharma Poland Sp z.o.o.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Tel.: + 48 22 8333177<\/span><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"DE\">Luxembourg\/Luxemburg<\/span><\/b><span lang=\"DE\"><br\/> <\/span><strong><span lang=\"EN-GB\" style=\"font-weight:normal\">Orion Pharma   BVBA\/SPRL<\/span><\/strong><\/p> <p class=\"Text\" style=\"margin-top:0in\"><span style=\"font-size:11.0pt\">T\u00e9l\/Tel:   +32 (0)15 64 10 20<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"MsoNormal\"><b><span lang=\"SV\">\u010cesk\u00e1 republika<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"FI\">Orion Pharma s.r.o.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel:  <\/span><span lang=\"SV\">+420 234 703   305<\/span><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"SV\">Magyarorsz\u00e1g<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:13.0pt\"><strong><span lang=\"EN-GB\" style=\"font-weight:normal\">Orion Pharma Kft.<\/span><\/strong><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel.: +<\/span><span lang=\"EN-GB\">36 1 239   9095<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><b><span lang=\"EN-GB\">Danmark<\/span><\/b><span lang=\"EN-GB\"><br\/>\r   Orion Pharma A\/S<br\/>\r   Tlf: +45 8614 0000<\/span><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"FR\">Malta<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"IT\">Salomone Pharma<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-2.25pt;margin-bottom:\r   9.0pt;margin-left:0in\"><span lang=\"IT\">Tel: +356 21220174<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><b><span lang=\"DE\">Deutschland<\/span><\/b><span lang=\"DE\"><br\/>\r   Orion Pharma GmbH<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><span lang=\"DE\">Tel: +49 40 899 6890<\/span><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"SV\">Nederland<\/span><\/b><span lang=\"SV\"><br\/> <\/span><strong><span lang=\"EN-GB\" style=\"font-weight:normal\">Orion Pharma   BVBA\/SPRL<\/span><\/strong><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:9.0pt;\r   margin-left:0in\"><span style=\"font-size:11.0pt\">T\u00e9l\/Tel: +32 (0)15 64 10 20<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"MsoNormal\"><b><span lang=\"FI\">Eesti<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"FI\">Orion Pharma Eesti O\u00dc<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"FI\">Tel: +372 66 44 550<\/span><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><b><span lang=\"EN-GB\">Norge<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Orion Pharma   AS<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-2.25pt;margin-bottom:\r   9.0pt;margin-left:0in\"><span lang=\"EN-GB\">Tlf: +47 40 00 42 10<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"Text\" style=\"margin-top:0in\"><b><span lang=\"EN-GB\" style=\"font-size:\r   11.0pt\">\u0395\u03bb\u03bb\u03ac\u03b4\u03b1<\/span><\/b><span lang=\"FI\" style=\"font-size:11.0pt\"><br\/>\r   Orion Pharma Hellas M.E.<\/span><span style=\"font-size:11.0pt\">\u03a0<\/span><span lang=\"FI\" style=\"font-size:11.0pt\">.E<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in\"><span style=\"font-size:11.0pt\">\u03a4\u03b7\u03bb<\/span><span lang=\"FI\" style=\"font-size:11.0pt\">: + 30 210 980 3355<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><b><span lang=\"DE\">\u00d6sterreich<\/span><\/b><span lang=\"DE\"><br\/>\r   Orion Pharma GmbH<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:9.0pt;\r   margin-left:0in\"><span lang=\"DE\" style=\"font-size:11.0pt\">Tel: +49 40 899 6890<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"Text\" style=\"margin-top:0in\"><b><span lang=\"IT\" style=\"font-size:11.0pt\">Espa\u00f1a<\/span><\/b><span lang=\"IT\" style=\"font-size:11.0pt\"><br\/> <\/span><span style=\"font-size:11.0pt\">Orion Pharma S.L.<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in\"><span style=\"font-size:11.0pt\">Tel: + 34   91  599 86 01<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Polska<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"SV\">Orion Pharma Poland Sp z.o.o.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:9.0pt\"><span lang=\"EN-GB\">Tel.: + 48 22   8333177<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"Text\" style=\"margin-top:0in\"><b><span lang=\"FR\" style=\"font-size:11.0pt\">France<\/span><\/b><span lang=\"FR\" style=\"font-size:11.0pt\"><br\/> <\/span><span style=\"font-size:11.0pt\">Centre Sp\u00e9cialit\u00e9s Pharmaceutiques<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in\"><span style=\"font-size:11.0pt\">Tel: + 33   (0) 1 47 04 80 46<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><b><span lang=\"IT\" style=\"font-size:11.0pt\">Portugal<\/span><\/b><span lang=\"IT\" style=\"font-size:11.0pt\"><br\/> <\/span><span style=\"font-size:11.0pt\">Orionfin Unipessoal Lda<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-2.25pt;margin-bottom:\r   9.0pt;margin-left:0in\"><span lang=\"EN-GB\">Tel: + 351 21 154 68 20<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><b><span lang=\"FI\">Hrvatska<\/span><\/b><\/p> <p class=\"MsoNormal\"><strong><span lang=\"FI\" style=\"font-weight:normal\">Orion   Pharma d.o.o.<\/span><\/strong><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><span lang=\"FI\">Tel:<\/span><span lang=\"FI\"> +386 (0) 1 600 8015<\/span><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"line-height:12.0pt;text-autospace:none\"><b><span lang=\"FR\" style=\"color:black\">Rom\u00e2nia<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"IT\">Orion Corporation<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"FR\" style=\"color:black\">Tel: +358 10 4261<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Ireland<\/span><\/b><span lang=\"EN-GB\"><br\/>\r   Orion Pharma (Ireland) Ltd.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">c\/o Allphar   Services Ltd.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: +353 1   428 7777<\/span><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"IT\">Slovenija<\/span><\/b><\/p> <p class=\"MsoNormal\"><strong><span lang=\"FI\" style=\"font-weight:normal\">Orion   Pharma d.o.o.<\/span><\/strong><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:9.0pt\"><span lang=\"FI\">Tel:<\/span><span lang=\"FI\"> +386 (0) 1 600 8015<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><b><span lang=\"EN-GB\">\u00cdsland<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Vistor hf.<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in\"><span style=\"font-size:11.0pt\">S\u00edmi:   +354 535 7000<\/span><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"SV\">Slovensk\u00e1 republika<\/span><\/b><\/p> <p class=\"MsoNormal\"><strong><span lang=\"SV\" style=\"font-weight:normal\">Orion   Pharma s.r.o<\/span><\/strong><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-2.25pt;margin-bottom:\r   9.0pt;margin-left:0in;line-height:normal\"><span lang=\"SV\">Tel: <\/span><span lang=\"SV\">+420 234 703 305<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"Text\" style=\"margin-top:0in\"><b><span lang=\"IT\" style=\"font-size:11.0pt\">Italia<\/span><\/b><span lang=\"IT\" style=\"font-size:11.0pt\"><br\/> <\/span><span lang=\"FI\" style=\"font-size:11.0pt\">Orion Pharma S.r.l.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:9.0pt\"><span lang=\"EN-GB\">Tel: + 39   02 67876111<\/span><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><b><span lang=\"IT\">Suomi\/Finland<br\/> <\/span><\/b><span lang=\"IT\">Orion Corporation<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><span lang=\"IT\">Puh.\/Tel: +358 10 4261<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"MsoNormal\"><b><span lang=\"EL\">\u039a\u03cd\u03c0\u03c1\u03bf\u03c2<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"DE\">Lifepharma (ZAM) Ltd<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">\u03a4\u03b7\u03bb<\/span><span lang=\"DE\">.:   +357 22056300<\/span><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><b><span lang=\"DE\">Sverige<\/span><\/b><span lang=\"DE\"><br\/>\r   Orion Pharma AB<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><span lang=\"DE\">Tel: +46 8 623 6440<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"MsoNormal\"><b><span lang=\"FI\">Latvija<\/span><\/b><\/p> <p class=\"MsoNormal\">Orion Corporation<\/p> <p class=\"MsoNormal\">Orion Pharma p\u0101rst\u0101vniec\u012bba<\/p> <p class=\"MsoNormal\">Tel: +371 20028332<\/p> <p class=\"MsoNormal\"> <\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><b><span lang=\"EN-GB\">United   Kingdom<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Orion Pharma   (UK) Ltd.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +44 1635 520 300<\/span><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><b><span lang=\"EN-GB\">This leaflet was last revised in.<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Other sources of information<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Detailed information on this medicine is\r available on the European Medicines Agency web site: <a href=\"http:\/\/www.ema.europa.eu\">http:\/\/www.ema.europa.eu<\/a>. <\/span><\/p> <b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\" style=\"color:black\">Package leaflet: Information for the user<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"IT\" style=\"text-transform:uppercase\">s<\/span><\/b><b><span lang=\"IT\">talevo <\/span><\/b><b><span lang=\"EN-GB\">75 mg\/18.75 mg\/200 mg<\/span><\/b><b><span lang=\"IT\"> film-coated tablets<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"IT\">levodopa\/carbidopa\/entacapone<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">Keep this leaflet. You may need to read it again.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">If you have any further questions, ask your doctor or pharmacist.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-        This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">If you get any side effects, talk to your doctor or pharmacist.<\/span><span lang=\"EN-GB\">This includes any possible side effects not listed in this leaflet. See section 4.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">What is in this leaflet:<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">1.       What Stalevo is and what it is used for<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">2.       What you need to know before you take Stalevo<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">3.       How to take Stalevo<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">4.       Possible side effects<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">5        How to store Stalevo<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">6.        <\/span><span lang=\"EN-GB\">Contents of the pack and other information<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">1.       <\/span><span lang=\"EN-GB\">What Stalevo is and what it is used for<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p align=\"left\" class=\"MsoBodyText3\" style=\"text-align:left;line-height:normal\"><span lang=\"EN-GB\" style=\"font-weight:normal;font-style:normal\">Stalevo contains three active substances (levodopa, carbidopa and entacapone) in one film-coated tablet. Stalevo is used for the treatment of Parkinson\u2019s disease. <\/span><\/p> <p align=\"left\" class=\"MsoBodyText3\" style=\"text-align:left;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Parkinson\u2019s disease is caused by low levels of a substance called dopamine in the brain. Levodopa increases the amount of dopamine and hence reduces the symptoms of Parkinson\u2019s disease. Carbidopa and entacapone improve the antiparkinson effects of levodopa. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">2.       <\/span><span lang=\"EN-GB\">What you need to know before you take Stalevo<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Do not take Stalevo if you:<\/span><\/b><\/p> <p class=\"MsoNormal\"> <\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">are allergic to levodopa, carbidopa or entacapone, or any of the other ingredients of this medicine <\/span><span style=\"font-size:11.0pt\">(listed in section 6)<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">have narrow-angle glaucoma (an eye disorder)<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">have a tumour of the adrenal gland<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">are taking certain medicines for treating depression (<\/span><span style=\"font-size:11.0pt\">combinations of <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">selective MAO-A and MAO-B inhibitors, or non-selective MAO-inhibitors)<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">have ever had neuroleptic malignant syndrome (NMS \u2013 this is a rare reaction to medicines used to treat severe mental disorders)<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">have ever had non-traumatic rhabdomyolysis (a rare muscle disorder)<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">have a severe liver disease. <\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Warnings and precautions <\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Talk to your doctor or pharmacist before taking Stalevo if you have or have ever had<\/span><\/u><span lang=\"EN-GB\">:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">a heart attack or any other diseases of the heart including cardiac arrhythmias, or of the blood vessels<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">asthma or any other disease of the lungs<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">a liver problem, because your dose may need to be adjusted<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">kidney or hormone-related diseases<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">stomach ulcers or convulsions<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">if you experience prolonged diarrhoea consult your doctor as it may be a sign of inflammation of the colon<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">any form of severe mental disorder like psychosis<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">chronic wide-angle glaucoma, because your dose may need to be adjusted and the pressure in your eyes may need to be monitored.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Consult your doctor if you are currently taking<\/span><\/u><span lang=\"EN-GB\">:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">antipsychotics (medicines used to treat psychosis)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">a medicine which may cause low blood pressure when rising from a chair or bed. You should be aware that Stalevo may make these reactions worse.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Consult your doctor if during the treatment with Stalevo you<\/span><\/u><span lang=\"EN-GB\">:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">notice that your muscles get very rigid or jerk\r violently, or if you get tremors, agitation, confusion, fever, rapid pulse, or\r wide fluctuations in your blood pressure. If any of this happens, <b>contact your doctor immediately<\/b><\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">feel depressed, have suicidal thoughts, or notice unusual changes in your behaviour<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">find yourself suddenly falling asleep, or if you feel very drowsy. If this happens, you should not drive or use any tools or machines (see also section 'Driving and using machines')<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">notice that uncontrolled movements begin or get worse after you started to take Stalevo. If this happens, your doctor may need to change the dose of your antiparkinson medicine <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">experience diarrhoea: monitoring of your weight is recommended in order to avoid potentially excessive weight loss<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">experience progressive anorexia, asthenia (weakness, exhaustion) and weight decrease within a relatively short period of time. If this happens, a general medical evaluation including liver function should be considered<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">feel the need to stop using Stalevo, see section 'If you stop taking Stalevo'.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Tell your doctor if you or your family\/carer notices you are developing addiction-like symptoms leading to craving for large doses of Stalevo and other medicines used to treat Parkinson\u2019s disease.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\">Tell your doctor if you or your family\/carer notices you are\r developing urges or cravings to behave in ways that are unusual for you or you\r cannot resist the impulse, drive or temptation to carry out certain activities\r that could harm yourself or others. These behaviours are called impulse control\r disorders and can include addictive gambling, excessive eating or spending, an\r abnormally high sex drive or a preoccupation with an increase in sexual\r thoughts or feelings. <u>Your doctor may need to review your treatments.<\/u><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Your doctor may take some regular laboratory tests during a long term treatment with Stalevo.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">If you must undergo surgery, please tell your doctor that you are using Stalevo.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Stalevo is not recommended to be used for\r treatment of extrapyramidal symptoms (e.g. involuntary movements, <a name=\"OLE_LINK1\">shaking<\/a>, muscle rigidity and muscle contractions<\/span><span lang=\"EN\">)<\/span><span lang=\"EN-GB\"> caused by other medicines.<\/span><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Children <\/span><span lang=\"EN-GB\" style=\"color:black\">and adolescents<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Experience with Stalevo in patients under 18 years is limited. Therefore, the use of Stalevo in children or adolescents is not recommended.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Other medicines and Stalevo<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoBodyText\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"font-weight:normal;font-style:normal\">Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.<\/span><\/p> <p class=\"MsoBodyText\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Do not take Stalevo if you are taking certain medicines for treating depression (combinations of selective MAO-A and MAO-B inhibitors, or non-selective MAO inhibitors).<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Stalevo may increase the effects and side effects of certain medicines. These include: <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">medicines used to treat depression such as moclobemide, amitriptyline, desipramine, maprotiline, venlafaxine and paroxetine <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif'>-<\/span><span lang=\"EN-GB\">rimiterole and isoprenaline, used to treat respiratory diseases<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">adrenaline, used <\/span><span lang=\"PT\">for severe allergic reactions<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">noradrenaline, dopamine and dobutamine, used to treat heart diseases and low blood pressure<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-        alpha-methyldopa, used to treat high blood pressure <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-        apomorphine, which is used to treat Parkinson\u2019s disease.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">The effects of Stalevo may be weakened by certain medicines. These include: <\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-        dopamine antagonists used to treat mental disorders<\/span><span style=\"font-size:11.0pt\">, nausea and vomiting<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">phenytoin, used to prevent convulsions <\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">papaverine used to relax the muscles.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Stalevo may make it harder for you to digest iron. Therefore, do not take Stalevo and iron supplements at the same time. After taking one of them, wait at least 2 to 3 hours before taking the other.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Stalevo with food and drink<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoBodyText\" style=\"text-align:justify;line-height:normal\"><span lang=\"EN-GB\" style=\"font-weight:normal;font-style:normal\">Stalevo may be taken with or without food. For some patients, Stalevo may not be well absorbed if it is taken with, or shortly after eating protein-rich food (such as meats, fish, dairy products, seeds and nuts). Consult your doctor if you think this applies to you.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Pregnancy, breast-feeding and fertility<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoBodyText\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"font-weight:normal;font-style:normal\">If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. <\/span><\/p> <p class=\"MsoBodyText\" style=\"line-height:normal\"><\/p> <p class=\"MsoBodyText\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"font-weight:normal;font-style:normal\">You should not breast-feed during treatment with Stalevo.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Driving and using machines<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Stalevo may lower your blood pressure, which may make you feel light-headed or dizzy. Therefore, be particularly careful when you drive or when you use any tools or machines.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">If you feel very drowsy, or if you sometimes find yourself suddenly falling asleep, wait until you feel fully awake again before driving or doing anything else that requires you to be alert. Otherwise, you may put yourself and others at risk of serious injury or death.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Stalevo contains sucrose<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Stalevo contains sucrose (1.4 mg\/tablet). If you have been told by your doctor that you have intolerance to some sugars, contact your doctor before taking this medicinal product.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">3.       <\/span><span lang=\"EN-GB\">How to take Stalevo<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><u><span lang=\"EN-GB\">For adults and elderly<\/span><\/u><span lang=\"EN-GB\">:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-        Your doctor will tell you exactly how many tablets of Stalevo to take each day. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif'>-<\/span><span lang=\"EN-GB\">The tablets are not intended to be split or broken into smaller pieces.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif'>-<\/span><span lang=\"EN-GB\">You should take only one tablet each time.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif'>-<\/span><span lang=\"EN-GB\">Depending on how you respond to treatment, your doctor may suggest a higher or lower dose. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif'>-<\/span><span lang=\"EN-GB\">If you are taking Stalevo 50 mg\/12.5 mg\/200 mg, 75 mg\/18.75 mg\/200 mg, 100 mg\/25 mg\/200 mg, 125 mg\/31.25 mg\/200 mg or 150 mg\/37.5 mg\/200 mg tablets, do not take more than 10 tablets per day.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;text-align:justify;line-height:\r normal\"><span lang=\"EN-GB\">Talk to your doctor or pharmacist if you think the effect of Stalevo is too strong or too weak, or if you experience possible side effects.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;text-align:justify;line-height:\r 12.0pt\"><span lang=\"EN-GB\"><img border=\"0\" height=\"122\" src=\"data:image\/png;base64,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\" width=\"624\"\/><\/span><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">If you take more Stalevo than you should<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">If you have accidentally taken more Stalevo tablets than you should, talk to your doctor or pharmacist immediately. In case of an overdose you may feel confused or agitated, your heart rate may be slower or faster than normal or the colour of your skin, tongue, eyes or urine may change.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">If you forget to take Stalevo<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Do not take a double dose to make up for a forgotten tablet.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><u><span lang=\"EN-GB\">If it is more than 1 hour until your next dose<\/span><\/u><span lang=\"EN-GB\">: <\/span><\/p> <p class=\"MsoBodyText\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"font-weight:normal;font-style:normal\">Take one tablet as soon as you remember, and the next tablet at the normal time. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><u><span lang=\"EN-GB\">If it is less than 1 hour until your next dose<\/span><\/u><span lang=\"EN-GB\">: <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Take a tablet as soon as you remember, wait 1 hour, then take another tablet. After that carry on as normal. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Always leave at least an hour between Stalevo tablets, to avoid possible side effects.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">If you stop taking Stalevo <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Do not stop taking Stalevo unless your doctor tells you to. In such a case your doctor may need to adjust your other antiparkinson medicines, especially levodopa, to give sufficient control of your symptoms. If you suddenly stop taking Stalevo and other antiparkinsonian medicines it may result in unwanted side effects. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">If you have any further questions on the use of this medicine, ask your doctor or pharmacist.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">4.       <\/span><span lang=\"EN-GB\">Possible side effects<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.4pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.4pt;line-height:normal\"><span lang=\"EN-GB\">Like all medicines, this medicine can cause side effects, although not everybody gets them. Many of the side effects can be relieved by adjusting the dose. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.4pt;line-height:normal\"><\/p> <p class=\"Text\" style=\"margin-top:0in\"><span style=\"font-size:11.0pt\">If you\r during the treatment with Stalevo experience the following symptoms, <b>contact your doctor immediately<\/b>: <\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:25.65pt;margin-bottom:.0001pt;text-indent:-25.65pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span style=\"font-size:11.0pt\">Your muscles get very rigid or jerk violently, you get tremors, agitation, confusion, fever, rapid pulse, or wide fluctuations in your blood pressure. These can be symptoms <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">of neuroleptic malignant syndrome (NMS, a rare severe reaction to medicines used to treat disorders of the central nervous system) or rhabdomyolysis (a rare severe muscle disorder).<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:25.65pt;margin-bottom:.0001pt;text-indent:-25.65pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Allergic reaction, the signs may include hives (nettle rash), itching, rash, swelling of your face, lips, tongue or throat. This may cause difficulties in breathing or swallowing.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.4pt;line-height:normal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Very common (may affect more than 1 in 10 people)<\/span><\/u><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">uncontrolled movements (dyskinesias)<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">feeling sick (nausea)<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">harmless reddish-brown discolouration of urine<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">muscle pain<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">diarrhoea<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Common (may affect up to 1 in 10 people)<\/span><\/u><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">light-headedness or fainting due to low blood pressure, high blood pressure<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">worsening of Parkinson\u2019s symptoms, dizziness, drowsiness<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">vomiting, abdominal pain and discomfort, heartburn, dry mouth, constipation<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">inability to sleep, hallucinations, confusion abnormal dreams (including nightmares), tiredness<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">mental changes \u2013 including problems with memory, anxiety and depression (possibly with thoughts of suicide) <\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span style=\"font-size:11.0pt\">heart or artery disease events (e.g. chest pain), irregular heart rate or rhythm <\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">more frequent falling <\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">shortness of breath <\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">increased sweating, rashes<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">muscle cramps, swelling of legs<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">blurred vision<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">anaemia<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">decreased appetite, decreased weight<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">headache, joint pain<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">urinary tract infection<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Uncommon <\/span><\/u><u><span style=\"font-size:11.0pt;color:black\">(may affect up to 1 in 100 people)<\/span><\/u><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">heart attack<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">bleeding in the gut<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">changes in the blood cell count which may result in bleeding, abnormal liver function tests<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">convulsions<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">feeling agitated<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">psychotic symptoms<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">colitis (inflammation of the colon)<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">discolourations other than urine (e.g. skin, nail, hair, sweat)<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">swallowing difficulties<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span style=\"font-size:11.0pt\">inability to urinate<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Not known (cannot be estimated from the available data)<\/span><\/u><\/p> <p class=\"Text\" style=\"margin-top:0in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Craving for large doses of Stalevo in excess of that required to control motor symptoms, known as dopamine dysregulation syndrome. Some patients experience severe abnormal involuntary movements (dyskinesias), mood swings or other side effects after taking large doses of Stalevo.<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in\"><\/p> <p class=\"Text\" style=\"margin-top:0in\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">The following side effects have also been reported<\/span><\/u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">:<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">hepatitis <\/span><span style=\"font-size:11.0pt\">(inflammation of the liver)<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">itching<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:25.65pt;margin-bottom:.0001pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:4.8pt\"><u><span lang=\"EN-GB\" style=\"color:black\">You may experience the following side effects: <\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:4.8pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif;color:black'>-<\/span><span lang=\"EN-GB\" style=\"color:black\">Inability to resist the impulse to perform an action that could be harmful, which may include:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:4.8pt;margin-bottom:0in;\r margin-left:42.55pt;margin-bottom:.0001pt;text-indent:-14.2pt;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif;color:black'>-<\/span><span lang=\"EN-GB\" style=\"color:black\">strong impulse to gamble excessively despite serious personal or family consequences<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:4.8pt;margin-bottom:0in;\r margin-left:42.55pt;margin-bottom:.0001pt;text-indent:-14.2pt;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif;color:black'>-<\/span><span lang=\"EN-GB\" style=\"color:black\">altered or increased sexual interest and behaviour of significant concern to you or to others for example, an increased sexual drive<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:4.8pt;margin-bottom:0in;\r margin-left:42.55pt;margin-bottom:.0001pt;text-indent:-14.2pt;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif;color:black'>-<\/span><span lang=\"EN-GB\" style=\"color:black\">uncontrollable excessive shopping or spending<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:4.8pt;margin-bottom:0in;\r margin-left:42.55pt;margin-bottom:.0001pt;text-indent:-14.2pt;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif;color:black'>-<\/span><span lang=\"EN-GB\" style=\"color:black\">binge eating (eating large amounts of food in a short time period) or compulsive eating (eating more food than normal and more than is needed to satisfy your hunger).<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:4.8pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:4.8pt\"><span lang=\"EN-GB\" style=\"color:black\">Tell your doctor if you experience any of these behaviours; they will discuss ways of managing or reducing the symptoms.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><b><span lang=\"EN-GB\">Reporting of side effects<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">If you get any side effects, talk to your doctor or pharmacist. This\r includes any possible side effects not listed in this leaflet. You can also\r report side effects directly via <span style=\"background:silver\">the national\r reporting system listed in <a href=\"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Template_or_form\/2013\/03\/WC500139752.doc\">Appendix\r V<\/a><\/span>. By reporting side effects you can help provide more information\r on the safety of this medicine.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">5.       <\/span><span lang=\"EN-GB\">How to store Stalevo<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Keep this medicine out of the sight and reach of children.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Do not use this medicine after the expiry date which is stated on the bottle and the carton after EXP. The expiry date refers to the last day of that month.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">This medicinal product does not require any special storage conditions.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Do not <\/span><span lang=\"EN-GB\">throw away any medicines<\/span><span lang=\"EN-GB\"> via wastewater or household waste. Ask your pharmacist how to <\/span><span lang=\"EN-GB\">throw away <\/span><span lang=\"EN-GB\">medicines you no longer use. These measures will help to protect the environment.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">6.       <\/span><span lang=\"EN-GB\">Contents of the pack and other information<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">What Stalevo contains<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:27.0pt;margin-bottom:.0001pt;text-indent:-27.0pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">The active substances of Stalevo are levodopa, carbidopa and entacapone.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Each Stalevo 75 mg\/18.75 mg\/200 mg tablet contains 75 mg of levodopa, 18.75 mg of carbidopa and 200 mg of entacapone.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">The other ingredients in the tablet core are croscarmellose sodium, magnesium stearate, maize starch, mannitol (E421) and povidone (E1201)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">The ingredients in the film-coating are glycerol (85 per cent) (E422), hypromellose, magnesium stearate, polysorbate 80, red iron oxide (E172), sucrose, and titanium dioxide (E171).<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;line-height:\r normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;line-height:\r normal\"><b><span lang=\"EN-GB\">What Stalevo looks like and contents of the pack<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;line-height:\r normal\"><\/p> <p class=\"MsoEndnoteText\"><span lang=\"EN-GB\">Stalevo 75 mg\/18.75 mg\/200 mg: light brownish red, oval film-coated tablets marked with \u2018LCE 75\u2019 on one side.<\/span><\/p> <p class=\"MsoEndnoteText\"><\/p> <p class=\"MsoEndnoteText\"><span lang=\"EN-GB\">Stalevo 75 mg\/18.75 mg\/200 mg tablet comes in five different pack sizes (10, 30, 100, 130 or 175 tablets). Not all pack sizes may be marketed.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;line-height:\r normal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Marketing Authorisation Holder<\/span><\/b><\/p> <p class=\"MsoEndnoteText\"><span lang=\"IT\">Orion Corporation<\/span><\/p> <p class=\"MsoEndnoteText\"><span lang=\"IT\">Orionintie 1<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"IT\">FI-02200 Espoo<\/span><\/p> <p class=\"MsoEndnoteText\"><span lang=\"IT\">Finland<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><b><span lang=\"EN-GB\">Manufacturer<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><span lang=\"EN-GB\">Orion Corporation Orion Pharma<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><span lang=\"EN-GB\">Joensuunkatu 7<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><span lang=\"EN-GB\">FI-24100 Salo<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Finland<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><span lang=\"EN-GB\">Orion Corporation Orion Pharma<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><span lang=\"EN-GB\">Orionintie 1<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><span lang=\"EN-GB\">FI-02200 Espoo<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Finland<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse\" width=\"628\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"MsoNormal\"><b><span lang=\"FR\">Belgi\u00eb\/Belgique\/Belgien<\/span><\/b><span lang=\"FR\"><br\/> <\/span><strong><span lang=\"EN-GB\" style=\"font-weight:normal\">Orion Pharma   BVBA\/SPRL<\/span><\/strong><\/p> <p class=\"Text\" style=\"margin-top:0in\"><span style=\"font-size:11.0pt\">T\u00e9l\/Tel:   +32 (0)15 64 10 20<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"FI\">Lietuva<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"FI\">UAB Orion Pharma<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"FI\">Tel. +370 5 276 9499<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"color:black\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Orion Pharma Poland Sp z.o.o.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Tel.: + 48 22 833317<\/span><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"DE\">Luxembourg\/Luxemburg<\/span><\/b><span lang=\"DE\"><br\/> <\/span><strong><span lang=\"EN-GB\" style=\"font-weight:normal\">Orion Pharma   BVBA\/SPRL<\/span><\/strong><\/p> <p class=\"Text\" style=\"margin-top:0in\"><span style=\"font-size:11.0pt\">T\u00e9l\/Tel:   +32 (0)15 64 10 20<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"MsoNormal\"><b><span lang=\"SV\">\u010cesk\u00e1 republika<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"FI\">Orion Pharma s.r.o.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel:  <\/span><span lang=\"SV\">+420 234 703   305<\/span><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"SV\">Magyarorsz\u00e1g<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:13.0pt\"><strong><span lang=\"EN-GB\" style=\"font-weight:normal\">Orion Pharma Kft.<\/span><\/strong><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel.: +<\/span><span lang=\"EN-GB\">36 1 239   9095<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><b><span lang=\"EN-GB\">Danmark<\/span><\/b><span lang=\"EN-GB\"><br\/>\r   Orion Pharma A\/S<br\/>\r   Tlf: +45 8614 0000<\/span><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"FR\">Malta<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"IT\">Salomone Pharma<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-2.25pt;margin-bottom:\r   9.0pt;margin-left:0in\"><span lang=\"IT\">Tel: +356 21220174<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><b><span lang=\"DE\">Deutschland<\/span><\/b><span lang=\"DE\"> <br\/>\r   Orion Pharma GmbH<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><span lang=\"DE\">Tel: +49 40 899 6890<\/span><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"SV\">Nederland<\/span><\/b><span lang=\"SV\"><br\/> <\/span><strong><span lang=\"EN-GB\" style=\"font-weight:normal\">Orion Pharma   BVBA\/SPRL<\/span><\/strong><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:9.0pt;\r   margin-left:0in\"><span style=\"font-size:11.0pt\">T\u00e9l\/Tel: +32 (0)15 64 10 20<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"MsoNormal\"><b><span lang=\"FI\">Eesti<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"FI\">Orion Pharma Eesti O\u00dc<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"FI\">Tel: +372 66 44 550<\/span><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><b><span lang=\"EN-GB\">Norge<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Orion Pharma   AS<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-2.25pt;margin-bottom:\r   9.0pt;margin-left:0in\"><span lang=\"EN-GB\">Tlf: +47 40 00 42 10<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"Text\" style=\"margin-top:0in\"><b><span lang=\"EN-GB\" style=\"font-size:\r   11.0pt\">\u0395\u03bb\u03bb\u03ac\u03b4\u03b1<\/span><\/b><span lang=\"FI\" style=\"font-size:11.0pt\"><br\/>\r   Orion Pharma Hellas M.E.<\/span><span style=\"font-size:11.0pt\">\u03a0<\/span><span lang=\"FI\" style=\"font-size:11.0pt\">.E<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in\"><span style=\"font-size:11.0pt\">\u03a4\u03b7\u03bb<\/span><span lang=\"FI\" style=\"font-size:11.0pt\">: + 30 210 980 3355<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><b><span lang=\"DE\">\u00d6sterreich<\/span><\/b><span lang=\"DE\"><br\/>\r   Orion Pharma GmbH<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:9.0pt;\r   margin-left:0in\"><span lang=\"DE\" style=\"font-size:11.0pt\">Tel: +49 40 899 6890<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"Text\" style=\"margin-top:0in\"><b><span lang=\"IT\" style=\"font-size:11.0pt\">Espa\u00f1a<\/span><\/b><span lang=\"IT\" style=\"font-size:11.0pt\"><br\/> <\/span><span style=\"font-size:11.0pt\">Orion Pharma S.L.<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in\"><span style=\"font-size:11.0pt\">Tel: + 34   91  599 86 01<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Polska<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"SV\">Orion Pharma Poland Sp z.o.o.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:9.0pt\"><span lang=\"EN-GB\">Tel.: + 48 22   8333177<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"Text\" style=\"margin-top:0in\"><b><span lang=\"FR\" style=\"font-size:11.0pt\">France<\/span><\/b><span lang=\"FR\" style=\"font-size:11.0pt\"><br\/> <\/span><span style=\"font-size:11.0pt\">Centre Sp\u00e9cialit\u00e9s Pharmaceutiques<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in\"><span style=\"font-size:11.0pt\">Tel: + 33   (0) 1 47 04 80 46<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><b><span lang=\"IT\" style=\"font-size:11.0pt\">Portugal<\/span><\/b><span lang=\"IT\" style=\"font-size:11.0pt\"><br\/> <\/span><span style=\"font-size:11.0pt\">Orionfin Unipessoal Lda<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-2.25pt;margin-bottom:\r   9.0pt;margin-left:0in\"><span lang=\"EN-GB\">Tel: + 351 21 154 68 20<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><b><span lang=\"FI\">Hrvatska<\/span><\/b><\/p> <p class=\"MsoNormal\"><strong><span lang=\"FI\" style=\"font-weight:normal\">Orion   Pharma d.o.o.<\/span><\/strong><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><span lang=\"FI\">Tel:<\/span><span lang=\"FI\"> +386 (0) 1 600 8015<\/span><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"line-height:12.0pt;text-autospace:none\"><b><span lang=\"FR\" style=\"color:black\">Rom\u00e2nia<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"IT\">Orion Corporation<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"FR\" style=\"color:black\">Tel: +358 10 4261<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Ireland<\/span><\/b><span lang=\"EN-GB\"><br\/>\r   Orion Pharma (Ireland) Ltd.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">c\/o Allphar   Services Ltd.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: +353 1   428 7777<\/span><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"IT\">Slovenija<\/span><\/b><\/p> <p class=\"MsoNormal\"><strong><span lang=\"FI\" style=\"font-weight:normal\">Orion   Pharma d.o.o.<\/span><\/strong><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:9.0pt\"><span lang=\"FI\">Tel:<\/span><span lang=\"FI\"> +386 (0) 1 600 8015<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><b><span lang=\"EN-GB\">\u00cdsland<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Vistor hf.<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in\"><span style=\"font-size:11.0pt\">S\u00edmi:   +354 535 7000<\/span><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"SV\">Slovensk\u00e1 republika<\/span><\/b><\/p> <p class=\"MsoNormal\"><strong><span lang=\"SV\" style=\"font-weight:normal\">Orion   Pharma s.r.o<\/span><\/strong><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-2.25pt;margin-bottom:\r   9.0pt;margin-left:0in;line-height:normal\"><span lang=\"SV\">Tel: <\/span><span lang=\"SV\">+420 234 703 305<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"Text\" style=\"margin-top:0in\"><b><span lang=\"IT\" style=\"font-size:11.0pt\">Italia<\/span><\/b><span lang=\"IT\" style=\"font-size:11.0pt\"><br\/> <\/span><span lang=\"FI\" style=\"font-size:11.0pt\">Orion Pharma S.r.l.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:9.0pt\"><span lang=\"EN-GB\">Tel: + 39   02 67876111<\/span><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><b><span lang=\"IT\">Suomi\/Finland<br\/> <\/span><\/b><span lang=\"IT\">Orion Corporation<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><span lang=\"IT\">Puh.\/Tel: +358 10 4261<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"MsoNormal\"><b><span lang=\"EL\">\u039a\u03cd\u03c0\u03c1\u03bf\u03c2<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"DE\">Lifepharma (ZAM) Ltd<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">\u03a4\u03b7\u03bb<\/span><span lang=\"DE\">.:   +357 22056300<\/span><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><b><span lang=\"DE\">Sverige<\/span><\/b><span lang=\"DE\"><br\/>\r   Orion Pharma AB<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><span lang=\"DE\">Tel: +46 8 623 6440<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"MsoNormal\"><b><span lang=\"FI\">Latvija<\/span><\/b><\/p> <p class=\"MsoNormal\">Orion Corporation<\/p> <p class=\"MsoNormal\">Orion Pharma p\u0101rst\u0101vniec\u012bba<\/p> <p class=\"MsoNormal\">Tel: +371 20028332<\/p> <p class=\"MsoNormal\"> <\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><b><span lang=\"EN-GB\">United   Kingdom<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Orion Pharma   (UK) Ltd.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +44 1635 520 300<\/span><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><b><span lang=\"EN-GB\">This leaflet was last revised in.<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Other sources of information<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Detailed information on this medicine is\r available on the European Medicines Agency web site: <a href=\"http:\/\/www.ema.europa.eu\">http:\/\/www.ema.europa.eu<\/a>. <\/span><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\" style=\"color:black\">Package leaflet: Information for the user<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-right:-.1pt;text-align:center\"><b><span lang=\"EN-GB\">Stalevo 100 mg\/25 mg\/200 mg film-coated tablets<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"IT\">levodopa\/carbidopa\/entacapone<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:27.0pt;margin-bottom:.0001pt;text-indent:-27.0pt;line-height:normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">Keep this leaflet. You may need to read it again.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:27.0pt;margin-bottom:.0001pt;text-indent:-27.0pt;line-height:normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">If you have any further questions, ask your doctor or pharmacist.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:27.0pt;margin-bottom:.0001pt;text-indent:-27.0pt;line-height:normal\"><span lang=\"EN-GB\">-        This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">If you get any side effects, talk to your doctor or pharmacist.<\/span><span lang=\"EN-GB\">This includes any possible side effects not listed in this leaflet. See section 4.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">What is in this leaflet:<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">1.       What Stalevo is and what it is used for<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">2.       What you need to know before you take Stalevo<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">3.       How to take Stalevo<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">4.       Possible side effects<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">5        How to store Stalevo<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">6.       Contents of the pack and other information<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">1.       <\/span><span lang=\"EN-GB\">What Stalevo is and what it is used for<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p align=\"left\" class=\"MsoBodyText3\" style=\"text-align:left;line-height:normal\"><span lang=\"EN-GB\" style=\"font-weight:normal;font-style:normal\">Stalevo contains three active substances (levodopa, carbidopa and entacapone) in one film-coated tablet. Stalevo is used for the treatment of Parkinson\u2019s disease. <\/span><\/p> <p align=\"left\" class=\"MsoBodyText3\" style=\"text-align:left;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Parkinson\u2019s disease is caused by low levels of a substance called dopamine in the brain. Levodopa increases the amount of dopamine and hence reduces the symptoms of Parkinson\u2019s disease. Carbidopa and entacapone improve the antiparkinson effects of levodopa. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">2.       <\/span><span lang=\"EN-GB\">What you need to know before you take Stalevo<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Do not take Stalevo if you:<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">are allergic to levodopa, carbidopa or entacapone, or any of the other ingredients of this medicine <\/span><span style=\"font-size:11.0pt\">(listed in section 6)<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">have narrow-angle glaucoma (an eye disorder)<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">have a tumour of the adrenal gland<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">are taking certain medicines for treating depression (<\/span><span style=\"font-size:11.0pt\">combinations of <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">selective MAO-A and MAO-B inhibitors, or non-selective MAO-inhibitors)<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">have ever had neuroleptic malignant syndrome (NMS \u2013 this is a rare reaction to medicines used to treat severe mental disorders)<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">have ever had non-traumatic rhabdomyolysis (a rare muscle disorder)<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">have a severe liver disease. <\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Warnings and precautions<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Talk to your doctor or pharmacist before taking Stalevo if you have or have ever had<\/span><\/u><span lang=\"EN-GB\">:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">a heart attack or any other diseases of the heart including cardiac arrhythmias, or of the blood vessels<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">asthma or any other disease of the lungs<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">a liver problem, because your dose may need to be adjusted<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">kidney or hormone-related diseases<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">stomach ulcers or convulsions<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">if you experience prolonged diarrhoea consult your doctor as it may be a sign of inflammation of the colon<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">any form of severe mental disorder like psychosis<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">chronic wide-angle glaucoma, because your dose may need to be adjusted and the pressure in your eyes may need to be monitored.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Consult your doctor if you are currently taking<\/span><\/u><span lang=\"EN-GB\">:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">antipsychotics (medicines used to treat psychosis)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">a medicine which may cause low blood pressure when rising from a chair or bed. You should be aware that Stalevo may make these reactions worse.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Consult your doctor if during the treatment with Stalevo you<\/span><\/u><span lang=\"EN-GB\">:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><a name=\"OLE_LINK2\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">notice<\/span><\/a><span lang=\"EN-GB\"> that your\r muscles get very rigid or jerk violently, or if you get tremors, agitation,\r confusion, fever, rapid pulse, or wide fluctuations in your blood pressure. If\r any of this happens, <b>contact your doctor immediately<\/b><\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">feel depressed, have suicidal thoughts, or notice unusual changes in your behaviour<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">find yourself suddenly falling asleep, or if you feel very drowsy. If this happens, you should not drive or use any tools or machines (see also section 'Driving and using machines')<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">notice that uncontrolled movements begin or get worse after you started to take Stalevo. If this happens, your doctor may need to change the dose of your antiparkinson medicine <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">experience diarrhoea: monitoring of your weight is recommended in order to avoid potentially excessive weight loss<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">experience progressive anorexia, asthenia (weakness, exhaustion) and weight decrease within a relatively short period of time. If this happens, a general medical evaluation including liver function should be considered<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">feel the need to stop using Stalevo, see section 'If you stop taking Stalevo'.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Tell your doctor if you or your family\/carer notices you are developing addiction-like symptoms leading to craving for large doses of Stalevo and other medicines used to treat Parkinson\u2019s disease.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\">Tell your doctor if you or your family\/carer notices you are\r developing urges or cravings to behave in ways that are unusual for you or you\r cannot resist the impulse, drive or temptation to carry out certain activities\r that could harm yourself or others. These behaviours are called impulse control\r disorders and can include addictive gambling, excessive eating or spending, an\r abnormally high sex drive or a preoccupation with an increase in sexual\r thoughts or feelings. <u>Your doctor may need to review your treatments.<\/u><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Your doctor may take some regular laboratory tests during a long term treatment with Stalevo.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">If you must undergo surgery, please tell your doctor that you are using Stalevo.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Stalevo is not recommended to be used for treatment of extrapyramidal symptoms (e.g. involuntary movements, shaking, muscle rigidity and muscle contractions<\/span><span lang=\"EN\">)<\/span><span lang=\"EN-GB\"> caused by other medicines.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Children <\/span><span lang=\"EN-GB\" style=\"color:black\">and adolescents<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Experience with Stalevo in patients under 18 years is limited. Therefore, the use of Stalevo in children or adolescents is not recommended.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Other medicines and Stalevo<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoBodyText\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"font-weight:normal;font-style:normal\">Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.<\/span><\/p> <p class=\"MsoBodyText\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Do not take Stalevo if you are taking certain medicines for treating depression (combinations of selective MAO-A and MAO-B inhibitors, or non-selective MAO inhibitors).<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Stalevo may increase the effects and side effects of certain medicines. These include: <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">medicines used to treat depression such as moclobemide, amitriptyline, desipramine, maprotiline, venlafaxine and paroxetine<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">rimiterole and isoprenaline, used to treat respiratory diseases<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">adrenaline, used <\/span><span lang=\"PT\">for severe allergic reactions<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">noradrenaline, dopamine and dobutamine, used to treat heart diseases and low blood pressure<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-        alpha-methyldopa, used to treat high blood pressure <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-        apomorphine, which is used to treat Parkinson\u2019s disease.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">The effects of Stalevo may be weakened by certain medicines. These include: <\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-        dopamine antagonists used to treat mental disorders, nausea and vomiting<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-        phenytoin, used to prevent convulsions<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-        papaverine used to relax the muscles.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Stalevo may make it harder for you to digest iron. Therefore, do not take Stalevo and iron supplements at the same time. After taking one of them, wait at least 2 to 3 hours before taking the other.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Stalevo with food and drink<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoBodyText\" style=\"text-align:justify;line-height:normal\"><span lang=\"EN-GB\" style=\"font-weight:normal;font-style:normal\">Stalevo may be taken with or without food. For some patients, Stalevo may not be well absorbed if it is taken with, or shortly after eating protein-rich food (such as meats, fish, dairy products, seeds and nuts). Consult your doctor if you think this applies to you.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Pregnancy, breast-feeding and fertility<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoBodyText\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"font-weight:normal;font-style:normal\">If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. <\/span><\/p> <p class=\"MsoBodyText\" style=\"line-height:normal\"><\/p> <p class=\"MsoBodyText\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"font-weight:normal;font-style:normal\">You should not breast-feed during treatment with Stalevo.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Driving and using machines<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Stalevo may lower your blood pressure, which may make you feel light-headed or dizzy. Therefore, be particularly careful when you drive or when you use any tools or machines.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">If you feel very drowsy, or if you sometimes find yourself suddenly falling asleep, wait until you feel fully awake again before driving or doing anything else that requires you to be alert. Otherwise, you may put yourself and others at risk of serious injury or death.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Stalevo contains sucrose<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Stalevo contains sucrose (1.6 mg\/tablet). If you have been told by your doctor that you have intolerance to some sugars, contact your doctor before taking this medicinal product.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">3.       <\/span><span lang=\"EN-GB\">How to take Stalevo<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><u><span lang=\"EN-GB\">For adults and elderly<\/span><\/u><span lang=\"EN-GB\">:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-        Your doctor will tell you exactly how many tablets of Stalevo to take each day. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif'>-<\/span><span lang=\"EN-GB\">The tablets are not intended to be split or broken into smaller pieces.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif'>-<\/span><span lang=\"EN-GB\">You should take only one tablet each time.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif'>-<\/span><span lang=\"EN-GB\">Depending on how you respond to treatment, your doctor may suggest a higher or lower dose. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif'>-<\/span><span lang=\"EN-GB\">If you are taking Stalevo 50 mg\/12.5 mg\/200 mg, 75 mg\/18.75 mg\/200 mg, 100 mg\/25 mg\/200 mg, 125 mg\/31.25 mg\/200 mg or 150 mg\/37.5 mg\/200 mg tablets, do not take more than 10 tablets per day.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;text-align:justify;line-height:\r normal\"><span lang=\"EN-GB\">Talk to your doctor or pharmacist if you think the effect of Stalevo is too strong or too weak, or if you experience possible side effects.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;text-align:justify;line-height:\r 12.0pt\"><span lang=\"EN-GB\"><img border=\"0\" height=\"122\" src=\"data:image\/png;base64,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\" width=\"624\"\/><\/span><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">If you take more Stalevo than you should<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">If you have accidentally taken more Stalevo tablets than you should, talk to your doctor or pharmacist immediately. In case of an overdose you may feel confused or agitated, your heart rate may be slower or faster than normal or the colour of your skin, tongue, eyes or urine may change.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">If you forget to take Stalevo<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Do not take a double dose to make up for a forgotten tablet.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><u><span lang=\"EN-GB\">If it is more than 1 hour until your next dose<\/span><\/u><span lang=\"EN-GB\">: <\/span><\/p> <p class=\"MsoBodyText\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"font-weight:normal;font-style:normal\">Take one tablet as soon as you remember, and the next tablet at the normal time. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><u><span lang=\"EN-GB\">If it is less than 1 hour until your next dose<\/span><\/u><span lang=\"EN-GB\">: <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Take a tablet as soon as you remember, wait 1 hour, then take another tablet. After that carry on as normal.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Always leave at least an hour between Stalevo tablets, to avoid possible side effects.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">If you stop taking Stalevo <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Do not stop taking Stalevo unless your doctor tells you to. In such a case your doctor may need to adjust your other antiparkinson medicines, especially levodopa, to give sufficient control of your symptoms. If you suddenly stop taking Stalevo and other antiparkinsonian medicines it may result in unwanted side effects. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">If you have any further questions on the use of this medicine, ask your doctor or pharmacist.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">4.       <\/span><span lang=\"EN-GB\">Possible side effects<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.4pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.4pt;line-height:normal\"><span lang=\"EN-GB\">Like all medicines, this medicine can cause side effects, although not everybody gets them. Many of the side effects can be relieved by adjusting the dose. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.4pt;line-height:normal\"><\/p> <p class=\"Text\" style=\"margin-top:0in\"><span style=\"font-size:11.0pt\">If you\r during the treatment with Stalevo experience the following symptoms, <b>contact your doctor immediately<\/b>: <\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:25.65pt;margin-bottom:.0001pt;text-indent:-25.65pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span style=\"font-size:11.0pt\">Your muscles get very rigid or jerk violently, you get tremors, agitation, confusion, fever, rapid pulse, or wide fluctuations in your blood pressure. These can be symptoms <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">of neuroleptic malignant syndrome (NMS, a rare severe reaction to medicines used to treat disorders of the central nervous system) or rhabdomyolysis (a rare severe muscle disorder).<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:25.65pt;margin-bottom:.0001pt;text-indent:-25.65pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Allergic reaction, the signs may include hives (nettle rash), itching, rash, swelling of your face, lips, tongue or throat. This may cause difficulties in breathing or swallowing.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.4pt;line-height:normal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Very common (may affect more than 1 in 10 people)<\/span><\/u><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">uncontrolled movements (dyskinesias)<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">feeling sick (nausea)<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">harmless reddish-brown discolouration of urine<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">muscle pain<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">diarrhoea<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in\"><\/p> <p class=\"Normal11\"><u><span lang=\"FR\">Common (may affect up to 1 in 10 people)<\/span><\/u><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">light-headedness or fainting due to low blood pressure, high blood pressure<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">worsening of Parkinson\u2019s symptoms, dizziness, drowsiness<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">vomiting, abdominal pain and discomfort, heartburn, dry mouth, constipation<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">inability to sleep, hallucinations, confusion abnormal dreams (including nightmares), tiredness<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">mental changes \u2013 including problems with memory, anxiety and depression (possibly with thoughts of suicide) <\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span style=\"font-size:11.0pt\">heart or artery disease events (e.g. chest pain), irregular heart rate or rhythm <\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">more frequent falling <\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">shortness of breath <\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">increased sweating, rashes<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">muscle cramps, swelling of legs<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">blurred vision<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">anaemia<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">decreased appetite, decreased weight<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">headache, joint pain<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">urinary tract infection<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Uncommon <\/span><\/u><u><span style=\"font-size:11.0pt;color:black\">(may affect up to 1 in 100 people)<\/span><\/u><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">heart attack<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">bleeding in the gut<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">changes in the blood cell count which may result in bleeding, abnormal liver function tests<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">convulsions<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">feeling agitated<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">psychotic symptoms<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">colitis (inflammation of the colon)<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">discolourations other than urine (e.g. skin, nail, hair, sweat)<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">swallowing difficulties<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span style=\"font-size:11.0pt\">inability to urinate<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Not known (cannot be estimated from the available data)<\/span><\/u><\/p> <p class=\"Text\" style=\"margin-top:0in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Craving for large doses of Stalevo in excess of that required to control motor symptoms, known as dopamine dysregulation syndrome. Some patients experience severe abnormal involuntary movements (dyskinesias), mood swings or other side effects after taking large doses of Stalevo.<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in\"><\/p> <p class=\"Text\" style=\"margin-top:0in\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">The following side effects have also been reported<\/span><\/u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">: <\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">hepatitis <\/span><span style=\"font-size:11.0pt\">(inflammation of the liver)<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">itching<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:4.8pt\"><u><span lang=\"EN-GB\" style=\"color:black\">You may experience the following side effects: <\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:4.8pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif;color:black'>-<\/span><span lang=\"EN-GB\" style=\"color:black\">Inability to resist the impulse to perform an action that could be harmful, which may include:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:4.8pt;margin-bottom:0in;\r margin-left:42.55pt;margin-bottom:.0001pt;text-indent:-14.2pt;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif;color:black'>-<\/span><span lang=\"EN-GB\" style=\"color:black\">strong impulse to gamble excessively despite serious personal or family consequences<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:4.8pt;margin-bottom:0in;\r margin-left:42.55pt;margin-bottom:.0001pt;text-indent:-14.2pt;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif;color:black'>-<\/span><span lang=\"EN-GB\" style=\"color:black\">altered or increased sexual interest and behaviour of significant concern to you or to others, for example, an increased sexual drive<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:4.8pt;margin-bottom:0in;\r margin-left:42.55pt;margin-bottom:.0001pt;text-indent:-14.2pt;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif;color:black'>-<\/span><span lang=\"EN-GB\" style=\"color:black\">uncontrollable excessive shopping or spending<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:4.8pt;margin-bottom:0in;\r margin-left:42.55pt;margin-bottom:.0001pt;text-indent:-14.2pt;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif;color:black'>-<\/span><span lang=\"EN-GB\" style=\"color:black\">binge eating (eating large amounts of food in a short time period) or compulsive eating (eating more food than normal and more than is needed to satisfy your hunger).<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:4.8pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:4.8pt\"><span lang=\"EN-GB\" style=\"color:black\">Tell your doctor if you experience any of these behaviours; they will discuss ways of managing or reducing the symptoms.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><b><span lang=\"EN-GB\">Reporting of side effects<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">If you get any side effects, talk to your doctor or pharmacist. This\r includes any possible side effects not listed in this leaflet. You can also\r report side effects directly via <span style=\"background:silver\">the national\r reporting system listed in <a href=\"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Template_or_form\/2013\/03\/WC500139752.doc\">Appendix\r V<\/a><\/span>. By reporting side effects you can help provide more information\r on the safety of this medicine.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">5.       <\/span><span lang=\"EN-GB\">How to store Stalevo<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Keep this medicine out of the sight and reach of children.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Do not use this medicine after the expiry date which is stated on the bottle and the carton after EXP. The expiry date refers to the last day of that month.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">This medicinal product does not require any special storage conditions.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Do not <\/span><span lang=\"EN-GB\">throw away any medicines<\/span><span lang=\"EN-GB\"> via wastewater or household waste. Ask your pharmacist how to <\/span><span lang=\"EN-GB\">throw away<\/span><span lang=\"EN-GB\"> of medicines you no longer use. These measures will help to protect the environment.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">6.       <\/span><span lang=\"EN-GB\">Contents of the pack and other information<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">What Stalevo contains<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:27.0pt;margin-bottom:.0001pt;text-indent:-27.0pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">The active substances of Stalevo are levodopa, carbidopa and entacapone.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Each Stalevo 100 mg\/25 mg\/200 mg tablet contains 100 mg of levodopa, 25 mg of carbidopa and 200 mg of entacapone.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">The other ingredients in the tablet core are croscarmellose sodium, magnesium stearate, maize starch, mannitol (E421) and povidone (E1201)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">The ingredients in the film-coating are glycerol (85 per cent) (E422), hypromellose, magnesium stearate, polysorbate 80, red iron oxide (E172), sucrose, titanium dioxide (E171), and yellow iron oxide (E172).<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;line-height:\r normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;line-height:\r normal\"><b><span lang=\"EN-GB\">What Stalevo looks like and contents of the pack<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;line-height:\r normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">Stalevo 100 mg\/25 mg\/200 mg: brownish or greyish red, oval, unscored film-coated tablets marked with \u2018LCE 100\u2019 on one side.<\/span><\/p> <p class=\"MsoEndnoteText\"><\/p> <p class=\"MsoEndnoteText\"><span lang=\"EN-GB\">Stalevo comes in six different pack sizes (10, 30, 100, 130, 175 or 250 tablets). Not all pack sizes may be marketed.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;line-height:\r normal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Marketing Authorisation Holder<\/span><\/b><\/p> <p class=\"MsoEndnoteText\"><span lang=\"IT\">Orion Corporation<\/span><\/p> <p class=\"MsoEndnoteText\"><span lang=\"IT\">Orionintie 1<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"IT\">FI-02200 Espoo<\/span><\/p> <p class=\"MsoEndnoteText\"><span lang=\"IT\">Finland<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><b><span lang=\"EN-GB\">Manufacturer<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><span lang=\"EN-GB\">Orion Corporation Orion Pharma<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><span lang=\"EN-GB\">Joensuunkatu 7<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><span lang=\"EN-GB\">FI-24100 Salo<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Finland<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><span lang=\"EN-GB\">Orion Corporation Orion Pharma<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><span lang=\"EN-GB\">Orionintie 1<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><span lang=\"EN-GB\">FI-02200 Espoo<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Finland<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse\" width=\"628\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:234.75pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"313\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style='font-family:\"TimesNewRomanPS-BoldMT\",serif'>Belgi\u00eb\/Belgique\/Belgien<\/span><\/b><span lang=\"FR\"><br\/> <\/span><strong><span lang=\"EN-GB\" style=\"font-weight:normal\">Orion Pharma   BVBA\/SPRL<\/span><\/strong><\/p> <p class=\"Text\" style=\"margin-top:0in\"><span style=\"font-size:11.0pt\">T\u00e9l\/Tel:   +32 (0)15 64 10 20<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><\/p> <\/td> <td style=\"width:236.4pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"315\"> <p class=\"MsoNormal\"><b><span lang=\"FI\">Lietuva<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"FI\">UAB Orion Pharma<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"FI\">Tel. +370 5 276 9499<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:234.75pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"313\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"color:black\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Orion Pharma Poland Sp z.o.o.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Tel.: + 48 22 8333177<\/span><\/p> <\/td> <td style=\"width:236.4pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"315\"> <p class=\"MsoNormal\"><b><span lang=\"DE\">Luxembourg\/Luxemburg<\/span><\/b><span lang=\"DE\"><br\/> <\/span><strong><span lang=\"EN-GB\" style=\"font-weight:normal\">Orion Pharma   BVBA\/SPRL<\/span><\/strong><\/p> <p class=\"Text\" style=\"margin-top:0in\"><span style=\"font-size:11.0pt\">T\u00e9l\/Tel:   +32 (0)15 64 10 20<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:234.75pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"313\"> <p class=\"MsoNormal\"><b><span lang=\"SV\">\u010cesk\u00e1 republika<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"FI\">Orion Pharma s.r.o.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel:  <\/span><span lang=\"SV\">+420 234 703   305<\/span><\/p> <\/td> <td style=\"width:236.4pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"315\"> <p class=\"MsoNormal\"><b><span lang=\"SV\">Magyarorsz\u00e1g<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:13.0pt\"><strong><span lang=\"EN-GB\" style=\"font-weight:normal\">Orion Pharma Kft.<\/span><\/strong><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel.: +<\/span><span lang=\"EN-GB\">36 1 239   9095<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:234.75pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"313\"> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><b><span lang=\"EN-GB\">Danmark<\/span><\/b><span lang=\"EN-GB\"><br\/>\r   Orion Pharma A\/S<br\/>\r   Tlf: +45 8614 0000<\/span><\/p> <\/td> <td style=\"width:236.4pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"315\"> <p class=\"MsoNormal\"><b><span lang=\"FR\">Malta<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"IT\">Salomone Pharma<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-2.25pt;margin-bottom:\r   9.0pt;margin-left:0in\"><span lang=\"IT\">Tel: +356 21220174<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:234.75pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"313\"> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><b><span lang=\"DE\">Deutschland<\/span><\/b><span lang=\"DE\"><br\/>\r   Orion Pharma GmbH<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><span lang=\"DE\">Tel: +49 40 899 6890<\/span><\/p> <\/td> <td style=\"width:236.4pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"315\"> <p class=\"MsoNormal\"><b><span lang=\"SV\">Nederland<\/span><\/b><span lang=\"SV\"><br\/> <\/span><strong><span lang=\"EN-GB\" style=\"font-weight:normal\">Orion Pharma   BVBA\/SPRL<\/span><\/strong><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:9.0pt;\r   margin-left:0in\"><span style=\"font-size:11.0pt\">T\u00e9l\/Tel: +32 (0)15 64 10 20<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:234.75pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"313\"> <p class=\"MsoNormal\"><b><span lang=\"FI\">Eesti<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"FI\">Orion Pharma Eesti O\u00dc<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"FI\">Tel: +372 66 44 550<\/span><\/p> <\/td> <td style=\"width:236.4pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"315\"> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><b><span lang=\"EN-GB\">Norge<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Orion Pharma   AS<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-2.25pt;margin-bottom:\r   9.0pt;margin-left:0in\"><span lang=\"EN-GB\">Tlf: +47 40 00 42 10<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:234.75pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"313\"> <p class=\"Text\" style=\"margin-top:0in\"><b><span lang=\"EN-GB\" style=\"font-size:\r   11.0pt\">\u0395\u03bb\u03bb\u03ac\u03b4\u03b1<\/span><\/b><span lang=\"FI\" style=\"font-size:11.0pt\"> <br\/>\r   Orion Pharma Hellas M.E.<\/span><span style=\"font-size:11.0pt\">\u03a0<\/span><span lang=\"FI\" style=\"font-size:11.0pt\">.E<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in\"><span style=\"font-size:11.0pt\">\u03a4\u03b7\u03bb<\/span><span lang=\"FI\" style=\"font-size:11.0pt\">: + 30 210 980 3355<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><\/p> <\/td> <td style=\"width:236.4pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"315\"> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><b><span lang=\"DE\">\u00d6sterreich<\/span><\/b><span lang=\"DE\"><br\/>\r   Orion Pharma GmbH<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:9.0pt;\r   margin-left:0in\"><span lang=\"DE\" style=\"font-size:11.0pt\">Tel: +49 40 899 6890<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:234.75pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"313\"> <p class=\"Text\" style=\"margin-top:0in\"><b><span lang=\"IT\" style=\"font-size:11.0pt\">Espa\u00f1a<\/span><\/b><span lang=\"IT\" style=\"font-size:11.0pt\"><br\/> <\/span><span style=\"font-size:11.0pt\">Orion Pharma S.L.<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in\"><span style=\"font-size:11.0pt\">Tel: + 34   91  599 86 01<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><\/p> <\/td> <td style=\"width:236.4pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"315\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Polska<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"SV\">Orion Pharma Poland Sp z.o.o.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:9.0pt\"><span lang=\"EN-GB\">Tel.: + 48 22   8333177<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:234.75pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"313\"> <p class=\"Text\" style=\"margin-top:0in\"><b><span lang=\"FR\" style=\"font-size:11.0pt\">France<\/span><\/b><span lang=\"FR\" style=\"font-size:11.0pt\"><br\/> <\/span><span style=\"font-size:11.0pt\">Centre Sp\u00e9cialit\u00e9s Pharmaceutiques<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in\"><span style=\"font-size:11.0pt\">Tel: + 33   (0) 1 47 04 80 46<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><\/p> <\/td> <td style=\"width:236.4pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"315\"> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><b><span lang=\"IT\" style=\"font-size:11.0pt\">Portugal<\/span><\/b><span lang=\"IT\" style=\"font-size:11.0pt\"><br\/> <\/span><span style=\"font-size:11.0pt\">Orionfin Unipessoal Lda<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-2.25pt;margin-bottom:\r   9.0pt;margin-left:0in\"><span lang=\"EN-GB\">Tel: + 351 21 154 68 20<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:234.75pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"313\"> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><b><span lang=\"FI\">Hrvatska<\/span><\/b><\/p> <p class=\"MsoNormal\"><strong><span lang=\"FI\" style=\"font-weight:normal\">Orion   Pharma d.o.o.<\/span><\/strong><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><span lang=\"FI\">Tel:<\/span><span lang=\"FI\"> +386 (0) 1 600 8015<\/span><\/p> <\/td> <td style=\"width:236.4pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"315\"> <p class=\"MsoNormal\" style=\"line-height:12.0pt;text-autospace:none\"><b><span lang=\"FR\" style=\"color:black\">Rom\u00e2nia<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"IT\">Orion Corporation<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"FR\" style=\"color:black\">Tel: +358 10 4261<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:234.75pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"313\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Ireland<\/span><\/b><span lang=\"EN-GB\"><br\/>\r   Orion Pharma (Ireland) Ltd.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">c\/o Allphar   Services Ltd.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: +353 1   428 7777<\/span><\/p> <\/td> <td style=\"width:236.4pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"315\"> <p class=\"MsoNormal\"><b><span lang=\"IT\">Slovenija<\/span><\/b><\/p> <p class=\"MsoNormal\"><strong><span lang=\"FI\" style=\"font-weight:normal\">Orion   Pharma d.o.o.<\/span><\/strong><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:9.0pt\"><span lang=\"FI\">Tel:<\/span><span lang=\"FI\"> +386 (0) 1 600 8015<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:234.75pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"313\"> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><b><span lang=\"EN-GB\">\u00cdsland<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Vistor hf.<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in\"><span style=\"font-size:11.0pt\">S\u00edmi:   +354 535 7000<\/span><\/p> <\/td> <td style=\"width:236.4pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"315\"> <p class=\"MsoNormal\"><b><span lang=\"SV\">Slovensk\u00e1 republika<\/span><\/b><\/p> <p class=\"MsoNormal\"><strong><span lang=\"SV\" style=\"font-weight:normal\">Orion   Pharma s.r.o<\/span><\/strong><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-2.25pt;margin-bottom:\r   9.0pt;margin-left:0in;line-height:normal\"><span lang=\"SV\">Tel: <\/span><span lang=\"SV\">+420 234 703 305<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:234.75pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"313\"> <p class=\"Text\" style=\"margin-top:0in\"><b><span lang=\"IT\" style=\"font-size:11.0pt\">Italia<\/span><\/b><span lang=\"IT\" style=\"font-size:11.0pt\"><br\/> <\/span><span lang=\"FI\" style=\"font-size:11.0pt\">Orion Pharma S.r.l.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:9.0pt\"><span lang=\"EN-GB\">Tel: + 39   02 67876111<\/span><\/p> <\/td> <td style=\"width:236.4pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"315\"> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><b><span lang=\"IT\">Suomi\/Finland<br\/> <\/span><\/b><span lang=\"IT\">Orion Corporation<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><span lang=\"IT\">Puh.\/Tel: +358 10 4261<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:234.75pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"313\"> <p class=\"MsoNormal\"><b><span lang=\"EL\">\u039a\u03cd\u03c0\u03c1\u03bf\u03c2<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"DE\">Lifepharma (ZAM) Ltd<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">\u03a4\u03b7\u03bb<\/span><span lang=\"DE\">.:   +357 22056300<\/span><\/p> <\/td> <td style=\"width:236.4pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"315\"> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><b><span lang=\"DE\">Sverige<\/span><\/b><span lang=\"DE\"><br\/>\r   Orion Pharma AB<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><span lang=\"DE\">Tel: +46 8 623 6440<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:234.75pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"313\"> <p class=\"MsoNormal\"><b><span lang=\"FI\">Latvija<\/span><\/b><\/p> <p class=\"MsoNormal\">Orion Corporation<\/p> <p class=\"MsoNormal\">Orion Pharma p\u0101rst\u0101vniec\u012bba<\/p> <p class=\"MsoNormal\">Tel: +371 20028332<\/p> <p class=\"MsoNormal\"> <\/p> <\/td> <td style=\"width:236.4pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"315\"> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><b><span lang=\"EN-GB\">United   Kingdom<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Orion Pharma   (UK) Ltd.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +44 1635 520 300<\/span><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><b><span lang=\"EN-GB\">This leaflet was last revised in.<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Other sources of information<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Detailed information on this medicine is\r available on the European Medicines Agency web site: <a href=\"http:\/\/www.ema.europa.eu\">http:\/\/www.ema.europa.eu<\/a>. <\/span><\/p> <p class=\"MsoNormal\"><\/p> <b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\" style=\"color:black\">Package leaflet: Information for the user<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"IT\" style=\"text-transform:uppercase\">s<\/span><\/b><b><span lang=\"IT\">talevo <\/span><\/b><b><span lang=\"EN-GB\">125 mg\/31.25 mg\/200 mg<\/span><\/b><b><span lang=\"IT\"> film-coated tablets<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"IT\">levodopa\/carbidopa\/entacapone<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">Keep this leaflet. You may need to read it again.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">If you have any further questions, ask your doctor or pharmacist.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-        This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">If you get any side effects, talk to your doctor or pharmacist.<\/span><span lang=\"EN-GB\">This includes any possible side effects not listed in this leaflet. See section 4.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">What is in this leaflet:<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">1.       What Stalevo is and what it is used for<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">2.       What you need to know before you take Stalevo<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">3.       How to take Stalevo<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">4.       Possible side effects<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">5        How to store Stalevo<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">6.       Contents of the pack and other information<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">1.       <\/span><span lang=\"EN-GB\">What Stalevo is and what it is used for<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p align=\"left\" class=\"MsoBodyText3\" style=\"text-align:left;line-height:normal\"><span lang=\"EN-GB\" style=\"font-weight:normal;font-style:normal\">Stalevo contains three active substances (levodopa, carbidopa and entacapone) in one film-coated tablet. Stalevo is used for the treatment of Parkinson\u2019s disease. <\/span><\/p> <p align=\"left\" class=\"MsoBodyText3\" style=\"text-align:left;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Parkinson\u2019s disease is caused by low levels of a substance called dopamine in the brain. Levodopa increases the amount of dopamine and hence reduces the symptoms of Parkinson\u2019s disease. Carbidopa and entacapone improve the antiparkinson effects of levodopa. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">2.       <\/span><span lang=\"EN-GB\">What you need to know before you take Stalevo<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Do not take Stalevo if you:<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">are allergic to levodopa, carbidopa or entacapone, or any of the other ingredients of this medicine <\/span><span style=\"font-size:11.0pt\">(listed in section 6)<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">have narrow-angle glaucoma (an eye disorder)<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">have a tumour of the adrenal gland<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">are taking certain medicines for treating depression (<\/span><span style=\"font-size:11.0pt\">combinations of <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">selective MAO-A and MAO-B inhibitors, or non-selective MAO-inhibitors)<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">have ever had neuroleptic malignant syndrome (NMS \u2013 this is a rare reaction to medicines used to treat severe mental disorders)<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">have ever had non-traumatic rhabdomyolysis (a rare muscle disorder)<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">have a severe liver disease. <\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Warnings and precautions<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Talk to your doctor or pharmacist before taking Stalevo if you have or have ever had<\/span><\/u><span lang=\"EN-GB\">:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">a heart attack or any other diseases of the heart including cardiac arrhythmias, or of the blood vessels<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">asthma or any other disease of the lungs<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">a liver problem, because your dose may need to be adjusted<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">kidney or hormone-related diseases<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">stomach ulcers or convulsions<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">if you experience prolonged diarrhoea consult your doctor as it may be a sign of inflammation of the colon<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">any form of severe mental disorder like psychosis<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">chronic wide-angle glaucoma, because your dose may need to be adjusted and the pressure in your eyes may need to be monitored.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Consult your doctor if you are currently taking<\/span><\/u><span lang=\"EN-GB\">:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">antipsychotics (medicines used to treat psychosis)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">a medicine which may cause low blood pressure when rising from a chair or bed. You should be aware that Stalevo may make these reactions worse.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Consult your doctor if during the treatment with Stalevo you<\/span><\/u><span lang=\"EN-GB\">:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">notice that your muscles get very rigid or jerk\r violently, or if you get tremors, agitation, confusion, fever, rapid pulse, or\r wide fluctuations in your blood pressure. If any of this happens, <b>contact your doctor immediately<\/b><\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">feel depressed, have suicidal thoughts, or notice unusual changes in your behaviour<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">find yourself suddenly falling asleep, or if you feel very drowsy. If this happens, you should not drive or use any tools or machines (see also section 'Driving and using machines')<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">notice that uncontrolled movements begin or get worse after you started to take Stalevo. If this happens, your doctor may need to change the dose of your antiparkinson medicine <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">experience diarrhoea: monitoring of your weight is recommended in order to avoid potentially excessive weight loss<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">experience progressive anorexia, asthenia (weakness, exhaustion) and weight decrease within a relatively short period of time. If this happens, a general medical evaluation including liver function should be considered<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">feel the need to stop using Stalevo, see section 'If you stop taking Stalevo'.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Tell your doctor if you or your family\/carer notices you are developing addiction-like symptoms leading to craving for large doses of Stalevo and other medicines used to treat Parkinson\u2019s disease.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\">Tell your doctor if you or your family\/carer notices you are\r developing urges or cravings to behave in ways that are unusual for you or you\r cannot resist the impulse, drive or temptation to carry out certain activities\r that could harm yourself or others. These behaviours are called impulse control\r disorders and can include addictive gambling, excessive eating or spending, an\r abnormally high sex drive or a preoccupation with an increase in sexual\r thoughts or feelings. <u>Your doctor may need to review your treatments.<\/u> <\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Your doctor may take some regular laboratory tests during a long term treatment with Stalevo.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">If you must undergo surgery, please tell your doctor that you are using Stalevo.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Stalevo is not recommended to be used for treatment of extrapyramidal symptoms (e.g. involuntary movements, shaking, muscle rigidity and muscle contractions<\/span><span lang=\"EN\">)<\/span><span lang=\"EN-GB\"> caused by other medicines.<\/span><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Children <\/span><span lang=\"EN-GB\" style=\"color:black\">and adolescents<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Experience with Stalevo in patients under 18 years is limited. Therefore, the use of Stalevo in children or adolescents is not recommended.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Other medicines and Stalevo<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoBodyText\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"font-weight:normal;font-style:normal\">Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.<\/span><\/p> <p class=\"MsoBodyText\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Do not take Stalevo if you are taking certain medicines for treating depression (combinations of selective MAO-A and MAO-B inhibitors, or non-selective MAO inhibitors).<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Stalevo may increase the effects and side effects of certain medicines. These include: <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">medicines used to treat depression such as moclobemide, amitriptyline, desipramine, maprotiline, venlafaxine and paroxetine <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif'>-<\/span><span lang=\"EN-GB\">rimiterole and isoprenaline, used to treat respiratory diseases<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">adrenaline, used <\/span><span lang=\"PT\">for severe allergic reactions<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">noradrenaline, dopamine and dobutamine, used to treat heart diseases and low blood pressure<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-        alpha-methyldopa, used to treat high blood pressure <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-        apomorphine, which is used to treat Parkinson\u2019s disease.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">The effects of Stalevo may be weakened by certain medicines. These include: <\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-        dopamine antagonists used to treat mental disorders<\/span><span style=\"font-size:11.0pt\">, nausea and vomiting<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">phenytoin, used to prevent convulsions <\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">papaverine used to relax the muscles.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Stalevo may make it harder for you to digest iron. Therefore, do not take Stalevo and iron supplements at the same time. After taking one of them, wait at least 2 to 3 hours before taking the other.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Stalevo with food and drink<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoBodyText\" style=\"text-align:justify;line-height:normal\"><span lang=\"EN-GB\" style=\"font-weight:normal;font-style:normal\">Stalevo may be taken with or without food. For some patients, Stalevo may not be well absorbed if it is taken with, or shortly after eating protein-rich food (such as meats, fish, dairy products, seeds and nuts). Consult your doctor if you think this applies to you.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Pregnancy, breast-feeding and fertility<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoBodyText\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"font-weight:normal;font-style:normal\">If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. <\/span><\/p> <p class=\"MsoBodyText\" style=\"line-height:normal\"><\/p> <p class=\"MsoBodyText\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"font-weight:normal;font-style:normal\">You should not breast-feed during treatment with Stalevo.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Driving and using machines<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Stalevo may lower your blood pressure, which may make you feel light-headed or dizzy. Therefore, be particularly careful when you drive or when you use any tools or machines.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">If you feel very drowsy, or if you sometimes find yourself suddenly falling asleep, wait until you feel fully awake again before driving or doing anything else that requires you to be alert. Otherwise, you may put yourself and others at risk of serious injury or death.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Stalevo contains sucrose<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Stalevo contains sucrose (1.6 mg\/tablet). If you have been told by your doctor that you have intolerance to some sugars, contact your doctor before taking this medicinal product.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">3.       <\/span><span lang=\"EN-GB\">How to take Stalevo<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><u><span lang=\"EN-GB\">For adults and elderly<\/span><\/u><span lang=\"EN-GB\">:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-        Your doctor will tell you exactly how many tablets of Stalevo to take each day. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif'>-<\/span><span lang=\"EN-GB\">The tablets are not intended to be split or broken into smaller pieces.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif'>-<\/span><span lang=\"EN-GB\">You should take only one tablet each time.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif'>-<\/span><span lang=\"EN-GB\">Depending on how you respond to treatment, your doctor may suggest a higher or lower dose. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif'>-<\/span><span lang=\"EN-GB\">If you are taking Stalevo 50 mg\/12.5 mg\/200 mg, 75 mg\/18.75 mg\/200 mg, 100 mg\/25 mg\/200 mg, 125 mg\/31.25 mg\/200 mg or 150 mg\/37.5 mg\/200 mg tablets, do not take more than 10 tablets per day.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;text-align:justify;line-height:\r normal\"><span lang=\"EN-GB\">Talk to your doctor or pharmacist if you think the effect of Stalevo is too strong or too weak, or if you experience possible side effects.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;text-align:justify;line-height:\r 12.0pt\"><span lang=\"EN-GB\"><img border=\"0\" height=\"122\" src=\"data:image\/png;base64,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\" width=\"624\"\/><\/span><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">If you take more Stalevo than you should<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">If you have accidentally taken more Stalevo tablets than you should, talk to your doctor or pharmacist immediately. In case of an overdose you may feel confused or agitated, your heart rate may be slower or faster than normal or the colour of your skin, tongue, eyes or urine may change.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">If you forget to take Stalevo<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Do not take a double dose to make up for a forgotten tablet.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><u><span lang=\"EN-GB\">If it is more than 1 hour until your next dose<\/span><\/u><span lang=\"EN-GB\">: <\/span><\/p> <p class=\"MsoBodyText\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"font-weight:normal;font-style:normal\">Take one tablet as soon as you remember, and the next tablet at the normal time. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><u><span lang=\"EN-GB\">If it is less than 1 hour until your next dose<\/span><\/u><span lang=\"EN-GB\">: <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Take a tablet as soon as you remember, wait 1 hour, then take another tablet. After that carry on as normal. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Always leave at least an hour between Stalevo tablets, to avoid possible side effects.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">If you stop taking Stalevo <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Do not stop taking Stalevo unless your doctor tells you to. In such a case your doctor may need to adjust your other antiparkinson medicines, especially levodopa, to give sufficient control of your symptoms. If you suddenly stop taking Stalevo and other antiparkinsonian medicines it may result in unwanted side effects. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">If you have any further questions on the use of this medicine, ask your doctor or pharmacist.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">4.       <\/span><span lang=\"EN-GB\">Possible side effects<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.4pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.4pt;line-height:normal\"><span lang=\"EN-GB\">Like all medicines, this medicine can cause side effects, although not everybody gets them. Many of the side effects can be relieved by adjusting the dose. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.4pt;line-height:normal\"><\/p> <p class=\"Text\" style=\"margin-top:0in\"><span style=\"font-size:11.0pt\">If you\r during the treatment with Stalevo experience the following symptoms, <b>contact your doctor immediately<\/b>: <\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-25.65pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span style=\"font-size:11.0pt\">Your muscles get very rigid or jerk violently, you get tremors, agitation, confusion, fever, rapid pulse, or wide fluctuations in your blood pressure. These can be symptoms <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">of neuroleptic malignant syndrome (NMS, a rare severe reaction to medicines used to treat disorders of the central nervous system) or rhabdomyolysis (a rare severe muscle disorder).<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-25.65pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Allergic reaction, the signs may include hives (nettle rash), itching, rash, swelling of your face, lips, tongue or throat. This may cause difficulties in breathing or swallowing.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.4pt;line-height:normal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Very common (may affect more than 1 in 10 people)<\/span><\/u><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">uncontrolled movements (dyskinesias)<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">feeling sick (nausea)<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">harmless reddish-brown discolouration of urine<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">muscle pain<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">diarrhoea<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Common (may affect up to 1 in 10 people)<\/span><\/u><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">light-headedness or fainting due to low blood pressure, high blood pressure<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">worsening of Parkinson\u2019s symptoms, dizziness, drowsiness<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">vomiting, abdominal pain and discomfort, heartburn, dry mouth, constipation<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">inability to sleep, hallucinations, confusion abnormal dreams (including nightmares), tiredness<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">mental changes \u2013 including problems with memory, anxiety and depression (possibly with thoughts of suicide) <\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span style=\"font-size:11.0pt\">heart or artery disease events (e.g. chest pain), irregular heart rate or rhythm <\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">more frequent falling <\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">shortness of breath <\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">increased sweating, rashes<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">muscle cramps, swelling of legs<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">blurred vision <\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">anaemia<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">decreased appetite, decreased weight<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">headache, joint pain<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">urinary tract infection<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Uncommon <\/span><\/u><u><span style=\"font-size:11.0pt;color:black\">(may affect up to 1 in 100 people)<\/span><\/u><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">heart attack<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">bleeding in the gut<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">changes in the blood cell count which may result in bleeding, abnormal liver function tests<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">convulsions<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">feeling agitated<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">psychotic symptoms<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">colitis (inflammation of the colon)<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">discolourations other than urine (e.g. skin, nail, hair, sweat)<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">swallowing difficulties<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span style=\"font-size:11.0pt\">inability to urinate<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Not known (cannot be estimated from the available data)<\/span><\/u><\/p> <p class=\"Text\" style=\"margin-top:0in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Craving for large doses of Stalevo in excess of that required to control motor symptoms, known as dopamine dysregulation syndrome. Some patients experience severe abnormal involuntary movements (dyskinesias), mood swings or other side effects after taking large doses of Stalevo.<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in\"><\/p> <p class=\"Text\" style=\"margin-top:0in\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">The following side effects have also been reported<\/span><\/u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">: <\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">hepatitis <\/span><span style=\"font-size:11.0pt\">(inflammation of the liver)<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">itching<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:4.8pt\"><u><span lang=\"EN-GB\" style=\"color:black\">You may experience the following side effects: <\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:4.8pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif;color:black'>-<\/span><span lang=\"EN-GB\" style=\"color:black\">Inability to resist the impulse to perform an action that could be harmful, which may include:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:4.8pt;margin-bottom:0in;\r margin-left:42.55pt;margin-bottom:.0001pt;text-indent:-14.2pt;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif;color:black'>-<\/span><span lang=\"EN-GB\" style=\"color:black\">strong impulse to gamble excessively despite serious personal or family consequences<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:4.8pt;margin-bottom:0in;\r margin-left:42.55pt;margin-bottom:.0001pt;text-indent:-14.2pt;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif;color:black'>-<\/span><span lang=\"EN-GB\" style=\"color:black\">altered or increased sexual interest and behaviour of significant concern to you or to others, for example, an increased sexual drive<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:4.8pt;margin-bottom:0in;\r margin-left:42.55pt;margin-bottom:.0001pt;text-indent:-14.2pt;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif;color:black'>-<\/span><span lang=\"EN-GB\" style=\"color:black\">uncontrollable excessive shopping or spending<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:4.8pt;margin-bottom:0in;\r margin-left:42.55pt;margin-bottom:.0001pt;text-indent:-14.2pt;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif;color:black'>-<\/span><span lang=\"EN-GB\" style=\"color:black\">binge eating (eating large amounts of food in a short time period) or compulsive eating (eating more food than normal and more than is needed to satisfy your hunger).<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:4.8pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:4.8pt\"><span lang=\"EN-GB\" style=\"color:black\">Tell your doctor if you experience any of these behaviours; they will discuss ways of managing or reducing the symptoms.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><b><span lang=\"EN-GB\">Reporting of side effects<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">If you get any side effects, talk to your doctor or pharmacist. This\r includes any possible side effects not listed in this leaflet. You can also\r report side effects directly via <span style=\"background:silver\">the national\r reporting system listed in <a href=\"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Template_or_form\/2013\/03\/WC500139752.doc\">Appendix\r V<\/a><\/span>. By reporting side effects you can help provide more information\r on the safety of this medicine.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">5.       <\/span><span lang=\"EN-GB\">How to store Stalevo<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Keep this medicine out of the sight and reach of children.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Do not use this medicine after the expiry date which is stated on the bottle and the carton after EXP. The expiry date refers to the last day of that month.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">This medicinal product does not require any special storage conditions.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Do not <\/span><span lang=\"EN-GB\">throw away any medicines<\/span><span lang=\"EN-GB\"> via wastewater or household waste. Ask your pharmacist how to <\/span><span lang=\"EN-GB\">throw away<\/span><span lang=\"EN-GB\"> medicines you no longer use. These measures will help to protect the environment.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">6.       <\/span><span lang=\"EN-GB\">Contents of the pack and other information<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">What Stalevo contains<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:27.0pt;margin-bottom:.0001pt;text-indent:-27.0pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">The active substances of Stalevo are levodopa, carbidopa and entacapone.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Each Stalevo 125 mg\/31.25 mg\/200 mg tablet contains 125 mg of levodopa, 31.25 mg of carbidopa and 200 mg of entacapone.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">The other ingredients in the tablet core are croscarmellose sodium, magnesium stearate, maize starch, mannitol (E421) and povidone (E1201)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">The ingredients in the film-coating are glycerol (85 per cent) (E422), hypromellose, magnesium stearate, polysorbate 80, red iron oxide (E172), sucrose, and titanium dioxide (E171).<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;line-height:\r normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;line-height:\r normal\"><b><span lang=\"EN-GB\">What Stalevo looks like and contents of the pack<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;line-height:\r normal\"><\/p> <p class=\"MsoEndnoteText\"><span lang=\"EN-GB\">Stalevo 125 mg\/31.25 mg\/200 mg: light brownish red, oval film-coated tablets marked with \u2018LCE 125\u2019 on one side.<\/span><\/p> <p class=\"MsoEndnoteText\"><\/p> <p class=\"MsoEndnoteText\"><span lang=\"EN-GB\">Stalevo 125 mg\/31.25 mg\/200 mg tablet comes in five different pack sizes (10, 30, 100, 130 or 175 tablets). Not all pack sizes may be marketed.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;line-height:\r normal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Marketing Authorisation Holder<\/span><\/b><\/p> <p class=\"MsoEndnoteText\"><span lang=\"IT\">Orion Corporation<\/span><\/p> <p class=\"MsoEndnoteText\"><span lang=\"IT\">Orionintie 1<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"IT\">FI-02200 Espoo<\/span><\/p> <p class=\"MsoEndnoteText\"><span lang=\"IT\">Finland<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><b><span lang=\"EN-GB\">Manufacturer<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><span lang=\"EN-GB\">Orion Corporation Orion Pharma<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><span lang=\"EN-GB\">Joensuunkatu 7<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><span lang=\"EN-GB\">FI-24100 Salo<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Finland<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><span lang=\"EN-GB\">Orion Corporation Orion Pharma<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><span lang=\"EN-GB\">Orionintie 1<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><span lang=\"EN-GB\">FI-02200 Espoo<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Finland<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse\" width=\"628\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style='font-family:\"TimesNewRomanPS-BoldMT\",serif'>Belgi\u00eb\/Belgique\/Belgien<\/span><\/b><span lang=\"FR\"><br\/> <\/span><strong><span lang=\"EN-GB\" style=\"font-weight:normal\">Orion Pharma   BVBA\/SPRL<\/span><\/strong><\/p> <p class=\"Text\" style=\"margin-top:0in\"><span style=\"font-size:11.0pt\">T\u00e9l\/Tel:   +32 (0)15 64 10 20<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"FI\">Lietuva<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"FI\">UAB Orion Pharma<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"FI\">Tel. +370 5 276 9499<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"color:black\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Orion Pharma Poland Sp z.o.o.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Tel.: + 48 22 8333177<\/span><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"DE\">Luxembourg\/Luxemburg<\/span><\/b><span lang=\"DE\"><br\/> <\/span><strong><span lang=\"EN-GB\" style=\"font-weight:normal\">Orion Pharma   BVBA\/SPRL<\/span><\/strong><\/p> <p class=\"Text\" style=\"margin-top:0in\"><span style=\"font-size:11.0pt\">T\u00e9l\/Tel:   +32 (0)15 64 10 20<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"MsoNormal\"><b><span lang=\"SV\">\u010cesk\u00e1 republika<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"FI\">Orion Pharma s.r.o.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel:  <\/span><span lang=\"SV\">+420 234 703   305<\/span><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"SV\">Magyarorsz\u00e1g<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:13.0pt\"><strong><span lang=\"EN-GB\" style=\"font-weight:normal\">Orion Pharma Kft.<\/span><\/strong><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel.: +<\/span><span lang=\"EN-GB\">36 1 239   9095<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><b><span lang=\"EN-GB\">Danmark<\/span><\/b><span lang=\"EN-GB\"><br\/>\r   Orion Pharma A\/S<br\/>\r   Tlf: +45 8614 0000<\/span><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"FR\">Malta<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"IT\">Salomone Pharma<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-2.25pt;margin-bottom:\r   9.0pt;margin-left:0in\"><span lang=\"IT\">Tel: +356 21220174<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><b><span lang=\"DE\">Deutschland<\/span><\/b><span lang=\"DE\"> <br\/>\r   Orion Pharma GmbH<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><span lang=\"DE\">Tel: +49 40 899 6890<\/span><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"SV\">Nederland<\/span><\/b><span lang=\"SV\"><br\/> <\/span><strong><span lang=\"EN-GB\" style=\"font-weight:normal\">Orion Pharma   BVBA\/SPRL<\/span><\/strong><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:9.0pt;\r   margin-left:0in\"><span style=\"font-size:11.0pt\">T\u00e9l\/Tel: +32 (0)15 64 10 20<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"MsoNormal\"><b><span lang=\"FI\">Eesti<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"FI\">Orion Pharma Eesti O\u00dc<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"FI\">Tel: +372 66 44 550<\/span><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><b><span lang=\"EN-GB\">Norge<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Orion Pharma   AS<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-2.25pt;margin-bottom:\r   9.0pt;margin-left:0in\"><span lang=\"EN-GB\">Tlf: +47 40 00 42 10<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"Text\" style=\"margin-top:0in\"><b><span lang=\"EN-GB\" style=\"font-size:\r   11.0pt\">\u0395\u03bb\u03bb\u03ac\u03b4\u03b1<\/span><\/b><span lang=\"FI\" style=\"font-size:11.0pt\"> <br\/>\r   Orion Pharma Hellas M.E.<\/span><span style=\"font-size:11.0pt\">\u03a0<\/span><span lang=\"FI\" style=\"font-size:11.0pt\">.E<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in\"><span style=\"font-size:11.0pt\">\u03a4\u03b7\u03bb<\/span><span lang=\"FI\" style=\"font-size:11.0pt\">: + 30 210 980 3355<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><b><span lang=\"DE\">\u00d6sterreich<\/span><\/b><span lang=\"DE\"><br\/>\r   Orion Pharma GmbH<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:9.0pt;\r   margin-left:0in\"><span lang=\"DE\" style=\"font-size:11.0pt\">Tel: +49 40 899 6890<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"Text\" style=\"margin-top:0in\"><b><span lang=\"IT\" style=\"font-size:11.0pt\">Espa\u00f1a<\/span><\/b><span lang=\"IT\" style=\"font-size:11.0pt\"> <br\/> <\/span><span style=\"font-size:11.0pt\">Orion Pharma S.L.<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in\"><span style=\"font-size:11.0pt\">Tel: + 34   91  599 86 01<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Polska<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"SV\">Orion Pharma Poland Sp z.o.o.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:9.0pt\"><span lang=\"EN-GB\">Tel.: + 48 22   8333177<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"Text\" style=\"margin-top:0in\"><b><span lang=\"FR\" style=\"font-size:11.0pt\">France<\/span><\/b><span lang=\"FR\" style=\"font-size:11.0pt\"> <br\/> <\/span><span style=\"font-size:11.0pt\">Centre Sp\u00e9cialit\u00e9s Pharmaceutiques<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in\"><span style=\"font-size:11.0pt\">Tel: + 33   (0) 1 47 04 80 46<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><b><span lang=\"IT\" style=\"font-size:11.0pt\">Portugal<\/span><\/b><span lang=\"IT\" style=\"font-size:11.0pt\"><br\/> <\/span><span style=\"font-size:11.0pt\">Orionfin Unipessoal Lda<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-2.25pt;margin-bottom:\r   9.0pt;margin-left:0in\"><span lang=\"EN-GB\">Tel: + 351 21 154 68 20<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><b><span lang=\"FI\">Hrvatska<\/span><\/b><\/p> <p class=\"MsoNormal\"><strong><span lang=\"FI\" style=\"font-weight:normal\">Orion   Pharma d.o.o.<\/span><\/strong><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><span lang=\"FI\">Tel:<\/span><span lang=\"FI\"> +386 (0) 1 600 8015<\/span><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"line-height:12.0pt;text-autospace:none\"><b><span lang=\"FR\" style=\"color:black\">Rom\u00e2nia<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"IT\">Orion Corporation<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"FR\" style=\"color:black\">Tel: +358 10 4261<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Ireland<\/span><\/b><span lang=\"EN-GB\"><br\/>\r   Orion Pharma (Ireland) Ltd.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">c\/o Allphar   Services Ltd.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: +353 1   428 7777<\/span><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"IT\">Slovenija<\/span><\/b><\/p> <p class=\"MsoNormal\"><strong><span lang=\"FI\" style=\"font-weight:normal\">Orion   Pharma d.o.o.<\/span><\/strong><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:9.0pt\"><span lang=\"FI\">Tel:<\/span><span lang=\"FI\"> +386 (0) 1 600 8015<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><b><span lang=\"EN-GB\">\u00cdsland<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Vistor hf.<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in\"><span style=\"font-size:11.0pt\">S\u00edmi:   +354 535 7000<\/span><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"SV\">Slovensk\u00e1 republika<\/span><\/b><\/p> <p class=\"MsoNormal\"><strong><span lang=\"SV\" style=\"font-weight:normal\">Orion   Pharma s.r.o<\/span><\/strong><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-2.25pt;margin-bottom:\r   9.0pt;margin-left:0in;line-height:normal\"><span lang=\"SV\">Tel: <\/span><span lang=\"SV\">+420 234 703 305<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"Text\" style=\"margin-top:0in\"><b><span lang=\"IT\" style=\"font-size:11.0pt\">Italia<\/span><\/b><span lang=\"IT\" style=\"font-size:11.0pt\"><br\/> <\/span><span lang=\"FI\" style=\"font-size:11.0pt\">Orion Pharma S.r.l.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:9.0pt\"><span lang=\"EN-GB\">Tel: + 39   02 67876111<\/span><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><b><span lang=\"IT\">Suomi\/Finland<br\/> <\/span><\/b><span lang=\"IT\">Orion Corporation<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><span lang=\"IT\">Puh.\/Tel: +358 10 4261<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"MsoNormal\"><b><span lang=\"EL\">\u039a\u03cd\u03c0\u03c1\u03bf\u03c2<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"DE\">Lifepharma (ZAM) Ltd<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">\u03a4\u03b7\u03bb<\/span><span lang=\"DE\">.:   +357 22056300<\/span><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><b><span lang=\"DE\">Sverige<\/span><\/b><span lang=\"DE\"><br\/>\r   Orion Pharma AB<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><span lang=\"DE\">Tel: +46 8 623 6440<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"MsoNormal\"><b><span lang=\"FI\">Latvija<\/span><\/b><\/p> <p class=\"MsoNormal\">Orion Corporation<\/p> <p class=\"MsoNormal\">Orion Pharma p\u0101rst\u0101vniec\u012bba<\/p> <p class=\"MsoNormal\">Tel: +371 20028332<\/p> <p class=\"MsoNormal\"> <\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><b><span lang=\"EN-GB\">United   Kingdom<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Orion Pharma   (UK) Ltd.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +44 1635 520 300<\/span><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><b><span lang=\"EN-GB\">This leaflet was last revised in.<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Other sources of information<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Detailed information on this medicine is\r available on the European Medicines Agency web site: <a href=\"http:\/\/www.ema.europa.eu\">http:\/\/www.ema.europa.eu<\/a>. <\/span><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\" style=\"color:black\">Package leaflet: Information for the user<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">Stalevo 150 mg\/37.5 mg\/200 mg film-coated tablets<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"IT\">levodopa\/carbidopa\/entacapone<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">Keep this leaflet. You may need to read it again.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">If you have any further questions, ask your doctor or pharmacist.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-        This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">If you get any side effects, talk to your doctor or pharmacist.<\/span><span lang=\"EN-GB\">This includes any possible side effects not listed in this leaflet. See section 4.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><\/p> <p class=\"Normal11\"><b><span lang=\"FR\">What is in this leaflet:<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">1.       What Stalevo is and what it is used for<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">2.       What you need to know before you take Stalevo<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">3.       How to take Stalevo<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">4.       Possible side effects<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">5        How to store Stalevo<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">6.       Contents of the pack and other information<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">1.       <\/span><span lang=\"EN-GB\">What Stalevo is and what it is used for<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p align=\"left\" class=\"MsoBodyText3\" style=\"text-align:left;line-height:normal\"><span lang=\"EN-GB\" style=\"font-weight:normal;font-style:normal\">Stalevo contains three active substances (levodopa, carbidopa and entacapone) in one film-coated tablet. Stalevo is used for the treatment of Parkinson\u2019s disease. <\/span><\/p> <p align=\"left\" class=\"MsoBodyText3\" style=\"text-align:left;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Parkinson\u2019s disease is caused by low levels of a substance called dopamine in the brain. Levodopa increases the amount of dopamine and hence reduces the symptoms of Parkinson\u2019s disease. Carbidopa and entacapone improve the antiparkinson effects of levodopa. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">2.       <\/span><span lang=\"EN-GB\">What you need to know before you take Stalevo<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Do not take Stalevo if you:<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">are allergic to levodopa, carbidopa or entacapone, or any of the other ingredients of this medicine <\/span><span style=\"font-size:11.0pt\">(listed in section 6)<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">have narrow-angle glaucoma (an eye disorder)<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">have a tumour of the adrenal gland<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">are taking certain medicines for treating depression (<\/span><span style=\"font-size:11.0pt\">combinations of <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">selective MAO-A and MAO-B inhibitors, or non-selective MAO-inhibitors)<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">have ever had neuroleptic malignant syndrome (NMS \u2013 this is a rare reaction to medicines used to treat severe mental disorders)<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">have ever had non-traumatic rhabdomyolysis (a rare muscle disorder)<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">have a severe liver disease. <\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Warnings and precautions<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Talk to your doctor or pharmacist before taking Stalevo if you have or have ever had<\/span><\/u><span lang=\"EN-GB\">:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">a heart attack or any other diseases of the heart including cardiac arrhythmias, or of the blood vessels<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">asthma or any other disease of the lungs<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">a liver problem, because your dose may need to be adjusted<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">kidney or hormone-related diseases<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">stomach ulcers or convulsions<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">if you experience prolonged diarrhoea consult your doctor as it may be a sign of inflammation of the colon<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">any form of severe mental disorder like psychosis<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">chronic wide-angle glaucoma, because your dose may need to be adjusted and the pressure in your eyes may need to be monitored.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Consult your doctor if you are currently taking<\/span><\/u><span lang=\"EN-GB\">:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">antipsychotics (medicines used to treat psychosis)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">a medicine which may cause low blood pressure when rising from a chair or bed. You should be aware that Stalevo may make these reactions worse.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Consult your doctor if during the treatment with Stalevo you<\/span><\/u><span lang=\"EN-GB\">:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">notice that your muscles get very rigid or jerk\r violently, or if you get tremors, agitation, confusion, fever, rapid pulse, or\r wide fluctuations in your blood pressure. If any of this happens, <b>contact your doctor immediately<\/b><\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">feel depressed, have suicidal thoughts, or notice unusual changes in your behaviour<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">find yourself suddenly falling asleep, or if you feel very drowsy. If this happens, you should not drive or use any tools or machines (see also section 'Driving and using machines')<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">notice that uncontrolled movements begin or get worse after you started to take Stalevo. If this happens, your doctor may need to change the dose of your antiparkinson medicine <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">experience diarrhoea: monitoring of your weight is recommended in order to avoid potentially excessive weight loss<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">experience progressive anorexia, asthenia (weakness, exhaustion) and weight decrease within a relatively short period of time. If this happens, a general medical evaluation including liver function should be considered<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">feel the need to stop using Stalevo, see section 'If you stop taking Stalevo'.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Tell your doctor if you or your family\/carer notices you are developing addiction-like symptoms leading to craving for large doses of Stalevo and other medicines used to treat Parkinson\u2019s disease.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\">Tell your doctor if you or your family\/carer notices you are\r developing urges or cravings to behave in ways that are unusual for you or you\r cannot resist the impulse, drive or temptation to carry out certain activities\r that could harm yourself or others. These behaviours are called impulse control\r disorders and can include addictive gambling, excessive eating or spending, an\r abnormally high sex drive or a preoccupation with an increase in sexual\r thoughts or feelings. <u>Your doctor may need to review your treatments.<\/u> <\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Your doctor may take some regular laboratory tests during a long term treatment with Stalevo.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">If you must undergo surgery, please tell your doctor that you are using Stalevo.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Stalevo is not recommended to be used for treatment of extrapyramidal symptoms (e.g. involuntary movements, shaking, muscle rigidity and muscle contractions<\/span><span lang=\"EN\">)<\/span><span lang=\"EN-GB\"> caused by other medicines.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Children <\/span><span lang=\"EN-GB\" style=\"color:black\">and adolescents<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Experience with Stalevo in patients under 18 years is limited. Therefore, the use of Stalevo in children or adolescents is not recommended.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Other medicines and Stalevo<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoBodyText\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"font-weight:normal;font-style:normal\">Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.<\/span><\/p> <p class=\"MsoBodyText\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Do not take Stalevo if you are taking certain medicines for treating depression (combinations of selective MAO-A and MAO-B inhibitors, or non-selective MAO inhibitors).<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Stalevo may increase the effects and side effects of certain medicines. These include:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">medicines used to treat depression such as moclobemide, amitriptyline, desipramine, maprotiline, venlafaxine and paroxetine <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-        rimiterole and isoprenaline, used to treat respiratory diseases<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">adrenaline, used <\/span><span lang=\"PT\">for severe allergic reactions<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">noradrenaline, dopamine and dobutamine, used to treat heart diseases and low blood pressure<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-        alpha-methyldopa, used to treat high blood pressure<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-        apomorphine, which is used to treat Parkinson\u2019s disease. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">The effects of Stalevo may be weakened by certain medicines. These include: <\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-        dopamine antagonists used to treat mental disorders, nausea and vomiting<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">phenytoin, used to prevent convulsions <\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">papaverine used to relax the muscles.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Stalevo may make it harder for you to digest iron. Therefore, do not take Stalevo and iron supplements at the same time. After taking one of them, wait at least 2 to 3 hours before taking the other.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Stalevo with food and drink<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoBodyText\" style=\"text-align:justify;line-height:normal\"><span lang=\"EN-GB\" style=\"font-weight:normal;font-style:normal\">Stalevo may be taken with or without food. For some patients, Stalevo may not be well absorbed if it is taken with, or shortly after eating protein-rich food (such as meats, fish, dairy products, seeds and nuts). Consult your doctor if you think this applies to you.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Pregnancy, breast-feeding and fertility<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoBodyText\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"font-weight:normal;font-style:normal\">If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. <\/span><\/p> <p class=\"MsoBodyText\" style=\"line-height:normal\"><\/p> <p class=\"MsoBodyText\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"font-weight:normal;font-style:normal\">You should not breast-feed during treatment with Stalevo.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Driving and using machines<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Stalevo may lower your blood pressure, which may make you feel light-headed or dizzy. Therefore, be particularly careful when you drive or when you use any tools or machines.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">If you feel very drowsy, or if you sometimes find yourself suddenly falling asleep, wait until you feel fully awake again before driving or doing anything else that requires you to be alert. Otherwise, you may put yourself and others at risk of serious injury or death.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Stalevo contains sucrose<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Stalevo contains sucrose (1.9 mg\/tablet). If you have been told by your doctor that you have intolerance to some sugars, contact your doctor before taking this medicinal product.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">3.       <\/span><span lang=\"EN-GB\">How to take Stalevo<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><u><span lang=\"EN-GB\">For adults and elderly<\/span><\/u><span lang=\"EN-GB\">:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><b><i><span lang=\"EN-GB\">-        <\/span><\/i><\/b><span lang=\"EN-GB\">Your doctor will tell you exactly how many tablets of Stalevo to take each day. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif'>-<\/span><span lang=\"EN-GB\">The tablets are not intended to be split or broken into smaller pieces.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif'>-<\/span><span lang=\"EN-GB\">You should take only one tablet each time.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif'>-<\/span><span lang=\"EN-GB\">Depending on how you respond to treatment, your doctor may suggest a higher or lower dose. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif'>-<\/span><span lang=\"EN-GB\">If you are taking Stalevo 50 mg\/12.5 mg\/200 mg, 75 mg\/18.75 mg\/200 mg, 100 mg\/25 mg\/200 mg, 125 mg\/31.25 mg\/200 mg or 150 mg\/37.5 mg\/200 mg tablets, do not take more than 10 tablets each day.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;text-align:justify;line-height:\r normal\"><span lang=\"EN-GB\">Talk to your doctor or pharmacist if you think the effect of Stalevo is too strong or too weak, or if you experience possible side effects.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;text-align:justify;line-height:\r 12.0pt\"><span lang=\"EN-GB\"><img border=\"0\" height=\"122\" src=\"data:image\/png;base64,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\" width=\"624\"\/><\/span><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">If you take more Stalevo than you should<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">If you have accidentally taken more Stalevo tablets than you should, talk to your doctor or pharmacist immediately. In case of an overdose you may feel confused or agitated, your heart rate may be slower or faster than normal or the colour of your skin, tongue, eyes or urine may change.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">If you forget to take Stalevo<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Do not take a double dose to make up for a forgotten tablet.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><u><span lang=\"EN-GB\">If it is more than 1 hour until your next dose<\/span><\/u><span lang=\"EN-GB\">: <\/span><\/p> <p class=\"MsoBodyText\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"font-weight:normal;font-style:normal\">Take one tablet as soon as you remember, and the next tablet at the normal time. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><u><span lang=\"EN-GB\">If it is less than 1 hour until your next dose<\/span><\/u><span lang=\"EN-GB\">: <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Take a tablet as soon as you remember, wait 1 hour, then take another tablet. After that carry on as normal. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Always leave at least an hour between Stalevo tablets, to avoid possible side effects.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">If you stop taking Stalevo <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Do not stop taking Stalevo unless your doctor tells you to. In such a case your doctor may need to adjust your other antiparkinson medicines, especially levodopa, to give sufficient control of your symptoms. If you suddenly stop taking of Stalevo and other antiparkinsonian medicines it may result in unwanted side effects. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">If you have any further questions on the use of this medicine, ask your doctor or pharmacist.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">4.       <\/span><span lang=\"EN-GB\">Possible side effects<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.4pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.4pt;line-height:normal\"><span lang=\"EN-GB\">Like all medicines, this medicine can cause side effects, although not everybody gets them. Many of the side effects can be relieved by adjusting the dose. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.4pt;line-height:normal\"><\/p> <p class=\"Text\" style=\"margin-top:0in\"><span style=\"font-size:11.0pt\">If you\r during the treatment with Stalevo experience the following symptoms, <b>contact your doctor immediately<\/b>: <\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:25.65pt;margin-bottom:.0001pt;text-indent:-25.65pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span style=\"font-size:11.0pt\">Your muscles get very rigid or jerk violently, you get tremors, agitation, confusion, fever, rapid pulse, or wide fluctuations in your blood pressure. These can be symptoms <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">of neuroleptic malignant syndrome (NMS, a rare severe reaction to medicines used to treat disorders of the central nervous system) or rhabdomyolysis (a rare severe muscle disorder).<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:25.65pt;margin-bottom:.0001pt;text-indent:-25.65pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Allergic reaction, the signs may include hives (nettle rash), itching, rash, swelling of your face, lips, tongue or throat. This may cause difficulties in breathing or swallowing.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.4pt;line-height:normal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Very common (may affect more than 1 in 10 people)<\/span><\/u><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">uncontrolled movements (dyskinesias)<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">feeling sick (nausea)<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">harmless reddish-brown discolouration of urine<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">muscle pain<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">diarrhoea<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Common (may affect up to 1 in 10 people)<\/span><\/u><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">light-headedness or fainting due to low blood pressure, high blood pressure<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">worsening of Parkinson\u2019s symptoms, dizziness, drowsiness<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">vomiting, abdominal pain and discomfort, heartburn, dry mouth, constipation<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">inability to sleep, hallucinations, confusion abnormal dreams (including nightmares), tiredness<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">mental changes \u2013 including problems with memory, anxiety and depression (possibly with thoughts of suicide) <\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span style=\"font-size:11.0pt\">heart or artery disease events (e.g. chest pain), irregular heart rate or rhythm <\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">more frequent falling <\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">shortness of breath <\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">increased sweating, rashes<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">muscle cramps, swelling of legs<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">blurred vision<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">anaemia<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">decreased appetite, decreased weight<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">headache, joint pain<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">urinary tract infection<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Uncommon <\/span><\/u><u><span style=\"font-size:11.0pt;color:black\">(may affect up to 1 in 100 people)<\/span><\/u><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">heart attack<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">bleeding in the gut<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">changes in the blood cell count which may result in bleeding, abnormal liver function tests<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">convulsions<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">feeling agitated<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">psychotic symptoms<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">colitis (inflammation of the colon)<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">discolourations other than urine (e.g. skin, nail, hair, sweat)<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">swallowing difficulties<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span style=\"font-size:11.0pt\">inability to urinate<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Not known (cannot be estimated from the available data)<\/span><\/u><\/p> <p class=\"Text\" style=\"margin-top:0in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Craving for large doses of Stalevo in excess of that required to control motor symptoms, known as dopamine dysregulation syndrome. Some patients experience severe abnormal involuntary movements (dyskinesias), mood swings or other side effects after taking large doses of Stalevo.<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in\"><\/p> <p class=\"Text\" style=\"margin-top:0in\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">The following side effects have also been reported<\/span><\/u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">: <\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">hepatitis <\/span><span style=\"font-size:11.0pt\">(inflammation of the liver)<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">itching<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:4.8pt\"><u><span lang=\"EN-GB\" style=\"color:black\">You may experience the following side effects: <\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:4.8pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif;color:black'>-<\/span><span lang=\"EN-GB\" style=\"color:black\">Inability to resist the impulse to perform an action that could be harmful, which may include:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:4.8pt;margin-bottom:0in;\r margin-left:.75in;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif;color:black'>-<\/span><span lang=\"EN-GB\" style=\"color:black\">strong impulse to gamble excessively despite serious personal or family consequences<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:4.8pt;margin-bottom:0in;\r margin-left:.75in;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif;color:black'>-<\/span><span lang=\"EN-GB\" style=\"color:black\">altered or increased sexual interest and behaviour of significant concern to you or to others, for example, an increased sexual drive<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:4.8pt;margin-bottom:0in;\r margin-left:.75in;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif;color:black'>-<\/span><span lang=\"EN-GB\" style=\"color:black\">uncontrollable excessive shopping or spending<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:4.8pt;margin-bottom:0in;\r margin-left:.75in;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif;color:black'>-<\/span><span lang=\"EN-GB\" style=\"color:black\">binge eating (eating large amounts of food in a short time period) or compulsive eating (eating more food than normal and more than is needed to satisfy your hunger).<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:4.8pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:4.8pt\"><span lang=\"EN-GB\" style=\"color:black\">Tell your doctor if you experience any of these behaviours; they will discuss ways of managing or reducing the symptoms.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><b><span lang=\"EN-GB\">Reporting of side effects<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">If you get any\r side effects, talk to your doctor or pharmacist. This includes any possible\r side effects not listed in this leaflet. You can also report side effects\r directly via <span style=\"background:silver\">the national reporting system\r listed in <a href=\"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Template_or_form\/2013\/03\/WC500139752.doc\">Appendix\r V<\/a><\/span>. By reporting side effects you can help provide more information\r on the safety of this medicine.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">5.       <\/span><span lang=\"EN-GB\">How to store Stalevo<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Keep this medicine out of the sight and reach of children.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Do not use this medicine after the expiry date which is stated on the bottle and the carton after EXP. The expiry date refers to the last day of that month.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">This medicinal product does not require any special storage conditions.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Do not <\/span><span lang=\"EN-GB\">throw away any medicines<\/span><span lang=\"EN-GB\"> via wastewater or household waste. Ask your pharmacist how to <\/span><span lang=\"EN-GB\">throw away<\/span><span lang=\"EN-GB\"> of medicines you no longer use. These measures will help to protect the environment.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">6.       <\/span><span lang=\"EN-GB\">Contents of the pack and other information<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">What Stalevo contains<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:27.0pt;margin-bottom:.0001pt;text-indent:-27.0pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">The active substances of Stalevo are levodopa, carbidopa and entacapone.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Each Stalevo 150 mg\/37.5 mg\/200 mg tablet contains 150 mg of levodopa, 37.5 mg of carbidopa and 200 mg of entacapone.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">The other ingredients in the tablet core are croscarmellose sodium, magnesium stearate, maize starch, mannitol (E421) and povidone (E1201).<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">The ingredients in the film-coating are glycerol (85 per cent) (E422), hypromellose, magnesium stearate, polysorbate 80, red iron oxide (E172), sucrose, titanium dioxide (E171), and yellow iron oxide (E172).<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;line-height:\r normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;line-height:\r normal\"><b><span lang=\"EN-GB\">What Stalevo looks like and contents of the pack<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;line-height:\r normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">Stalevo 150 mg\/37.5 mg\/200 mg: brownish or greyish red, elongated-ellipse shaped, unscored film-coated tablets marked with \u2018LCE 150\u2019 on one side.<\/span><\/p> <p class=\"MsoEndnoteText\"><\/p> <p class=\"MsoEndnoteText\"><span lang=\"EN-GB\">Stalevo comes in six different pack sizes (10, 30, 100, 130, 175 or 250 tablets). Not all pack sizes may be marketed.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;line-height:\r normal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Marketing Authorisation Holder<\/span><\/b><\/p> <p class=\"MsoEndnoteText\"><span lang=\"IT\">Orion Corporation<\/span><\/p> <p class=\"MsoEndnoteText\"><span lang=\"IT\">Orionintie 1<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"IT\">FI-02200 Espoo<\/span><\/p> <p class=\"MsoEndnoteText\"><span lang=\"IT\">Finland<\/span><\/p> <p class=\"MsoEndnoteText\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><b><span lang=\"EN-GB\">Manufacturer<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><span lang=\"EN-GB\">Orion Corporation Orion Pharma<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><span lang=\"EN-GB\">Joensuunkatu 7<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><span lang=\"EN-GB\">FI-24100 Salo<\/span><\/p> <p class=\"MsoEndnoteText\"><span lang=\"EN-GB\">Finland<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><span lang=\"EN-GB\">Orion Corporation Orion Pharma<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><span lang=\"EN-GB\">Orionintie 1<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><span lang=\"EN-GB\">FI-02200 Espoo<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Finland<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse\" width=\"628\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style='font-family:\"TimesNewRomanPS-BoldMT\",serif'>Belgi\u00eb\/Belgique\/Belgien<\/span><\/b><span lang=\"FR\"><br\/> <\/span><strong><span lang=\"EN-GB\" style=\"font-weight:normal\">Orion Pharma   BVBA\/SPRL<\/span><\/strong><\/p> <p class=\"Text\" style=\"margin-top:0in\"><span style=\"font-size:11.0pt\">T\u00e9l\/Tel:   +32 (0)15 64 10 20<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"FI\">Lietuva<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"FI\">UAB Orion Pharma<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"FI\">Tel. +370 5 276 9499<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"color:black\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Orion Pharma Poland Sp z.o.o.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Tel.: + 48 22 8333177<\/span><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"DE\">Luxembourg\/Luxemburg<\/span><\/b><span lang=\"DE\"><br\/> <\/span><strong><span lang=\"EN-GB\" style=\"font-weight:normal\">Orion Pharma   BVBA\/SPRL<\/span><\/strong><\/p> <p class=\"Text\" style=\"margin-top:0in\"><span style=\"font-size:11.0pt\">T\u00e9l\/Tel:   +32 (0)15 64 10 20<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"MsoNormal\"><b><span lang=\"SV\">\u010cesk\u00e1 republika<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"FI\">Orion Pharma s.r.o.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel:  <\/span><span lang=\"SV\">+420 234 703   305<\/span><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"SV\">Magyarorsz\u00e1g<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:13.0pt\"><strong><span lang=\"EN-GB\" style=\"font-weight:normal\">Orion Pharma Kft.<\/span><\/strong><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel.: +<\/span><span lang=\"EN-GB\">36 1 239   9095<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><b><span lang=\"EN-GB\">Danmark<\/span><\/b><span lang=\"EN-GB\"> <br\/>\r   Orion Pharma A\/S<br\/>\r   Tlf: +45 8614 0000<\/span><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"FR\">Malta<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"IT\">Salomone Pharma<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-2.25pt;margin-bottom:\r   9.0pt;margin-left:0in\"><span lang=\"IT\">Tel: +356 21220174<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><b><span lang=\"DE\">Deutschland<\/span><\/b><span lang=\"DE\"> <br\/>\r   Orion Pharma GmbH<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><span lang=\"DE\">Tel: +49 40 899 6890<\/span><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"SV\">Nederland<\/span><\/b><span lang=\"SV\"><br\/> <\/span><strong><span lang=\"EN-GB\" style=\"font-weight:normal\">Orion Pharma   BVBA\/SPRL<\/span><\/strong><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:9.0pt;\r   margin-left:0in\"><span style=\"font-size:11.0pt\">T\u00e9l\/Tel: +32 (0)15 64 10 20<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"MsoNormal\"><b><span lang=\"FI\">Eesti<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"FI\">Orion Pharma Eesti O\u00dc<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"FI\">Tel: +372 66 44 550<\/span><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><b><span lang=\"EN-GB\">Norge<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Orion Pharma   AS<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-2.25pt;margin-bottom:\r   9.0pt;margin-left:0in\"><span lang=\"EN-GB\">Tlf: +47 40 00 42 10<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"Text\" style=\"margin-top:0in\"><b><span lang=\"EN-GB\" style=\"font-size:\r   11.0pt\">\u0395\u03bb\u03bb\u03ac\u03b4\u03b1<\/span><\/b><span lang=\"FI\" style=\"font-size:11.0pt\"> <br\/>\r   Orion Pharma Hellas M.E.<\/span><span style=\"font-size:11.0pt\">\u03a0<\/span><span lang=\"FI\" style=\"font-size:11.0pt\">.E<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in\"><span style=\"font-size:11.0pt\">\u03a4\u03b7\u03bb<\/span><span lang=\"FI\" style=\"font-size:11.0pt\">: + 30 210 980 3355<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><b><span lang=\"DE\">\u00d6sterreich<\/span><\/b><span lang=\"DE\"><br\/>\r   Orion Pharma GmbH<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:9.0pt;\r   margin-left:0in\"><span lang=\"DE\" style=\"font-size:11.0pt\">Tel: +49 40 899 6890<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"Text\" style=\"margin-top:0in\"><b><span lang=\"IT\" style=\"font-size:11.0pt\">Espa\u00f1a<\/span><\/b><span lang=\"IT\" style=\"font-size:11.0pt\"> <br\/> <\/span><span style=\"font-size:11.0pt\">Orion Pharma S.L.<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in\"><span style=\"font-size:11.0pt\">Tel: + 34   91  599 86 01<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Polska<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"SV\">Orion Pharma Poland Sp z.o.o.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:9.0pt\"><span lang=\"EN-GB\">Tel.: + 48 22   8333177<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"Text\" style=\"margin-top:0in\"><b><span lang=\"FR\" style=\"font-size:11.0pt\">France<\/span><\/b><span lang=\"FR\" style=\"font-size:11.0pt\"> <br\/> <\/span><span style=\"font-size:11.0pt\">Centre Sp\u00e9cialit\u00e9s Pharmaceutiques<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in\"><span style=\"font-size:11.0pt\">Tel: + 33   (0) 1 47 04 80 46<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><b><span lang=\"IT\" style=\"font-size:11.0pt\">Portugal<\/span><\/b><span lang=\"IT\" style=\"font-size:11.0pt\"><br\/> <\/span><span style=\"font-size:11.0pt\">Orionfin Unipessoal Lda<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-2.25pt;margin-bottom:\r   9.0pt;margin-left:0in\"><span lang=\"EN-GB\">Tel: + 351 21 154 68 20<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><b><span lang=\"FI\">Hrvatska<\/span><\/b><\/p> <p class=\"MsoNormal\"><strong><span lang=\"FI\" style=\"font-weight:normal\">Orion   Pharma d.o.o.<\/span><\/strong><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><span lang=\"FI\">Tel:<\/span><span lang=\"FI\"> +386 (0) 1 600 8015<\/span><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"line-height:12.0pt;text-autospace:none\"><b><span lang=\"FR\" style=\"color:black\">Rom\u00e2nia<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"IT\">Orion Corporation<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"FR\" style=\"color:black\">Tel: +358 10 4261<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Ireland<\/span><\/b><span lang=\"EN-GB\"> <br\/>\r   Orion Pharma (Ireland) Ltd.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">c\/o Allphar   Services Ltd.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: +353 1   428 7777<\/span><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"IT\">Slovenija<\/span><\/b><\/p> <p class=\"MsoNormal\"><strong><span lang=\"FI\" style=\"font-weight:normal\">Orion   Pharma d.o.o.<\/span><\/strong><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:9.0pt\"><span lang=\"FI\">Tel:<\/span><span lang=\"FI\"> +386 (0) 1 600 8015<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><b><span lang=\"EN-GB\">\u00cdsland<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Vistor hf.<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in\"><span style=\"font-size:11.0pt\">S\u00edmi:   +354 535 7000<\/span><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"SV\">Slovensk\u00e1 republika<\/span><\/b><\/p> <p class=\"MsoNormal\"><strong><span lang=\"SV\" style=\"font-weight:normal\">Orion   Pharma s.r.o<\/span><\/strong><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-2.25pt;margin-bottom:\r   9.0pt;margin-left:0in;line-height:normal\"><span lang=\"SV\">Tel: <\/span><span lang=\"SV\">+420 234 703 305<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"Text\" style=\"margin-top:0in\"><b><span lang=\"IT\" style=\"font-size:11.0pt\">Italia<\/span><\/b><span lang=\"IT\" style=\"font-size:11.0pt\"><br\/> <\/span><span lang=\"FI\" style=\"font-size:11.0pt\">Orion Pharma S.r.l.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:9.0pt\"><span lang=\"EN-GB\">Tel: + 39   02 67876111<\/span><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><b><span lang=\"IT\">Suomi\/Finland<br\/> <\/span><\/b><span lang=\"IT\">Orion Corporation<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><span lang=\"IT\">Puh.\/Tel: +358 10 4261<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"MsoNormal\"><b><span lang=\"EL\">\u039a\u03cd\u03c0\u03c1\u03bf\u03c2<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"DE\">Lifepharma (ZAM) Ltd<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">\u03a4\u03b7\u03bb<\/span><span lang=\"DE\">.:   +357 22056300<\/span><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><b><span lang=\"DE\">Sverige<\/span><\/b><span lang=\"DE\"><br\/>\r   Orion Pharma AB<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><span lang=\"DE\">Tel: +46 8 623 6440<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"MsoNormal\"><b><span lang=\"FI\">Latvija<\/span><\/b><\/p> <p class=\"MsoNormal\">Orion Corporation<\/p> <p class=\"MsoNormal\">Orion Pharma p\u0101rst\u0101vniec\u012bba<\/p> <p class=\"MsoNormal\">Tel: +371 20028332<\/p> <p class=\"MsoNormal\"> <\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><b><span lang=\"EN-GB\">United   Kingdom<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Orion Pharma   (UK) Ltd.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +44 1635 520 300<\/span><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><b><span lang=\"EN-GB\">This leaflet was last revised in.<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Other sources of information<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Detailed information on this medicine is\r available on the European Medicines Agency web site: <a href=\"http:\/\/www.ema.europa.eu\">http:\/\/www.ema.europa.eu<\/a>.<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\" style=\"color:black\">Package leaflet: Information for the user<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"IT\" style=\"text-transform:uppercase\">s<\/span><\/b><b><span lang=\"IT\">talevo 1<\/span><\/b><b><span lang=\"EN-GB\">75 mg\/43.75 mg\/200 mg<\/span><\/b><b><span lang=\"IT\"> film-coated tablets<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"IT\">levodopa\/carbidopa\/entacapone<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">Keep this leaflet. You may need to read it again.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">If you have any further questions, ask your doctor or pharmacist.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-        This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-        <\/span><span lang=\"EN-GB\">If you get any side effects, talk to your doctor or pharmacist.<\/span><span lang=\"EN-GB\">This includes any possible side effects not listed in this leaflet. See section 4.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">What is in this leaflet:<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">1.       What Stalevo is and what it is used for<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">2.       What you need to know before you take Stalevo<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">3.       How to take Stalevo<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">4.       Possible side effects<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">5        How to store Stalevo<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">6.       Contents of the pack and other information<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">1.       <\/span><span lang=\"EN-GB\">What Stalevo is and what it is used for<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p align=\"left\" class=\"MsoBodyText3\" style=\"text-align:left;line-height:normal\"><span lang=\"EN-GB\" style=\"font-weight:normal;font-style:normal\">Stalevo contains three active substances (levodopa, carbidopa and entacapone) in one film-coated tablet. Stalevo is used for the treatment of Parkinson\u2019s disease. <\/span><\/p> <p align=\"left\" class=\"MsoBodyText3\" style=\"text-align:left;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Parkinson\u2019s disease is caused by low levels of a substance called dopamine in the brain. Levodopa increases the amount of dopamine and hence reduces the symptoms of Parkinson\u2019s disease. Carbidopa and entacapone improve the antiparkinson effects of levodopa. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">2.       <\/span><span lang=\"EN-GB\">What you need to know before you take Stalevo<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Do not take Stalevo if you:<\/span><\/b><\/p> <p class=\"MsoNormal\"> <\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">are allergic to levodopa, carbidopa or entacapone, or any of the other ingredients of this medicine <\/span><span style=\"font-size:11.0pt\">(listed in section 6)<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">have narrow-angle glaucoma (an eye disorder)<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">have a tumour of the adrenal gland<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">are taking certain medicines for treating depression (<\/span><span style=\"font-size:11.0pt\">combinations of <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">selective MAO-A and MAO-B inhibitors, or non-selective MAO-inhibitors)<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">have ever had neuroleptic malignant syndrome (NMS \u2013 this is a rare reaction to medicines used to treat severe mental disorders)<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">have ever had non-traumatic rhabdomyolysis (a rare muscle disorder)<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">have a severe liver disease. <\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Warnings and precautions<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Talk to your doctor or pharmacist before taking Stalevo if you have or have ever had<\/span><\/u><span lang=\"EN-GB\">:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">a heart attack or any other diseases of the heart including cardiac arrhythmias, or of the blood vessels<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">asthma or any other disease of the lungs<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">a liver problem, because your dose may need to be adjusted<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">kidney or hormone-related diseases<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">stomach ulcers or convulsions<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">if you experience prolonged diarrhoea consult your doctor as it may be a sign of inflammation of the colon<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">any form of severe mental disorder like psychosis<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">chronic wide-angle glaucoma, because your dose may need to be adjusted and the pressure in your eyes may need to be monitored.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Consult your doctor if you are currently taking<\/span><\/u><span lang=\"EN-GB\">:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">antipsychotics (medicines used to treat psychosis)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">a medicine which may cause low blood pressure when rising from a chair or bed. You should be aware that Stalevo may make these reactions worse.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Consult your doctor if during the treatment with Stalevo you<\/span><\/u><span lang=\"EN-GB\">:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">notice that your muscles get very rigid or jerk\r violently, or if you get tremors, agitation, confusion, fever, rapid pulse, or\r wide fluctuations in your blood pressure. If any of this happens, <b>contact your doctor immediately<\/b><\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">feel depressed, have suicidal thoughts, or notice unusual changes in your behaviour<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">find yourself suddenly falling asleep, or if you feel very drowsy. If this happens, you should not drive or use any tools or machines (see also section 'Driving and using machines')<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">notice that uncontrolled movements begin or get worse after you started to take Stalevo. If this happens, your doctor may need to change the dose of your antiparkinson medicine <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">experience diarrhoea: monitoring of your weight is recommended in order to avoid potentially excessive weight loss<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">experience progressive anorexia, asthenia (weakness, exhaustion) and weight decrease within a relatively short period of time. If this happens, a general medical evaluation including liver function should be considered<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">feel the need to stop using Stalevo, see section 'If you stop taking Stalevo'.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Tell your doctor if you or your family\/carer notices you are developing addiction-like symptoms leading to craving for large doses of Stalevo and other medicines used to treat Parkinson\u2019s disease.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\">Tell your doctor if you or your family\/carer notices you are\r developing urges or cravings to behave in ways that are unusual for you or you\r cannot resist the impulse, drive or temptation to carry out certain activities\r that could harm yourself or others. These behaviours are called impulse control\r disorders and can include addictive gambling, excessive eating or spending, an\r abnormally high sex drive or a preoccupation with an increase in sexual\r thoughts or feelings. <u>Your doctor may need to review your treatments.<\/u> <\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Your doctor may take some regular laboratory tests during a long term treatment with Stalevo.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">If you must undergo surgery, please tell your doctor that you are using Stalevo.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Stalevo is not recommended to be used for treatment of extrapyramidal symptoms (e.g. involuntary movements, shaking, muscle rigidity and muscle contractions<\/span><span lang=\"EN\">)<\/span><span lang=\"EN-GB\"> caused by other medicines.<\/span><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Children <\/span><span lang=\"EN-GB\" style=\"color:black\">and adolescents<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Experience with Stalevo in patients under 18 years is limited. Therefore, the use of Stalevo in children or adolescents is not recommended.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Other medicines and Stalevo<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoBodyText\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"font-weight:normal;font-style:normal\">Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.<\/span><\/p> <p class=\"MsoBodyText\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Do not take Stalevo if you are taking certain medicines for treating depression (combinations of selective MAO-A and MAO-B inhibitors, or non-selective MAO inhibitors).<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Stalevo may increase the effects and side effects of certain medicines. These include: <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">medicines used to treat depression such as moclobemide, amitriptyline, desipramine, maprotiline, venlafaxine and paroxetine <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif'>-<\/span><span lang=\"EN-GB\">rimiterole and isoprenaline, used to treat respiratory diseases<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">adrenaline, used <\/span><span lang=\"PT\">for severe allergic reactions<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">noradrenaline, dopamine and dobutamine, used to treat heart diseases and low blood pressure<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-        alpha-methyldopa, used to treat high blood pressure <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-        apomorphine, which is used to treat Parkinson\u2019s disease.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">The effects of Stalevo may be weakened by certain medicines. These include: <\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-        dopamine antagonists used to treat mental disorders<\/span><span style=\"font-size:11.0pt\">, nausea and vomiting<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">phenytoin, used to prevent convulsions <\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">papaverine used to relax the muscles.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Stalevo may make it harder for you to digest iron. Therefore, do not take Stalevo and iron supplements at the same time. After taking one of them, wait at least 2 to 3 hours before taking the other.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Stalevo with food and drink<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoBodyText\" style=\"text-align:justify;line-height:normal\"><span lang=\"EN-GB\" style=\"font-weight:normal;font-style:normal\">Stalevo may be taken with or without food. For some patients, Stalevo may not be well absorbed if it is taken with, or shortly after eating protein-rich food (such as meats, fish, dairy products, seeds and nuts). Consult your doctor if you think this applies to you.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Pregnancy, breast-feeding and fertility<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoBodyText\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"font-weight:normal;font-style:normal\">If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. <\/span><\/p> <p class=\"MsoBodyText\" style=\"line-height:normal\"><\/p> <p class=\"MsoBodyText\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"font-weight:normal;font-style:normal\">You should not breast-feed during treatment with Stalevo.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Driving and using machines<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Stalevo may lower your blood pressure, which may make you feel light-headed or dizzy. Therefore, be particularly careful when you drive or when you use any tools or machines.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">If you feel very drowsy, or if you sometimes find yourself suddenly falling asleep, wait until you feel fully awake again before driving or doing anything else that requires you to be alert. Otherwise, you may put yourself and others at risk of serious injury or death.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Stalevo contains sucrose<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Stalevo contains sucrose (1.89 mg\/tablet). If you have been told by your doctor that you have intolerance to some sugars, contact your doctor before taking this medicinal product.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">3.       <\/span><span lang=\"EN-GB\">How to take Stalevo<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><u><span lang=\"EN-GB\">For adults and elderly<\/span><\/u><span lang=\"EN-GB\">:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-        Your doctor will tell you exactly how many tablets of Stalevo to take each day. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif'>-<\/span><span lang=\"EN-GB\">The tablets are not intended to be split or broken into smaller pieces.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif'>-<\/span><span lang=\"EN-GB\">You should take only one tablet each time.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif'>-<\/span><span lang=\"EN-GB\">Depending on how you respond to treatment, your doctor may suggest a higher or lower dose. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif'>-<\/span><span lang=\"EN-GB\">If you are taking Stalevo 175 mg\/43.75 mg\/200 mg tablets, do not take more than 8 tablets of this strength per day.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;text-align:justify;line-height:\r normal\"><span lang=\"EN-GB\">Talk to your doctor or pharmacist if you think the effect of Stalevo is too strong or too weak, or if you experience possible side effects.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;text-align:justify;line-height:\r 12.0pt\"><span lang=\"EN-GB\"><img border=\"0\" height=\"122\" src=\"data:image\/png;base64,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\" width=\"624\"\/><\/span><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">If you take more Stalevo than you should<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">If you have accidentally taken more Stalevo tablets than you should, talk to your doctor or pharmacist immediately. In case of an overdose you may feel confused or agitated, your heart rate may be slower or faster than normal or the colour of your skin, tongue, eyes or urine may change.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">If you forget to take Stalevo<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Do not take a double dose to make up for a forgotten tablet.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><u><span lang=\"EN-GB\">If it is more than 1 hour until your next dose<\/span><\/u><span lang=\"EN-GB\">: <\/span><\/p> <p class=\"MsoBodyText\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"font-weight:normal;font-style:normal\">Take one tablet as soon as you remember, and the next tablet at the normal time. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><u><span lang=\"EN-GB\">If it is less than 1 hour until your next dose<\/span><\/u><span lang=\"EN-GB\">: <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Take a tablet as soon as you remember, wait 1 hour, then take another tablet. After that carry on as normal. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Always leave at least an hour between Stalevo tablets, to avoid possible side effects.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">If you stop taking Stalevo <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Do not stop taking Stalevo unless your doctor tells you to. In such a case your doctor may need to adjust your other antiparkinson medicines, especially levodopa, to give sufficient control of your symptoms. If you suddenly stop taking Stalevo and other antiparkinsonian medicines it may result in unwanted side effects. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">If you have any further questions on the use of this medicine, ask your doctor or pharmacist.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">4.       <\/span><span lang=\"EN-GB\">Possible side effects<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.4pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.4pt;line-height:normal\"><span lang=\"EN-GB\">Like all medicines, this medicine can cause side effects, although not everybody gets them. Many of the side effects can be relieved by adjusting the dose. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.4pt;line-height:normal\"><\/p> <p class=\"Text\" style=\"margin-top:0in\"><span style=\"font-size:11.0pt\">If you\r during the treatment with Stalevo experience the following symptoms, <b>contact your doctor immediately<\/b>: <\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:25.65pt;margin-bottom:.0001pt;text-indent:-25.65pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span style=\"font-size:11.0pt\">Your muscles get very rigid or jerk violently, you get tremors, agitation, confusion, fever, rapid pulse, or wide fluctuations in your blood pressure. These can be symptoms <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">of neuroleptic malignant syndrome (NMS, a rare severe reaction to medicines used to treat disorders of the central nervous system) or rhabdomyolysis (a rare severe muscle disorder).<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:25.65pt;margin-bottom:.0001pt;text-indent:-25.65pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Allergic reaction, the signs may include hives (nettle rash), itching, rash, swelling of your face, lips, tongue or throat. This may cause difficulties in breathing or swallowing.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.4pt;line-height:normal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Very common (may affect more than 1 in 10 people)<\/span><\/u><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">uncontrolled movements (dyskinesias)<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">feeling sick (nausea)<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">harmless reddish-brown discolouration of urine<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">muscle pain<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">diarrhoea<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Common (may affect up to 1 in 10 people)<\/span><\/u><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">light-headedness or fainting due to low blood pressure, high blood pressure<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">worsening of Parkinson\u2019s symptoms, dizziness, drowsiness<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">vomiting, abdominal pain and discomfort, heartburn, dry mouth, constipation<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">inability to sleep, hallucinations, confusion abnormal dreams (including nightmares), tiredness<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">mental changes \u2013 including problems with memory, anxiety and depression (possibly with thoughts of suicide) <\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span style=\"font-size:11.0pt\">heart or artery disease events (e.g. chest pain), irregular heart rate or rhythm <\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">more frequent falling <\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">shortness of breath <\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">increased sweating, rashes<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">muscle cramps, swelling of legs<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">blurred vision<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">anaemia<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">decreased appetite, decreased weight<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">headache, joint pain<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">urinary tract infection<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Uncommon <\/span><\/u><u><span style=\"font-size:11.0pt;color:black\">(may affect up to 1 in 100 people)<\/span><\/u><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">heart attack<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">bleeding in the gut<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">changes in the blood cell count which may result in bleeding, abnormal liver function tests<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">convulsions<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">feeling agitated<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">psychotic symptoms<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">colitis (inflammation of the colon)<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">discolourations other than urine (e.g. skin, nail, hair, sweat)<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">swallowing difficulties<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span style=\"font-size:11.0pt\">inability to urinate<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Not known (cannot be estimated from the available data)<\/span><\/u><\/p> <p class=\"Text\" style=\"margin-top:0in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Craving for large doses of Stalevo in excess of that required to control motor symptoms, known as dopamine dysregulation syndrome. Some patients experience severe abnormal involuntary movements (dyskinesias), mood swings or other side effects after taking large doses of Stalevo.<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in\"><\/p> <p class=\"Text\" style=\"margin-top:0in\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">The following side effects have also been reported<\/span><\/u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">:<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">hepatitis <\/span><span style=\"font-size:11.0pt\">(inflammation of the liver)<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">itching<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:4.8pt\"><u><span lang=\"EN-GB\" style=\"color:black\">You may experience the following side effects:<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:4.8pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif;color:black'>-<\/span><span lang=\"EN-GB\" style=\"color:black\">Inability to resist the impulse to perform an action that could be harmful, which may include:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:4.8pt;margin-bottom:0in;\r margin-left:42.55pt;margin-bottom:.0001pt;text-indent:-14.2pt;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif;color:black'>-<\/span><span lang=\"EN-GB\" style=\"color:black\">strong impulse to gamble excessively despite serious personal or family consequences<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:4.8pt;margin-bottom:0in;\r margin-left:42.55pt;margin-bottom:.0001pt;text-indent:-14.2pt;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif;color:black'>-<\/span><span lang=\"EN-GB\" style=\"color:black\">altered or increased sexual interest and behaviour of significant concern to you or to others, for example, an increased sexual drive<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:4.8pt;margin-bottom:0in;\r margin-left:42.55pt;margin-bottom:.0001pt;text-indent:-14.2pt;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif;color:black'>-<\/span><span lang=\"EN-GB\" style=\"color:black\">uncontrollable excessive shopping or spending<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:4.8pt;margin-bottom:0in;\r margin-left:42.55pt;margin-bottom:.0001pt;text-indent:-14.2pt;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif;color:black'>-<\/span><span lang=\"EN-GB\" style=\"color:black\">binge eating (eating large amounts of food in a short time period) or compulsive eating (eating more food than normal and more than is needed to satisfy your hunger).<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:4.8pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:4.8pt\"><span lang=\"EN-GB\" style=\"color:black\">Tell your doctor if you experience any of these behaviours; they will discuss ways of managing or reducing the symptoms.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><b><span lang=\"EN-GB\">Reporting of side effects<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">If you get any side effects, talk to your doctor or pharmacist. This\r includes any possible side effects not listed in this leaflet. You can also\r report side effects directly via <span style=\"background:silver\">the national\r reporting system listed in <a href=\"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Template_or_form\/2013\/03\/WC500139752.doc\">Appendix\r V<\/a><\/span>. By reporting side effects you can help provide more information\r on the safety of this medicine.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">5.       <\/span><span lang=\"EN-GB\">How to store Stalevo<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Keep this medicine out of the sight and reach of children.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Do not use this medicine after the expiry date which is stated on the bottle and the carton after EXP. The expiry date refers to the last day of that month.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">This medicinal product does not require any special storage conditions.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Do not <\/span><span lang=\"EN-GB\">throw away any medicines<\/span><span lang=\"EN-GB\"> via wastewater or household waste. Ask your pharmacist how to <\/span><span lang=\"EN-GB\">throw away<\/span><span lang=\"EN-GB\"> of medicines you no longer use. These measures will help to protect the environment.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">6.       <\/span><span lang=\"EN-GB\">Contents of the pack and other information<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">What Stalevo contains<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:27.0pt;margin-bottom:.0001pt;text-indent:-27.0pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">The active substances of Stalevo are levodopa, carbidopa and entacapone.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Each Stalevo 175 mg\/43.75 mg\/200 mg tablet contains 175 mg of levodopa, 43.75 mg of carbidopa and 200 mg of entacapone.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">The other ingredients in the tablet core are croscarmellose sodium, magnesium stearate, maize starch, mannitol (E421) and povidone (E1201)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">The ingredients in the film-coating are glycerol (85 per cent) (E422), hypromellose, magnesium stearate, polysorbate 80, red iron oxide (E172), sucrose, and titanium dioxide (E171).<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;line-height:\r normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;line-height:\r normal\"><b><span lang=\"EN-GB\">What Stalevo looks like and contents of the pack<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;line-height:\r normal\"><\/p> <p class=\"MsoEndnoteText\"><span lang=\"EN-GB\">Stalevo 175 mg\/43.75 mg\/200 mg: light brownish red, oval, unscored film-coated tablets marked with \u2018LCE 175\u2019 on one side.<\/span><\/p> <p class=\"MsoEndnoteText\"><\/p> <p class=\"MsoEndnoteText\"><span lang=\"EN-GB\">Stalevo 175 mg\/43.75 mg\/200 mg tablet comes in five different pack sizes (10, 30, 100, 130 or 175 tablets). Not all pack sizes may be marketed.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;line-height:\r normal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Marketing Authorisation Holder<\/span><\/b><\/p> <p class=\"MsoEndnoteText\"><span lang=\"IT\">Orion Corporation<\/span><\/p> <p class=\"MsoEndnoteText\"><span lang=\"IT\">Orionintie 1<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"IT\">FI-02200 Espoo<\/span><\/p> <p class=\"MsoEndnoteText\"><span lang=\"IT\">Finland<\/span><\/p> <p class=\"MsoEndnoteText\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><b><span lang=\"EN-GB\">Manufacturer<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><span lang=\"EN-GB\">Orion Corporation Orion Pharma<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><span lang=\"EN-GB\">Joensuunkatu 7<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><span lang=\"EN-GB\">FI-24100 Salo<\/span><\/p> <p class=\"MsoEndnoteText\"><span lang=\"EN-GB\">Finland<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><span lang=\"EN-GB\">Orion Corporation Orion Pharma<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><span lang=\"EN-GB\">Orionintie 1<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><span lang=\"EN-GB\">FI-02200 Espoo<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Finland<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse\" width=\"628\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style='font-family:\"TimesNewRomanPS-BoldMT\",serif'>Belgi\u00eb\/Belgique\/Belgien<\/span><\/b><span lang=\"FR\"><br\/> <\/span><strong><span lang=\"EN-GB\" style=\"font-weight:normal\">Orion Pharma   BVBA\/SPRL<\/span><\/strong><\/p> <p class=\"Text\" style=\"margin-top:0in\"><span style=\"font-size:11.0pt\">T\u00e9l\/Tel:   +32 (0)15 64 10 20<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"FI\">Lietuva<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"FI\">UAB Orion Pharma<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"FI\">Tel. +370 5 276 9499<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"color:black\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Orion Pharma Poland Sp z.o.o.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Tel.: + 48 22 8333177<\/span><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"DE\">Luxembourg\/Luxemburg<\/span><\/b><span lang=\"DE\"><br\/> <\/span><strong><span lang=\"EN-GB\" style=\"font-weight:normal\">Orion Pharma   BVBA\/SPRL<\/span><\/strong><\/p> <p class=\"Text\" style=\"margin-top:0in\"><span style=\"font-size:11.0pt\">T\u00e9l\/Tel:   +32 (0)15 64 10 20<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"MsoNormal\"><b><span lang=\"SV\">\u010cesk\u00e1 republika<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"FI\">Orion Pharma s.r.o.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel:  <\/span><span lang=\"SV\">+420 234 703   305<\/span><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"SV\">Magyarorsz\u00e1g<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:13.0pt\"><strong><span lang=\"EN-GB\" style=\"font-weight:normal\">Orion Pharma Kft.<\/span><\/strong><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel.: +<\/span><span lang=\"EN-GB\">36 1 239   9095<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><b><span lang=\"EN-GB\">Danmark<\/span><\/b><span lang=\"EN-GB\"> <br\/>\r   Orion Pharma A\/S<br\/>\r   Tlf: +45 8614 0000<\/span><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"FR\">Malta<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"IT\">Salomone Pharma<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-2.25pt;margin-bottom:\r   9.0pt;margin-left:0in\"><span lang=\"IT\">Tel: +356 21220174<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><b><span lang=\"DE\">Deutschland<\/span><\/b><span lang=\"DE\"> <br\/>\r   Orion Pharma GmbH<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><span lang=\"DE\">Tel: +49 40 899 6890<\/span><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"SV\">Nederland<\/span><\/b><span lang=\"SV\"><br\/> <\/span><strong><span lang=\"EN-GB\" style=\"font-weight:normal\">Orion Pharma   BVBA\/SPRL<\/span><\/strong><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:9.0pt;\r   margin-left:0in\"><span style=\"font-size:11.0pt\">T\u00e9l\/Tel: +32 (0)15 64 10 20<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"MsoNormal\"><b><span lang=\"FI\">Eesti<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"FI\">Orion Pharma Eesti O\u00dc<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"FI\">Tel: +372 66 44 550<\/span><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><b><span lang=\"EN-GB\">Norge<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Orion Pharma   AS<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-2.25pt;margin-bottom:\r   9.0pt;margin-left:0in\"><span lang=\"EN-GB\">Tlf: +47 40 00 42 10<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"Text\" style=\"margin-top:0in\"><b><span lang=\"EN-GB\" style=\"font-size:\r   11.0pt\">\u0395\u03bb\u03bb\u03ac\u03b4\u03b1<\/span><\/b><span lang=\"FI\" style=\"font-size:11.0pt\"> <br\/>\r   Orion Pharma Hellas M.E.<\/span><span style=\"font-size:11.0pt\">\u03a0<\/span><span lang=\"FI\" style=\"font-size:11.0pt\">.E<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in\"><span style=\"font-size:11.0pt\">\u03a4\u03b7\u03bb<\/span><span lang=\"FI\" style=\"font-size:11.0pt\">: + 30 210 980 3355<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><b><span lang=\"DE\">\u00d6sterreich<\/span><\/b><span lang=\"DE\"><br\/>\r   Orion Pharma GmbH<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:9.0pt;\r   margin-left:0in\"><span lang=\"DE\" style=\"font-size:11.0pt\">Tel: +49 40 899 6890<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"Text\" style=\"margin-top:0in\"><b><span lang=\"IT\" style=\"font-size:11.0pt\">Espa\u00f1a<\/span><\/b><span lang=\"IT\" style=\"font-size:11.0pt\"> <br\/> <\/span><span style=\"font-size:11.0pt\">Orion Pharma S.L.<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in\"><span style=\"font-size:11.0pt\">Tel: + 34   91  599 86 01<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Polska<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"SV\">Orion Pharma Poland Sp z.o.o.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:9.0pt\"><span lang=\"EN-GB\">Tel.: + 48 22   8333177<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"Text\" style=\"margin-top:0in\"><b><span lang=\"FR\" style=\"font-size:11.0pt\">France<\/span><\/b><span lang=\"FR\" style=\"font-size:11.0pt\"> <br\/> <\/span><span style=\"font-size:11.0pt\">Centre Sp\u00e9cialit\u00e9s Pharmaceutiques<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in\"><span style=\"font-size:11.0pt\">Tel: + 33   (0) 1 47 04 80 46<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><b><span lang=\"IT\" style=\"font-size:11.0pt\">Portugal<\/span><\/b><span lang=\"IT\" style=\"font-size:11.0pt\"><br\/> <\/span><span style=\"font-size:11.0pt\">Orionfin Unipessoal Lda<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-2.25pt;margin-bottom:\r   9.0pt;margin-left:0in\"><span lang=\"EN-GB\">Tel: + 351 21 154 68 20<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><b><span lang=\"FI\">Hrvatska<\/span><\/b><\/p> <p class=\"MsoNormal\"><strong><span lang=\"FI\" style=\"font-weight:normal\">Orion   Pharma d.o.o.<\/span><\/strong><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><span lang=\"FI\">Tel:<\/span><span lang=\"FI\"> +386 (0) 1 600 8015<\/span><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"line-height:12.0pt;text-autospace:none\"><b><span lang=\"FR\" style=\"color:black\">Rom\u00e2nia<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"IT\">Orion Corporation<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"FR\" style=\"color:black\">Tel: +358 10 4261<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Ireland<\/span><\/b><span lang=\"EN-GB\"> <br\/>\r   Orion Pharma (Ireland) Ltd.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">c\/o Allphar   Services Ltd.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: +353 1   428 7777<\/span><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"IT\">Slovenija<\/span><\/b><\/p> <p class=\"MsoNormal\"><strong><span lang=\"FI\" style=\"font-weight:normal\">Orion   Pharma d.o.o.<\/span><\/strong><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:9.0pt\"><span lang=\"FI\">Tel:<\/span><span lang=\"FI\"> +386 (0) 1 600 8015<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><b><span lang=\"EN-GB\">\u00cdsland<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Vistor hf.<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in\"><span style=\"font-size:11.0pt\">S\u00edmi:   +354 535 7000<\/span><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"SV\">Slovensk\u00e1 republika<\/span><\/b><\/p> <p class=\"MsoNormal\"><strong><span lang=\"SV\" style=\"font-weight:normal\">Orion   Pharma s.r.o<\/span><\/strong><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-2.25pt;margin-bottom:\r   9.0pt;margin-left:0in;line-height:normal\"><span lang=\"SV\">Tel: <\/span><span lang=\"SV\">+420 234 703 305<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"Text\" style=\"margin-top:0in\"><b><span lang=\"IT\" style=\"font-size:11.0pt\">Italia<\/span><\/b><span lang=\"IT\" style=\"font-size:11.0pt\"><br\/> <\/span><span lang=\"FI\" style=\"font-size:11.0pt\">Orion Pharma S.r.l.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:9.0pt\"><span lang=\"EN-GB\">Tel: + 39   02 67876111<\/span><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><b><span lang=\"IT\">Suomi\/Finland<br\/> <\/span><\/b><span lang=\"IT\">Orion Corporation<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><span lang=\"IT\">Puh.\/Tel: +358 10 4261<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"MsoNormal\"><b><span lang=\"EL\">\u039a\u03cd\u03c0\u03c1\u03bf\u03c2<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"DE\">Lifepharma (ZAM) Ltd<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">\u03a4\u03b7\u03bb<\/span><span lang=\"DE\">.:   +357 22056300<\/span><\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><b><span lang=\"DE\">Sverige<\/span><\/b><span lang=\"DE\"><br\/>\r   Orion Pharma AB<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><span lang=\"DE\">Tel: +46 8 623 6440<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.05pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"309\"> <p class=\"MsoNormal\"><b><span lang=\"FI\">Latvija<\/span><\/b><\/p> <p class=\"MsoNormal\">Orion Corporation<\/p> <p class=\"MsoNormal\">Orion Pharma p\u0101rst\u0101vniec\u012bba<\/p> <p class=\"MsoNormal\">Tel: +371 20028332<\/p> <p class=\"MsoNormal\"> <\/p> <\/td> <td style=\"width:233.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><b><span lang=\"EN-GB\">United   Kingdom<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Orion Pharma   (UK) Ltd.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +44 1635 520 300<\/span><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><b><span lang=\"EN-GB\">This leaflet was last revised in.<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Other sources of information<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Detailed information on this medicine is\r available on the European Medicines Agency web site: <a href=\"http:\/\/www.ema.europa.eu\">http:\/\/www.ema.europa.eu<\/a>. <\/span><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\" style=\"color:black\">Package leaflet: Information for the user<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">s<\/span><\/b><b><span lang=\"EN-GB\">talevo 200 mg\/50 mg\/200 mg film-coated tablets<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"IT\">levodopa\/carbidopa\/entacapone<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">Keep this leaflet. You may need to read it again.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">If you have any further questions, ask your doctor or pharmacist.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-        This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">If you get any side effects, talk to your doctor or pharmacist.<\/span><span lang=\"EN-GB\">This includes any possible side effects not listed in this leaflet. See section 4.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">What is in this leaflet:<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">1.       What Stalevo is and what it is used for<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">2.       What you need to know before you take Stalevo<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">3.       How to take Stalevo<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">4.       Possible side effects<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">5        How to store Stalevo<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">6.       Contents of the pack and other information<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">1.       <\/span><span lang=\"EN-GB\">What Stalevo is and what it is used for<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p align=\"left\" class=\"MsoBodyText3\" style=\"text-align:left;line-height:normal\"><span lang=\"EN-GB\" style=\"font-weight:normal;font-style:normal\">Stalevo contains three active substances (levodopa, carbidopa and entacapone) in one film-coated tablet. Stalevo is used for the treatment of Parkinson\u2019s disease. <\/span><\/p> <p align=\"left\" class=\"MsoBodyText3\" style=\"text-align:left;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Parkinson\u2019s disease is caused by low levels of a substance called dopamine in the brain. Levodopa increases the amount of dopamine and hence reduces the symptoms of Parkinson\u2019s disease. Carbidopa and entacapone improve the antiparkinson effects of levodopa. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">2.       <\/span><span lang=\"EN-GB\">What you need to know before you take Stalevo<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Do not take Stalevo if you:<\/span><\/b><\/p> <p class=\"MsoNormal\"> <\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">are allergic to levodopa, carbidopa or entacapone, or any of the other ingredients of this medicine <\/span><span style=\"font-size:11.0pt\">(listed in section 6)<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">have narrow-angle glaucoma (an eye disorder)<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">have a tumour of the adrenal gland<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">are taking certain medicines for treating depression (<\/span><span style=\"font-size:11.0pt\">combinations of <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">selective MAO-A and MAO-B inhibitors, or non-selective MAO-inhibitors)<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">have ever had neuroleptic malignant syndrome (NMS \u2013 this is a rare reaction to medicines used to treat severe mental disorders)<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">have ever had non-traumatic rhabdomyolysis (a rare muscle disorder)<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">have a severe liver disease. <\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Warnings and precautions<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Talk to your doctor or pharmacist before taking Stalevoif you have or have ever had<\/span><\/u><span lang=\"EN-GB\">:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">a heart attack or any other diseases of the heart including cardiac arrhythmias, or of the blood vessels<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">asthma or any other disease of the lungs<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">a liver problem, because your dose may need to be adjusted<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">kidney or hormone-related diseases<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">stomach ulcers or convulsions<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">if you experience prolonged diarrhoea consult your doctor as it may be a sign of inflammation of the colon<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">any form of severe mental disorder like psychosis<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">chronic wide-angle glaucoma, because your dose may need to be adjusted and the pressure in your eyes may need to be monitored.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Consult your doctor if you are currently taking<\/span><\/u><span lang=\"EN-GB\">:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">antipsychotics (medicines used to treat psychosis)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">a medicine which may cause low blood pressure when rising from a chair or bed. You should be aware that Stalevo may make these reactions worse.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Consult your doctor if during the treatment with Stalevo you<\/span><\/u><span lang=\"EN-GB\">:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">notice that your muscles get very rigid or jerk\r violently, or if you get tremors, agitation, confusion, fever, rapid pulse, or\r wide fluctuations in your blood pressure. If any of this happens, <b>contact your doctor immediately<\/b><\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">feel depressed, have suicidal thoughts, or notice unusual changes in your behaviour<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">find yourself suddenly falling asleep, or if you feel very drowsy. If this happens, you should not drive or use any tools or machines (see also section 'Driving and using machines')<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">notice that uncontrolled movements begin or get worse after you started to take Stalevo. If this happens, your doctor may need to change the dose of your antiparkinson medicine <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">experience diarrhoea: monitoring of your weight is recommended in order to avoid potentially excessive weight loss<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">experience progressive anorexia, asthenia (weakness, exhaustion) and weight decrease within a relatively short period of time. If this happens, a general medical evaluation including liver function should be considered<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">feel the need to stop using Stalevo, see section 'If you stop taking Stalevo'.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Tell your doctor if you or your family\/carer notices you are developing addiction-like symptoms leading to craving for large doses of Stalevo and other medicines used to treat Parkinson\u2019s disease.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\">Tell your doctor if you or your family\/carer notices you are\r developing urges or cravings to behave in ways that are unusual for you or you\r cannot resist the impulse, drive or temptation to carry out certain activities\r that could harm yourself or others. These behaviours are called impulse control\r disorders and can include addictive gambling, excessive eating or spending, an\r abnormally high sex drive or a preoccupation with an increase in sexual\r thoughts or feelings. <u>Your doctor may need to review your treatments.<\/u> <\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Your doctor may take some regular laboratory tests during a long term treatment with Stalevo.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">If you must undergo surgery, please tell your doctor that you are using Stalevo.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Stalevo is not recommended to be used for treatment of extrapyramidal symptoms (e.g. involuntary movements, shaking, muscle rigidity and muscle contractions<\/span><span lang=\"EN\">)<\/span><span lang=\"EN-GB\"> caused by other medicines.<\/span><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Children <\/span><span lang=\"EN-GB\" style=\"color:black\">and adolescents<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Experience with Stalevo in patients under 18 years is limited. Therefore, the use of Stalevo in children or adolescents is not recommended.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Other medicines and Stalevo<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoBodyText\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"font-weight:normal;font-style:normal\">Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Do not take Stalevo if you are taking certain medicines for treating depression (combinations of selective MAO-A and MAO-B inhibitors, or non-selective MAO inhibitors).<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Stalevo may increase the effects and side effects of certain medicines. These include: <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">medicines used to treat depression such as moclobemide, amitriptyline, desipramine, maprotiline, venlafaxine and paroxetine <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">rimiterole and isoprenaline, used to treat respiratory diseases <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">adrenaline, used <\/span><span lang=\"PT\">for severe allergic reactions<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">noradrenaline, dopamine and dobutamine, used to treat heart diseases and low blood pressure<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-        alpha-methyldopa, used to treat high blood pressure <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-        apomorphine, which is used to treat Parkinson\u2019s disease.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">The effects of Stalevo may be weakened by certain medicines. These include: <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">dopamine antagonists used to treat mental disorders, nausea and vomiting<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">phenytoin, used to prevent convulsions <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">papaverine used to relax the muscles.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Stalevo may make it harder for you to digest iron. Therefore, do not take Stalevo and iron supplements at the same time. After taking one of them, wait at least 2 to 3 hours before taking the other.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Stalevo with food and drink<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoBodyText\" style=\"text-align:justify;line-height:normal\"><span lang=\"EN-GB\" style=\"font-weight:normal;font-style:normal\">Stalevo may be taken with or without food. For some patients, Stalevo may not be well absorbed if it is taken with, or shortly after eating protein-rich food (such as meats, fish, dairy products, seeds and nuts). Consult your doctor if you think this applies to you.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Pregnancy, breast-feeding and fertility<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoBodyText\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"font-weight:normal;font-style:normal\">If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. <\/span><\/p> <p class=\"MsoBodyText\" style=\"line-height:normal\"><\/p> <p class=\"MsoBodyText\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"font-weight:normal;font-style:normal\">You should not breast-feed during treatment with Stalevo.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Driving and using machines<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Stalevo may lower your blood pressure, which may make you feel light-headed or dizzy. Therefore, be particularly careful when you drive or when you use any tools or machines.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">If you feel very drowsy, or if you sometimes find yourself suddenly falling asleep, wait until you feel fully awake again before driving or doing anything else that requires you to be alert. Otherwise, you may put yourself and others at risk of serious injury or death.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Stalevo contains sucrose<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Stalevo contains sucrose (2.3 mg\/tablet). If you have been told by your doctor that you have intolerance to some sugars, contact your doctor before taking this medicinal product.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">3.       <\/span><span lang=\"EN-GB\">How to take Stalevo<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><u><span lang=\"EN-GB\">For adults and elderly<\/span><\/u><span lang=\"EN-GB\">:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">Your doctor will tell you exactly how many tablets of Stalevo to take each day. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">The tablets are not intended to be split or broken into smaller pieces.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">You should take only one tablet each time.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">Depending on how you respond to treatment, your doctor may suggest a higher or lower dose. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">If you are taking Stalevo 200 mg\/50 mg\/200 mg, do not take more than 7 tablets of this strength per day.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;text-align:justify;line-height:\r normal\"><span lang=\"EN-GB\">Talk to your doctor or pharmacist if you think the effect of Stalevo is too strong or too weak, or if you experience possible side effects.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:13.0pt\"><span lang=\"EN-GB\"><img border=\"0\" height=\"122\" src=\"data:image\/png;base64,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\" width=\"624\"\/><\/span><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">If you take more Stalevo than you should<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">If you have accidentally taken more Stalevo tablets than you should, talk to your doctor or pharmacist immediately. In case of an overdose you may feel confused or agitated, your heart rate may be slower or faster than normal or the colour of your skin, tongue, eyes or urine may change.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">If you forget to take Stalevo<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Do not take a double dose to make up for a forgotten tablet.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><u><span lang=\"EN-GB\">If it is more than 1 hour until your next dose<\/span><\/u><span lang=\"EN-GB\">: <\/span><\/p> <p class=\"MsoBodyText\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"font-weight:normal;font-style:normal\">Take one tablet as soon as you remember, and the next tablet at the normal time. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><u><span lang=\"EN-GB\">If it is less than 1 hour until your next dose<\/span><\/u><span lang=\"EN-GB\">: <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Take a tablet as soon as you remember, wait 1 hour, then take another tablet. After that carry on as normal.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Always leave at least an hour between Stalevo tablets, to avoid possible side effects.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">If you stop taking Stalevo <\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Do not stop taking Stalevo unless your doctor tells you to. In such a case your doctor may need to adjust your other antiparkinson medicines, especially levodopa, to give sufficient control of your symptoms. If you suddenly stop taking of Stalevo and other antiparkinsonian medicines it may result in unwanted side effects. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">If you have any further questions on the use of this medicine, ask your doctor or pharmacist.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">4.       <\/span><span lang=\"EN-GB\">Possible side effects<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.4pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.4pt;line-height:normal\"><span lang=\"EN-GB\">Like all medicines, this medicine can cause side effects, although not everybody gets them. Many of the side effects can be relieved by adjusting the dose. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.4pt;line-height:normal\"><\/p> <p class=\"Text\" style=\"margin-top:0in\"><span style=\"font-size:11.0pt\">If you\r during the treatment with Stalevo experience the following symptoms, <b>contact your doctor immediately<\/b>: <\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:25.65pt;margin-bottom:.0001pt;text-indent:-25.65pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span style=\"font-size:11.0pt\">Your muscles get very rigid or jerk violently, you get tremors, agitation, confusion, fever, rapid pulse, or wide fluctuations in your blood pressure. These can be symptoms <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">of neuroleptic malignant syndrome (NMS, a rare severe reaction to medicines used to treat disorders of the central nervous system) or rhabdomyolysis (a rare severe muscle disorder).<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:25.65pt;margin-bottom:.0001pt;text-indent:-25.65pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Allergic reaction, the signs may include hives (nettle rash), itching, rash, swelling of your face, lips, tongue or throat. This may cause difficulties in breathing or swallowing.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.4pt;line-height:normal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Very common (may affect more than 1 in 10 people)<\/span><\/u><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">uncontrolled movements (dyskinesias)<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">feeling sick (nausea)<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">harmless reddish-brown discolouration of urine<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">muscle pain<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">diarrhoea<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Common (may affect up to 1 in 10 people)<\/span><\/u><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">light-headedness or fainting due to low blood pressure, high blood pressure<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">worsening of Parkinson\u2019s symptoms, dizziness, drowsiness<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">vomiting, abdominal pain and discomfort, heartburn, dry mouth, constipation<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">inability to sleep, hallucinations, confusion abnormal dreams (including nightmares), tiredness<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">mental changes \u2013 including problems with memory, anxiety and depression (possibly with thoughts of suicide) <\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span style=\"font-size:11.0pt\">heart or artery disease events (e.g. chest pain), irregular heart rate or rhythm <\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">more frequent falling <\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">shortness of breath <\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">increased sweating, rashes<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">muscle cramps, swelling of legs<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">blurred vision<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">anaemia<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">decreased appetite, decreased weight<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">headache, joint pain<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">urinary tract infection<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Uncommon <\/span><\/u><u><span style=\"font-size:11.0pt;color:black\">(may affect up to 1 in 100 people)<\/span><\/u><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">heart attack<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">bleeding in the gut<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">changes in the blood cell count which may result in bleeding, abnormal liver function tests<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">convulsions<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">feeling agitated<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">psychotic symptoms<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">colitis (inflammation of the colon)<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">discolourations other than urine (e.g. skin, nail, hair, sweat)<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">swallowing difficulties<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span style=\"font-size:11.0pt\">inability to urinate<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Not known (cannot be estimated from the available data)<\/span><\/u><\/p> <p class=\"Text\" style=\"margin-top:0in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Craving for large doses of Stalevo in excess of that required to control motor symptoms, known as dopamine dysregulation syndrome. Some patients experience severe abnormal involuntary movements (dyskinesias), mood swings or other side effects after taking large doses of Stalevo.<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in\"><\/p> <p class=\"Text\" style=\"margin-top:0in\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">The following side effects have also been reported<\/span><\/u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">: <\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">hepatitis <\/span><span style=\"font-size:11.0pt\">(inflammation of the liver)<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">itching<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:4.8pt\"><u><span lang=\"EN-GB\" style=\"color:black\">You may experience the following side effects: <\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:4.8pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif;color:black'>-<\/span><span lang=\"EN-GB\" style=\"color:black\">Inability to resist the impulse to perform an action that could be harmful, which may include:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:4.8pt;margin-bottom:0in;\r margin-left:.75in;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif;color:black'>-<\/span><span lang=\"EN-GB\" style=\"color:black\">strong impulse to gamble excessively despite serious personal or family consequences<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:4.8pt;margin-bottom:0in;\r margin-left:.75in;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif;color:black'>-<\/span><span lang=\"EN-GB\" style=\"color:black\">altered or increased sexual interest and behaviour of significant concern to you or to others, for example, an increased sexual drive<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:4.8pt;margin-bottom:0in;\r margin-left:.75in;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif;color:black'>-<\/span><span lang=\"EN-GB\" style=\"color:black\">uncontrollable excessive shopping or spending<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:4.8pt;margin-bottom:0in;\r margin-left:.75in;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif;color:black'>-<\/span><span lang=\"EN-GB\" style=\"color:black\">binge eating (eating large amounts of food in a short time period) or compulsive eating (eating more food than normal and more than is needed to satisfy your hunger).<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:4.8pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:4.8pt\"><span lang=\"EN-GB\" style=\"color:black\">Tell your doctor if you experience any of these behaviours; they will discuss ways of managing or reducing the symptoms.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><b><span lang=\"EN-GB\">Reporting of side effects<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">If you get any side effects, talk to your doctor or pharmacist. This\r includes any possible side effects not listed in this leaflet. You can also\r report side effects directly via <span style=\"background:silver\">the national\r reporting system listed in <a href=\"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Template_or_form\/2013\/03\/WC500139752.doc\">Appendix\r V<\/a><\/span>. By reporting side effects you can help provide more information\r on the safety of this medicine.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">5.       <\/span><span lang=\"EN-GB\">How to store Stalevo<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Keep this medicine out of the sight and reach of children.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Do not use this medicine after the expiry date which is stated on the bottle and the carton after EXP. The expiry date refers to the last day of that month.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">This medicinal product does not require any special storage conditions.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Do not <\/span><span lang=\"EN-GB\">throw away any medicines<\/span><span lang=\"EN-GB\"> via wastewater or household waste. Ask your pharmacist how to <\/span><span lang=\"EN-GB\">throw away<\/span><span lang=\"EN-GB\"> of medicines you no longer use. These measures will help to protect the environment.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">6.       <\/span><span lang=\"EN-GB\">Contents of the pack and other information<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">What Stalevo contains<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:27.0pt;margin-bottom:.0001pt;text-indent:-27.0pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif'>-<\/span><span lang=\"EN-GB\">The active substances of Stalevo are levodopa, carbidopa and entacapone.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Arial\",sans-serif'>-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Each Stalevo 200 <\/span><span style=\"font-size:11.0pt\">mg<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">\/50 <\/span><span style=\"font-size:11.0pt\">mg<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">\/200 mg tablet contains 200 mg of levodopa, 50 mg of carbidopa and 200 mg of entacapone.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">The other ingredients in the tablet core are croscarmellose sodium, magnesium stearate, maize starch, mannitol (E421) and povidone (E1201).<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">The ingredients in the film-coating are glycerol (85 per cent) (E422), hypromellose, magnesium stearate, polysorbate 80, red iron oxide (E172), sucrose and titanium dioxide (E171).<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;line-height:\r normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;line-height:\r normal\"><b><span lang=\"EN-GB\">What Stalevo looks like and contents of the pack<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;line-height:\r normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">Stalevo 200 mg\/50 mg\/200 mg: dark brownish red, oval, unscored film-coated tablets marked with \u2018LCE 200\u2019 on one side.<\/span><\/p> <p class=\"MsoEndnoteText\"><\/p> <p class=\"MsoEndnoteText\"><span lang=\"EN-GB\">Stalevo 200 mg\/50 mg\/200 mg tablet comes in five different pack sizes (10, 30, 100, 130 or 175). Not all pack sizes may be marketed.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;line-height:\r normal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Marketing Authorisation Holder<\/span><\/b><\/p> <p class=\"MsoEndnoteText\"><span lang=\"IT\">Orion Corporation<\/span><\/p> <p class=\"MsoEndnoteText\"><span lang=\"IT\">Orionintie 1<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"IT\">FI-02200 Espoo<\/span><\/p> <p class=\"MsoEndnoteText\"><span lang=\"IT\">Finland<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><b><span lang=\"EN-GB\">Manufacturer<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><span lang=\"EN-GB\">Orion Corporation Orion Pharma<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><span lang=\"EN-GB\">Joensuunkatu 7<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><span lang=\"EN-GB\">FI-24100 Salo<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Finland<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><span lang=\"EN-GB\">Orion Corporation Orion Pharma<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><span lang=\"EN-GB\">Orionintie 1<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><span lang=\"EN-GB\">FI-02200 Espoo<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Finland<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse\" width=\"621\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><a name=\"_GoBack\"><\/a><b><span lang=\"EN-GB\" style='font-family:\"TimesNewRomanPS-BoldMT\",serif'>Belgi\u00eb\/Belgique\/Belgien<\/span><\/b><span lang=\"FR\"><br\/> <\/span><strong><span lang=\"EN-GB\" style=\"font-weight:normal\">Orion Pharma   BVBA\/SPRL<\/span><\/strong><\/p> <p class=\"Text\" style=\"margin-top:0in\"><span style=\"font-size:11.0pt\">T\u00e9l\/Tel:   +32 (0)15 64 10 20<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"FI\">Lietuva<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"FI\">UAB Orion Pharma<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"FI\">Tel. +370 5 276 9499<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"color:black\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Orion Pharma Poland Sp z.o.o.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Tel.: + 48 22 8333177<\/span><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"DE\">Luxembourg\/Luxemburg<\/span><\/b><span lang=\"DE\"><br\/> <\/span><strong><span lang=\"EN-GB\" style=\"font-weight:normal\">Orion Pharma   BVBA\/SPRL<\/span><\/strong><\/p> <p class=\"Text\" style=\"margin-top:0in\"><span style=\"font-size:11.0pt\">T\u00e9l\/Tel:   +32 (0)15 64 10 20<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"SV\">\u010cesk\u00e1 republika<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"FI\">Orion Pharma s.r.o.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +420 234 703 305<\/span><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"SV\">Magyarorsz\u00e1g<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:13.0pt\"><strong><span lang=\"EN-GB\" style=\"font-weight:normal\">Orion Pharma Kft.<\/span><\/strong><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel.: +<\/span><span lang=\"EN-GB\">36 1 239   9095<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><b><span lang=\"EN-GB\">Danmark<\/span><\/b><span lang=\"EN-GB\"> <br\/>\r   Orion Pharma A\/S<br\/>\r   Tlf: +45 8614 0000<\/span><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"FR\">Malta<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"IT\">Salomone Pharma<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-2.25pt;margin-bottom:\r   9.0pt;margin-left:0in\"><span lang=\"IT\">Tel: +356 21220174<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><b><span lang=\"DE\">Deutschland<\/span><\/b><span lang=\"DE\"> <br\/>\r   Orion Pharma GmbH<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><span lang=\"DE\">Tel: +49 40 899 6890<\/span><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"SV\">Nederland<\/span><\/b><span lang=\"SV\"><br\/> <\/span><strong><span lang=\"EN-GB\" style=\"font-weight:normal\">Orion Pharma   BVBA\/SPRL<\/span><\/strong><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:9.0pt;\r   margin-left:0in\"><span style=\"font-size:11.0pt\">T\u00e9l\/Tel: +32 (0)15 64 10 20<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"FI\">Eesti<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"FI\">Orion Pharma Eesti O\u00dc<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"FI\">Tel: +372 66 44 550<\/span><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><b><span lang=\"EN-GB\">Norge<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Orion Pharma   AS<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-2.25pt;margin-bottom:\r   9.0pt;margin-left:0in\"><span lang=\"EN-GB\">Tlf: +47 40 00 42 10<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"Text\" style=\"margin-top:0in\"><b><span lang=\"EN-GB\" style=\"font-size:\r   11.0pt\">\u0395\u03bb\u03bb\u03ac\u03b4\u03b1<\/span><\/b><span lang=\"FI\" style=\"font-size:11.0pt\"> <br\/>\r   Orion Pharma Hellas M.E.<\/span><span style=\"font-size:11.0pt\">\u03a0<\/span><span lang=\"FI\" style=\"font-size:11.0pt\">.E<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in\"><span style=\"font-size:11.0pt\">\u03a4\u03b7\u03bb<\/span><span lang=\"FI\" style=\"font-size:11.0pt\">: + 30 210 980 3355<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><b><span lang=\"DE\">\u00d6sterreich<\/span><\/b><span lang=\"DE\"><br\/>\r   Orion Pharma GmbH<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:9.0pt;\r   margin-left:0in\"><span lang=\"DE\" style=\"font-size:11.0pt\">Tel: +49 40 899 6890<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"Text\" style=\"margin-top:0in\"><b><span lang=\"IT\" style=\"font-size:11.0pt\">Espa\u00f1a<\/span><\/b><span lang=\"IT\" style=\"font-size:11.0pt\"> <br\/> <\/span><span style=\"font-size:11.0pt\">Orion Pharma S.L.<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in\"><span style=\"font-size:11.0pt\">Tel: + 34   91  599 86 01<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Polska<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"SV\">Orion Pharma Poland Sp z.o.o.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:9.0pt\"><span lang=\"EN-GB\">Tel.: + 48 22   8333177<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"Text\" style=\"margin-top:0in\"><b><span lang=\"FR\" style=\"font-size:11.0pt\">France<\/span><\/b><span lang=\"FR\" style=\"font-size:11.0pt\"> <br\/> <\/span><span style=\"font-size:11.0pt\">Centre Sp\u00e9cialit\u00e9s Pharmaceutiques<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in\"><span style=\"font-size:11.0pt\">Tel: + 33   (0) 1 47 04 80 46<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><b><span lang=\"IT\" style=\"font-size:11.0pt\">Portugal<\/span><\/b><span lang=\"IT\" style=\"font-size:11.0pt\"><br\/> <\/span><span style=\"font-size:11.0pt\">Orionfin Unipessoal Lda<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-2.25pt;margin-bottom:\r   9.0pt;margin-left:0in\"><span lang=\"EN-GB\">Tel: + 351 21 154 68 20<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><b><span lang=\"FI\">Hrvatska<\/span><\/b><\/p> <p class=\"MsoNormal\"><strong><span lang=\"FI\" style=\"font-weight:normal\">Orion   Pharma d.o.o.<\/span><\/strong><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><span lang=\"FI\">Tel:<\/span><span lang=\"FI\"> +386 (0) 1 600 8015<\/span><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"line-height:12.0pt;text-autospace:none\"><b><span lang=\"FR\" style=\"color:black\">Rom\u00e2nia<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"IT\">Orion Corporation<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"FR\" style=\"color:black\">Tel: +358 10 4261<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Ireland<\/span><\/b><span lang=\"EN-GB\"> <br\/>\r   Orion Pharma (Ireland) Ltd.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">c\/o Allphar   Services Ltd.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: +353 1   428 7777<\/span><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"IT\">Slovenija<\/span><\/b><\/p> <p class=\"MsoNormal\"><strong><span lang=\"FI\" style=\"font-weight:normal\">Orion   Pharma d.o.o.<\/span><\/strong><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:9.0pt\"><span lang=\"FI\">Tel:<\/span><span lang=\"FI\"> +386 (0) 1 600 8015<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><b><span lang=\"EN-GB\">\u00cdsland<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Vistor hf.<\/span><\/p> <p class=\"Text\" style=\"margin-top:0in\"><span style=\"font-size:11.0pt\">S\u00edmi:   +354 535 7000<\/span><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"SV\">Slovensk\u00e1 republika<\/span><\/b><\/p> <p class=\"MsoNormal\"><strong><span lang=\"SV\" style=\"font-weight:normal\">Orion   Pharma s.r.o<\/span><\/strong><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-2.25pt;margin-bottom:\r   9.0pt;margin-left:0in;line-height:normal\"><span lang=\"SV\">Tel: <\/span><span lang=\"SV\">+420 234 703 305<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"Text\" style=\"margin-top:0in\"><b><span lang=\"IT\" style=\"font-size:11.0pt\">Italia<\/span><\/b><span lang=\"IT\" style=\"font-size:11.0pt\"><br\/> <\/span><span lang=\"FI\" style=\"font-size:11.0pt\">Orion Pharma S.r.l.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:9.0pt\"><span lang=\"EN-GB\">Tel: + 39   02 67876111<\/span><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><b><span lang=\"IT\">Suomi\/Finland<br\/> <\/span><\/b><span lang=\"IT\">Orion Corporation<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><span lang=\"IT\">Puh.\/Tel: +358 10 4261<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"EL\">\u039a\u03cd\u03c0\u03c1\u03bf\u03c2<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"DE\">Lifepharma (ZAM) Ltd<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">\u03a4\u03b7\u03bb<\/span><span lang=\"DE\">.:   +357 22056300<\/span><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><b><span lang=\"DE\">Sverige<\/span><\/b><span lang=\"DE\"><br\/>\r   Orion Pharma AB<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt;line-height:normal\"><span lang=\"DE\">Tel: +46 8 623 6440<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"FI\">Latvija<\/span><\/b><\/p> <p class=\"MsoNormal\">Orion Corporation<\/p> <p class=\"MsoNormal\">Orion Pharma p\u0101rst\u0101vniec\u012bba<\/p> <p class=\"MsoNormal\">Tel: +371 20028332<\/p> <p class=\"MsoNormal\"> <\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><b><span lang=\"EN-GB\">United   Kingdom<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Orion Pharma   (UK) Ltd.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +44 1635 520 300<\/span><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><b><span lang=\"EN-GB\">This leaflet was last revised in.<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><b><span lang=\"EN-GB\">Other sources of information<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Detailed information on this medicine is available on the European\r Medicines Agency web site: <a href=\"http:\/\/www.ema.europa.eu\">http:\/\/www.ema.europa.eu<\/a>.<\/span><\/p> <\/div>","ID":"ebaf396e-55d5-457b-b1c1-537df189c466","Styles":"None","Classes":"['WordSection1']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             ","ParentId":"0e136847-6216-4137-a2b6-0f02887c55e6"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"82710821-458d-468a-91fb-7fd230022c05","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p>","ID":"d746dde5-5fce-497b-9e29-84a6fc9cfcfa","Styles":"text-align:center;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p>","ID":"4509b433-5f0d-4508-915d-c55f83b85d96","Styles":"text-align:center;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p>","ID":"baa79ad6-2cdd-41b0-9c4f-261bb732db00","Styles":"text-align:center;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p>","ID":"4814ab8b-bb00-48e2-95f0-007eab056c59","Styles":"text-align:center;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p>","ID":"0de61371-a1a5-4aa0-9c89-9d2877347a87","Styles":"text-align:center;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p>","ID":"9098ad84-682e-4f59-8cb7-3e9cda0793b4","Styles":"text-align:center;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p>","ID":"9186a5fc-a861-43d9-89b9-0e11c3ce3c60","Styles":"text-align:center;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p>","ID":"07739fbc-1462-4f1b-9439-48ac237507c2","Styles":"text-align:center;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p>","ID":"81611367-703a-4b0c-aeed-5b34344a50ba","Styles":"text-align:center;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p>","ID":"58dc6eb1-ff6c-4f8f-b848-b46c80b1cef9","Styles":"text-align:center;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p>","ID":"3eda221e-24eb-452a-9263-d05f9a908f09","Styles":"text-align:center;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p>","ID":"8842dbe9-26c5-41b1-87e5-27ef71b5799c","Styles":"text-align:center;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p>","ID":"573dab3b-19c3-4d6b-9b34-84e995658ff9","Styles":"text-align:center;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p>","ID":"ea4a4ba7-73e8-4be4-b3bf-2cb5cad872e5","Styles":"text-align:center;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p>","ID":"31d55d2e-91bf-450a-b305-f1d8466ea94d","Styles":"text-align:center;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p>","ID":"f9984476-a48f-4c99-ac63-7c157c468cdb","Styles":"text-align:center;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p>","ID":"a4e9a0bd-2c1c-4d1b-a3d8-3770b7f7362c","Styles":"text-align:center;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p>","ID":"fc121534-7090-4123-b4c2-8f1267e3bb63","Styles":"text-align:center;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p>","ID":"1ec5d126-143f-4360-9773-4a4db8023fc4","Styles":"text-align:center;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p>","ID":"bd14734a-59a3-42d2-b0e3-08ed4a5dc6ac","Styles":"text-align:center;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p>","ID":"95ff7ade-b82e-4b10-8c94-f5727df67224","Styles":"text-align:center;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p>","ID":"f506b1ae-9c70-4ab8-af6d-b143fcd4540b","Styles":"text-align:center;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">ANNEX I<\/span><\/b><\/p>","ID":"bae935c9-bfdd-4115-be68-0efd3a0a8f40","Styles":"text-align:center","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":null,"IsULTag":null,"Text":"ANNEX I","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p>","ID":"1ea53945-f6c4-4ae0-8b51-325d1e8ed92d","Styles":"text-align:center","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<h1><span lang=\"EN-GB\">SUMMARY OF PRODUCT CHARACTERISTICS<\/span><\/h1>","ID":"f0158055-e412-4516-ab2d-fb71531dbafc","Styles":"None","Classes":"None","Bold":false,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"SUMMARY OF PRODUCT CHARACTERISTICS","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b>","ID":"5e1641ab-2f12-4a97-9896-64739167f373","Styles":"None","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span>","ID":"2e6de6bd-bac7-4108-9f5e-92757b446d5d","Styles":"font-size:11.0pt;font-family:\"Times New Roman\",serif","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":" ","ParentId":"5e1641ab-2f12-4a97-9896-64739167f373"},{"Element":"<br clear=\"all\" style=\"page-break-before:always\"\/>","ID":"61db7ecf-e6fb-46e9-9e86-9d8c8bfc11ea","Styles":"page-break-before:always","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"2e6de6bd-bac7-4108-9f5e-92757b446d5d"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:27.0pt;margin-bottom:.0001pt;text-align:left;text-indent:-27.0pt\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">1.      NAME OF THE MEDICINAL PRODUCT<\/span><\/b><\/p>","ID":"cc02f75c-c395-4c48-85a0-b12a97ccdc39","Styles":"margin-top:0in;margin-right:0in;margin-bottom:\r\n0in;margin-left:27.0pt;margin-bottom:.0001pt;text-align:left;text-indent:-27.0pt","Classes":"['Text']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"1.      NAME OF THE MEDICINAL PRODUCT","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"15900f68-0f54-4a4a-92a4-9b56fd672b85","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Stalevo 50 mg\/12.5 mg\/200 mg film-coated tablets<\/span><\/p>","ID":"93bf8171-38ad-49b5-b557-498229c4432e","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Stalevo 50 mg\/12.5 mg\/200 mg film-coated tablets","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Stalevo 75 mg\/18.75 mg\/200 mg film-coated tablets<\/span><\/p>","ID":"1df73b29-2460-470e-8ac1-99ccf62f203c","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Stalevo 75 mg\/18.75 mg\/200 mg film-coated tablets","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Stalevo 100 mg\/25 mg\/200 mg film-coated tablets<\/span><\/p>","ID":"8da83cfe-a662-46a1-afbe-2ee73ca397eb","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Stalevo 100 mg\/25 mg\/200 mg film-coated tablets","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Stalevo 125<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">mg\/31.25<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">mg\/200<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">mg film-coated tablets<\/span><\/p>","ID":"bb4e7873-fa14-4d9e-948e-72b5db64aed0","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Stalevo 125mg\/31.25mg\/200mg film-coated tablets","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Stalevo 150 mg\/37.5 mg\/200 mg film-coated tablets<\/span><\/p>","ID":"0c949995-687d-4d85-810b-fd1d68004b4f","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Stalevo 150 mg\/37.5 mg\/200 mg film-coated tablets","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Stalevo 175 mg\/43.75 mg\/200 mg film-coated tablets<\/span><\/p>","ID":"5473ea11-881f-4776-8cb4-2d77a4bf974b","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Stalevo 175 mg\/43.75 mg\/200 mg film-coated tablets","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Stalevo 200 mg\/50 mg\/200 mg film-coated tablets <\/span><\/p>","ID":"8c911012-9916-473c-83fa-37d49f8253d1","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Stalevo 200 mg\/50 mg\/200 mg film-coated tablets ","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"54970c24-3005-45f5-bf90-8f1a36aeecd8","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"a993250e-b1ca-4d1e-b520-e41470192c79","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:27.0pt;margin-bottom:.0001pt;text-align:left;text-indent:-27.0pt\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">2.      QUALITATIVE AND QUANTITATIVE COMPOSITION<\/span><\/b><\/p>","ID":"4b3c3197-605e-4747-b998-9af12733685b","Styles":"margin-top:0in;margin-right:0in;margin-bottom:\r\n0in;margin-left:27.0pt;margin-bottom:.0001pt;text-align:left;text-indent:-27.0pt","Classes":"['Text']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"2.      QUALITATIVE AND QUANTITATIVE COMPOSITION","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"b1f9b289-5cce-4add-855e-3a18d10e64b5","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">50 mg\/12.5 mg\/200 mg<\/span><\/u><\/p>","ID":"6ee8d1f7-c9a9-4e0f-8760-88e89298cef3","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"50 mg\/12.5 mg\/200 mg","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Each tablet contains 50 mg of levodopa, 12.5 mg of carbidopa and 200 mg of entacapone.<\/span><\/p>","ID":"ae58dff8-94ca-40e5-b3aa-76fb785d0a50","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Each tablet contains 50 mg of levodopa, 12.5 mg of carbidopa and 200 mg of entacapone.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"1cd0ff07-72a9-4cd4-a742-81e1f5342aae","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Excipient with known effect:<\/span><\/p>","ID":"6e8ac5a9-3a38-43be-9e02-0a764e7bae7f","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Excipient with known effect:","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">Each tablet contains 1.2 mg of sucrose<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">.<\/span><\/p>","ID":"075d04a8-45ee-458d-b725-302cbd47136d","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Each tablet contains 1.2 mg of sucrose.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"d190c216-cf12-420c-9ab9-dfe1cc695dd8","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">75 mg\/18.75 mg\/200 mg<\/span><\/u><\/p>","ID":"73f24d9d-6ea3-47c2-807c-bfc7ac370691","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"75 mg\/18.75 mg\/200 mg","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Each tablet contains 75 mg of levodopa, 18.75 mg of carbidopa and 200 mg of entacapone.<\/span><\/p>","ID":"73ac8404-b6e0-4154-b42c-e156f5ae34b8","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Each tablet contains 75 mg of levodopa, 18.75 mg of carbidopa and 200 mg of entacapone.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"c5afec79-b867-45b4-a982-6114f187447e","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Excipient with known effect: <\/span><\/p>","ID":"71b527a2-9b77-42bf-a5ad-d5abe585a756","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Excipient with known effect: ","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">Each tablet contains <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">1.4 <\/span><span style=\"font-size:11.0pt\">mg of sucrose<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">.<\/span><\/p>","ID":"d80cf067-9bec-4c38-94b7-383b42c6dcdb","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Each tablet contains 1.4 mg of sucrose.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"a1bf409d-e422-4628-88ba-cbc1924dec71","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">100 mg\/25 mg\/200 mg <\/span><\/u><\/p>","ID":"add6bb5a-86a6-4846-a245-71846f9bb18e","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"100 mg\/25 mg\/200 mg ","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Each tablet contains 100 mg of levodopa, 25 mg of carbidopa and 200 mg of entacapone.<\/span><\/p>","ID":"aebd74b0-8ef0-400f-aa39-35e06a6a6c7e","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Each tablet contains 100 mg of levodopa, 25 mg of carbidopa and 200 mg of entacapone.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"b10e1d57-93e1-48c2-8d82-fea7a37e785f","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Excipient with known effect: <\/span><\/p>","ID":"8469f5c1-12b2-4f9b-bc56-58cc43c05c97","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Excipient with known effect: ","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">Each tablet contains <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">1.6 mg<\/span><span style=\"font-size:11.0pt\"> of sucrose<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">.<\/span><\/p>","ID":"51e4118b-59d1-4a6c-8791-46cc019bbec7","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Each tablet contains 1.6 mg of sucrose.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"1c106485-aad5-4a85-b53d-0ace281e40d8","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">125<\/span><\/u><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">mg\/31.25<\/span><\/u><u><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">mg\/200<\/span><\/u><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">mg<\/span><\/u><\/p>","ID":"4cf68371-5071-4584-8e62-91c492c7bfb9","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"125mg\/31.25mg\/200mg","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Each tablet contains 125 mg of levodopa, 31.25 mg of carbidopa and 200 mg of entacapone.<\/span><\/p>","ID":"2ce380ac-cb12-44d6-9930-d0e8a63dde31","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Each tablet contains 125 mg of levodopa, 31.25 mg of carbidopa and 200 mg of entacapone.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"8ebd4e92-f038-413a-a578-a2e8ec3df2e2","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Excipient with known effect: <\/span><\/p>","ID":"b7331747-fdae-43fa-a871-11f22be50514","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Excipient with known effect: ","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">Each tablet contains <\/span><span style=\"font-size:\r 11.0pt\">1.6 <\/span><span style=\"font-size:11.0pt\">mg of sucrose<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">.<\/span><\/p>","ID":"111fef46-b279-45f1-a1cb-65282d46603e","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Each tablet contains 1.6 mg of sucrose.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"0da22069-e793-4d56-b8ce-e3a6c3ef393b","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">150 mg\/37.5 mg\/200 mg<\/span><\/u><\/p>","ID":"a66884b8-9492-419e-967e-b084375b7a3a","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"150 mg\/37.5 mg\/200 mg","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Each tablet contains 150 mg of levodopa, 37.5 mg of carbidopa and 200 mg of entacapone.<\/span><\/p>","ID":"70b21acb-7949-4ea7-aaa0-71801ff0b98b","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Each tablet contains 150 mg of levodopa, 37.5 mg of carbidopa and 200 mg of entacapone.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"318fd040-93ff-4436-a2f1-7fdba8b51e48","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Excipient with known effect: <\/span><\/p>","ID":"4eaf0afa-b90f-495d-8eef-5dba8e411b55","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Excipient with known effect: ","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">Each tablet contains <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">1.9 mg<\/span><span style=\"font-size:11.0pt\"> of sucrose<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">.<\/span><\/p>","ID":"41b51dad-1375-4366-bb3e-9822e8c4ef0d","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Each tablet contains 1.9 mg of sucrose.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"7a408e35-340a-4fc6-953b-4710d25d92ee","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">175 mg\/43.75 mg\/200 mg<\/span><\/u><\/p>","ID":"a6721667-fed3-4939-b2f2-1ab92eb34653","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"175 mg\/43.75 mg\/200 mg","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Each tablet contains 175 mg of levodopa, 43.75 mg of carbidopa and 200 mg of entacapone.<\/span><\/p>","ID":"5fed1255-386c-4154-b4aa-7f67d746aa90","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Each tablet contains 175 mg of levodopa, 43.75 mg of carbidopa and 200 mg of entacapone.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"2d8e9a74-14e6-453b-bf7b-c2f55ebaa10f","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Excipient with known effect: <\/span><\/p>","ID":"ea0dd04d-4644-4fec-b4f0-e4778bb3b50f","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Excipient with known effect: ","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">Each tablet contains <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">1.89 <\/span><span style=\"font-size:11.0pt\">mg of sucrose<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">.<\/span><\/p>","ID":"9db05c3c-6d43-4a3c-81ac-266d1221cc56","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Each tablet contains 1.89 mg of sucrose.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"585235b7-a7fa-4571-8423-2bda54e707c3","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">200 mg\/50 mg\/200 mg<\/span><\/u><\/p>","ID":"eac801a3-6615-4045-9da7-642c5eeb1aa9","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"200 mg\/50 mg\/200 mg","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Each tablet contains 200 mg of levodopa, 50 mg of carbidopa and 200 mg of entacapone.<\/span><\/p>","ID":"1e7ec032-3678-4e07-8601-cbf7928bd5a2","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Each tablet contains 200 mg of levodopa, 50 mg of carbidopa and 200 mg of entacapone.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"9e901ea0-3142-4d72-a1b6-6c112bd71f80","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Excipient with known effect: <\/span><\/p>","ID":"fca07038-25b9-4baf-a032-537cd8c0917a","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Excipient with known effect: ","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">Each tablet contains <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">2.3 mg<\/span><span style=\"font-size:11.0pt\"> of sucrose<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">.<\/span><\/p>","ID":"a7cc2fd9-922d-4433-881a-531d18ab0374","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Each tablet contains 2.3 mg of sucrose.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"16a24257-728d-4c96-a006-f16a2eb864ef","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">For the full list of excipients, see section 6.1.<\/span><\/p>","ID":"3e71b3c6-f600-4d42-9df4-e8fde6fb8823","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"For the full list of excipients, see section 6.1.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"accacded-d350-480f-ae0c-725477ac7fa2","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"039f9e56-97f5-4e15-a57b-23e88891ed24","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:27.0pt;margin-bottom:.0001pt;text-align:left;text-indent:-27.0pt\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">3.      PHARMACEUTICAL FORM<\/span><\/b><\/p>","ID":"ea1f2661-88c8-45b5-9ad8-fe52ed82a00f","Styles":"margin-top:0in;margin-right:0in;margin-bottom:\r\n0in;margin-left:27.0pt;margin-bottom:.0001pt;text-align:left;text-indent:-27.0pt","Classes":"['Text']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"3.      PHARMACEUTICAL FORM","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"c7538929-96a5-4430-a2c4-457d205c544c","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Film-coated tablet (tablet)<\/span><\/p>","ID":"0fc7fba6-1ad1-4293-a0fc-c95113edb976","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Film-coated tablet (tablet)","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"57462b3b-0585-4bc2-b830-bbc37e14e218","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">50 mg\/12.5 mg\/200 mg<\/span><\/u><\/p>","ID":"a426cafa-401d-4028-9ecd-88648881a102","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"50 mg\/12.5 mg\/200 mg","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Brownish or greyish red, round, convex, unscored film-coated tablets marked with \u2018LCE 50\u2019 on one side.<\/span><\/p>","ID":"82abef15-f739-4e95-89cf-cf46cce9ae42","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Brownish or greyish red, round, convex, unscored film-coated tablets marked with \u2018LCE 50\u2019 on one side.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"74fa2cd8-0c46-4d32-b2f2-14d051461236","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">75 mg\/18.75 mg\/200 mg<\/span><\/u><\/p>","ID":"c26116ce-2d8a-4834-9c7d-b16a52944e25","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"75 mg\/18.75 mg\/200 mg","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Light b<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">rownish red, <\/span><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">oval<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> film-coated tablets marked with <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">\u2018LCE 75\u2019 <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">on one side.<\/span><\/p>","ID":"91c4ef53-56ff-45b9-96d5-4d3e9dee112c","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Light brownish red, oval film-coated tablets marked with \u2018LCE 75\u2019 on one side.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"2bb26975-ec03-4d6e-9848-ab1f58e80035","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">100 mg\/25 mg\/200 mg<\/span><\/u><\/p>","ID":"0f5f38b7-5643-4764-b6f2-d02c3eefb158","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"100 mg\/25 mg\/200 mg","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Brownish or greyish red, oval, unscored film-coated tablets marked with \u2018LCE 100\u2019 on one side.<\/span><\/p>","ID":"860032b9-4ecb-4167-ac96-0c8d4b89afbd","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Brownish or greyish red, oval, unscored film-coated tablets marked with \u2018LCE 100\u2019 on one side.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"32152609-615d-4ae7-a7dc-67a5799191e3","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">125<\/span><\/u><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">mg\/31.25<\/span><\/u><u><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">mg\/200<\/span><\/u><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">mg<\/span><\/u><\/p>","ID":"d7c8181c-61d9-46a6-9a3e-543f6750c826","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"125mg\/31.25mg\/200mg","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Light b<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">rownish red, <\/span><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">oval<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> film-coated tablets marked with <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">\u2018LCE 125\u2019 <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">on one side.<\/span><\/p>","ID":"26e98d36-67b8-4205-9200-af01b7a88427","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Light brownish red, oval film-coated tablets marked with \u2018LCE 125\u2019 on one side.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"d896f2b4-2fee-4f4b-b96f-957709b2adc8","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">150 mg\/37.5 mg\/200 mg<\/span><\/u><\/p>","ID":"4335061a-6e65-4ff1-afa7-29cb57808ea8","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"150 mg\/37.5 mg\/200 mg","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Brownish or greyish red, elongated-ellipse shaped, unscored film-coated tablets marked with \u2018LCE 150\u2019 on one side.<\/span><\/p>","ID":"13af59eb-63d3-4a6d-97cc-28a3fd2bf829","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Brownish or greyish red, elongated-ellipse shaped, unscored film-coated tablets marked with \u2018LCE 150\u2019 on one side.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"af48bbfc-bc8c-4c52-8f84-1703cde2120c","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">175 mg\/43.75 mg\/200 mg<\/span><\/u><\/p>","ID":"0a917b3b-2e4f-4ef0-a40f-fae486d2b2f7","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"175 mg\/43.75 mg\/200 mg","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Light b<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">rownish red, <\/span><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">oval, <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">unscored film-coated tablets marked with <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">\u2018LCE 175\u2019 <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">on one side.<\/span><\/p>","ID":"679c835c-b059-4bc5-93b2-40b0598a5821","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Light brownish red, oval, unscored film-coated tablets marked with \u2018LCE 175\u2019 on one side.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"fe6e60e0-93fb-4a24-95ce-5feb42820734","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">200 mg\/50 mg\/200 mg<\/span><\/u><\/p>","ID":"1d12b97e-4cc7-463f-a8ff-1d865f7c0ed4","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"200 mg\/50 mg\/200 mg","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Dark brownish red, oval, unscored film-coated tablets marked with \u2018LCE 200\u2019 on one side.<\/span><\/p>","ID":"ab4de132-d29c-4c37-b011-940a960d25af","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Dark brownish red, oval, unscored film-coated tablets marked with \u2018LCE 200\u2019 on one side.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"b5d49683-ebd2-45aa-aec0-a4bf9b332992","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"817de7ac-d456-4dc2-9a45-b11257ea14cf","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:27.0pt;margin-bottom:.0001pt;text-align:left;text-indent:-27.0pt\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">4.      <span style=\"text-transform:uppercase\">Clinical particulars<\/span><\/span><\/b><\/p>","ID":"2ab92a0f-f306-4856-a5d0-6e0c2683f1f0","Styles":"margin-top:0in;margin-right:0in;margin-bottom:\r\n0in;margin-left:27.0pt;margin-bottom:.0001pt;text-align:left;text-indent:-27.0pt","Classes":"['Text']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"4.      Clinical particulars","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"a4ac59cd-fbb6-4e30-bc0d-dea1b5abc643","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:27.0pt;margin-bottom:.0001pt;text-indent:-27.0pt\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">4.1    Therapeutic indications<\/span><\/b><\/p>","ID":"bbf2e572-a25a-4171-9c39-0d9a6a6f984f","Styles":"margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:27.0pt;margin-bottom:.0001pt;text-indent:-27.0pt","Classes":"['Text']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.1    Therapeutic indications","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"53ae4f0e-944a-420f-9d96-93c42fec4a63","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Stalevo is indicated for the treatment of adult patients with Parkinson\u2019s disease and end-of-dose motor fluctuations not stabilised on levodopa\/dopa decarboxylase (DDC) inhibitor treatment.<\/span><\/p>","ID":"73a2f5ae-9092-4ecc-8130-be526c6e2b24","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Stalevo is indicated for the treatment of adult patients with Parkinson\u2019s disease and end-of-dose motor fluctuations not stabilised on levodopa\/dopa decarboxylase (DDC) inhibitor treatment.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoEndnoteText\"><\/p>","ID":"d27f4c5d-4b1a-4d2b-bbba-72732db7ff0c","Styles":"None","Classes":"['MsoEndnoteText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:27.0pt;margin-bottom:.0001pt;text-align:left;text-indent:-27.0pt\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">4.2    Posology and method of administration<\/span><\/b><\/p>","ID":"4b7aed4e-cea8-4d7c-b729-c1a56001702d","Styles":"margin-top:0in;margin-right:0in;margin-bottom:\r\n0in;margin-left:27.0pt;margin-bottom:.0001pt;text-align:left;text-indent:-27.0pt","Classes":"['Text']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.2    Posology and method of administration","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"9ee750a7-2129-4202-bc51-e49f3d6bcbc2","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Posology<\/span><\/u><\/p>","ID":"fe41bb76-b799-4c74-8b7a-80e863a10499","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Posology","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"584c7241-bfc5-4579-9f8e-b5ded727d751","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">The optimum daily dose must be determined by careful titration of levodopa in each patient. The daily dose should be preferably optimised using one of the seven available tablet strengths (50 mg\/12.5 mg\/200 mg, 75 mg\/18.75 mg\/200 mg, 100 mg\/25 mg\/200 mg, 125 mg\/31.25 mg\/200 mg, 150 mg\/37.5 mg\/200 mg, 175 mg\/43.75 mg\/200 mg or 200 mg\/50 mg\/200 mg levodopa\/carbidopa\/entacapone). <\/span><\/p>","ID":"a8f0c8f9-1a1f-4e44-b5fe-e9db30764ed3","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The optimum daily dose must be determined by careful titration of levodopa in each patient. The daily dose should be preferably optimised using one of the seven available tablet strengths (50 mg\/12.5 mg\/200 mg, 75 mg\/18.75 mg\/200 mg, 100 mg\/25 mg\/200 mg, 125 mg\/31.25 mg\/200 mg, 150 mg\/37.5 mg\/200 mg, 175 mg\/43.75 mg\/200 mg or 200 mg\/50 mg\/200 mg levodopa\/carbidopa\/entacapone). ","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"b64ed563-484c-4e47-b442-afe0b4bc5761","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">Patients should be instructed to take only one Stalevo tablet per dose administration. Patients receiving less than 70-100 mg carbidopa a day are more likely to experience nausea and vomiting. While the experience with total daily dose greater than 200 mg carbidopa is limited, the maximum recommended daily dose of entacapone is 2,000 mg and therefore the maximum dose is 10 tablets per day for the Stalevo strengths of 50 mg\/12.5 mg\/200 mg, 75 mg\/18.75 mg\/200 mg 100 mg\/25 mg\/200 mg, 125 mg\/31.25 mg\/200 mg and 150 mg\/37.5 mg\/200 mg. Ten tablets of Stalevo 150 mg\/37.5 mg\/200 mg equals 375 mg of carbidopa a day. According to this daily carbidopa dose, the maximum recommended daily dose of Stalevo 175 mg\/43.75 mg\/200 mg is 8 tablets per day and Stalevo 200 mg\/50 mg\/200 mg dose is 7 tablets per day.<\/span><\/p>","ID":"83250565-c7d5-4c80-8452-faaeed6e1c60","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Patients should be instructed to take only one Stalevo tablet per dose administration. Patients receiving less than 70-100 mg carbidopa a day are more likely to experience nausea and vomiting. While the experience with total daily dose greater than 200 mg carbidopa is limited, the maximum recommended daily dose of entacapone is 2,000 mg and therefore the maximum dose is 10 tablets per day for the Stalevo strengths of 50 mg\/12.5 mg\/200 mg, 75 mg\/18.75 mg\/200 mg 100 mg\/25 mg\/200 mg, 125 mg\/31.25 mg\/200 mg and 150 mg\/37.5 mg\/200 mg. Ten tablets of Stalevo 150 mg\/37.5 mg\/200 mg equals 375 mg of carbidopa a day. According to this daily carbidopa dose, the maximum recommended daily dose of Stalevo 175 mg\/43.75 mg\/200 mg is 8 tablets per day and Stalevo 200 mg\/50 mg\/200 mg dose is 7 tablets per day.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"780c4cb1-873b-4707-891a-521df14a5dd2","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Usually Stalevo is to be used in patients who are currently treated with corresponding doses of standard release levodopa\/DDC inhibitor and entacapone. <\/span><\/p>","ID":"f2e55f2a-1cb4-41fc-ab2e-7d4d605eff5e","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Usually Stalevo is to be used in patients who are currently treated with corresponding doses of standard release levodopa\/DDC inhibitor and entacapone. ","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"fad75444-0c1c-4566-95de-5448db78f60e","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">How to transfer patients taking levodopa\/DDC inhibitor (carbidopa or benserazide) preparations and entacapone tablets to Stalevo <\/span><\/i><\/p>","ID":"ea85f722-8c54-4b22-bd90-a1f7fc498db3","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"How to transfer patients taking levodopa\/DDC inhibitor (carbidopa or benserazide) preparations and entacapone tablets to Stalevo ","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"b30c53bc-3003-49ba-869a-ece92f053c8a","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">a<\/span><\/i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">. Patients who are currently treated with entacapone\r and with standard release levodopa\/carbidopa in doses equal to Stalevo tabletstrengths can be directly transferred to corresponding Stalevo tablets. <\/span><\/p>","ID":"bc3712bb-18cb-4d97-bc58-faa875bf81b6","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"a. Patients who are currently treated with entacapone\r and with standard release levodopa\/carbidopa in doses equal to Stalevo tabletstrengths can be directly transferred to corresponding Stalevo tablets. ","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">For example, a patient taking one tablet of 50 mg\/12.5 mg of levodopa\/carbidopa with one tablet of entacapone 200 mg four times daily can take one 50 mg\/12.5 mg\/200 mg Stalevo tablet four times daily in place of their usual levodopa\/carbidopa and entacapone doses. <\/span><\/p>","ID":"7014ac64-cf54-4bed-8afc-d05c4856636f","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"For example, a patient taking one tablet of 50 mg\/12.5 mg of levodopa\/carbidopa with one tablet of entacapone 200 mg four times daily can take one 50 mg\/12.5 mg\/200 mg Stalevo tablet four times daily in place of their usual levodopa\/carbidopa and entacapone doses. ","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"0b66a85d-adac-4dd1-8476-b4739c247737","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">b. <\/span><\/i><span lang=\"EN-GB\">When initiating Stalevo therapy for patients currently treated with entacapone and levodopa\/carbidopa in doses not equal to Stalevo tablets (50 mg\/12.5 mg\/200 mg or 75 mg\/18.75 mg\/200 mg or 100 mg\/25 mg\/200 mg or 125 mg\/31.25 mg\/200 mg or 150 mg\/37.5 mg\/200 mg or 175 mg\/43.75 mg\/200 mg or 200 mg\/50 mg\/200 mg), Stalevo dosing should be carefully titrated for optimal clinical response. At the initiation, Stalevo should be adjusted to correspond as closely as possible to the total daily dose of levodopa currently used. <\/span><\/p>","ID":"00671ea6-0933-4379-99b2-bbe666d23c09","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"b. When initiating Stalevo therapy for patients currently treated with entacapone and levodopa\/carbidopa in doses not equal to Stalevo tablets (50 mg\/12.5 mg\/200 mg or 75 mg\/18.75 mg\/200 mg or 100 mg\/25 mg\/200 mg or 125 mg\/31.25 mg\/200 mg or 150 mg\/37.5 mg\/200 mg or 175 mg\/43.75 mg\/200 mg or 200 mg\/50 mg\/200 mg), Stalevo dosing should be carefully titrated for optimal clinical response. At the initiation, Stalevo should be adjusted to correspond as closely as possible to the total daily dose of levodopa currently used. ","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"48d5f067-dd38-47e0-b685-02e86c689666","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">c.<\/span><\/i><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> When initiating Stalevo in patients currently treated with entacapone and levodopa\/benserazide in a standard release formulation, <\/span><span style=\"font-size:11.0pt\">the<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> dosing of levodopa\/benserazide should be discontinued in the previous night, and Stalevo should be started in the next morning. The starting dose of Stalevo should provide either the same amount of levodopa or slightly (5-10%) more. <\/span><\/p>","ID":"94af37cb-0ec6-4585-a2f9-a79ce787da3a","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"c. When initiating Stalevo in patients currently treated with entacapone and levodopa\/benserazide in a standard release formulation, the dosing of levodopa\/benserazide should be discontinued in the previous night, and Stalevo should be started in the next morning. The starting dose of Stalevo should provide either the same amount of levodopa or slightly (5-10%) more. ","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\" style=\"margin-right:6.8pt\"><\/p>","ID":"48c21be3-7dc8-4490-a69e-07aa3b9b1ef0","Styles":"margin-right:6.8pt","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"Text\" style=\"margin-top:0in\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">How to transfer patients not currently treated with entacapone to Stalevo<\/span><\/i><\/p>","ID":"929cdc07-bc6a-47ee-a09f-1cf69b3c9c58","Styles":"margin-top:0in","Classes":"['Text']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"How to transfer patients not currently treated with entacapone to Stalevo","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"Text\" style=\"margin-top:0in\"><\/p>","ID":"d40b3b4d-53f1-4586-88ef-a9ba82abc4c0","Styles":"margin-top:0in","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Initiation of Stalevo may be considered at corresponding doses to current treatment in some patients with Parkinson's disease and end-of-dose motor fluctuations, who are not stabilised on their current standard release levodopa\/DDC inhibitor treatment. However, a direct switch from levodopa\/DDC inhibitor to Stalevo is not recommended for patients who have dyskinesias or whose daily levodopa dose is above 800 mg. In such patients it is advisable to introduce entacapone treatment as a separate treatment (entacapone tablets) and adjust the levodopa dose if necessary, before switching to Stalevo.<\/span><\/p>","ID":"9ccabace-dd7c-434d-8eb8-1997f265aeb3","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Initiation of Stalevo may be considered at corresponding doses to current treatment in some patients with Parkinson's disease and end-of-dose motor fluctuations, who are not stabilised on their current standard release levodopa\/DDC inhibitor treatment. However, a direct switch from levodopa\/DDC inhibitor to Stalevo is not recommended for patients who have dyskinesias or whose daily levodopa dose is above 800 mg. In such patients it is advisable to introduce entacapone treatment as a separate treatment (entacapone tablets) and adjust the levodopa dose if necessary, before switching to Stalevo.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"2eac2c90-e07e-419b-a430-fc49b6d112e4","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">Entacapone enhances the effects of levodopa. It may therefore be necessary, particularly in patients with dyskinesia, to reduce levodopa dose by 10-30% within the first days to first weeks after initiating Stalevo treatment. The daily dose of levodopa can be reduced by extending the dosing intervals and\/or by reducing the amount of levodopa per dose, according to the clinical condition of the patient. <\/span><\/p>","ID":"592ff36a-c2fe-44e1-a814-d15f9f58dbf3","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Entacapone enhances the effects of levodopa. It may therefore be necessary, particularly in patients with dyskinesia, to reduce levodopa dose by 10-30% within the first days to first weeks after initiating Stalevo treatment. The daily dose of levodopa can be reduced by extending the dosing intervals and\/or by reducing the amount of levodopa per dose, according to the clinical condition of the patient. ","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"0769dc0c-8bc2-4b94-b756-40ab7acb67ab","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"Text\" style=\"margin-top:0in\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Dose adjustment during the course of the treatment<\/span><\/i><\/p>","ID":"7c61c9dc-332a-461e-84f3-670fc119189b","Styles":"margin-top:0in","Classes":"['Text']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Dose adjustment during the course of the treatment","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"Text\" style=\"margin-top:0in\"><\/p>","ID":"5ed87726-e281-475b-916b-4a162546d13a","Styles":"margin-top:0in","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">When more levodopa is required, an increase in the frequency of doses and\/or the use of an alternative strength of Stalevo should be considered, within the dose recommendations. <\/span><\/p>","ID":"0de6c354-c723-46e6-832f-c637cd319798","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"When more levodopa is required, an increase in the frequency of doses and\/or the use of an alternative strength of Stalevo should be considered, within the dose recommendations. ","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"2adf2e79-b416-4bcd-9c1e-422d6e617c5e","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">When less levodopa is required, the total daily dose of Stalevo should be reduced either by decreasing the frequency of administration by extending the time between doses, or by decreasing the strength of Stalevo at an administration.<\/span><\/p>","ID":"747f1972-f3fa-4b5e-95de-06794a30f19e","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"When less levodopa is required, the total daily dose of Stalevo should be reduced either by decreasing the frequency of administration by extending the time between doses, or by decreasing the strength of Stalevo at an administration.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"280e6c28-0c26-43e7-a8fa-7cb8e2a3194a","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">If other levodopa products are used concomitantly with a Stalevo tablet, the maximum dose recommendations should be followed.<\/span><\/p>","ID":"81bc870a-5087-448d-9a19-98228690c4dc","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"If other levodopa products are used concomitantly with a Stalevo tablet, the maximum dose recommendations should be followed.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><i><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\"><\/span><\/u><\/i><\/p>","ID":"cd152e6c-a612-4408-85c7-3159e06792be","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><i><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Discontinuation of Stalevo therapy<\/span><\/u><\/i><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">: <\/span><\/i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">If Stalevo treatment (levodopa\/carbidopa\/entacapone) is discontinued and the patient is transferred to levodopa\/DDC inhibitor therapy without entacapone, it is necessary to adjust the dosing of other antiparkinsonian treatments, especially levodopa, to achieve a sufficient level of control of the parkinsonian symptoms.<\/span><\/p>","ID":"63bf205b-ec62-48ce-b0f7-76ea4b235ce2","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Discontinuation of Stalevo therapy: If Stalevo treatment (levodopa\/carbidopa\/entacapone) is discontinued and the patient is transferred to levodopa\/DDC inhibitor therapy without entacapone, it is necessary to adjust the dosing of other antiparkinsonian treatments, especially levodopa, to achieve a sufficient level of control of the parkinsonian symptoms.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><i><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\"><\/span><\/u><\/i><\/p>","ID":"ab7969dd-a4e8-4f44-993c-fdb0830e085c","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><i><u><span style=\"font-size:11.0pt\">Paediatric population<\/span><\/u><\/i><i><span style=\"font-size:11.0pt\">:<\/span><\/i><span style=\"font-size:11.0pt\"> The safety and efficacy of Stalevo in children aged below 18 years have not been established. No data are available.<\/span><\/p>","ID":"a22201f1-a210-49a5-98fe-2f05933c2391","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Paediatric population: The safety and efficacy of Stalevo in children aged below 18 years have not been established. No data are available.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"1dc85eb6-b83a-450d-ba8e-02f2826b4797","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><i><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Elderly<\/span><\/u><\/i><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">:<\/span><\/i><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> No dose adjustment of Stalevo is required for elderly.<\/span><\/p>","ID":"b60f45ef-e9a8-4f42-800b-ad0e6ca30528","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Elderly: No dose adjustment of Stalevo is required for elderly.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><i><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\"><\/span><\/u><\/i><\/p>","ID":"07fe900b-8a76-4eaa-acb9-c29f58685221","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><i><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Hepatic impairment<\/span><\/u><\/i><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">: <\/span><\/i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">It is advised that Stalevo should be administered cautiously to patients with mild to moderate hepatic impairment. Dose reduction may be needed (see section 5.2). <\/span><span style=\"font-size:11.0pt\">For severe hepatic impairment see section 4.3.<\/span><\/p>","ID":"33ec9b23-226f-4383-822c-4350017ca99c","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Hepatic impairment: It is advised that Stalevo should be administered cautiously to patients with mild to moderate hepatic impairment. Dose reduction may be needed (see section 5.2). For severe hepatic impairment see section 4.3.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"b46f1dd7-accd-454a-a373-b247ab4cb45d","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><i><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Renal impairment<\/span><\/u><\/i><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">:<\/span><\/i><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> Renal <\/span><span style=\"font-size:11.0pt\">impairment<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> does not affect the pharmacokinetics of entacapone. No particular studies are reported on the pharmacokinetics of levodopa and carbidopa in patients with renal insufficiency, therefore Stalevo therapy should be administered cautiously to patients in severe renal impairment including those receiving dialysis therapy (see section 5.2). <\/span><\/p>","ID":"e8b7113d-b7d6-4812-9306-283f30c00b79","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Renal impairment: Renal impairment does not affect the pharmacokinetics of entacapone. No particular studies are reported on the pharmacokinetics of levodopa and carbidopa in patients with renal insufficiency, therefore Stalevo therapy should be administered cautiously to patients in severe renal impairment including those receiving dialysis therapy (see section 5.2). ","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"565790da-9e80-44e9-a6d3-add3b767c555","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Method of administration<\/span><\/u><\/p>","ID":"31b47dbc-5ed6-4940-91ad-0d11e30d7a34","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Method of administration","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Each tablet is to be taken orally either with or without food (see section 5.2). One tablet contains one treatment dose and the tablet may only be administered as whole tablets.<\/span><\/p>","ID":"cca68c89-adbd-4fbe-9c8b-3f2b63cd0198","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Each tablet is to be taken orally either with or without food (see section 5.2). One tablet contains one treatment dose and the tablet may only be administered as whole tablets.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"e5b778f9-447c-427f-affb-571dd6eba3ce","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt\"><b><span lang=\"EN-GB\">4.3    Contraindications<\/span><\/b><\/p>","ID":"053bb4c2-fc0f-45e1-a34e-9ce8e6be7e7a","Styles":"margin-left:27.0pt;text-indent:-27.0pt","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.3    Contraindications","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"99d0a218-1c59-474a-9d64-ace54d55a698","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Hypersensitivity to the active substances or to any of the excipients <\/span><span style=\"font-size:\r 11.0pt\">listed in section 6.1<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">.<\/span><\/p>","ID":"10e2c058-70dd-463b-a9a5-e0c8e9b39a76","Styles":"margin-top:0in;margin-right:0in;margin-bottom:\r\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"-Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Severe hepatic impairment.<\/span><\/p>","ID":"ca477581-b17e-4083-b5ec-602b36bf6fe7","Styles":"margin-top:0in;margin-right:0in;margin-bottom:\r\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"-Severe hepatic impairment.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Narrow-angle glaucoma.<\/span><\/p>","ID":"bb1b4326-eefa-4310-a173-ef16de5cbcea","Styles":"margin-top:0in;margin-right:0in;margin-bottom:\r\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"-Narrow-angle glaucoma.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Pheochromocytoma.<\/span><\/p>","ID":"73443e0f-ea40-42a3-ba5b-dddbc370ec83","Styles":"margin-top:0in;margin-right:0in;margin-bottom:\r\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"-Pheochromocytoma.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Coadministration of Stalevo with non-selective monoamine oxidase (MAO-A and MAO-B) inhibitors (e.g. phenelzine, tranylcypromine). <\/span><\/p>","ID":"7c73fb42-9302-456e-a729-23665e703bec","Styles":"margin-top:0in;margin-right:0in;margin-bottom:\r\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"-Coadministration of Stalevo with non-selective monoamine oxidase (MAO-A and MAO-B) inhibitors (e.g. phenelzine, tranylcypromine). ","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Coadministration with a selective MAO-A inhibitor and a selective MAO-B inhibitor (see section 4.5). <\/span><\/p>","ID":"43b43946-1785-40cd-95cb-6a77c3c68083","Styles":"margin-top:0in;margin-right:0in;margin-bottom:\r\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"-Coadministration with a selective MAO-A inhibitor and a selective MAO-B inhibitor (see section 4.5). ","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">A previous history of Neuroleptic Malignant Syndrome (NMS) and\/or non-traumatic rhabdomyolysis.<\/span><\/p>","ID":"88a78058-26f6-4e0a-b575-ed3074c363b4","Styles":"margin-top:0in;margin-right:0in;margin-bottom:\r\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"-A previous history of Neuroleptic Malignant Syndrome (NMS) and\/or non-traumatic rhabdomyolysis.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><\/p>","ID":"77348abf-d220-4c6b-bcc6-1e340ac1f957","Styles":"margin-top:0in;margin-right:0in;margin-bottom:\r\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">4.4     Special warnings and precautions for use <\/span><\/b><\/p>","ID":"53fdf26d-1e52-4be5-9e5c-9573db6f7933","Styles":"margin-top:0in;margin-right:0in;margin-bottom:\r\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt","Classes":"['Text']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.4     Special warnings and precautions for use ","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><\/p>","ID":"e929ddb2-1811-4d2c-9eba-5aa36ffbd1b7","Styles":"margin-top:0in;margin-right:0in;margin-bottom:\r\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Stalevo is not recommended for the treatment of drug-induced extrapyramidal reactions. <\/span><\/p>","ID":"0b18fe79-4dc5-4e7e-8692-440efc171155","Styles":"margin-top:0in;margin-right:0in;margin-bottom:\r\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"-Stalevo is not recommended for the treatment of drug-induced extrapyramidal reactions. ","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;text-transform:uppercase\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Stalevo therapy should be administered cautiously to patients with ischemic heart disease, severe cardiovascular or pulmonary disease, bronchial asthma, renal or endocrine disease, history of peptic ulcer disease or history of convulsions. <\/span><\/p>","ID":"4a5c901f-6853-44ce-9b0e-1997eb2918c4","Styles":"margin-top:0in;margin-right:0in;margin-bottom:\r\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"-Stalevo therapy should be administered cautiously to patients with ischemic heart disease, severe cardiovascular or pulmonary disease, bronchial asthma, renal or endocrine disease, history of peptic ulcer disease or history of convulsions. ","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">In patients with a history of myocardial infarction who have residual atrial nodal or ventricular arrhythmias; cardiac function should be monitored with particular care during the period of initial dose adjustments.<\/span><\/p>","ID":"62738688-aad4-46d8-801a-6ae16cbfd6e7","Styles":"margin-top:0in;margin-right:0in;margin-bottom:\r\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"-In patients with a history of myocardial infarction who have residual atrial nodal or ventricular arrhythmias; cardiac function should be monitored with particular care during the period of initial dose adjustments.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">All patients treated with Stalevo should be monitored carefully for the development of mental changes, depression with suicidal tendencies, and other serious antisocial behaviour. Patients with past or current psychosis should be treated with caution.<\/span><\/p>","ID":"cf441a96-f5b7-4ae6-9a0c-a4fb14425ddc","Styles":"margin-top:0in;margin-right:0in;margin-bottom:\r\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"-All patients treated with Stalevo should be monitored carefully for the development of mental changes, depression with suicidal tendencies, and other serious antisocial behaviour. Patients with past or current psychosis should be treated with caution.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Concomitant\r administration of antipsychotics with dopamine receptor-blocking properties,\r particularly D<sub>2<\/sub> receptor antagonists should be carried out with\r caution, and the patient carefully observed for loss of antiparkinsonian effect\r or worsening of parkinsonian symptoms.<\/span><\/p>","ID":"512bdb9a-0775-4b67-b262-32e3e83da9ed","Styles":"margin-top:0in;margin-right:0in;margin-bottom:\r\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"-Concomitant\r administration of antipsychotics with dopamine receptor-blocking properties,\r particularly D2 receptor antagonists should be carried out with\r caution, and the patient carefully observed for loss of antiparkinsonian effect\r or worsening of parkinsonian symptoms.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Patients with chronic wide-angle glaucoma may be treated with Stalevo with caution, provided the intra-ocular pressure is well controlled and the patient is monitored carefully for changes in intra-ocular pressure.<\/span><\/p>","ID":"3af2df50-66ec-4f39-b46a-08ef463f1b93","Styles":"margin-top:0in;margin-right:0in;margin-bottom:\r\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"-Patients with chronic wide-angle glaucoma may be treated with Stalevo with caution, provided the intra-ocular pressure is well controlled and the patient is monitored carefully for changes in intra-ocular pressure.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Stalevo may induce orthostatic hypotension. Therefore Stalevo should be given cautiously to patients who are taking other medicinal products which may cause orthostatic hypotension.<\/span><\/p>","ID":"143473fd-136a-48e0-95be-598cfead37fa","Styles":"margin-top:0in;margin-right:0in;margin-bottom:\r\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"-Stalevo may induce orthostatic hypotension. Therefore Stalevo should be given cautiously to patients who are taking other medicinal products which may cause orthostatic hypotension.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Entacapone in association with levodopa has been associated with somnolence and episodes of sudden sleep onset in patients with Parkinson\u2019s disease and caution should therefore be exercised when driving or operating machines (see section 4.7).<\/span><\/p>","ID":"41cfba1e-946a-40dd-96ca-b2c8507b7470","Styles":"margin-top:0in;margin-right:0in;margin-bottom:\r\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"-Entacapone in association with levodopa has been associated with somnolence and episodes of sudden sleep onset in patients with Parkinson\u2019s disease and caution should therefore be exercised when driving or operating machines (see section 4.7).","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">In clinical studies, <\/span><span style=\"font-size:11.0pt\">dopaminergic adverse reactions<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">, e.g. dyskinesia, were more common in patients who received entacapone and dopamine agonists (such as bromocriptine), selegiline or amantadine compared to those who received placebo with this combination. The doses of other antiparkinsonian medicinal products may need to be adjusted when Stalevo treatment is substituted for a patient currently not treated with entacapone.<\/span><\/p>","ID":"490736ed-10a2-43ee-b014-182658bd98df","Styles":"margin-top:0in;margin-right:0in;margin-bottom:\r\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"-In clinical studies, dopaminergic adverse reactions, e.g. dyskinesia, were more common in patients who received entacapone and dopamine agonists (such as bromocriptine), selegiline or amantadine compared to those who received placebo with this combination. The doses of other antiparkinsonian medicinal products may need to be adjusted when Stalevo treatment is substituted for a patient currently not treated with entacapone.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Rhabdomyolysis secondary to severe dyskinesias or neuroleptic malignant syndrome (NMS) has been observed rarely in patients with Parkinson\u2019s disease. Therefore, any abrupt dose reduction or withdrawal of levodopa should be carefully observed, particularly in patients who are also receiving neuroleptics. NMS, including rhabdomyolysis and hyperthermia, is characterised by motor symptoms (rigidity, myoclonus, tremor), mental status changes (e.g., agitation, confusion, coma), hyperthermia, autonomic dysfunction (tachycardia, labile blood pressure) and elevated serum creatine phosphokinase. In individual cases, only some of these symptoms and\/or findings may be evident. The early diagnosis is important for the appropriate management of NMS. A syndrome resembling the neuroleptic malignant syndrome including muscular rigidity, elevated body temperature, mental changes and increased serum creatine phosphokinase has been reported with the abrupt withdrawal of antiparkinsonian agents. Neither NMS nor rhabdomyolysis have been reported in association with entacapone treatment from controlled trials in which entacapone was discontinued abruptly. Since the introduction of entacapone into the market, isolated cases of NMS have been reported, especially following abrupt reduction or discontinuation of entacapone and other concomitant dopaminergic medicinal products. When considered necessary, the replacement of Stalevo with levodopa and DDC inhibitor without entacapone or other dopaminergic treatment should proceed slowly and an increase in levodopa dose may be necessary.<\/span><\/p>","ID":"b2e46200-a6fa-4f18-a0a5-2f9d5648d9d0","Styles":"margin-top:0in;margin-right:0in;margin-bottom:\r\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"-Rhabdomyolysis secondary to severe dyskinesias or neuroleptic malignant syndrome (NMS) has been observed rarely in patients with Parkinson\u2019s disease. Therefore, any abrupt dose reduction or withdrawal of levodopa should be carefully observed, particularly in patients who are also receiving neuroleptics. NMS, including rhabdomyolysis and hyperthermia, is characterised by motor symptoms (rigidity, myoclonus, tremor), mental status changes (e.g., agitation, confusion, coma), hyperthermia, autonomic dysfunction (tachycardia, labile blood pressure) and elevated serum creatine phosphokinase. In individual cases, only some of these symptoms and\/or findings may be evident. The early diagnosis is important for the appropriate management of NMS. A syndrome resembling the neuroleptic malignant syndrome including muscular rigidity, elevated body temperature, mental changes and increased serum creatine phosphokinase has been reported with the abrupt withdrawal of antiparkinsonian agents. Neither NMS nor rhabdomyolysis have been reported in association with entacapone treatment from controlled trials in which entacapone was discontinued abruptly. Since the introduction of entacapone into the market, isolated cases of NMS have been reported, especially following abrupt reduction or discontinuation of entacapone and other concomitant dopaminergic medicinal products. When considered necessary, the replacement of Stalevo with levodopa and DDC inhibitor without entacapone or other dopaminergic treatment should proceed slowly and an increase in levodopa dose may be necessary.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">If general anaesthesia is required, therapy with Stalevo may be continued for as long as the patient is permitted to take fluids and medicinal products by mouth. If therapy has to be stopped temporarily, Stalevo may be restarted as soon as oral medicinal products can be taken at the same daily dose as before. <\/span><\/p>","ID":"952abb9d-96a3-46c0-aa8c-ba52a3d05c92","Styles":"margin-top:0in;margin-right:0in;margin-bottom:\r\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"-If general anaesthesia is required, therapy with Stalevo may be continued for as long as the patient is permitted to take fluids and medicinal products by mouth. If therapy has to be stopped temporarily, Stalevo may be restarted as soon as oral medicinal products can be taken at the same daily dose as before. ","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Periodic evaluation of hepatic, haematopoietic, cardiovascular and renal function is recommended during extended therapy with Stalevo.<\/span><\/p>","ID":"a8747fda-64ec-45f7-9c59-f3bc233790ca","Styles":"margin-top:0in;margin-right:0in;margin-bottom:\r\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"-Periodic evaluation of hepatic, haematopoietic, cardiovascular and renal function is recommended during extended therapy with Stalevo.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">For patients experiencing diarrhoea, a follow-up of weight is recommended in order to avoid potential excessive weight decrease. Prolonged or persistent diarrhoea appearing during use of entacapone may be a sign of colitis. In the event of prolonged or persistent diarrhoea, the drug should be discontinued and appropriate medical therapy and investigations considered.<\/span><\/p>","ID":"beb9c5d5-ae8a-4d0a-9f2c-ee6e9e679f7f","Styles":"margin-top:0in;margin-right:0in;margin-bottom:\r\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"-For patients experiencing diarrhoea, a follow-up of weight is recommended in order to avoid potential excessive weight decrease. Prolonged or persistent diarrhoea appearing during use of entacapone may be a sign of colitis. In the event of prolonged or persistent diarrhoea, the drug should be discontinued and appropriate medical therapy and investigations considered.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Patients should be regularly monitored for the development of impulse control disorders. Patients and carers should be made aware that behavioural symptoms of impulse control disorders including pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists and\/or other dopaminergic treatments containing levodopa including Stalevo. Review of treatment is recommended if such symptoms develop.<\/span><\/p>","ID":"cbee2587-8297-4c09-b474-ba32d357cad1","Styles":"margin-top:0in;margin-right:0in;margin-bottom:\r\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"-Patients should be regularly monitored for the development of impulse control disorders. Patients and carers should be made aware that behavioural symptoms of impulse control disorders including pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists and\/or other dopaminergic treatments containing levodopa including Stalevo. Review of treatment is recommended if such symptoms develop.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Dopamine Dysregulation Syndrome (DDS) is an addictive disorder resulting in excessive use of the product seen in some patients treated with carbidopa\/levodopa. Before initiation of treatment, patients and caregivers should be warned of the potential risk of developing DDS (see also section 4.8).<\/span><\/p>","ID":"31026d51-fbec-4002-a709-252416bb14e9","Styles":"margin-top:0in;margin-right:0in;margin-bottom:\r\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"-Dopamine Dysregulation Syndrome (DDS) is an addictive disorder resulting in excessive use of the product seen in some patients treated with carbidopa\/levodopa. Before initiation of treatment, patients and caregivers should be warned of the potential risk of developing DDS (see also section 4.8).","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">For patients who experience progressive anorexia, asthenia and weight decrease within a relatively short period of time, a general medical evaluation including liver function should be considered.<\/span><\/p>","ID":"f389245c-1bfa-4a17-b661-1337389886fd","Styles":"margin-top:0in;margin-right:0in;margin-bottom:\r\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"-For patients who experience progressive anorexia, asthenia and weight decrease within a relatively short period of time, a general medical evaluation including liver function should be considered.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Levodopa\/carbidopa may cause false positive result when a dipstick is used to test for urinary ketone and this reaction is not altered by boiling the urine sample. The use of glucose oxidase methods may give false negative results for glycosuria.<\/span><\/p>","ID":"2d509883-228c-4531-bd25-49a5648288c9","Styles":"margin-top:0in;margin-right:0in;margin-bottom:\r\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"-Levodopa\/carbidopa may cause false positive result when a dipstick is used to test for urinary ketone and this reaction is not altered by boiling the urine sample. The use of glucose oxidase methods may give false negative results for glycosuria.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">-<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Stalevo contains sucrose, and therefore patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.<\/span><\/p>","ID":"55caca3b-a129-4b82-b461-774dbd256b50","Styles":"margin-top:0in;margin-right:0in;margin-bottom:\r\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"-Stalevo contains sucrose, and therefore patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:27.0pt;margin-bottom:.0001pt;text-align:left;text-indent:-27.0pt\"><\/p>","ID":"86ffed5f-0e18-458f-8457-b52f92f506e1","Styles":"margin-top:0in;margin-right:0in;margin-bottom:\r\n0in;margin-left:27.0pt;margin-bottom:.0001pt;text-align:left;text-indent:-27.0pt","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:27.0pt;margin-bottom:.0001pt;text-indent:-27.0pt\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">4.5    Interaction with other medicinal products and other forms of interaction <\/span><\/b><\/p>","ID":"85d64d85-2fa4-4453-b593-6600fb065347","Styles":"margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:27.0pt;margin-bottom:.0001pt;text-indent:-27.0pt","Classes":"['Text']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.5    Interaction with other medicinal products and other forms of interaction ","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"Text\" style=\"margin-top:0in\"><\/p>","ID":"5dddf8fa-3410-4cd8-8061-5abe1d72ce52","Styles":"margin-top:0in","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Other antiparkinsonian medicinal products<\/span><\/i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">: To date there has been no indication of interactions that would preclude concurrent use of standard antiparkinsonian medicinal products with Stalevo therapy. Entacapone in high doses may affect the absorption of carbidopa. However, no interaction with carbidopa has been observed with the recommended treatment schedule (200 mg of entacapone up to 10 times daily). Interactions between entacapone and selegiline have been investigated in repeated dose studies in Parkinson's disease patients treated with levodopa\/DDC inhibitor and no interaction was observed. When used with Stalevo, the daily dose of selegiline should not exceed 10 mg.<\/span><\/p>","ID":"df82e8cb-ef9e-4344-82f0-6d4b1ff6bdf4","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Other antiparkinsonian medicinal products: To date there has been no indication of interactions that would preclude concurrent use of standard antiparkinsonian medicinal products with Stalevo therapy. Entacapone in high doses may affect the absorption of carbidopa. However, no interaction with carbidopa has been observed with the recommended treatment schedule (200 mg of entacapone up to 10 times daily). Interactions between entacapone and selegiline have been investigated in repeated dose studies in Parkinson's disease patients treated with levodopa\/DDC inhibitor and no interaction was observed. When used with Stalevo, the daily dose of selegiline should not exceed 10 mg.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><s><span lang=\"EN-GB\" style=\"font-size:11.0pt\"><\/span><\/s><\/p>","ID":"8f076ea7-654a-4f16-8da3-6905711c682f","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Caution should be exercised when the following active substances are administered concomitantly with levodopa therapy.<\/span><\/p>","ID":"d2f78aa6-1413-4704-8de0-af5effd24150","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Caution should be exercised when the following active substances are administered concomitantly with levodopa therapy.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"7d358ddf-fb85-4459-a906-432e6b380fcb","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Antihypertensives<\/span><\/i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">: Symptomatic postural hypotension may occur when levodopa is added to the treatment of patients already receiving antihypertensives. Dose adjustment of the antihypertensive agent may be required. <\/span><\/p>","ID":"067599ae-daf7-43a5-b1f9-d7289990c8da","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Antihypertensives: Symptomatic postural hypotension may occur when levodopa is added to the treatment of patients already receiving antihypertensives. Dose adjustment of the antihypertensive agent may be required. ","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"b441f2de-7748-4ade-8aa5-bc9ac387e743","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Antidepressants: <\/span><\/i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Rarely, reactions including hypertension and dyskinesia have been reported with the concomitant use of tricyclic antidepressants and levodopa\/carbidopa. Interactions between entacapone and imipramine and between entacapone and moclobemide have been investigated in single dose studies in healthy volunteers. No pharmacodynamic interactions were observed. A significant number of Parkinson's disease patients have been treated with the combination of levodopa, carbidopa and entacapone with several active substances including MAO-A inhibitors, tricyclic antidepressants, noradrenaline reuptake inhibitors such as desipramine, maprotiline and venlafaxine and medicinal products that are metabolised by COMT (e.g. catechol-structured compounds, paroxetine). No pharmacodynamic interactions have been observed. However, caution should be exercised when these medicinal products are used concomitantly with Stalevo (see sections 4.3 and 4.4).<\/span><\/p>","ID":"05a1165e-5179-4596-a040-dd5bd4708c0e","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Antidepressants: Rarely, reactions including hypertension and dyskinesia have been reported with the concomitant use of tricyclic antidepressants and levodopa\/carbidopa. Interactions between entacapone and imipramine and between entacapone and moclobemide have been investigated in single dose studies in healthy volunteers. No pharmacodynamic interactions were observed. A significant number of Parkinson's disease patients have been treated with the combination of levodopa, carbidopa and entacapone with several active substances including MAO-A inhibitors, tricyclic antidepressants, noradrenaline reuptake inhibitors such as desipramine, maprotiline and venlafaxine and medicinal products that are metabolised by COMT (e.g. catechol-structured compounds, paroxetine). No pharmacodynamic interactions have been observed. However, caution should be exercised when these medicinal products are used concomitantly with Stalevo (see sections 4.3 and 4.4).","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"8c86005e-933e-4a7b-b078-beb414926786","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Other active substances: <\/span><\/i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Dopamine receptor antagonists (e.g. some antipsychotics and antiemetics), phenytoin and papaverine may reduce the therapeutic effect of levodopa. Patients taking these medicinal products with Stalevo should be carefully observed for loss of therapeutic response.<\/span><\/p>","ID":"3946eebf-7e38-43fb-8300-4fe9de8cb4e5","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Other active substances: Dopamine receptor antagonists (e.g. some antipsychotics and antiemetics), phenytoin and papaverine may reduce the therapeutic effect of levodopa. Patients taking these medicinal products with Stalevo should be carefully observed for loss of therapeutic response.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"d0ab27cd-b0c0-4877-9b17-fd1cb30e17a1","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Due to entacapone's affinity to cytochrome\r P450 2C9 <i>in vitro<\/i> (see section 5.2), Stalevo may potentially\r interfere with active substances whose metabolism is dependent on this\r isoenzyme, such as S-warfarin. However, in an interaction study with healthy\r volunteers, entacapone did not change the plasma levels of S-warfarin, while\r the AUC for R-warfarin increased on average by 18% [CI<sub>90<\/sub> 11-26%].\r The INR values increased on average by 13% [CI<sub>90<\/sub> 6-19%]. Thus, a\r control of INR is recommended when Stalevo is initiated for patients receiving\r warfarin.<\/span><\/p>","ID":"df82a705-5df7-4367-8948-2b0a512ae347","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Due to entacapone's affinity to cytochrome\r P450 2C9 in vitro (see section 5.2), Stalevo may potentially\r interfere with active substances whose metabolism is dependent on this\r isoenzyme, such as S-warfarin. However, in an interaction study with healthy\r volunteers, entacapone did not change the plasma levels of S-warfarin, while\r the AUC for R-warfarin increased on average by 18% [CI90 11-26%].\r The INR values increased on average by 13% [CI90 6-19%]. Thus, a\r control of INR is recommended when Stalevo is initiated for patients receiving\r warfarin.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"583f99a9-1ed5-419e-9959-2f58afd8c15a","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Other forms of interactions:<\/span><\/i><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> Since levodopa competes with certain amino acids, the absorption of Stalevo may be impaired in some patients on high protein diet.<\/span><\/p>","ID":"a22a84b5-7bd3-436a-9dd2-236957c1343c","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Other forms of interactions: Since levodopa competes with certain amino acids, the absorption of Stalevo may be impaired in some patients on high protein diet.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"b55b62a6-b6aa-4959-b093-8fb4fb11e583","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Levodopa and entacapone may form chelates with iron in the gastrointestinal tract. Therefore, Stalevo and iron preparations should be taken at least 2-3 hours apart (see section 4.8).<\/span><\/p>","ID":"074d9d38-b4c5-4c73-9cf0-3dca16ef0530","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Levodopa and entacapone may form chelates with iron in the gastrointestinal tract. Therefore, Stalevo and iron preparations should be taken at least 2-3 hours apart (see section 4.8).","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"bf16ead6-c2a6-4339-9408-c67a7a3a47b5","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">In vitro data:<\/span><\/i><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> Entacapone binds to human albumin binding site II\r which also binds several other medicinal products, including diazepam and\r ibuprofen. According to <i>in vitro<\/i> studies, significant displacement is\r not anticipated at therapeutic concentrations of the medicinal products.\r Accordingly, to date there has been no indication of such interactions.<\/span><\/p>","ID":"b3b33a31-1eb3-4e8c-be2a-80c42f94a839","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"In vitro data: Entacapone binds to human albumin binding site II\r which also binds several other medicinal products, including diazepam and\r ibuprofen. According to in vitro studies, significant displacement is\r not anticipated at therapeutic concentrations of the medicinal products.\r Accordingly, to date there has been no indication of such interactions.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"53c884a8-80c8-40bb-8ac7-97cd179ce4fa","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"Text\" style=\"margin-top:0in\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">4.6     Fertility, pregnancy and lactation<\/span><\/b><\/p>","ID":"bf5842c4-d26a-4cc3-8a70-47d064ff1302","Styles":"margin-top:0in","Classes":"['Text']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.6     Fertility, pregnancy and lactation","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"9804ff30-4713-402a-80e0-4cab336a6dd1","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Pregnancy<\/span><\/u><\/p>","ID":"47e37fcc-6bb1-4a41-bcb7-3f8ecac1286e","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Pregnancy","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">There are no adequate data from the use of the combination of levodopa\/carbidopa\/entacapone in pregnant women. Studies in animals have shown reproductive toxicity of the separate compounds (see section 5.3). The potential risk for humans is unknown. Stalevo should not be used during pregnancy unless the benefits for the mother outweigh the possible risks to the foetus.<\/span><\/p>","ID":"53dc2357-97c3-4317-9132-132898f405f0","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"There are no adequate data from the use of the combination of levodopa\/carbidopa\/entacapone in pregnant women. Studies in animals have shown reproductive toxicity of the separate compounds (see section 5.3). The potential risk for humans is unknown. Stalevo should not be used during pregnancy unless the benefits for the mother outweigh the possible risks to the foetus.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"bf53ecf3-dc55-45cc-a168-280c0a0b2f27","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Breast-feeding<\/span><\/u><\/p>","ID":"b9db58e9-8393-4b99-bd42-cdf603afe2c0","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Breast-feeding","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Levodopa is excreted in human breast milk. There is evidence that breast-feeding is suppressed during treatment with levodopa. Carbidopa and entacapone were excreted in milk in animals but is not known whether they are excreted in human breast milk. The safety of levodopa, carbidopa or entacapone in the infant is not known. Women should not breast-feed during treatment with Stalevo.<\/span><\/p>","ID":"0f0c0e32-082b-458e-9b12-a6535e8b1cb7","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Levodopa is excreted in human breast milk. There is evidence that breast-feeding is suppressed during treatment with levodopa. Carbidopa and entacapone were excreted in milk in animals but is not known whether they are excreted in human breast milk. The safety of levodopa, carbidopa or entacapone in the infant is not known. Women should not breast-feed during treatment with Stalevo.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"Text\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Fertility <\/span><\/u><\/p>","ID":"3a65ba7e-de06-4479-bbdb-2768d8aef39c","Styles":"None","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Fertility ","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">No adverse reactions on fertility were observed in preclinical studies with entacapone, carbidopa or levodopa alone. Fertility studies in animals have not been conducted with the combination of entacapone, levodopa and carbidopa.<\/span><\/p>","ID":"40e67ee5-bb1b-4193-a6f3-68ad61470faa","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"No adverse reactions on fertility were observed in preclinical studies with entacapone, carbidopa or levodopa alone. Fertility studies in animals have not been conducted with the combination of entacapone, levodopa and carbidopa.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"1dedc3f9-0b3f-49ad-acd9-6901638054cd","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"Text\" style=\"margin-top:0in\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">4.7     Effects on ability to drive and use machines<\/span><\/b><\/p>","ID":"6e9f06ea-2642-4da2-bd82-43b0d029994b","Styles":"margin-top:0in","Classes":"['Text']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.7     Effects on ability to drive and use machines","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"a9250f41-3d4b-4ea6-8acb-f200c6886355","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Stalevo may have a major influence on the ability to drive and use machines. Levodopa, carbidopa and entacapone together may cause dizziness and symptomatic orthostatism. Therefore, caution should be exercised when driving or using machines.<\/span><\/p>","ID":"31f636a0-c079-422f-b596-b1dac9f384ef","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Stalevo may have a major influence on the ability to drive and use machines. Levodopa, carbidopa and entacapone together may cause dizziness and symptomatic orthostatism. Therefore, caution should be exercised when driving or using machines.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"6e80cd92-a85c-4938-a1a2-efd8af614f96","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Patients being treated with Stalevo and presenting with somnolence and\/or sudden sleep onset episodes must be instructed to refrain from driving or engaging in activities where impaired alertness may put themselves or others at risk of serious injury or death (e.g. operating machines) until such recurrent episodes have resolved (see section 4.4).<\/span><\/p>","ID":"8a6893fb-b0c2-434a-8a59-1a0a28cdc0e5","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Patients being treated with Stalevo and presenting with somnolence and\/or sudden sleep onset episodes must be instructed to refrain from driving or engaging in activities where impaired alertness may put themselves or others at risk of serious injury or death (e.g. operating machines) until such recurrent episodes have resolved (see section 4.4).","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"08f9af3c-cba2-46d9-974e-f10afecd7b6d","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"Text\" style=\"margin-top:0in\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">4.8     Undesirable effects<\/span><\/b><\/p>","ID":"8f4ba120-edd5-450a-8fde-a4468f52edf0","Styles":"margin-top:0in","Classes":"['Text']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.8     Undesirable effects","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"Text\" style=\"margin-top:0in\"><\/p>","ID":"c0024bfb-6642-4f6d-9c69-cb75061f9cc9","Styles":"margin-top:0in","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:0in;text-indent:0in;line-height:normal\"><b><span lang=\"EN-GB\">a.<\/span><\/b><b><span lang=\"EN-GB\">Summary of the safety profile<\/span><\/b><\/p>","ID":"971379c4-df69-4163-978f-750f575245e5","Styles":"margin-left:0in;text-indent:0in;line-height:normal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"a.Summary of the safety profile","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\" style=\"text-align:justify\"><\/p>","ID":"2a3f9574-bcb7-432b-986a-d1bfe5200b81","Styles":"text-align:justify","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\" style=\"text-align:justify\"><span lang=\"EN-GB\">The most frequently reported adverse reactions with Stalevo are dyskinesias occurring in approximately 19% of patients; gastrointestinal symptoms including nausea and diarrhoea occurring in approximately 15% and 12% of patients, respectively; muscle, musculoskeletal and connective tissue pain occurring in approximately 12% of patients; and harmless reddish-brown discolouration of urine (chromaturia) occurring in approximately 10% of patients. Serious events of gastrointestinal haemorrhage (uncommon) and angioedema (rare) have been identified from the clinical trials with Stalevo or entacapone combined with levodopa\/DDC inhibitor. Serious hepatitis with mainly cholestatic features, rhabdomyolysis and neuroleptic malignant syndrome may occur with Stalevo although no cases have been identified from the clinical trial data. <\/span><\/p>","ID":"f0b464cb-7975-4f62-beaf-fb1a74d4ee67","Styles":"text-align:justify","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The most frequently reported adverse reactions with Stalevo are dyskinesias occurring in approximately 19% of patients; gastrointestinal symptoms including nausea and diarrhoea occurring in approximately 15% and 12% of patients, respectively; muscle, musculoskeletal and connective tissue pain occurring in approximately 12% of patients; and harmless reddish-brown discolouration of urine (chromaturia) occurring in approximately 10% of patients. Serious events of gastrointestinal haemorrhage (uncommon) and angioedema (rare) have been identified from the clinical trials with Stalevo or entacapone combined with levodopa\/DDC inhibitor. Serious hepatitis with mainly cholestatic features, rhabdomyolysis and neuroleptic malignant syndrome may occur with Stalevo although no cases have been identified from the clinical trial data. ","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"6fcdee57-b2a4-4c60-80ee-b001ff734e54","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:0in;text-indent:0in;line-height:normal\"><b><span lang=\"EN-GB\">b.<\/span><\/b><b><span lang=\"EN-GB\">Tabulated list of adverse reactions<\/span><\/b><\/p>","ID":"279c34bd-0281-4869-b665-557a7842d0f6","Styles":"margin-left:0in;text-indent:0in;line-height:normal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"b.Tabulated list of adverse reactions","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"2be012a4-53ea-41e7-8cbc-fe34bb4be78a","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">The following adverse reactions, listed in Table 1, have been accumulated both from a pooled data of eleven double-blind clinical trials consisting of 3230 patients (1810 treated with Stalevo or entacapone combined with levodopa\/DDC inhibitor, and 1420 treated with placebo combined with levodopa\/DDC inhibitor or cabergoline combined with levodopa\/ DDC inhibitor), and from the post-marketing data since the introduction of entacapone into the market for the combination use of entacapone with levodopa\/DDC inhibitor. <\/span><\/p>","ID":"89598ff4-d2a2-4a59-9aec-e39173052941","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The following adverse reactions, listed in Table 1, have been accumulated both from a pooled data of eleven double-blind clinical trials consisting of 3230 patients (1810 treated with Stalevo or entacapone combined with levodopa\/DDC inhibitor, and 1420 treated with placebo combined with levodopa\/DDC inhibitor or cabergoline combined with levodopa\/ DDC inhibitor), and from the post-marketing data since the introduction of entacapone into the market for the combination use of entacapone with levodopa\/DDC inhibitor. ","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"2e529b48-f24d-44cf-9b3c-36d0331e4bb8","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\" style=\"text-align:justify\"><span lang=\"EN-GB\">Adverse reactions are ranked under headings of frequency, the most frequent first, using the following convention: Very common (\u22651\/10); common (\u22651\/100 to &lt;1\/10); uncommon (\u22651\/1,000 to &lt;1\/100); rare (\u22651\/10,000 to &lt;1\/1,000), very rare (&lt;1\/10,000), not known (cannot be estimated from the available data, since no valid estimate can be derived from clinical trials or epidemiological studies).<\/span><\/p>","ID":"c9dd4c8c-de4c-4a8b-bddb-68cd65447ea6","Styles":"text-align:justify","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Adverse reactions are ranked under headings of frequency, the most frequent first, using the following convention: Very common (\u22651\/10); common (\u22651\/100 to <1\/10); uncommon (\u22651\/1,000 to <1\/100); rare (\u22651\/10,000 to <1\/1,000), very rare (<1\/10,000), not known (cannot be estimated from the available data, since no valid estimate can be derived from clinical trials or epidemiological studies).","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"79ea5d0c-afbb-4b8c-98f2-ade8506b04d9","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Table 1.<\/span><\/b><span lang=\"EN-GB\"> Adverse reactions<\/span><\/p>","ID":"2e972f3f-72ac-4364-b6d1-8b48784c1b9a","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Table 1. Adverse reactions","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"c037196e-47eb-4862-aa19-6ed2aca2472c","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Blood and lymphatic system disorders<\/span><\/i><\/b><\/p>","ID":"3d5bad78-c16f-408b-8fb7-f44a676eef66","Styles":"None","Classes":"['MsoNormal']","Bold":true,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Blood and lymphatic system disorders","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">Common:              Anaemia<\/span><\/p>","ID":"0ec018da-0349-48aa-ad01-5cced950b024","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Common:              Anaemia","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">Uncommon:          Thrombocytopenia<\/span><\/p>","ID":"215bf3ad-5b1d-42f2-8c84-a910c3c548a0","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Uncommon:          Thrombocytopenia","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><b><\/b><\/p>","ID":"aaa14fb9-3117-4d86-8455-8678cca3f19f","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Metabolism and nutrition disorders<\/span><\/i><\/b><\/p>","ID":"c1543446-fa3f-478e-8a03-4a281d3db007","Styles":"None","Classes":"['MsoNormal']","Bold":true,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Metabolism and nutrition disorders","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">Common:              Weight decreased*, decreased appetite*<\/span><\/p>","ID":"3721cc4a-bcfd-4bff-890d-2290a6815eec","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Common:              Weight decreased*, decreased appetite*","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"92abd1ef-90b1-4d7b-b030-341b5c61d913","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><b><i><span lang=\"FR\">Psychiatric disorders<\/span><\/i><\/b><\/p>","ID":"e4ae2976-c425-4572-9181-00e0daa8248a","Styles":"None","Classes":"['MsoNormal']","Bold":true,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Psychiatric disorders","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:85.05pt;text-indent:-85.05pt\"><span lang=\"FR\">Common:              Depression, hallucination, confusional state*, abnormal dreams*, anxiety, insomnia<\/span><\/p>","ID":"b62d523d-10ec-4471-b82b-0f382b5600a6","Styles":"margin-left:85.05pt;text-indent:-85.05pt","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Common:              Depression, hallucination, confusional state*, abnormal dreams*, anxiety, insomnia","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:85.05pt;text-indent:-85.05pt\"><span lang=\"FR\">Uncommon:          P<\/span><span lang=\"EN-GB\">sychosis,<\/span><span lang=\"FR\"> agitation* <\/span><\/p>","ID":"08cfd050-2c99-4fbc-a056-944660de9813","Styles":"margin-left:85.05pt;text-indent:-85.05pt","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Uncommon:          Psychosis, agitation* ","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:85.05pt;text-indent:-85.05pt\"><span lang=\"EN-GB\">Not known:           Suicidal behaviour, Dopamine dysregulation syndrome<\/span><\/p>","ID":"37345409-17af-490a-8bb8-1a8be6c634d2","Styles":"margin-left:85.05pt;text-indent:-85.05pt","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not known:           Suicidal behaviour, Dopamine dysregulation syndrome","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"3da936eb-4b71-4088-aa55-5020013e9df1","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Nervous system disorders<\/span><\/i><\/b><\/p>","ID":"ba48fda5-19a6-48c0-b526-0d90bbd0824a","Styles":"None","Classes":"['MsoNormal']","Bold":true,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Nervous system disorders","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:85.05pt;text-indent:-85.05pt\"><span lang=\"EN-GB\">Very common:      Dyskinesia*<\/span><\/p>","ID":"6642a349-c9e9-4486-91a9-be3cb7612739","Styles":"margin-left:85.05pt;text-indent:-85.05pt","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Very common:      Dyskinesia*","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:85.05pt;text-indent:-85.05pt\"><span lang=\"EN-GB\">Common:              Parkinsonism aggravated (e.g. bradykinesia)*, tremor, on and off phenomenon, dystonia, mental impairment (e.g. memory impairment, dementia), somnolence, dizziness*, headache<\/span><\/p>","ID":"8a0f54d7-44c0-4211-aaff-ef6cc12e478e","Styles":"margin-left:85.05pt;text-indent:-85.05pt","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Common:              Parkinsonism aggravated (e.g. bradykinesia)*, tremor, on and off phenomenon, dystonia, mental impairment (e.g. memory impairment, dementia), somnolence, dizziness*, headache","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:85.05pt;text-indent:-85.05pt\"><span lang=\"EN-GB\">Not known:           Neuroleptic malignant syndrome*<\/span><\/p>","ID":"ed636e18-32dd-48e9-9719-d3eeaba949a4","Styles":"margin-left:85.05pt;text-indent:-85.05pt","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not known:           Neuroleptic malignant syndrome*","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:85.05pt;text-indent:-85.05pt\"><b><\/b><\/p>","ID":"136d83e5-b992-41bd-b648-94ad44a278a5","Styles":"margin-left:85.05pt;text-indent:-85.05pt","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:85.05pt;text-indent:-85.05pt\"><b><i><span lang=\"EN-GB\">Eye disorders<\/span><\/i><\/b><\/p>","ID":"b53a5b61-8b8b-4fac-a05f-2984e1fe575c","Styles":"margin-left:85.05pt;text-indent:-85.05pt","Classes":"['MsoNormal']","Bold":true,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Eye disorders","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:85.05pt;text-indent:-85.05pt\"><span lang=\"EN-GB\">Common:              Blurred vision<\/span><\/p>","ID":"939e90bf-d54b-422d-8f46-9f0a0626a01e","Styles":"margin-left:85.05pt;text-indent:-85.05pt","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Common:              Blurred vision","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:85.05pt;text-indent:-85.05pt\"><\/p>","ID":"e765eb4c-21d6-428c-a393-ad9d4825af73","Styles":"margin-left:85.05pt;text-indent:-85.05pt","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:85.05pt;text-indent:-85.05pt\"><b><i><span lang=\"EN-GB\">Cardiac disorders<\/span><\/i><\/b><\/p>","ID":"ef174615-a039-48e5-8b89-6931ce345b4b","Styles":"margin-left:85.05pt;text-indent:-85.05pt","Classes":"['MsoNormal']","Bold":true,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Cardiac disorders","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:85.05pt;text-indent:-85.05pt\"><span lang=\"EN-GB\">Common:              Ischemic heart disease events other than myocardial infarction (e.g. angina pectoris)**, irregular heart rhythm <\/span><\/p>","ID":"9e4af783-20ac-48eb-9069-f62d77cb0bff","Styles":"margin-left:85.05pt;text-indent:-85.05pt","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Common:              Ischemic heart disease events other than myocardial infarction (e.g. angina pectoris)**, irregular heart rhythm ","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:85.05pt;text-indent:-85.05pt\"><span lang=\"EN-GB\">Uncommon:          Myocardial infarction**<\/span><\/p>","ID":"29e295d3-f8ca-4773-a416-0e36dcb3376d","Styles":"margin-left:85.05pt;text-indent:-85.05pt","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Uncommon:          Myocardial infarction**","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"bba8cc90-459b-4e0d-af7e-d80df5a1702e","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Vascular disorders<\/span><\/i><\/b><\/p>","ID":"20f85a3e-db67-482c-a06c-53ec4cc6707f","Styles":"None","Classes":"['MsoNormal']","Bold":true,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Vascular disorders","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">Common:              Orthostatic hypotension, hypertension<\/span><\/p>","ID":"926f2315-0b2d-4207-a396-61b47254f5e1","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Common:              Orthostatic hypotension, hypertension","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">Uncommon:          Gastrointestinal haemorrhage<\/span><\/p>","ID":"4636abed-cf7f-4f6a-9c13-0881165378e2","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Uncommon:          Gastrointestinal haemorrhage","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"e2a95886-4e1e-4328-92ec-03a654e42610","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Respiratory, thoracic and mediastinal disorders<\/span><\/i><\/b><\/p>","ID":"b42b3b32-b65a-45e5-bfa2-5bd2c19b4138","Styles":"None","Classes":"['MsoNormal']","Bold":true,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Respiratory, thoracic and mediastinal disorders","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">Common:              Dyspnoea<\/span><\/p>","ID":"85d374ba-77fe-415f-9c12-712301c4e3c1","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Common:              Dyspnoea","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"72d7e33f-7dec-4acd-884d-d4bbb8ff7bd5","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Gastrointestinal disorders<\/span><\/i><\/b><\/p>","ID":"b86f45f4-aee6-4840-9616-6448616e79d4","Styles":"None","Classes":"['MsoNormal']","Bold":true,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Gastrointestinal disorders","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">Very common:      Diarrhoea*, nausea*<\/span><\/p>","ID":"5b7992be-3d61-4d6c-9ef2-af9bb8ced2da","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Very common:      Diarrhoea*, nausea*","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:85.05pt;text-indent:-85.05pt\"><span lang=\"EN-GB\">Common:              Constipation*, vomiting*, dyspepsia, abdominal pain and discomfort*, dry mouth*<\/span><\/p>","ID":"a5eb170e-4f64-46cf-9e00-fa7ad910df1b","Styles":"margin-left:85.05pt;text-indent:-85.05pt","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Common:              Constipation*, vomiting*, dyspepsia, abdominal pain and discomfort*, dry mouth*","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:85.05pt;text-indent:-85.05pt\"><span lang=\"EN-GB\">Uncommon:          Colitis*, dysphagia<\/span><\/p>","ID":"0c1df844-7864-4130-a227-3a63005e663a","Styles":"margin-left:85.05pt;text-indent:-85.05pt","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Uncommon:          Colitis*, dysphagia","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"fb7fe332-576c-4320-a9f6-b8afd05e0795","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Hepatobiliary disorders<\/span><\/i><\/b><\/p>","ID":"15b52721-31ef-43e2-aae1-7a930c481b41","Styles":"None","Classes":"['MsoNormal']","Bold":true,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Hepatobiliary disorders","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">Uncommon:          Hepatic function test abnormal*<\/span><\/p>","ID":"e2f55850-48bb-4b74-9ee8-38d2d3b9f545","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Uncommon:          Hepatic function test abnormal*","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">Not known:           Hepatitis with mainly cholestatic features (see section 4.4)*<\/span><\/p>","ID":"a2925c88-c321-4554-b23e-12215fc4b6aa","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not known:           Hepatitis with mainly cholestatic features (see section 4.4)*","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"d1b0e2e8-acca-4fe1-a550-537633eb51f8","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Skin and subcutaneous tissue disorders<\/span><\/i><\/b><\/p>","ID":"32f64566-6670-488d-91cc-0ddd0145aae1","Styles":"None","Classes":"['MsoNormal']","Bold":true,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Skin and subcutaneous tissue disorders","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">Common:              Rash*, hyperhidrosis<\/span><\/p>","ID":"1f0fce07-13a3-49af-8baf-b7b6774bbf68","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Common:              Rash*, hyperhidrosis","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">Uncommon:          Discolourations other than urine (e.g. skin, nail, hair, sweat)*<\/span><\/p>","ID":"b42dbda6-360b-4399-bc8b-b15f6429994f","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Uncommon:          Discolourations other than urine (e.g. skin, nail, hair, sweat)*","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">Rare:                    Angioedema<\/span><\/p>","ID":"6b754b2a-6fed-44b4-a724-c2e5c2429667","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Rare:                    Angioedema","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">Not known:           Urticaria*<\/span><\/p>","ID":"50349307-ad98-4ea7-9a82-1d0c30efe42d","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not known:           Urticaria*","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"74edb78b-6164-4992-b1ee-d7b694034d73","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Musculoskeletal and connective tissue disorders<\/span><\/i><\/b><\/p>","ID":"ad9f1dae-4ee4-4216-b911-59e3795ab9d9","Styles":"None","Classes":"['MsoNormal']","Bold":true,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Musculoskeletal and connective tissue disorders","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">Very common:      Muscle, musculoskeletal and connective tissue pain*<\/span><\/p>","ID":"ee5c5b1d-bd56-452a-a691-9cea6879ff8c","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Very common:      Muscle, musculoskeletal and connective tissue pain*","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">Common:              Muscle spasms, arthralgia<\/span><\/p>","ID":"42cc92dd-b2e2-4e8f-8bf3-9295d0d4846a","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Common:              Muscle spasms, arthralgia","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">Not known:           Rhabdomyolysis*<\/span><\/p>","ID":"467ddffe-4cd4-4736-a0b9-4247b512e89a","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not known:           Rhabdomyolysis*","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"fa562e39-0189-4669-813b-8e6b81ed6210","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Renal and urinary disorders<\/span><\/i><\/b><\/p>","ID":"2358d7ce-789e-405a-a864-cd0147290ec8","Styles":"None","Classes":"['MsoNormal']","Bold":true,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Renal and urinary disorders","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">Very common:      Chromaturia*<\/span><\/p>","ID":"950e2dfd-ce99-4387-ad85-2c0bfea30df0","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Very common:      Chromaturia*","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">Common:              Urinary tract infection<\/span><\/p>","ID":"bbf7cb62-0209-4f1b-b5fb-e1f67c7e9c2c","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Common:              Urinary tract infection","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">Uncommon:          Urinary retention<\/span><\/p>","ID":"2f0c06e6-3a0b-4465-9e4d-dd8d76376f85","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Uncommon:          Urinary retention","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><b><\/b><\/p>","ID":"fb9e5769-fe03-4dd1-86e6-03238bc1fa7a","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">General disorders and administration site conditions<\/span><\/i><\/b><\/p>","ID":"2af1f795-f816-47a0-bc5b-db1fcba2ffb1","Styles":"None","Classes":"['MsoNormal']","Bold":true,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"General disorders and administration site conditions","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:85.05pt;text-indent:-85.05pt\"><span lang=\"EN-GB\">Common:              Chest pain, peripheral oedema, fall, gait disturbance, asthenia, fatigue<\/span><\/p>","ID":"ab9e7e5b-6109-4607-b1d6-ac325b3dd749","Styles":"margin-left:85.05pt;text-indent:-85.05pt","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Common:              Chest pain, peripheral oedema, fall, gait disturbance, asthenia, fatigue","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:85.05pt;text-indent:-85.05pt\"><span lang=\"EN-GB\">Uncommon:          Malaise<\/span><\/p>","ID":"7dd0106a-15e3-4800-84f6-cba0efd07340","Styles":"margin-left:85.05pt;text-indent:-85.05pt","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Uncommon:          Malaise","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"beaa919c-7966-46d6-88a7-31e06effad5f","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\" style=\"text-align:justify\"><span lang=\"EN-GB\">*Adverse reactions that are mainly attributable to entacapone or are more frequent (by the frequency difference of at least 1% in the clinical trial data) with entacapone than levodopa\/DDC inhibitor alone. See section c.<\/span><\/p>","ID":"906c09c0-1dc7-4942-b0c3-2a0e7ac899b0","Styles":"text-align:justify","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"*Adverse reactions that are mainly attributable to entacapone or are more frequent (by the frequency difference of at least 1% in the clinical trial data) with entacapone than levodopa\/DDC inhibitor alone. See section c.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"9b1aa18b-8e80-4f9d-81ae-0c193353881b","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\" style=\"text-align:justify\"><span lang=\"EN-GB\">**The incidence rates of myocardial infarction and other ischemic heart disease events (0.43% and 1.54%, respectively) are derived from an analysis of 13 double-blind studies involving 2082 patients with end-of-dose motor fluctuations receiving entacapone<\/span><span lang=\"EN\">.<\/span><\/p>","ID":"982f9152-15f2-47e1-897d-6fa5b79b44f9","Styles":"text-align:justify","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"**The incidence rates of myocardial infarction and other ischemic heart disease events (0.43% and 1.54%, respectively) are derived from an analysis of 13 double-blind studies involving 2082 patients with end-of-dose motor fluctuations receiving entacapone.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"d21f81fc-8417-4e5d-9ce0-9f7c982c9a0a","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:0in;text-indent:0in;line-height:normal\"><b><span lang=\"EN-GB\">c.<\/span><\/b><b><span lang=\"EN-GB\">Description of selected adverse reactions<\/span><\/b><\/p>","ID":"472cbd7a-7591-47b8-8424-384f515b3f08","Styles":"margin-left:0in;text-indent:0in;line-height:normal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"c.Description of selected adverse reactions","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\" style=\"text-align:justify\"><\/p>","ID":"c62f7e55-bf40-4bcb-9d21-7e7cf5944a44","Styles":"text-align:justify","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\" style=\"text-align:justify\"><span lang=\"EN-GB\">Adverse reactions that are mainly attributable to entacapone or are more frequent with entacapone than levodopa\/DDC inhibitor alone are indicated with an asterisk in Table 1, section 4.8b. Some of these adverse reactions relate to the increased dopaminergic activity (e.g. dyskinesia, nausea and vomiting) and occur most commonly at the beginning of the treatment. Reduction of levodopa dose decreases the severity and frequency of these dopaminergic reactions. Few adverse reactions are known to be directly attributable to the active substance entacapone including diarrhoea and reddish-brown discolouration of urine. Entacapone may in some cases cause also discolouration of e.g. skin, nail, hair and sweat. Other adverse reactions with an asterisk in Table 1, section 4.8b are marked based on either their more frequent occurring (by the frequency difference of at least 1%) in the clinical trial data with entacapone than levodopa\/DDCI alone or the individual case safety reports received after the introduction of entacapone into the market.<\/span><\/p>","ID":"cd930465-a5c5-43be-bdfd-8158d9f46cb2","Styles":"text-align:justify","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Adverse reactions that are mainly attributable to entacapone or are more frequent with entacapone than levodopa\/DDC inhibitor alone are indicated with an asterisk in Table 1, section 4.8b. Some of these adverse reactions relate to the increased dopaminergic activity (e.g. dyskinesia, nausea and vomiting) and occur most commonly at the beginning of the treatment. Reduction of levodopa dose decreases the severity and frequency of these dopaminergic reactions. Few adverse reactions are known to be directly attributable to the active substance entacapone including diarrhoea and reddish-brown discolouration of urine. Entacapone may in some cases cause also discolouration of e.g. skin, nail, hair and sweat. Other adverse reactions with an asterisk in Table 1, section 4.8b are marked based on either their more frequent occurring (by the frequency difference of at least 1%) in the clinical trial data with entacapone than levodopa\/DDCI alone or the individual case safety reports received after the introduction of entacapone into the market.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\" style=\"text-align:justify\"><\/p>","ID":"053a64d5-d358-440c-902c-17d97395174d","Styles":"text-align:justify","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Convulsions have occurred rarely with levodopa\/carbidopa; however a causal relationship to levodopa\/carbidopa therapy has not been established.<\/span><\/p>","ID":"a7f3959d-fd84-43be-abf0-903c0460aefc","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Convulsions have occurred rarely with levodopa\/carbidopa; however a causal relationship to levodopa\/carbidopa therapy has not been established.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"65a02415-2228-405c-8276-f414ce6a7de5","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Impulse control disorders: Pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists and\/or other dopaminergic treatments containing levodopa including Stalevo (see section 4.4).<\/span><\/p>","ID":"b78ef447-5698-4bc8-bbb5-e4156a920267","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Impulse control disorders: Pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists and\/or other dopaminergic treatments containing levodopa including Stalevo (see section 4.4).","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"Text\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Dopamine Dysregulation Syndrome (DDS) is an addictive disorder seen in some patients treated with carbidopa\/levodopa. Affected patients show a compulsive pattern of dopaminergic drug misuse above<\/span><\/p>","ID":"21c3070a-fd5b-4bad-9468-185719a42d6d","Styles":"None","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Dopamine Dysregulation Syndrome (DDS) is an addictive disorder seen in some patients treated with carbidopa\/levodopa. Affected patients show a compulsive pattern of dopaminergic drug misuse above","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">doses adequate to control motor symptoms, which may in some cases result in severe dyskinesias (see also section 4.4).<\/span><\/p>","ID":"f84f28c1-2164-4510-889b-6c3093328031","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"doses adequate to control motor symptoms, which may in some cases result in severe dyskinesias (see also section 4.4).","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"94bbc006-3e32-4cb6-99eb-dbfa92fa3fed","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\" style=\"text-align:justify\"><span lang=\"EN-GB\">Entacapone in association with levodopa has been associated with isolated cases of excessive daytime somnolence and sudden sleep onset episodes.<\/span><\/p>","ID":"bf61a2a1-70a8-4609-89ab-340eb78bf3c5","Styles":"text-align:justify","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Entacapone in association with levodopa has been associated with isolated cases of excessive daytime somnolence and sudden sleep onset episodes.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\" style=\"text-align:justify\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"78e380ea-b564-4398-ab14-a90e0be75b6e","Styles":"text-align:justify","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\" style=\"text-align:justify\"><u><span lang=\"EN-GB\">Reporting of suspected adverse reactions<\/span><\/u><\/p>","ID":"c4cded0f-3d98-4cff-a74d-528c9b333bb2","Styles":"text-align:justify","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Reporting of suspected adverse reactions","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\" style=\"text-align:justify\"><span lang=\"EN-GB\">Reporting suspected\r adverse reactions after authorisation of the medicinal product is important. It\r allows continued monitoring of the benefit\/risk balance of the medicinal\r product. Healthcare professionals are asked to report any suspected adverse\r reactions via <span style=\"background:silver\">the national reporting system\r listed in <a href=\"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Template_or_form\/2013\/03\/WC500139752.doc\">Appendix\r V<\/a><\/span>.<\/span><\/p>","ID":"fd2e15e3-2073-479e-bd59-d28f31be2f40","Styles":"text-align:justify","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Reporting suspected\r adverse reactions after authorisation of the medicinal product is important. It\r allows continued monitoring of the benefit\/risk balance of the medicinal\r product. Healthcare professionals are asked to report any suspected adverse\r reactions via the national reporting system\r listed in Appendix\r V.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"6770c821-232c-4f67-babb-760dd02b615b","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"Text\" style=\"margin-top:0in\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">4.9     Overdose<\/span><\/b><\/p>","ID":"04be7358-2773-4cda-b38b-25e71fd1ddb1","Styles":"margin-top:0in","Classes":"['Text']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.9     Overdose","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"37b5f44c-5d90-4a99-9ec8-ad1530585faf","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">The post-marketing data includes isolated cases of overdose in which the reported highest daily doses of levodopa and entacapone have been at least 10,000 mg and 40,000 mg, respectively. The acute symptoms and signs in these cases of overdose included agitation, confusional state, coma, bradycardia, ventricular tachycardia, Cheyne-Stokes respiration, discolourations of skin, tongue and conjunctiva, and chromaturia. Management of acute overdose with Stalevo therapy is similar to acute overdose with levodopa. Pyridoxine, however, is not effective in reversing the actions of Stalevo. Hospitalisation is advised and general supportive measures should be employed with immediate gastric lavage and repeated doses of charcoal over time. This may hasten the elimination of entacapone in particular by decreasing its absorption\/reabsorption from the GI tract. The adequacy of the respiratory, circulatory and renal systems should be carefully monitored and appropriate supportive measures employed. ECG monitoring should be started and the patient carefully monitored for the possible development of arrhythmias. If required, appropriate anti-arrhythmic therapy should be given. The possibility that the patient has taken other active substances in addition to Stalevo should be taken into consideration. The value of dialysis in the treatment of overdose is not known.<\/span><\/p>","ID":"1582b03b-0516-4cfd-9e4f-4d8c709ec1f1","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The post-marketing data includes isolated cases of overdose in which the reported highest daily doses of levodopa and entacapone have been at least 10,000 mg and 40,000 mg, respectively. The acute symptoms and signs in these cases of overdose included agitation, confusional state, coma, bradycardia, ventricular tachycardia, Cheyne-Stokes respiration, discolourations of skin, tongue and conjunctiva, and chromaturia. Management of acute overdose with Stalevo therapy is similar to acute overdose with levodopa. Pyridoxine, however, is not effective in reversing the actions of Stalevo. Hospitalisation is advised and general supportive measures should be employed with immediate gastric lavage and repeated doses of charcoal over time. This may hasten the elimination of entacapone in particular by decreasing its absorption\/reabsorption from the GI tract. The adequacy of the respiratory, circulatory and renal systems should be carefully monitored and appropriate supportive measures employed. ECG monitoring should be started and the patient carefully monitored for the possible development of arrhythmias. If required, appropriate anti-arrhythmic therapy should be given. The possibility that the patient has taken other active substances in addition to Stalevo should be taken into consideration. The value of dialysis in the treatment of overdose is not known.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"7639e82d-92ea-451c-a976-1f67bbdc7fd0","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"df83e689-f057-4734-85be-7c7586605d45","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:27.0pt;margin-bottom:.0001pt;text-indent:-27.0pt\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">5.      PHARMACOLOGICAL PROPERTIES<\/span><\/b><\/p>","ID":"5c1ddc24-a869-4c31-83e7-61d284654125","Styles":"margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:27.0pt;margin-bottom:.0001pt;text-indent:-27.0pt","Classes":"['Text']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"5.      PHARMACOLOGICAL PROPERTIES","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"bdfd558e-af9e-4054-b900-8410cf36890c","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:27.0pt;margin-bottom:.0001pt;text-indent:-27.0pt\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">5.1     Pharmacodynamic properties<\/span><\/b><\/p>","ID":"9a7168b9-cb33-4c34-9530-b9a43d7c1461","Styles":"margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:27.0pt;margin-bottom:.0001pt;text-indent:-27.0pt","Classes":"['Text']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"5.1     Pharmacodynamic properties","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:27.0pt;margin-bottom:.0001pt;text-indent:-27.0pt\"><\/p>","ID":"2ddea067-cc34-4950-bed2-851fb1e337b9","Styles":"margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:27.0pt;margin-bottom:.0001pt;text-indent:-27.0pt","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Pharmacotherapeutic group: anti-parkinson\r drugs, dopa and dopa derivatives, ATC code:N04BA03<\/span><\/p>","ID":"e96f0619-e40c-4f23-a546-3a09093a7770","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Pharmacotherapeutic group: anti-parkinson\r drugs, dopa and dopa derivatives, ATC code:N04BA03","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"ddce8733-f59d-498d-9123-4723a8769b72","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">According to the current understanding, the symptoms of Parkinson\u2019s disease are related to depletion of dopamine in the corpus striatum. Dopamine does not cross the blood-brain barrier. Levodopa, the precursor of dopamine, crosses the blood brain barrier and relieves the symptoms of the disease. As levodopa is extensively metabolised in the periphery, only a small portion of a given dose reaches the central nervous system when levodopa is administered without metabolic enzyme inhibitors. <\/span><\/p>","ID":"647d5518-f2b9-42d2-a290-1e7ca9eb7d20","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"According to the current understanding, the symptoms of Parkinson\u2019s disease are related to depletion of dopamine in the corpus striatum. Dopamine does not cross the blood-brain barrier. Levodopa, the precursor of dopamine, crosses the blood brain barrier and relieves the symptoms of the disease. As levodopa is extensively metabolised in the periphery, only a small portion of a given dose reaches the central nervous system when levodopa is administered without metabolic enzyme inhibitors. ","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"e4d90043-9ebf-4bdc-89b6-51924fd13cf3","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Carbidopa and benserazide are peripheral DDC inhibitors which reduce the peripheral metabolism of levodopa to dopamine, and thus, more levodopa is available to the brain. When decarboxylation of levodopa is reduced with the co-administration of a DDC inhibitor, a lower dose of levodopa can be used and the incidence of adverse reactions such as nausea is reduced. <\/span><\/p>","ID":"66665e46-67f9-4df1-aba8-e991f9e44cd7","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Carbidopa and benserazide are peripheral DDC inhibitors which reduce the peripheral metabolism of levodopa to dopamine, and thus, more levodopa is available to the brain. When decarboxylation of levodopa is reduced with the co-administration of a DDC inhibitor, a lower dose of levodopa can be used and the incidence of adverse reactions such as nausea is reduced. ","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"07970605-d99e-4c95-ba00-3463707cc8b0","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;background:white\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:black\">With inhibition of the\r decarboxylase by a DDC inhibitor, catechol-<i>O<\/i>-methyltransferase (COMT)\r becomes the major peripheral metabolic pathway catalyzing the conversion of\r levodopa to 3-O-methyldopa (3-OMD), a potentially harmful metabolite of\r levodopa. Entacapone is a reversible, specific and mainly peripherally acting COMT\r inhibitor designed for concomitant administration with levodopa. Entacapone\r slows the clearance of levodopa from the bloodstream resulting in an increased\r area under the curve (AUC) in the pharmacokinetic profile of levodopa.\r Consequently the clinical response to each dose of levodopa is enhanced and\r prolonged.<\/span><\/p>","ID":"000492e6-aa9c-4105-b399-2ad97e6650d6","Styles":"margin-top:0in;text-align:left;background:white","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"With inhibition of the\r decarboxylase by a DDC inhibitor, catechol-O-methyltransferase (COMT)\r becomes the major peripheral metabolic pathway catalyzing the conversion of\r levodopa to 3-O-methyldopa (3-OMD), a potentially harmful metabolite of\r levodopa. Entacapone is a reversible, specific and mainly peripherally acting COMT\r inhibitor designed for concomitant administration with levodopa. Entacapone\r slows the clearance of levodopa from the bloodstream resulting in an increased\r area under the curve (AUC) in the pharmacokinetic profile of levodopa.\r Consequently the clinical response to each dose of levodopa is enhanced and\r prolonged.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;background:white\"><\/p>","ID":"52ab551e-6765-400b-b27b-ab47bd0eb62c","Styles":"margin-top:0in;text-align:left;background:white","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">The evidence of the therapeutic effects of\r Stalevo is based on two phase III double-blind studies, in which 376\r Parkinson\u2019s disease patients with end-of-dose motor fluctuations received\r either entacapone or placebo with each levodopa\/DDC inhibitor dose. Daily ON\r time with and without entacapone was recorded in home-diaries by patients. In\r the first study, entacapone increased the mean daily ON time by\r 1 h 20 min (CI <sub>95%<\/sub> 45 min,\r 1 h 56 min) from baseline. This corresponded to an 8.3% increase\r in the proportion of daily ON time. Correspondingly, the decrease in daily OFF\r time was 24% in the entacapone group and 0% in the placebo group. In the second\r study, the mean proportion of daily ON time increased by 4.5% (CI<sub>95%<\/sub>\r 0.93%, 7.97%) from baseline. This is translated to a mean increase of\r 35 min in the daily ON time. Correspondingly, the daily OFF time decreased\r by 18% on entacapone and by 5% on placebo. Because the effects of Stalevo\r tablets are equivalent with entacapone 200 mg tablet administered\r concomitantly with the commercially available standard release\r carbidopa\/levodopa preparations in corresponding doses these results are applicable\r to describe the effects of Stalevo as well.<\/span><\/p>","ID":"2478adac-532f-45e0-9a1f-30facbcdba0b","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The evidence of the therapeutic effects of\r Stalevo is based on two phase III double-blind studies, in which 376\r Parkinson\u2019s disease patients with end-of-dose motor fluctuations received\r either entacapone or placebo with each levodopa\/DDC inhibitor dose. Daily ON\r time with and without entacapone was recorded in home-diaries by patients. In\r the first study, entacapone increased the mean daily ON time by\r 1 h 20 min (CI 95% 45 min,\r 1 h 56 min) from baseline. This corresponded to an 8.3% increase\r in the proportion of daily ON time. Correspondingly, the decrease in daily OFF\r time was 24% in the entacapone group and 0% in the placebo group. In the second\r study, the mean proportion of daily ON time increased by 4.5% (CI95%\r 0.93%, 7.97%) from baseline. This is translated to a mean increase of\r 35 min in the daily ON time. Correspondingly, the daily OFF time decreased\r by 18% on entacapone and by 5% on placebo. Because the effects of Stalevo\r tablets are equivalent with entacapone 200 mg tablet administered\r concomitantly with the commercially available standard release\r carbidopa\/levodopa preparations in corresponding doses these results are applicable\r to describe the effects of Stalevo as well.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"607ffaff-eb14-48aa-92ac-fc0c9c0d5d9d","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:27.0pt;margin-bottom:.0001pt;text-indent:-27.0pt\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">5.2    Pharmacokinetic properties<\/span><\/b><\/p>","ID":"2272e28a-1d50-4f4c-9053-a607a8ef8004","Styles":"margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:27.0pt;margin-bottom:.0001pt;text-indent:-27.0pt","Classes":"['Text']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"5.2    Pharmacokinetic properties","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"Text\" style=\"margin-top:0in\"><\/p>","ID":"b5b3174d-f193-4c23-b4b9-03b890087368","Styles":"margin-top:0in","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:27.0pt;margin-bottom:.0001pt;text-indent:-27.0pt\"><i><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">General characteristics of the active substances<\/span><\/u><\/i><\/p>","ID":"f705ab4a-a75d-4957-b465-23858acbc2d8","Styles":"margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:27.0pt;margin-bottom:.0001pt;text-indent:-27.0pt","Classes":"['Text']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"General characteristics of the active substances","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"Text\" style=\"margin-top:0in\"><b><\/b><\/p>","ID":"8c10b45a-14a9-44ed-8aeb-a6c1f7bd3414","Styles":"margin-top:0in","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><i><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Absorption\/distribution<\/span><\/u><\/i><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">:<\/span><\/i><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> There are substantial inter- and intra-individual\r variations in the absorption of levodopa, carbidopa<sup> <\/sup>and entacapone.\r Both levodopa and entacapone are rapidly absorbed and eliminated. Carbidopa is\r absorbed and eliminated slightly slower compared with levodopa. When given\r separately without the two other active substances, the bioavailability for\r levodopa is 15-33%, for carbidopa 40-70% and for entacapone 35% after a\r 200 mg oral dose. Meals rich in large neutral amino acids may delay and\r reduce the absorption of levodopa. Food does not significantly affect the\r absorption of entacapone. The distribution volume of both levodopa (Vd\r 0.36-1.6 l\/kg) and entacapone (Vd<sub>ss<\/sub> 0.27 l\/kg) is\r moderately small while no data for carbidopa are available.<\/span><\/p>","ID":"192ab63a-d2e6-4dbe-ac50-79601f01821c","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Absorption\/distribution: There are substantial inter- and intra-individual\r variations in the absorption of levodopa, carbidopa and entacapone.\r Both levodopa and entacapone are rapidly absorbed and eliminated. Carbidopa is\r absorbed and eliminated slightly slower compared with levodopa. When given\r separately without the two other active substances, the bioavailability for\r levodopa is 15-33%, for carbidopa 40-70% and for entacapone 35% after a\r 200 mg oral dose. Meals rich in large neutral amino acids may delay and\r reduce the absorption of levodopa. Food does not significantly affect the\r absorption of entacapone. The distribution volume of both levodopa (Vd\r 0.36-1.6 l\/kg) and entacapone (Vdss 0.27 l\/kg) is\r moderately small while no data for carbidopa are available.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\" style=\"text-align:justify\"><\/p>","ID":"8fa3de0f-8ade-46c8-9ec4-3e652e6f85b3","Styles":"text-align:justify","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\" style=\"margin-right:-2.25pt\"><span lang=\"EN-GB\">Levodopa is\r bound to plasma protein only to a minor extent of about 10-30% and c<span style=\"layout-grid-mode:line\">arbidopa <\/span>is bound <span style=\"layout-grid-mode:\r line\">approximately 36%<\/span>, <span style=\"layout-grid-mode:line\">while e<\/span>ntacapone\r is extensively bound to plasma proteins (about 98%) \u2013mainly to serum albumin.\r At therapeutic concentrations, entacapone does not displace other extensively\r bound active substances (e.g. warfarin, salicylic acid, phenylbutazone, or\r diazepam), nor is it displaced to any significant extent by any of these\r substances at therapeutic or higher concentrations.<\/span><\/p>","ID":"17100585-be5a-47b2-942c-1ee5a6272ea4","Styles":"margin-right:-2.25pt","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Levodopa is\r bound to plasma protein only to a minor extent of about 10-30% and carbidopa is bound approximately 36%, while entacapone\r is extensively bound to plasma proteins (about 98%) \u2013mainly to serum albumin.\r At therapeutic concentrations, entacapone does not displace other extensively\r bound active substances (e.g. warfarin, salicylic acid, phenylbutazone, or\r diazepam), nor is it displaced to any significant extent by any of these\r substances at therapeutic or higher concentrations.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><i><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\"><\/span><\/u><\/i><\/p>","ID":"f618587e-bcaa-4740-b0c7-d34301d96ea7","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><i><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Biotransformation and elimination<\/span><\/u><\/i><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">:<\/span><\/i><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> Levodopa is extensively metabolised to various metabolites: decarboxylation by dopa decarboxylase (DDC) and O-methylation by catechol-O-methyltransferase (COMT) being the most important pathways.<\/span><\/p>","ID":"53983e2c-7dc1-4d0f-a104-25ef263e60f4","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Biotransformation and elimination: Levodopa is extensively metabolised to various metabolites: decarboxylation by dopa decarboxylase (DDC) and O-methylation by catechol-O-methyltransferase (COMT) being the most important pathways.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"a2f7f04a-ef56-4e64-9847-c50af81b53d2","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Carbidopa is metabolized to two main metabolites which are excreted in the urine as glucuronides and unconjugated compounds. Unchanged carbidopa accounts for 30% of the total urinary excretion.<\/span><\/p>","ID":"d280c1e7-f530-4de2-9d9c-8e082068c434","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Carbidopa is metabolized to two main metabolites which are excreted in the urine as glucuronides and unconjugated compounds. Unchanged carbidopa accounts for 30% of the total urinary excretion.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"00b4ae3c-930c-43dd-b1ad-2cdfebdf5517","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Entacapone is almost completely metabolized\r prior to excretion via urine (10 to 20%) and bile\/faeces(80 to 90%).\r The main metabolic pathway is glucuronidation of entacapone and its active\r metabolite, the cis-isomer, which accounts for about 5% of plasma total amount.<\/span><\/p>","ID":"78b31dc6-e690-42cf-8401-f6b6dbdbbb03","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Entacapone is almost completely metabolized\r prior to excretion via urine (10 to 20%) and bile\/faeces(80 to 90%).\r The main metabolic pathway is glucuronidation of entacapone and its active\r metabolite, the cis-isomer, which accounts for about 5% of plasma total amount.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><s><span lang=\"EN-GB\" style=\"font-size:11.0pt\"><\/span><\/s><\/p>","ID":"e17b747d-f96a-4e46-96b5-76712407359a","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Total clearance for levodopa is in the\r range of 0.55-1.38 l\/kg\/h and for entacapone is in the range of\r 0.70 l\/kg\/h. The elimination-half life is (t<sub>1\/2<\/sub>) is 0.6-1.3\r hours for levodopa, 2-3 hours for carbidopa and 0.4-0.7 hours for entacapone,\r each given separately.<\/span><\/p>","ID":"e2c645ad-5036-41b0-9db1-1d88346b680f","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Total clearance for levodopa is in the\r range of 0.55-1.38 l\/kg\/h and for entacapone is in the range of\r 0.70 l\/kg\/h. The elimination-half life is (t1\/2) is 0.6-1.3\r hours for levodopa, 2-3 hours for carbidopa and 0.4-0.7 hours for entacapone,\r each given separately.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"e4e1a743-d87d-4310-b9db-7793d6c6bc6a","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Due to short elimination half-lives, no true accumulation of levodopa or entacapone occurs on repeated administration.<\/span><\/p>","ID":"03d8850a-e21c-4dff-9405-198dc5f29924","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Due to short elimination half-lives, no true accumulation of levodopa or entacapone occurs on repeated administration.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"401b1f33-a12b-410a-a457-16cc15ca5579","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Data from <i>in vitro<\/i> studies using\r human liver microsomal preparations indicate that entacapone inhibits\r cytochrome P450 2C9 (IC50 ~ 4 \u00b5M). Entacapone showed little or no\r inhibition of other types of P450 isoenzymes (CYP1A2, CYP2A6, CYP2D6, CYP2E1,\r CYP3A and CYP2C19); see section 4.5.<\/span><\/p>","ID":"31ee9ab9-db72-4649-bf10-d9652b59fbb9","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Data from in vitro studies using\r human liver microsomal preparations indicate that entacapone inhibits\r cytochrome P450 2C9 (IC50 ~ 4 \u00b5M). Entacapone showed little or no\r inhibition of other types of P450 isoenzymes (CYP1A2, CYP2A6, CYP2D6, CYP2E1,\r CYP3A and CYP2C19); see section 4.5.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"a8f07a4c-b9db-422e-8597-3a0ebfa271dc","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"Text\" style=\"margin-top:0in\"><i><u><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">Characteristics in patients<\/span><\/u><\/i><\/p>","ID":"b94795ed-c7a1-4eb1-8bd4-fecc3df6ecab","Styles":"margin-top:0in","Classes":"['Text']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Characteristics in patients","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"Text\" style=\"margin-top:0in\"><\/p>","ID":"ec0fa6f3-19a4-43da-b3ba-903643b6b908","Styles":"margin-top:0in","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><i><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Elderly<\/span><\/u><\/i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">: When given without carbidopa and entacapone, the absorption of levodopa is greater and elimination is slower in elderly than in young people. However, after combination of carbidopa with levodopa, the absorption of levodopa is similar between the elderly and the young people, but the AUC is still 1.5 fold greater in the elderly due to decreased DDC activity and lower clearance by aging. There are no significant differences in the AUC of carbidopa or entacapone between younger (45\u201364 years) and elderly (65\u201375 years).<\/span><\/p>","ID":"9cffb4e0-727b-4e96-878e-7933f8ca962c","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Elderly: When given without carbidopa and entacapone, the absorption of levodopa is greater and elimination is slower in elderly than in young people. However, after combination of carbidopa with levodopa, the absorption of levodopa is similar between the elderly and the young people, but the AUC is still 1.5 fold greater in the elderly due to decreased DDC activity and lower clearance by aging. There are no significant differences in the AUC of carbidopa or entacapone between younger (45\u201364 years) and elderly (65\u201375 years).","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"3a576c0a-c26a-4d86-9d75-d90d94675b73","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><i><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Gender<\/span><\/u><\/i><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">: <\/span><\/i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Bioavailability\r of levodopa is significantly higher in women than in men. In the\r pharmacokinetic studies with Stalevo<sup> <\/sup>the bioavailability of levodopa\r is higher in women than in men, primarily due to the difference in body weight,\r while there is no gender difference with carbidopa and entacapone.<\/span><\/p>","ID":"f2f40490-ff32-430e-afce-52f5a78fbad6","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Gender: Bioavailability\r of levodopa is significantly higher in women than in men. In the\r pharmacokinetic studies with Stalevo the bioavailability of levodopa\r is higher in women than in men, primarily due to the difference in body weight,\r while there is no gender difference with carbidopa and entacapone.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"3f1ae820-a1c1-4be9-9af3-76b5c32f4be1","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><i><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Hepatic impairment<\/span><\/u><\/i><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">: <\/span><\/i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">The metabolism of entacapone is slowed in patients\r with mild to moderate hepatic impairment (Child-Pugh Class A and B) leading to\r an increased plasma concentration of entacapone both in the absorption and\r elimination phases (see sections 4.2 and 4.3). No particular studies on the\r pharmacokinetics of carbidopa and levodopa in patients with hepatic impairment\r are reported, however, it is advised that Stalevo<sup> <\/sup>should be\r administered cautiously to patients with mild or moderate hepatic impairment. <\/span><\/p>","ID":"703ec246-fe22-47ce-abda-61748828d59b","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Hepatic impairment: The metabolism of entacapone is slowed in patients\r with mild to moderate hepatic impairment (Child-Pugh Class A and B) leading to\r an increased plasma concentration of entacapone both in the absorption and\r elimination phases (see sections 4.2 and 4.3). No particular studies on the\r pharmacokinetics of carbidopa and levodopa in patients with hepatic impairment\r are reported, however, it is advised that Stalevo should be\r administered cautiously to patients with mild or moderate hepatic impairment. ","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"cd6c4f5a-f5e1-457e-95a5-310e82f01ed9","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><i><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Renal impairment<\/span><\/u><\/i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">: Renal impairment does not affect the pharmacokinetics of entacapone. No particular studies are reported on the pharmacokinetics of levodopa and carbidopa in patients with renal impairment. However, a longer dosing interval of Stalevo may be considered for patients who are receiving dialysis therapy (see section 4.2).<\/span><\/p>","ID":"5d23e7a0-45a3-468a-b705-934895aa75a6","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Renal impairment: Renal impairment does not affect the pharmacokinetics of entacapone. No particular studies are reported on the pharmacokinetics of levodopa and carbidopa in patients with renal impairment. However, a longer dosing interval of Stalevo may be considered for patients who are receiving dialysis therapy (see section 4.2).","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"67f31890-9097-4d45-8ee1-c3afc81b3562","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:27.0pt;margin-bottom:.0001pt;text-indent:-27.0pt\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">5.3    Preclinical safety data<\/span><\/b><\/p>","ID":"6ec71d98-913e-4e72-84f3-d138635329f4","Styles":"margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:27.0pt;margin-bottom:.0001pt;text-indent:-27.0pt","Classes":"['Text']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"5.3    Preclinical safety data","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"Text\" style=\"margin-top:0in\"><\/p>","ID":"f3ba92e7-f11d-4e61-bf4b-daba6e72948d","Styles":"margin-top:0in","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Preclinical data of levodopa, carbidopa and entacapone, tested alone or in combination, revealed no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, and carcinogenic potential. In repeated dose toxicity studies with entacapone, anaemia most likely due to iron chelating properties of entacapone was observed. Regarding reproduction toxicity of entacapone, decreased foetal weight and a slightly delayed bone development were noticed in rabbits treated at systemic exposure levels in the therapeutic range. Both levodopa and combinations of carbidopa and levodopa have caused visceral and skeletal malformations in rabbits. <\/span><\/p>","ID":"95ed7951-4def-47c5-a1f7-8d1bf4fd8319","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Preclinical data of levodopa, carbidopa and entacapone, tested alone or in combination, revealed no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, and carcinogenic potential. In repeated dose toxicity studies with entacapone, anaemia most likely due to iron chelating properties of entacapone was observed. Regarding reproduction toxicity of entacapone, decreased foetal weight and a slightly delayed bone development were noticed in rabbits treated at systemic exposure levels in the therapeutic range. Both levodopa and combinations of carbidopa and levodopa have caused visceral and skeletal malformations in rabbits. ","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"2b9c396a-bc9b-4629-88f2-4d977bf7468e","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"dcf941cd-b1df-45de-9343-9d42fcc4749f","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt\"><b><span lang=\"EN-GB\">6.      PHARMACEUTICAL PARTICULARS<\/span><\/b><\/p>","ID":"ad4dded8-5f2b-4790-9047-d296998d544b","Styles":"margin-left:27.0pt;text-indent:-27.0pt","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"6.      PHARMACEUTICAL PARTICULARS","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"26a2fc29-b57a-4361-9afb-a1cafb5dafa7","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt\"><b><span lang=\"EN-GB\">6.1    List of excipients<\/span><\/b><\/p>","ID":"e0bbf0a1-bcd5-4172-9ad5-bd3cb299f2e9","Styles":"margin-left:27.0pt;text-indent:-27.0pt","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"6.1    List of excipients","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"d043ba84-1f2e-4216-9494-883727270f4c","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Tablet core<\/span><\/u><span lang=\"EN-GB\">:<\/span><\/p>","ID":"1c2b536d-766c-457e-9de5-de51f6a58df1","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Tablet core:","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><span lang=\"IT\">Croscarmellose sodium<br\/>\r Magnesium stearate<br\/>\r Maize starch<\/span><\/p>","ID":"b43fc941-0a32-4b54-beec-268c4ca0d2c3","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Croscarmellose sodium\r Magnesium stearate\r Maize starch","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><span lang=\"IT\">Mannitol (E421)<br\/>\r Povidone K 30 (E1201) <\/span><\/p>","ID":"9d1a8424-4cc0-4974-bd84-87ea5e4fe7ab","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Mannitol (E421)\r Povidone K 30 (E1201) ","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"63c7c502-4208-4ecb-9c62-5c1794774573","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><u><span lang=\"IT\">Film-coating of <\/span><\/u><u><span lang=\"EN-GB\">50\/12.5\/200 mg, 100\/25\/200 mg and 150<\/span><span lang=\"EN-GB\">\/37.5\/200 mg<\/span><\/u><span lang=\"IT\">:<\/span><\/p>","ID":"960e57d9-2921-462a-8786-8f962954ad4e","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Film-coating of 50\/12.5\/200 mg, 100\/25\/200 mg and 150\/37.5\/200 mg:","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"MsoBodyText3\" style=\"text-align:left\"><span lang=\"IT\" style=\"font-weight:normal;font-style:normal\">Glycerol (85 per cent) (E422)<\/span><\/p>","ID":"868dc3a0-4947-466c-a033-aa13b4f0b377","Styles":"text-align:left","Classes":"['MsoBodyText3']","Bold":true,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Glycerol (85 per cent) (E422)","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"MsoBodyText3\" style=\"text-align:left\"><span lang=\"IT\" style=\"font-weight:normal;font-style:normal\">Hypromellose<\/span><\/p>","ID":"a750e098-3f75-4d68-b62d-e0b32eb80ba5","Styles":"text-align:left","Classes":"['MsoBodyText3']","Bold":true,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Hypromellose","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"MsoBodyText3\" style=\"text-align:left\"><span lang=\"IT\" style=\"font-weight:normal;font-style:normal\">Magnesium stearate<\/span><\/p>","ID":"84c954a0-a520-4627-b6b5-da27d11de4cf","Styles":"text-align:left","Classes":"['MsoBodyText3']","Bold":true,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Magnesium stearate","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"MsoBodyText3\" style=\"text-align:left\"><span lang=\"IT\" style=\"font-weight:normal;font-style:normal\">Polysorbate 80<\/span><\/p>","ID":"f0876166-5bc4-4819-b521-249f012cf6bb","Styles":"text-align:left","Classes":"['MsoBodyText3']","Bold":true,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Polysorbate 80","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"MsoBodyText3\" style=\"text-align:left\"><span lang=\"IT\" style=\"font-weight:normal;font-style:normal\">Red iron oxide (E172)<\/span><\/p>","ID":"d35c93f6-d6a5-4866-983e-59c78879aa9d","Styles":"text-align:left","Classes":"['MsoBodyText3']","Bold":true,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Red iron oxide (E172)","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"MsoBodyText3\" style=\"text-align:left\"><span lang=\"IT\" style=\"font-weight:normal;font-style:normal\">Sucrose<\/span><\/p>","ID":"fbf74e7d-a98d-485c-ae9c-ac466b1450e8","Styles":"text-align:left","Classes":"['MsoBodyText3']","Bold":true,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Sucrose","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"MsoBodyText3\" style=\"text-align:left\"><span lang=\"IT\" style=\"font-weight:normal;font-style:normal\">Titanium dioxide (E171)<\/span><\/p>","ID":"25f5d4a5-9eac-4988-969f-ea1f8e8c37fa","Styles":"text-align:left","Classes":"['MsoBodyText3']","Bold":true,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Titanium dioxide (E171)","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"MsoBodyText3\" style=\"text-align:left\"><span lang=\"IT\" style=\"font-weight:normal;font-style:normal\">Yellow iron oxide (E172)<\/span><\/p>","ID":"2a5f4c01-9b9c-4c32-a98f-07537927a9f8","Styles":"text-align:left","Classes":"['MsoBodyText3']","Bold":true,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Yellow iron oxide (E172)","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"MsoBodyText3\" style=\"text-align:left\"><\/p>","ID":"37e258c3-7ade-4898-bd9f-db0d35b221c4","Styles":"text-align:left","Classes":"['MsoBodyText3']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Film-coating of 75\/18.75\/200 mg, 125\/31.25\/200 mg, 175\/43.75\/200 mg and 200\/50\/200 mg<\/span><\/u><span lang=\"EN-GB\">:<\/span><\/p>","ID":"939ea891-cd19-4968-9d49-9f529df4f233","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Film-coating of 75\/18.75\/200 mg, 125\/31.25\/200 mg, 175\/43.75\/200 mg and 200\/50\/200 mg:","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"MsoBodyText3\" style=\"text-align:left\"><span lang=\"IT\" style=\"font-weight:normal;font-style:normal\">Glycerol (85 per cent) (E422)<\/span><\/p>","ID":"b691e7f4-da31-4759-9169-7944f0c7d1ee","Styles":"text-align:left","Classes":"['MsoBodyText3']","Bold":true,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Glycerol (85 per cent) (E422)","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"MsoBodyText3\" style=\"text-align:left\"><span lang=\"IT\" style=\"font-weight:normal;font-style:normal\">Hypromellose<\/span><\/p>","ID":"3abdaa82-bf0d-4f9e-bcd7-270ccc85a8b0","Styles":"text-align:left","Classes":"['MsoBodyText3']","Bold":true,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Hypromellose","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"MsoBodyText3\" style=\"text-align:left\"><span lang=\"IT\" style=\"font-weight:normal;font-style:normal\">Magnesium stearate<\/span><\/p>","ID":"aa064d9f-d058-40d7-81bb-e902726f1471","Styles":"text-align:left","Classes":"['MsoBodyText3']","Bold":true,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Magnesium stearate","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"MsoBodyText3\" style=\"text-align:left\"><span lang=\"IT\" style=\"font-weight:normal;font-style:normal\">Polysorbate 80<\/span><\/p>","ID":"1e9f4031-bbc1-4965-a849-4c9d8837e71d","Styles":"text-align:left","Classes":"['MsoBodyText3']","Bold":true,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Polysorbate 80","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"MsoBodyText3\" style=\"text-align:left\"><span lang=\"IT\" style=\"font-weight:normal;font-style:normal\">Red iron oxide (E172)<\/span><\/p>","ID":"144e38f9-a376-4665-9122-1c3caa452fb4","Styles":"text-align:left","Classes":"['MsoBodyText3']","Bold":true,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Red iron oxide (E172)","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"MsoBodyText3\" style=\"text-align:left\"><span lang=\"IT\" style=\"font-weight:normal;font-style:normal\">Sucrose<\/span><\/p>","ID":"3b10010c-eaef-47e3-b465-d8045f4c99f2","Styles":"text-align:left","Classes":"['MsoBodyText3']","Bold":true,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Sucrose","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"MsoBodyText3\" style=\"text-align:left\"><span lang=\"IT\" style=\"font-weight:normal;font-style:normal\">Titanium dioxide (E171)<\/span><\/p>","ID":"b4453ea3-d1e5-4207-8917-e64cbc9e9f53","Styles":"text-align:left","Classes":"['MsoBodyText3']","Bold":true,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Titanium dioxide (E171)","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"54802ed4-17f3-481c-8b37-bcf5da7bb1a1","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt\"><b><span lang=\"EN-GB\">6.2    Incompatibilities<\/span><\/b><\/p>","ID":"668f133e-cf7c-484e-9186-b2a02d6383c2","Styles":"margin-left:27.0pt;text-indent:-27.0pt","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"6.2    Incompatibilities","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"960b7dd3-7e22-4f8f-8a6b-153be4efded2","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">Not applicable.<\/span><\/p>","ID":"532d2462-632e-47c3-bbf9-f238e6c7f86e","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not applicable.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"84bf40e7-e291-4a83-9521-aa60c2d90623","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt\"><b><span lang=\"EN-GB\">6.3    Shelf life<\/span><\/b><\/p>","ID":"7a8987f1-fd19-4486-8cd0-0131bf9eb1d1","Styles":"margin-left:27.0pt;text-indent:-27.0pt","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"6.3    Shelf life","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"c4397532-6622-4ecd-a585-38bb9b0df3bf","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">3 years.<\/span><\/p>","ID":"151c4c4a-727f-4e1f-9a33-915395ac3f23","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"3 years.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"977d5cd8-bf2c-477f-88a1-2bb6da8936f9","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt\"><b><span lang=\"EN-GB\">6.4    Special precautions for storage<\/span><\/b><\/p>","ID":"c80584e2-db57-4e80-a377-b58c67eaf81b","Styles":"margin-left:27.0pt;text-indent:-27.0pt","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"6.4    Special precautions for storage","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"493b1a63-6cbc-429a-b9e7-7487b1d00e2b","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">This medicinal product does not require any special storage conditions.<\/span><\/p>","ID":"6b431a48-eda3-49ba-b503-d7259fc2acbe","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"This medicinal product does not require any special storage conditions.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"f56648d4-ceb5-4a2d-a556-4d58c586cbb9","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt\"><b><span lang=\"EN-GB\">6.5    Nature and contents of container<\/span><\/b><\/p>","ID":"07056cbb-79b2-41a6-b0fb-4fcc2fe4ca5b","Styles":"margin-left:27.0pt;text-indent:-27.0pt","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"6.5    Nature and contents of container","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"007a57a6-e565-44f6-9d55-a35f60bd7619","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">HDPE bottle with a child resistant PP-closure.<\/span><\/p>","ID":"3ac14bcc-691c-4beb-8e00-0bef2ecb9785","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"HDPE bottle with a child resistant PP-closure.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoEndnoteText\"><\/p>","ID":"4f4ecfdf-ef56-44f4-8d1a-d1fbe1bd6690","Styles":"None","Classes":"['MsoEndnoteText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">Pack sizes of 50\/12.5\/200 mg, 100\/25\/200 mg and 150<\/span><span lang=\"EN-GB\">\/37.5\/200 mg<\/span><span lang=\"EN-GB\">:<\/span><\/p>","ID":"4464c12c-435e-40de-8005-83e4ed28d8ce","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Pack sizes of 50\/12.5\/200 mg, 100\/25\/200 mg and 150\/37.5\/200 mg:","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">10, 30, 100, 130, 175 and 250 tablets.<\/span><\/p>","ID":"8a93d755-1e27-4796-a082-e6cbf3cabb80","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"10, 30, 100, 130, 175 and 250 tablets.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"1130c76a-53f9-4e4b-867f-1da363347164","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">Pack sizes of 75\/18.75\/200 mg, 125\/31.25\/200 mg, 175\/43.75\/200 mg and 200\/50\/200 mg:<\/span><\/p>","ID":"a01fc953-893e-4328-a52f-2d7b62fa17b6","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Pack sizes of 75\/18.75\/200 mg, 125\/31.25\/200 mg, 175\/43.75\/200 mg and 200\/50\/200 mg:","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">10, 30, 100, 130 and 175 tablets.<\/span><\/p>","ID":"605b24f7-aa65-49df-8a03-6167f9980166","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"10, 30, 100, 130 and 175 tablets.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"de96d92c-7db3-4dce-a619-50bbd0bc781e","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">Not all pack sizes may be marketed.<\/span><\/p>","ID":"67c4179b-48a4-4408-a15c-735950a498da","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not all pack sizes may be marketed.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"714b9326-17a9-4016-a7c9-c34fff8c105f","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt\"><b><span lang=\"EN-GB\">6.6    Special precautions for disposal<\/span><\/b><\/p>","ID":"b1289abb-898a-427e-a444-77242968a98a","Styles":"margin-left:27.0pt;text-indent:-27.0pt","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"6.6    Special precautions for disposal","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"281d748b-bc11-4361-ae74-76a4d58346dd","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">Any unused medicinal product or waste material should be disposed of in accordance with local requirements.<\/span><\/p>","ID":"e7f2a972-18b9-4f57-9682-475019408e18","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Any unused medicinal product or waste material should be disposed of in accordance with local requirements.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"e0eeea05-0aae-43de-9b60-d57d5dfb7390","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"6074331f-a6b0-4d9c-b9dd-0ef171dc1fef","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt\"><b><span lang=\"EN-GB\">7.<\/span><\/b><b><span lang=\"EN-GB\">MARKETING AUTHORISATION HOLDER<\/span><\/b><\/p>","ID":"7ff9f7cd-17e5-4e71-8f67-2ba23a872e6a","Styles":"margin-left:27.0pt;text-indent:-27.0pt","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"7.MARKETING AUTHORISATION HOLDER","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"dfabf283-f687-4724-b9a0-e81eda9d6cac","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">Orion Corporation<\/span><\/p>","ID":"f9f1c7ec-4650-4c9a-b9f3-8ead5a810be3","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Orion Corporation","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"Figure\" style=\"margin-top:0in;page-break-after:auto\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Orionintie 1<\/span><\/p>","ID":"9c890164-b6cc-4d03-bec5-acd98caef247","Styles":"margin-top:0in;page-break-after:auto","Classes":"['Figure']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Orionintie 1","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">FI-02200 Espoo<\/span><\/p>","ID":"3790c08c-a1ec-448d-b0b8-428d2e9ccbb5","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"FI-02200 Espoo","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">Finland<\/span><\/p>","ID":"3aa1e14e-ffe7-4834-95e5-fd8aa32cfbc1","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Finland","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoEndnoteText\"><\/p>","ID":"b84191fd-6b8e-4c2c-842d-c48c5ca49eb5","Styles":"None","Classes":"['MsoEndnoteText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"d327505e-aaf0-41a7-92aa-3eb85510febc","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt\"><b><span lang=\"EN-GB\">8.      MARKETING AUTHORISATION NUMBERS <\/span><\/b><\/p>","ID":"2bbbd02b-9d42-4b1c-9eb0-892f9b094d08","Styles":"margin-left:27.0pt;text-indent:-27.0pt","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"8.      MARKETING AUTHORISATION NUMBERS ","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"bb745b3c-be70-4572-a8a2-f3cc0fed414e","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">50 mg\/12.5 mg\/200 mg<\/span><\/u><\/p>","ID":"b1743229-870e-41d2-9fd8-6beda606a243","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"50 mg\/12.5 mg\/200 mg","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">EU\/1\/03\/260\/001-004<\/span><\/p>","ID":"fa98219e-41df-4425-be69-a40358e39347","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"EU\/1\/03\/260\/001-004","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">EU\/1\/03\/260\/013<\/span><\/p>","ID":"a3cc469c-0240-46fa-8215-b916595ce33c","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"EU\/1\/03\/260\/013","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">EU\/1\/03\/260\/016<\/span><\/p>","ID":"7ebd1dbe-5a70-4b5f-acb2-68e63ceca649","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"EU\/1\/03\/260\/016","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"95d2e9e4-7721-46e3-91b8-4db425fb5b03","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">75 mg\/18.75 mg\/200 mg<\/span><\/u><\/p>","ID":"500579c5-7523-4c1a-9b4f-96a75975e72e","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"75 mg\/18.75 mg\/200 mg","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">EU\/1\/03\/260\/024-028<\/span><\/p>","ID":"ca582efa-b808-42c1-8ba7-93112992b3ab","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"EU\/1\/03\/260\/024-028","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"c2e38f88-92b9-49aa-8986-69c8a499cd1f","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">100 mg\/25 mg\/200 mg<\/span><\/u><\/p>","ID":"826c8fad-2da7-4f4a-9e42-10e5d4248b86","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"100 mg\/25 mg\/200 mg","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">EU\/1\/03\/260\/005-008<\/span><\/p>","ID":"26e1f9e3-f0d1-4e1a-a9a9-604d67c493df","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"EU\/1\/03\/260\/005-008","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">EU\/1\/03\/260\/014<\/span><\/p>","ID":"3f91cfcf-3f8e-4d43-8700-26b1efa446c3","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"EU\/1\/03\/260\/014","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">EU\/1\/03\/260\/017<\/span><\/p>","ID":"4a564d8c-2202-4feb-b49a-82bfc0a248bd","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"EU\/1\/03\/260\/017","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"ab9a87ff-8f75-4827-9bd7-c398db984305","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">125 mg\/31.25 mg\/200 mg<\/span><\/u><\/p>","ID":"2a2d2c0d-c377-45b2-9ec9-2fb19006f1a6","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"125 mg\/31.25 mg\/200 mg","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">EU\/1\/03\/260\/029-033<\/span><\/p>","ID":"3ba5940a-2a86-451f-8704-9cd729f0c4bb","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"EU\/1\/03\/260\/029-033","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"915db3ba-a0b3-47e3-bd07-fd5a2bdd6dc8","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">150 mg\/37.5 mg\/200 mg<\/span><\/u><\/p>","ID":"949cd22a-0a36-495c-ac1d-0568ccfbecad","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"150 mg\/37.5 mg\/200 mg","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">EU\/1\/03\/260\/009-012<\/span><\/p>","ID":"0a5c56e0-3608-4536-a9b9-26531852356a","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"EU\/1\/03\/260\/009-012","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">EU\/1\/03\/260\/015<\/span><\/p>","ID":"f2f47a0f-5a5b-4237-bbbf-c18bc7e16757","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"EU\/1\/03\/260\/015","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">EU\/1\/03\/260\/018<\/span><\/p>","ID":"433d9ae8-73f3-4bc4-8b22-2ab599f895ae","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"EU\/1\/03\/260\/018","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"f5b666a7-06db-4d48-81d9-182072592270","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">175 mg\/43.75 mg\/200 mg<\/span><\/u><\/p>","ID":"eb56b09d-88dd-43ba-9cab-acc79b2f8c9b","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"175 mg\/43.75 mg\/200 mg","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">EU\/1\/03\/260\/034-038<\/span><\/p>","ID":"72fd0920-b213-4dd2-906d-6377babae80f","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"EU\/1\/03\/260\/034-038","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"cfdbb32c-455e-48a2-a423-497f20f02b12","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">200 mg\/50 mg\/200 mg<\/span><\/u><\/p>","ID":"ff071f88-ef16-4f69-84b3-86b8541a91a5","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"200 mg\/50 mg\/200 mg","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">EU\/1\/03\/260\/019-023<\/span><\/p>","ID":"cd789a5c-4e2c-4820-96c8-c63ccac90a70","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"EU\/1\/03\/260\/019-023","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"778665ec-9d85-4c11-8097-1ec53a25a29f","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"109982d7-a5e7-488e-9ea0-a0d596c99eda","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt\"><b><span lang=\"EN-GB\">9.      DATE OF FIRST AUTHORISATION\/RENEWAL OF THE AUTHORISATION<\/span><\/b><\/p>","ID":"0293c3f0-ae3c-4737-bc99-4bd3bdb53ce8","Styles":"margin-left:27.0pt;text-indent:-27.0pt","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"9.      DATE OF FIRST AUTHORISATION\/RENEWAL OF THE AUTHORISATION","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"e68e2f21-caab-4163-b6a0-8ba182962156","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">Date of first authorisation: 17 October 2003<\/span><\/p>","ID":"e01ad15b-1768-45cd-838d-4cdb855641cf","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Date of first authorisation: 17 October 2003","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">Date of latest renewal: 17 October 2008<\/span><\/p>","ID":"76fbbd6a-0f7f-4973-97ba-a56491d68519","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Date of latest renewal: 17 October 2008","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"6d484256-6bd3-43ff-ae2d-6eac66adf276","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"acb7af0d-cea3-42a7-8b04-0adc7dd1f283","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt\"><b><span lang=\"EN-GB\">10.    DATE OF REVISION OF THE TEXT<\/span><\/b><\/p>","ID":"b8dd64ad-4280-4b26-a61b-1fb918e5c1ad","Styles":"margin-left:27.0pt;text-indent:-27.0pt","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"10.    DATE OF REVISION OF THE TEXT","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"df0ec95d-8ac3-46cf-9c3e-c238cb49db2f","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"a2b0f23c-acf7-42b1-82a2-9d5949fa2490","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","ID":"f87f492c-2e31-4a97-b7eb-61aa1c9f5b8a","Styles":"margin-top:0in;text-align:left","Classes":"['Text']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">Detailed information on this medicinal\r product is available on the website of European Medicines Agency <a href=\"http:\/\/www.ema.europa.eu\">http:\/\/www.ema.europa.eu<\/a>.<\/span><\/p>","ID":"7881fbf7-79d4-43d3-a78c-8956cf434aa8","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Detailed information on this medicinal\r product is available on the website of European Medicines Agency http:\/\/www.ema.europa.eu.","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<b><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b>","ID":"f67dbef8-0e80-4c3d-b441-59e148d80c10","Styles":"None","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"ebaf396e-55d5-457b-b1c1-537df189c466"},{"Element":"<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span>","ID":"d64c0c85-7569-4980-8e5d-c49d51db4c6c","Styles":"font-size:11.0pt;font-family:\"Times New Roman\",serif","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":" ","ParentId":"f67dbef8-0e80-4c3d-b441-59e148d80c10"}]